---
document_datetime: 2025-04-28 12:52:16
document_pages: 142
document_pathfilename: www.ema.europa.eu/en/documents/variation-report/enhertu-h-c-005124-ii-0048-epar-assessment-report-variation_en.pdf
document_name: enhertu-h-c-005124-ii-0048-epar-assessment-report-variation_en.pdf
version: success
processing_time: 461.4022285
conversion_datetime: 2025-12-30 11:43:13.425696
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

27 February 2025 EMA/109425/2025 Committee for Medicinal Products for Human Use (CHMP)

## Assessment report

Enhertu

International non-proprietary name: Trastuzumab deruxtecan

Procedure No. EMEA/H/C/005124/II/0048

## Note

Variation assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Background information on the procedure                                                                                | .............................................. 7                                                            |
|---------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------|
| 1.1. Type II variation .................................................................................................. | 7                                                                                                           |
| 1.2. Steps taken for the assessment of the product                                                                        | ......................................................... 8                                                 |
| 2. Scientific discussion                                                                                                  | ................................................................................ 9                          |
| 2.1. Introduction                                                                                                         | ......................................................................................................... 9 |
| 2.1.1. Problem statement                                                                                                  | ............................................................................................ 9              |
| 2.1.2. About the product ............................................................................................     | 10                                                                                                          |
| 2.1.3. The development programme/compliance with CHMP guidance/scientific advice                                          | ...... 11                                                                                                   |
| 2.1.4. General comments on compliance with GCP                                                                            | ........................................................ 11                                                 |
| 2.2. Non-clinical aspects                                                                                                 | ............................................................................................ 11             |
| 2.2.1. Ecotoxicity/environmental risk assessment .........................................................                | 11                                                                                                          |
| 2.2.2. Discussion on non-clinical aspects ......................................................................          | 12                                                                                                          |
| 2.2.3. Conclusion on the non-clinical aspects                                                                             | ................................................................ 12                                         |
| 2.3. Clinical aspects                                                                                                     | .................................................................................................. 12       |
| 2.3.1. Introduction                                                                                                       | .................................................................................................... 12     |
| 2.3.1. Bioanalytical methods                                                                                              | ...................................................................................... 13                   |
| 2.3.2. Pharmacokinetics .............................................................................................     | 14                                                                                                          |
| 2.3.3. Pharmacodynamics ..........................................................................................        | 16                                                                                                          |
| 2.3.4. PK/PD modelling ..............................................................................................     | 19                                                                                                          |
| 2.3.5. Discussion on clinical pharmacology                                                                                | ................................................................... 19                                      |
| 2.3.6. Conclusions on clinical pharmacology .................................................................             | 19                                                                                                          |
| 2.4. Clinical efficacy                                                                                                    | .................................................................................................. 20       |
| 2.4.1. Dose response study(ies) .................................................................................         | 20                                                                                                          |
| 2.4.2. Main study                                                                                                         | ...................................................................................................... 20   |
| 2.4.3. Discussion on clinical efficacy ............................................................................       | 68                                                                                                          |
| 2.4.4. Conclusions on the clinical efficacy .....................................................................         | 71                                                                                                          |
| 2.5. Clinical safety                                                                                                      | .................................................................................................... 71     |
| 2.5.1. Discussion on clinical safety ............................................................................         | 129                                                                                                         |
| 2.5.2. Conclusions on clinical safety ..........................................................................          | 131                                                                                                         |
| 2.5.3. PSUR cycle                                                                                                         | ................................................................................................... 132     |
| 2.6. Risk management plan                                                                                                 | ...................................................................................... 132                  |
| 2.7. Update of the Product information ......................................................................             | 134                                                                                                         |
| 2.7.1. User consultation ...........................................................................................      | 134                                                                                                         |
| 3. Benefit-Risk Balance ............................................................................                      | 135                                                                                                         |
| 3.1. Therapeutic Context                                                                                                  | ......................................................................................... 135               |
| 3.1.1. Disease or condition                                                                                               | ....................................................................................... 135                 |
| 3.1.2. Available therapies and unmet medical need                                                                         | ..................................................... 135                                                   |
| 3.1.3. Main clinical studies                                                                                              | ....................................................................................... 135                 |
| 3.2. Favourable effect ..............................................................................................     | 136                                                                                                         |
| 3.3. Uncertainties and limitations about favourable effects                                                               | ........................................... 136                                                             |
| 3.4. Unfavourable effects                                                                                                 | ......................................................................................... 137               |
| 3.5. Uncertainties and limitations about unfavourable effects                                                             | ....................................... 137                                                                 |
| 3.6. Effects Table ....................................................................................................   | 138                                                                                                         |

<div style=\"page-break-after: always\"></div>

3.7. Benefit-risk assessment and discussion

...............................................................

3.7.1. Importance of favourable and unfavourable effects

3.7.2. Balance of benefits and risks

138

............................................

138

...........................................................................

3.7.3. Additional considerations on the benefit-risk balance

3.8. Conclusions

139

.........................................

139

.....................................................................................................

4. Recommendations

140

...............................................................................

140

<div style=\"page-break-after: always\"></div>

## List of abbreviations

ADA

anti-drug antibody

ADC

antibody-drug conjugate

ADR

adverse drug reaction

AE

adverse event

AESI

adverse event of special interest

ASCO/CAP

American Society of Clinical Oncology/College of American Pathologists

BC

breast cancer

BICR

blinded independent central review

CDK 4/6

cyclin-dependent kinase 4 and 6

CDx

Companion diagnostic

CI

confidence interval

CMA

Conditional Marketing Authorisation

COVID-19

coronavirus disease 2019

CSP

clinical study protocol

CSR

clinical study report

CTCAE

Common Terminology Criteria for Adverse Events

CTD

common technical document

Ctrough

observed lowest concentration before the next dose is administered

DB-06

DESTINY-Breast06

DCO

data cut-off

DoR

duration of response

DXd

the released payload (MAAA-1181a)

EMA

European Medicines Agency

EORTC

European Organisation for Research and Treatment of Cancer

ER

estrogen receptor

ERA

environmental risk assessment

FAS

Full Analysis Set

FDA

Food and Drug Administration

GHS

Global Health Status

GI

gastrointestinal

HER2

human epidermal growth factor receptor 2

<div style=\"page-break-after: always\"></div>

| HR     | hazard ratio                                                                          |
|--------|---------------------------------------------------------------------------------------|
| HRQoL  | health-related quality of life                                                        |
| IA     | interim analysis                                                                      |
| ICH    | International Council for Harmonisation                                               |
| IHC    | immunohistochemistry                                                                  |
| ILD    | interstitial lung disease                                                             |
| ISH    | in situ hybridization                                                                 |
| IRT    | interactive response technology                                                       |
| ITT    | intent-to-treat                                                                       |
| IV     | intravenous                                                                           |
| LV     | left ventricular                                                                      |
| LVEF   | left ventricular ejection fraction                                                    |
| MedDRA | Medical Dictionary for Regulatory Activities                                          |
| mTOR   | mammalian target of rapamycin                                                         |
| MTP    | multiple testing procedure                                                            |
| N/A    | not applicable                                                                        |
| Nab    | neutralizing antibody                                                                 |
| NCCN   | National Comprehensive Cancer Network                                                 |
| NE     | not evaluable                                                                         |
| NSCLC  | non-small cell lung cancer                                                            |
| ORR    | objective response rate                                                               |
| OS     | overall survival                                                                      |
| PFS    | progression-free survival                                                             |
| PFS2   | time to second progression or death                                                   |
| PgR    | progesterone receptor                                                                 |
| PI3-K  | phosphoinositide 3-kinase                                                             |
| PIK3CA | phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha protein coding |
| PK     | pharmacokinetic(s)                                                                    |
| PopPK  | population PK                                                                         |
| PPD    | Pharmaceutical Product Development, Inc.                                              |
| PPE    | Palmar-plantar erythrodysaesthesia                                                    |
| PRO    | Patient Reported Outcomes                                                             |
| PS     | Performance status                                                                    |

<div style=\"page-break-after: always\"></div>

| PT          | preferred term                                           |
|-------------|----------------------------------------------------------|
| Q3W         | every 3 weeks                                            |
| QLQ         | Quality of Life (questionnaire)                          |
| RECIST v1.1 | Response Evaluation Criteria in Solid Tumors Version 1.1 |
| RCT         | Randomised clinical trial                                |
| REC         | Recommendation                                           |
| SAE         | serious adverse event                                    |
| SAP         | Statistical Analysis Plan                                |
| SMQ         | Standardized MedDRA Query                                |
| SOB         | Specific Obligation                                      |
| SoC         | standard of care                                         |
| T-DXd       | trastuzumab deruxtecan                                   |
| TEAE        | treatment-emergent adverse event                         |
| TPC         | treatment of physician's choice                          |
| US          | United States of America                                 |
| Vs          | versus                                                   |

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

## 1.1. Type II variation

Pursuant to Article 16 of Commission Regulation (EC) No 1234/2008, Daiichi Sankyo Europe GmbH submitted to the European Medicines Agency on 22 July 2024 an application for a variation.

The following variation was requested:

| Variation requested   | Variation requested                                                                                                            | Type    | Annexes affected     |
|-----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|----------------------|
| C.I.6.a               | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I, II, IIIA and IIIB |

Extension of indication to include treatment of adult patients with unresectable or metastatic HER2-low or HER2-ultralow breast cancer (BC) who have received at least one endocrine therapy in the metastatic setting for ENHERTU, based on results from study D9670C00001 (DESTINY-Breast06); this is a phase 3, randomized, multicentre, open-label study of trastuzumab deruxtecan (DS-8201a) compared with investigator's choice chemotherapy in, hormone receptor-positive, HER2-low and HER2ultralow BC patients whose disease has progressed on endocrine therapy in the metastatic setting. As a consequence, sections 4.1, 4.2, 4.4, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 8.1 of the RMP has also been submitted. In addition, the MAH took the opportunity to introduce editorial changes to the PI, to update the list of local representatives in the Package Leaflet and to update the PI according to the Excipients Guideline.

The variation requested amendments to the Summary of Product Characteristics, Annex II, Labelling and Package Leaflet and to the Risk Management Plan (RMP).

## Information on paediatric requirements

Pursuant to Article 8 of Regulation (EC) No 1901/2006, the application included an EMA Decision CW/0001/2015 on the granting of a class waiver.

## Information relating to orphan market exclusivity

Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No 847/2000, the MAH did not submit a critical report addressing the possible similarity with authorised orphan medicinal products because there is no authorised orphan medicinal product for a condition related to the proposed indication.

## Similarity

Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No 847/2000, the MAH did not submit a critical report addressing the possible similarity with authorised orphan medicinal products because there is no authorised orphan medicinal product for a condition related to the proposed indication.

<div style=\"page-break-after: always\"></div>

## Scientific advice

The MAH received Scientific Advice from the CHMP on 30 January 2020 (EMEA/H/SA/3715/1/FU/1/2019/II). The Scientific Advice pertained to clinical aspects of the dossier.

## 1.2. Steps taken for the assessment of the product

The Rapporteurs appointed by the CHMP were:

CHMP Rapporteur:

Boje Kvorning Pires Ehmsen

CHMP Co-Rapporteur:

Peter

Mol

PRAC Rapporteur:

Carla Torre

| Timetable                                            | Actual dates     |
|------------------------------------------------------|------------------|
| Submission date                                      | 22 July 2024     |
| Start of procedure:                                  | 17 August 2024   |
| CHMP Rapporteur Assessment Report                    | 9 October 2024   |
| PRAC Rapporteur Assessment Report                    | 18 October 2024  |
| PRAC members comments                                | 23 October 2024  |
| CHMP Co-Rapporteur Assessment                        | 23 October 2024  |
| PRAC Outcome                                         | 31 October 2024  |
| CHMP members comments                                | 4 November 2024  |
| Updated CHMP Rapporteur(s) (Joint) Assessment Report | 7 November 2024  |
| Request for supplementary information (RSI)          | 14 November 2024 |
| MAH's responses submitted to the CHMP on             | 13 December 2024 |
| Re-start of procedure                                | 30 December 2024 |
| CHMP Rapporteur Assessment Report                    | 29 January 2025  |
| PRAC Rapporteur Assessment Report                    | 31 January 2025  |
| PRAC members comments                                | 5 February 2025  |
| Updated PRAC Rapporteur Assessment Report            | 6 February 2025  |
| PRAC Outcome                                         | 13 February 2025 |
| CHMP members comments                                | 17 February 2025 |
| Updated CHMP Rapporteur Assessment Report            | 21 February 2025 |
| Opinion                                              | 27 February 2025 |

<div style=\"page-break-after: always\"></div>

## 2. Scientific discussion

## 2.1. Introduction

## 2.1.1. Problem statement

The scope of this variation is to extend the existing therapeutic indication for Enhertu as monotherapy for the treatment of adult patients with unresectable or metastatic HER2-low or HER2-ultralow breast cancer who have received at least one endocrine therapy in the metastatic setting, based on the results of phase III study DB-06.

## Disease or condition

The MAH initially applied for the following indication:

Enhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic HER2-low or HER2-ultralow breast cancer who have received at least one endocrine therapy in the metastatic setting (see section 5.1).

During the procedure the indication was amended. The agreed indication is as follows:

Enhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-low or HER2-ultralow breast cancer who have received at least one endocrine therapy in the metastatic setting and who are not considered suitable for endocrine therapy as the next line of treatment (see sections 4.2 and 5.1).

## Epidemiology and risk factors

In Europe, over 531,000 patients were diagnosed with BC and over 141,000 patients died from the disease in 2021 (Sung et al 2021). Advanced BC, which includes both locally advanced (inoperable) and metastatic BC, remains incurable. The 5-year survival rate for metastatic BC is known to be 38% (Gennari et al. 2021).

## Biologic features

Approximately 80-85% of patients with BC have tumours that are classified as HER2 negative, according to scoring recommended by the ASCO/CAP HER2 testing in BC guideline (Giuliani et al. 2016, Tarantino et al. 2023). Within what are traditionally considered HER2-negative BCs, there exists a spectrum of HER2 expression in tumours ranging from IHC 2+/ISH- and IHC 1+ to tumours that have lower than HER2 IHC 1+ expression or no HER2 expression and are determined as being IHC 0 according to scoring recommended by ASCO/CAP guidelines (Wolff et al 2018). Tumours that have HER2 IHC lower than 1+ but detectable HER2 staining, i.e. faint partial staining of the membrane in 10% or less of the cancer cells are referred to as HER2-ultralow tumours.

Based on literature of primary or metastatic hormone receptor-positive HER2-negative BC, approximately 60-65% of cases were HER2-low and approximately 20-25% were HER2 ultralow (Chen et al. 2023, Denkert et al. 2021, Mehta 2024, Viale et al. 2023).

<div style=\"page-break-after: always\"></div>

## Management

At the time the pivotal D9670C00001 study (DESTINY-Breast06 [Study DB 06 hereafter]) was initiated, patients with hormone receptor-positive, HER2-low (IHC 1+ and IHC 2+/ISH-) or HER2 ultralow (IHC 0 with membrane staining, described as IHC &gt; 0 &lt; 1+ in study DB-06) tumours followed the same treatment paradigm as for hormone receptor-positive, HER2 negative BC (NCCN 2024, Gennari et al. 2021, Shimoi et al. 2020), which includes multiple lines of endocrine therapy with or without targeted therapy (e.g., CDK 4/6 inhibitors) followed by single-agent chemotherapy (Cardoso et al. 2020).

Endocrine therapy, including aromatase inhibitors, selective ER modulators, and selective ER down regulators, as well as targeted therapies such as CDK 4/6 inhibitors, PI3-K inhibitors, and mTOR inhibitors have been shown to improve outcomes for patients with hormone receptor-positive, HER2 negative metastatic BC and are considered SoC for most patients in the metastatic setting (Allison et al. 2020, Andre et al. 2019, Matutino et al. 2018).

The optimal treatment sequence for patients with hormone receptor-positive (HR+), HER2-negative metastatic BC is considered to be the use of first-line endocrine therapy + CDK 4/6 inhibitors, followed by subsequent endocrine therapy with targeted therapies (e.g. mTOR or PI3-K inhibitors [for PIK3CA mutant tumours]) (NCCN 2024, Gennari et al. 2021, Cardoso et al. 2020). In patients whose disease has progressed after multiple lines of endocrine therapy with or without targeted therapies or who have a short median PFS on first-line endocrine-based therapy, chemotherapy is considered an appropriate option (Gennari et al. 2021).

When chemotherapy is recommended, the choice between single-agent and combination therapy is decided based on several factors to individualize therapy. Generally, sequential single-agent therapy is preferred over combination therapy (Cardoso et al. 2009, NCCN 2024, Cancer Facts and Figures 2024). Chemotherapy combinations may be used in selected patients with rapidly progressing disease and visceral crisis. Single-agent therapy options include taxanes, anti-metabolites (e.g. capecitabine) and anthracyclines. Because of the availability of many agents and the lack of clear superiority of one agent over others, there is no ideal sequence of treatments that can be applied to all patients.

In patients with HR+, HER2-negative BC who had received 0 to 1 prior line of chemotherapy for metastatic disease, single-agent chemotherapy led to a median PFS of approximately 6 to 7 months and a median OS of approximately 20 to 25 months (O'Shaughnessy at al. 2021a, O'Shaughnessy at al. 2021b, Robert et al. 2011, Baselga et al. 2017).

The ADC sacituzumab govitecan (Trodelvy) was recently approved based on the TROPiCS 02 study for patients with unresectable locally advanced or metastatic hormone receptor-positive, HER2-negative (IHC 0, IHC 1+ and IHC 2+/ISH-) BC who have received endocrine-based therapy and at least 2 additional systemic therapies in the metastatic setting based on improvement in median PFS over chemotherapy (5.5 months vs 4.0 months; HR: 0.66) (Rugo et al. 2022).

In patients with unresectable or metastatic HER2-low (IHC 1+ and IHC 2+/ISH-) BC, who have received a prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy, T-DXd is an approved option regardless of hormone receptor status.

## 2.1.2. About the product

Enhertu (trastuzumab deruxtecan, T-DXd) is a HER2-directed antibody-drug conjugate (ADC) composed of a humanized anti-HER2 immunoglobulin G1 monoclonal antibody with the same amino

<div style=\"page-break-after: always\"></div>

acid sequence as trastuzumab, covalently linked to the membrane-permeable topoisomerase I inhibitor payload DXd via a stable tetrapeptide based linker.

In Europe, Enhertu is currently approved as a Conditional Marketing Authorisation (CMA) as monotherapy for advanced HER2+ breast cancer in second or ulterior line of treatment (5.4 mg/kg Q3W), advanced HER2-low breast cancer after chemotherapy (5.4 mg/kg Q3W), advanced NSCLC HER2+ requiring systemic therapy following platinum-based chemotherapy with or without immunotherapy (5.4 mg/kg Q3W), and advanced HER2+ gastric or gastroesophageal adenocarcinoma after a trastuzumab-based regimen (6.4 mg/kg Q3W).

## 2.1.3. The development programme/compliance with CHMP guidance/scientific advice

This application is based on the phase 3 Randomized Clinical Trial DESTINY-Breast06 (study DB-06), which compared the efficacy and safety of T-DXd against investigator's choice chemotherapy (capecitabine, paclitaxel or nab-paclitaxel) in patients with HR+, HER2-low (IHC 1+ and IHC 2+/ISH-) and HER2-ultralow (IHC 0 with membrane staining, described as IHC &gt; 0 &lt; 1+ in the study) BC, whose disease had progressed on (a) at least 2 lines of endocrine therapy in the metastatic setting or (b) 1 line of prior endocrine therapy in the metastatic setting and demonstrated progression within 24 months of the start of adjuvant endocrine therapy, or within 6 months of starting first-line endocrine therapy in combination with a CDK 4/6 inhibitor in the metastatic setting.

The MAH received Scientific Advice from the CHMP on 30 January 2020 (EMEA/H/SA/3715/1/FU/1/2019/II). Overall, the study design was deemed acceptable. Considering that a low efficacy might be expected in the HER2-ultralow subgroup, subgroups' results should be considered in order to assess the consistency of the effect across the various HER2 expression levels. Anthracyclines were recommended to be included among the physician's choice comparator options, considering they are among the most widely used treatment options in this setting, and are also recommended by main guidelines. Depending on the actual magnitude of benefit in terms of PFS, the safety profile compared to SOC and the consistency of the effect among the various subgroups, mature OS data might be requested in order to conclude on the B/R in the ITT population.

## 2.1.4. General comments on compliance with GCP

The MAH has stated that their procedures, internal quality control measures, and audit programs provide reassurance that the clinical study program was carried out in accordance with Good Clinical Practice, as documented by the ICH, EMA, and the US FDA.

## 2.2. Non-clinical aspects

No new non-clinical data have been submitted in this application, which was considered acceptable by the CHMP.

## 2.2.1. Ecotoxicity/environmental risk assessment

A revised environmental risk assessment has not been provided (see discussion below) .

<div style=\"page-break-after: always\"></div>

## 2.2.2. Discussion on non-clinical aspects

No new non-clinical data have been submitted in this application, which is considered acceptable.

Trastuzumab deruxtecan is an antibody-drug conjugate (ADC) composed of a humanized anti-HER2 immunoglobulin G1 monoclonal antibody with the same amino acid sequence as trastuzumab, covalently linked to the membrane-permeable topoisomerase I inhibitor deruxtecan (DXd) via a stable tetrapeptide based linker. Antibodies are considered naturally occurring proteins, which are not expected to remain either stable or biologically active in the environment for any significant period. For the cytotoxic payload deruxtecan, the currently approved ERA implemented an Fpen based on a prevalence value for all breast cancer patients, irrespective of disease stage or previous treatments, as a worse case assumption. Therefore, this extension of indication will not result in any increase in the predicted environmental concentration of T-DXd, and based on the Guideline on the environmental risk assessment of medicinal products for human use (EMEA/CHMP/SWP/4447/00 Rev. 1- Corr.*), no updated ERA is required. The justification for not providing an updated ERA is accepted.

## 2.2.3. Conclusion on the non-clinical aspects

The updated data submitted in this application, does not lead to a significant increase in environmental exposure further to the use of trastuzumab deruxtecan. Considering the above data, trastuzumab deruxtecan  is not expected to pose a risk to the environment.

## 2.3. Clinical aspects

## 2.3.1. Introduction

The current application for T-DXd (Enhertu 5.4 mg/kg IV Q3W) for the treatment of adult patients with unresectable or metastatic HER2-low or HER2-ultralow BC is based on the results of pivotal study D9670C00001 (DESTINY-Breast06, hereafter referred to as study DB-06), a Phase III, randomized, multi-centre, open-label study of Trastuzumab Deruxtecan (T-DXd) versus investigator's choice chemotherapy in HER2-low, Hormone Receptor-Positive breast cancer patients whose disease has progressed on endocrine therapy in the metastatic setting.

## GCP

The Clinical trials were performed in accordance with GCP as claimed by the MAH.

The MAH has provided a statement to the effect that clinical trials conducted outside the community were carried out in accordance with the ethical standards of Directive 2001/20/EC.

<div style=\"page-break-after: always\"></div>

## · Tabular overview of clinical studies

Table 1 Summary of T-DXd Efficacy Studies to Support the Proposed Indication

| Study identifier; status; DCO                                         | Objective(s) of the study                                    | Study design/type of control                                                                                                                              | Test product, dosage regimen, route of administration                                                                                                                                                                                                                                                                | No. of patients randomised or enrolled/ treated                         | Patient population                                                                                                                                                                              |
|-----------------------------------------------------------------------|--------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Pivotal Study                                                         | Pivotal Study                                                | Pivotal Study                                                                                                                                             | Pivotal Study                                                                                                                                                                                                                                                                                                        | Pivotal Study                                                           | Pivotal Study                                                                                                                                                                                   |
| D9670C00001 (DESTINY- Breast06 [DB- 06]) Complete; DCO of 18 Mar 2024 | Efficacy, Safety and Tolerability, PK, HRQoL, Immunogenicity | Phase III, randomized, open-label multicenter, global study to assess the efficacy and safety of T-DXd vs investigator's choice single agent chemotherapy | T-DXd: 5.4 mg/kg IV infusion Q3W OR Investigator choice chemotherapy: Paclitaxel 80 mg/m 2 IV every week in 3-week cycles Capecitabine 1000 mg/m 2 or 1250 mg/m 2 twice daily orally 2 weeks on/1 week off in 3- week cycles Nab-paclitaxel 100 mg/m 2 IV every week for 3 weeks, then 1 week rest in 4- week cycles | Total: 866/851 T-DXd: 436/434 Investigator choice chemotherapy: 430/417 | Advanced or metastatic hormone receptor-positive breast cancer with HER2-low (IHC 1+ and IHC 2+/ISH-) and HER2- ultralow (IHC 0 with membrane staining, described as IHC > 0 < 1+ in the study) |

## 2.3.1. Bioanalytical methods

No new biopharmaceutical studies with different formulations were conducted.

No new methods were used to assay the drug substance and the drug product.

The bioanalytical methods used to determine serum concentrations of the intact drug (T-DXd), total anti-HER2 antibody and the released drug (DXd), and the detection of ADA, and nAb against T-DXd in study DB-06 are the same methods used supporting the initial marketing authorisation (EMEA/H/C005124) and subsequent BC applications (EMEA/H/C005124/II/14 &amp; EMEA/H/C005124/II/22).

<div style=\"page-break-after: always\"></div>

## 2.3.2. Pharmacokinetics

## Study D9670C00001(Study DB-06)

Study design and disposition : Study DB-06 is a phase III, open-label (sponsor-blind), multi-center, randomized study to assess the efficacy and safety of T-DXd at 5.4 mg/kg Q3W compared with Investigator's choice single-agent chemotherapy (capecitabine, paclitaxel or nab-paclitaxel), in patients with hormone receptor-positive, HER2-low (IHC 1+ and IHC 2+/ISH-) and HER2-ultralow (IHC &gt; 0 &lt; 1+ BC).

Clinical pharmacology objectives: To assess the PK of T-DXd and to investigate the immunogenicity of T DXd.

PK and immunogenicity sampling and measurements: In study DB-06 PK samples from patients who received T-DXd were collected pre-dose (within 6 hours before T DXd infusion) at Cycles 1, 2, 4, 6 and 8, post-dose end of infusion (within 15 minutes after end of T-DXd infusion) at Cycles 1, 2, and 4, and post-dose 5 hours (± 2 hours) after end of infusion at Cycle 1 only. In study DB-06, the serum concentrations of the intact drug (T-DXd), total anti-HER2 antibody and the released drug (DXd) were quantified. Blood samples for determination of anti-drug antibody (ADA) in serum was collected preinfusion on Day 1 Cycle 1, Day 1 Cycle 2, and Day 1 Cycle 4, then on Day1 of every 4 cycles.

PK-results and immunogenicity results: Following T-DXd 5.4 mg/kg Q3W, T-DXd concentrations were similar to total anti-HER2 antibody concentrations (3.36 µg/mL [T-DXd] and 4.46 µg/mL [total anti-HER2 antibody] at Cycle 2 pre-dose [Ctrough]), and 6.90 µg/mL [T-DXd] and 10.47 µg/mL [total anti-HER2 antibody] at Cycle 4 pre-dose [Ctrough]). DXd exposure was lower than either T-DXd or total anti-HER2 antibody exposure (0.23 ng/mL at Cycle 2 pre-dose [Ctrough] and 0.35 ng/mL at Cycle 4 pre-dose [Ctrough]). In the HER2 IHC &gt; 0 &lt; 1+ subgroup, concentrations of total T-DXd, anti-HER2 and DXd were consistent with those observed in patients in the PK analysis set. The concentration levels shown in study DB-06 were consistent with concentration levels observed in other BC indications dosed at 5.4 mg/kg Q3W, see figure below.

<div style=\"page-break-after: always\"></div>

Figure 1 Serum Concentration Box Plot (PK Population)

## T-DXd serum concentrations (µg/mL)

<!-- image -->

## Total anti-HER2 AB serum conc. (µg/mL)

<!-- image -->

<div style=\"page-break-after: always\"></div>

## DXd serum concentration (ng/mL)

<!-- image -->

Population Pharmacokinetic Evaluation of T-DXd: Prior population PK analyses have been conducted in support of multiple indications of T-DXd including the evaluation of various intrinsic and extrinsic covariates. The population PK evaluations in previous procedures confirmed there is no clinically meaningful PK difference among different tumor types and populations.

## 2.3.3. Pharmacodynamics

Primary and secondary pharmacology is described in the initial BC application (see initial MAA EMEA/H/C005124).

Immunogenicity results (study DB-06 ) : In the HER2-low population, ADA prevalence (ADA+ prevalence at baseline or post-baseline) was 11.1% (48/433 patients), and ADA incidence (TE-ADA+) was 5.1% (22/433 patients), see table below. The results indicate that the majority of ADA+ patients were not classified as TE-ADA+. ADA responses were primarily transient in nature (20/22 TE-ADA+ patients, 4.6% of the ADA analysis set), and few ADA+ patients were TE-nAb+ (2/433, 0.5%). The median of maximum ADA titers in TE-ADA+ patients and patients who were ADA+ at baseline only were low, at the limit of detection of 45. The data suggest that the magnitude of ADA response to TDXd in TE-ADA+ patients was no different than that of pre-existing ADA.

## Comparison of results across clinical trials of T-DXd, 5.4 mg/kg

Immunogenicity data from 2331 ADA-evaluable patients in the following pools (comprising 11 clinical studies) were collected to assess T-DXd ADA responses and the impact of immunogenicity on clinical PK and safety:

T-DXd 5.4 mg/kg All BC Pool : consisting of studies J101, DB-01, DB-02, DB-03, DB-04, DB-06, and DP-01. This pool comprised 1740 patients from 7 studies that evaluated the safety and tolerability of T-DXd 5.4 mg/kg in BC across stage and line of treatment.

T-DXd 5.4 mg/kg All Solid Tumour Pool : consisting of studies J101, DB-01, DB-02, DB-03, DB-04, DB-06, DL-01, DL-02, DC-02, DP-01, and DP-02. This pool comprised 2331 patients from 11 studies that evaluated the safety and tolerability of T-DXd 5.4 mg/kg across various tumor types, stages, and lines of treatment.

<div style=\"page-break-after: always\"></div>

## Summary of Immunogenicity Response

The prevalence of ADA was 9.2% (160 of 1740 patients) in the T-DXd All BC Pool, and 8.4% (195 of 2331 patients) in the T-DXd All Solid Tumor Pool, see table below. The incidence of ADA was 2.6% (45 of 1740 patients) in the T-DXd All BC Pool and 2.1% (49 of 2331 patients) in the T-DXd All Solid Tumour Pool.

The majority of T-DXd-treated patients who had positive ADA results were ADA+ at baseline only. Across the pools, a total of 11 tested positive for neutralising anti-body (nAb), and 3 were classified as TE-nAb+. Across all pools, ADA response to T-DXd was mostly transient in nature. In TE-ADA+ patients, the median of the maximum titer was low relative to the MRD of 45. There was no apparent effect of ADA on the PK of T-DXd based on observed data and as also shown in previous population PK analysis.

Table 2 Summary of ADA Responses to T-DXd for DB-06 and Pools (Immunogenicity Analysis Set)

| ADA category                                               | DB-06 (5.4 mg/kg) (N = 433)   | DB-06 HER2 IHC >0<1+(5.4 mg/kg) (N =76)   | All BC pool T-DXd (5.4 mg/kg) (N =1740)   | Allsolidtumorpool T-DXd (5.4 mg/kg) (N = 2331)   |
|------------------------------------------------------------|-------------------------------|-------------------------------------------|-------------------------------------------|--------------------------------------------------|
| ADA+prevalence atbaseline or post-baseline a,n (%)         | 48 (11.1)                     | 5 (6.6)                                   | 160 (9.2)                                 | 195 (8.4)                                        |
| Medianofmaximumtiter                                       | 45.0                          | 45.0                                      | 45.0                                      | 45.0                                             |
| TE-ADA+ (ADA incidence) , n (%)                            | 22 (5.1)                      | 1 (1.3)                                   | 45 (2.6)                                  | 49 (2.1)                                         |
| Medianofmaximumtiter                                       | 45.0                          | 45.0                                      | 45.0                                      | 45.0                                             |
| ADA+ post-baseline only (treatment-induced ADA+ 9) n (%)   | 22 (5.1)                      | 1 (1.3)                                   | 45 (2.6)                                  | 49 (2.1)                                         |
| Median of maximum titer                                    | 45.0                          | 45.0                                      | 45.0                                      | 45.0                                             |
| Treatment-boosted ADA+ d, n (%)                            | 0                             | 0                                         | 0                                         | 0                                                |
| Median of maximum titer                                    | NC                            | NC                                        | NC                                        | NC                                               |
| ADA+ prevalence at both baseline and post-baseline , n (%) | 4 (0.9)                       | 2 (2.6)                                   | 23 (1.3)                                  | 29 (1.2)                                         |
| Median of maximum titer                                    | 67.5                          | 45.0                                      | 45.0                                      | 45.0                                             |
| ADA+ prevalence at baseline f, n (%)                       | 22 (5.1)                      | 2 (2.6)                                   | 92 (5.3)                                  | 117 (5.0)                                        |
| Medianof maximum titer                                     | 45.0                          | 270.0                                     | 90.0                                      | 90.0                                             |
| TE-persistently ADA+ , n (%)                               | 2 (0.5)                       | 0                                         | 7 (0.4)                                   | 7 (0.3)                                          |
| Medianofmaximumtiter                                       | 225.0                         | NC                                        | 180.0                                     | 180.0                                            |
| TE-transiently ADA+ h, n (%)                               | 20 (4.6)                      | 1 (1.3)                                   | 38 (2.2)                                  | 42 (1.8)                                         |
| Median of maximum titer                                    | 45.0                          | 45.0                                      | 45.0                                      | 45.0                                             |
| nAb+ prevalence at baseline or post-baseline i, n (%)      | 3 (0.7)                       | 0                                         | 10 (0.6)                                  | 11 (0.5)                                         |
| Median of maximum titer j                                  | 202.5                         | NC                                        | 180.0                                     | 180.0                                            |
| TE-nAb+ (nAb incidence) k, n (%)                           | 2 (0.5)                       | 0                                         | 3 (0.2)                                   | 3 (0.1)                                          |
| Median of maximum titer j                                  | 202.5                         | NC                                        | 45.0                                      | 45.0                                             |

- Treatment-emergent ADA+: Patients who were either treatment-boosted ADA+ or treatment-induced ADA+. The percentage of these patients in a population is known as ADA incidence.
- Treatment-inducedADA+:PatientswhowereADAnegativeormissingatbaseline andbecameADApositivepost-baseline.
- Treatment-boostedADA+:PatientswhowereADA+at bothbaseline andpost-baseline,buthada meaningfulincrease inADA titerbyat least 4-foldfrom baseline topost-baseline.
- ADA+ prevalence at both baseline and post-baseline: Patients with both a positive ADA assessment at baseline and any positive ADA assessment post-baseline.
- ADA+prevalence at baseline:Patientswith apositiveADA assessment atbaselineandnopositiveADA assessment at anypost-baseline assessments.
- Treatment-emergent persistently ADA+: TE-ADA+ and having at least 2 post-baseline ADA+ measurements with ≥ 16 weeks between first and last positive.
- persistently positive.

nAb+ prevalence at baseline or post-baseline: Patients with any positive nAb assessment at baseline or post-baseline. The percentage of these patients in a population is known as nAb prevalence.

- ADA titers in patients who are nAb+

TE-nAb+: TE-ADA+ patients with any positive nAb assessment post-baseline. The percentage of these patients in a population is known as nAb incidence. nAb test results not available for DB-01.

<div style=\"page-break-after: always\"></div>

## Immunogenicity analysis of pooled data from all conducted clinical trials of T-DXd

The immunogenicity paragraph in section 4.8 of the SmPC is being on the basis of immunogenicity data from the updated 5.4 mg/kg all solid tumour type pool and the 6.4 mg/kg all solid tumour type pool, see table below.

Table 3 Summary of Anti-drug Antibody Response to T-DXd by 5.4 mg/kg and 6.4 mg/kg Pools (Immunogenicity Analysis Set)

|                                                                         | All Solid Tumor Pool T-DXd 5.4 mg/kg (N = 2331)   | All Solid Tumor Pool T-DXd 6.4 mg/kg (N = 793)   | Total (N = 3124)   |
|-------------------------------------------------------------------------|---------------------------------------------------|--------------------------------------------------|--------------------|
| ADA positive prevalence at baseline or post-baseline, n (%)             | 195 (8.4)                                         | 62 (7.8)                                         | 257 (8.2)          |
| Median of maximum titer                                                 | 45.0                                              | 45.0                                             | 45.0               |
| (Minimum, maximum)                                                      | (45, 1440)                                        | (45, 1440)                                       | (45, 1440)         |
| Treatment-emergent ADA positive (ADA incidence), n (%)                  | 49 (2.1)                                          | 21 (2.6)                                         | 70 (2.2)           |
| Median of maximum titer                                                 | 45.0                                              | 45.0                                             | 45.0               |
| (Minimum, maximum)                                                      | (45, 720)                                         | (45, 1440)                                       | (45, 1440)         |
| ADA positive post-baseline only (treatment-induced ADA positive), n (%) | 49 (2.1)                                          | 20 (2.5)                                         | 69 (2.2)           |
| Median of maximum titer                                                 | 45.0                                              | 45.0                                             | 45.0               |
| (Minimum, maximum)                                                      | (45, 720)                                         | (45, 90)                                         | (45, 720)          |
| Treatment-boosted ADA positive, n (%)                                   | 0                                                 | 1 (0.1)                                          | 1 (0.0)            |
| Median of maximum titer                                                 | NC                                                | 1440.0                                           | 1440.0             |
| (Minimum, maximum)                                                      | NC                                                | (1440, 1440)                                     | (1440, 1440)       |
| ADA positive prevalence at both baseline and post-baseline, n (%)       | 29 (1.2)                                          | 7 (0.9)                                          | 36 (1.2)           |
| Median of maximum titer                                                 | 45.0                                              | 90.0                                             | 45.0               |
| (Minimum, maximum)                                                      | (45, 1440)                                        | (45, 1440)                                       | (45, 1440)         |
| ADA positive prevalence at baseline, n (%)                              | 117 (5.0)                                         | 35 (4.4)                                         | 152 (4.9)          |
| Median of maximum titer                                                 | 90.0                                              | 45.0                                             | 45.0               |
| (Minimum, maximum)                                                      | (45, 4050)                                        | (45, 720)                                        | (45, 4050)         |
| Treatment-emergent persistently ADA positive, n (%)                     | 7 (0.3)                                           | 1 (0.1)                                          | 8 (0.3)            |
| Median of maximum titer                                                 | 180.0                                             | 1440.0                                           | 270.0              |
| (Minimum, maximum)                                                      | (45, 720)                                         | (1440. 1440)                                     | (45, 1440)         |
| Treatment-emergent transiently ADA positive, n (%)                      | 42 (1.8)                                          | 20 (2.5)                                         | 62 (2.0)           |
| Median of maximum titer                                                 | 45.0                                              | 45.0                                             | 45.0               |
| (Minimum, maximum)                                                      | (45, 720)                                         | (45, 90)                                         | (45, 720)          |
| NAb positive prevalence at baseline or post-baseline, n (%)             | 11 (0.5)                                          | 0                                                | 11 (0.4)           |
| Median of maximum titer                                                 | 180.0                                             | NC                                               | 180.0              |
| (Minimum, maximum)                                                      | (45, 1440)                                        | NC                                               | (45, 1440)         |
| Treatment-emergent NAb positive (NAb incidence), n (%)                  | 3 (0.1)                                           | 0                                                | 3 (0.1)            |

<div style=\"page-break-after: always\"></div>

|                         | All Solid Tumor Pool T-DXd 5.4 mg/kg (N = 2331)   | All Solid Tumor Pool T-DXd 6.4 mg/kg (N = 793)   | Total (N = 3124)   |
|-------------------------|---------------------------------------------------|--------------------------------------------------|--------------------|
| Median of maximum titer | 45.0                                              | NC                                               | 45.0               |
| (Minimum, maximum)      | (45, 360)                                         | NC                                               | (45, 360)          |

## 2.3.4. PK/PD modelling

## Exposure-Response Analyses

Prior ER relationship analyses have been conducted which have confirmed no clinically relevant ER difference for both efficacy and safety endpoints at the dose levels evaluated for each study. In Study DB-06, the exposure, observed response, and safety endpoints in the HER2 &gt;0 &lt;1+ subgroup were consistent with the overall population; therefore, no ER analyses were performed.

## 2.3.5. Discussion on clinical pharmacology

This variation application to extend the use of T-DXd (Enhertu; 5.4 mg/kg IV Q3W) for the treatment of adult patients with HER2-low or HER2-ultralow BC is supported by the pivotal clinical study DB-06. The same drug product and dosing regimen was utilized as previously approved for treatment of HER2positive BC. In study DB-06, the pharmacokinetics of T-DXd, total anti-HER2 AB (total AB) and payload DXd was investigated by sparse sampling (6 samples) over cycle 1, 2 and 4. PK-samples was taken after infusion of T-DXd, corresponding to ~Cmax, and pre-dose i.e. Ctrough. Therefore, both Cmax and Cmin of T-DXd, anti-HER2 total and DXd were determined, both after single dosing and multiple dosing. The serum concentration of T-DXd, anti-HER2 and DXd were adequately quantified with previously validated methods and summarized using descriptive statistics. The median (range), or geometric mean (geoCV%), serum concentration of T-DXd at the selected timepoints was comparable in both HER-2 low and HER-2 ultralow patients, additionally comparability was shown to data in other clinical studies of T-DXd, supporting already approved cancer indication, e.g. HER2 positive BC. Overall, the methodology used is considered adequate. The MAH has justified that no updated Pop-PK and ER analysis was conducted in the current application. Overall, the pharmacokinetics of T-DXd, anti-HER2 and DXd in BC was shown to be independent of HER-2 level. Immunogenicity was adequately evaluated in the DB-06 study using the already validated immunogenicity methods. Furthermore, a pooled immunogenicity analysis was conducted, including ADA-evaluable patients in an all BC-pool and an all solid tumour pool. The analysis showed that the immunogenicity in the DB-06 study is comparable to the two pools. Furthermore, there was no apparent effect between development of antibodies on the pharmacokinetics, safety and/or effectiveness of Enhertu. Finally, the immunogenicity paragraph in section 4.8 of the SmPC has been adequately updated on the basis of a pooled immunogenicity data analysis, including data all of 3124 patients treated with T-DXd.

## 2.3.6. Conclusions on clinical pharmacology

The pharmacokinetics and immunogenicity of T-DXd in adult patients with HER2-low or HER2-ultralow BC have been sufficiently investigated in the clinical study DB-06 and shown to be comparable to TDXd in other approved BC indications. In conclusion, the clinical pharmacology is considered adequately described for the treatment of HER2-low and ultra-low BC subjects with T-DXd at the recommended dose 5.4 mg/kg Q3W.

<div style=\"page-break-after: always\"></div>

## 2.4. Clinical efficacy

## 2.4.1. Dose response study(ies)

No dose-response studies were submitted as part of this application.

## 2.4.2. Main study

DESTINY-Breast06 -Study DB-06: A Phase III, Randomized, Multi-center, Openlabel Study of Trastuzumab Deruxtecan (T-DXd) Versus Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor-Positive Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy in the Metastatic Setting

## Methods

Figure 2 Study  D9670C00001 (DESTINY-Breast06) Design

DESTINY-Breast06:aPhase3,randomized,multicenter,open-label study(NCT04494425)

<!-- image -->

*Determined based on the most recent evaluable HER2 IHC sample prior to randomization; HER2-ultralow defined as faint, partial staining of the membrane in ≤10% of the cancer cells (also known as IHC &gt;0&lt;1+); fas determined by IRT (note: efficacy analyses in the HER2-ultralow subgroup were based on n=152 by central laboratory testing); to be presented separately BICR, blinded independent central review; CDK4/6i, cyclin-dependent kinase 4/6 inhibitor, DOR, duration of response; ET, endocrine therapy; HER2, human epidermal growth factor receptor 2; HR+, hormone receptor-positive; IHC, immunohistochemistry; INV, investigator assessed; IRT, interactive response technology; ISH, in situ hybridization; ITT, intent-to-treat; mBC, metastatic breast cancer, ORR, objective response rate; OS, overallsurvival; PD, progressive disease; PFS, progression-free survival;Q3W,every 3 weeks;R,randomization;T-DXd,trastuzumab deruxtecan;TPC,chemotherapy treatment of physician's choice NCT04494425. Updated April 12, 2024. Available from: https://clinicaltrials.gov/study/NCT04494425 (Accessed May 13, 2024)

## Study participants

## Main inclusion criteria

- 1 Male or female patients:
- (a) ≥ 18 years of age - applicable for all countries participating in the study except Japan
- (b) ≥ 20 years of age - applicable for Japan only
- 2 Pathologically documented breast cancer that:
- (a) Is advanced or metastatic.
- (b) Has a history of HER2-low or negative expression, defined as IHC 2+/ISH- or IHC 1+ (ISH- or untested) or IHC 0 (ISH- or untested) with a validated assay.

<div style=\"page-break-after: always\"></div>

(c) Patients with historical HER2-low or HER2 IHC 0 expression must be confirmed by central laboratory testing to have HER2-low expression or HER2 IHC &gt;0 &lt;1+ expression, respectively. If the local HER2 result is not confirmed by the central laboratory result (i.e. must be HER2-low by most recent local HER2 test and HER2-low by central test or HER2 IHC 0 by most recent local HER2 test and HER2 IHC &gt;0 &lt;1+ by central test), the patient will not be eligible for the study.

o If a patient has had multiple historical/local HER2 results, the most recent result will be compared with the central laboratory HER2 results to confirm eligibility.

o If most recent local HER2 testing only classified the patient's tumour as HER2-negative (IHC status not available), eligibility will be determined by the central laboratory testing results.

(d) Was never previously reported as HER2-positive (IHC 3+ or ISH+) as per ASCO/CAP guidelines.

(e) Is documented as HR+ (either ER and/or PgR positive [ER or PgR ≥1%]) per ASCO/CAP guidelines (Hammond et al, 2010) in the metastatic setting. If a patient has had multiple ER/PgR results after metastatic disease, the most recent test result will be used to confirm eligibility.

3 Must have an adequate tumour tissue sample available for assessment of HER2 by central laboratory and other exploratory biomarker analyses and is preferred in FFPE blocks based on a mandatory FFPE tumor sample obtained at the time of metastatic disease or later; the most recently collected prerandomization tumour sample from the time of metastatic disease or later that meets the tissue requirements specified in Section 8.6.1 is required. If no archival specimens are available, a newly acquired biopsy specimen is acceptable.

## 4 ECOG performance status of 0 or 1 at enrolment and randomization

5 Radiologic or objective evidence of disease progression on or after the last systemic therapy prior to starting study treatment.

6 Must have had disease progression on at least 2 previous lines of ET with or without a targeted therapy (such as CDK4/6, mTOR or PI3-K inhibitors; single agent anti-CDK4/6 therapy is considered a line) administered for the treatment of metastatic disease. Note that changes in dosing schedules, or discontinuations/re-starting of the same drugs or the addition of a targeted therapy to an ET without progression (e.g. adding a CDK4/6 to a current aromatase inhibitor regimen) will not be considered separate lines of therapy; however, disease progression within 24 months on adjuvant ET will count as 1 line.

7 No prior chemotherapy for advanced or metastatic breast cancer. Patients who have received chemotherapy in the neo-adjuvant or adjuvant setting are eligible, with a disease-free interval from completion of systemic chemotherapy to advanced or metastatic diagnosis of &gt;12 months.

8 Life expectancy ≥12 weeks at screening.

9 At least 1 lesion, not previously irradiated, that can be measured accurately at baseline as ≥10 mm in the longest diameter (except lymph nodes which must have short axis ≥15 mm) with CT or MRI which is suitable for accurate repeated measurements, or Non-measurable, bone-only disease that can be assessed by CT or MRI or X-Ray. Lytic or mixed lytic bone lesions that can be assessed by CT or MRI or X-Ray in the absence of measurable disease as defined above is acceptable; patients with sclerotic/osteoblastic bone lesions only in the absence of measurable disease are not eligible.

10 LVEF ≥ 50% within 28 days before randomization.

- 11 Adequate organ and bone marrow function within 14 days before randomization
- 12 Adequate treatment washout period before randomization/enrolment,

<div style=\"page-break-after: always\"></div>

13 Evidence of post-menopausal status or negative serum pregnancy test for females of childbearing potential who were sexually active with a non-sterilized male partner

14 Female patients of childbearing potential who were sexually active with a non-sterilized male partner must use at least one highly effective method of contraception from the time of screening and must had agreed to continue using such precautions for 7 months after the last dose of study treatment.

15 Non-sterilized male patients who were sexually active with a female partner of childbearing potential must use a condom with spermicide from screening to 4 months after the final dose of study treatment.

16 Female patients must not donate, or retrieve for their own use, ova from the time of screening and throughout the study treatment period, and for at least 7 months after the last dose of study treatment.

## Main exclusion criteria

1 Ineligible for all options in the investigator's choice chemotherapy arm.

2 Uncontrolled or significant cardiovascular disease including history of myocardial infarction within 6 months before randomization/enrollment, Uncontrolled hypertension; Uncontrolled and/or clinically important cardiac arrhythmias; Corrected QT interval by Fredericia's method (QTcF) prolongation to &gt;470 ms (females) or &gt;450 ms (male) based on average of screening triplicate 12-lead electrocardiogram (ECG) .

3 History of active primary immunodeficiency.

4 Clinically significant corneal disease in the opinion of the Investigator.

5 Has as a history of (non-infectious) ILD/pneumonitis that required steroids, has current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at screening.

6 Patients with prior use of immunosuppressive medication within 14 days prior to first study dose, except for intranasal and inhaled corticosteroids or systemic corticosteroids at doses less than 10 mg/day of prednisone or equivalent.

7 Clinically severe pulmonary compromise resulting from intercurrent pulmonary illnesses including, but not limited to, any underlying pulmonary disorder  and any autoimmune, connective tissue or inflammatory disorders with potential pulmonary involvement  and/or prior pneumonectomy.

8 Uncontrolled infection requiring IV antibiotics, antivirals, or antifungals.

9 Patients with spinal cord compression or a history of leptomeningeal carcinomatosis. By Day 1 of the study, patients with central nervous system metastases must have been treated and must be asymptomatic and meet the following criteria: (a) No concurrent treatment, inclusive of but not limited to surgery, radiation, and/or corticosteroids.

10 Receipt of live, attenuated vaccine within 30 days prior to the first dose of study treatment.

11 Has unresolved toxicities from previous anticancer therapy,

12 Any concurrent chemotherapy, investigational product (IP), biologic, or hormonal therapy for cancer treatment.

13 Pregnant or breastfeeding female patients.

<div style=\"page-break-after: always\"></div>

- 14 History of another primary malignancy within 3 years, except adequately resected non-melanoma skin cancer, curatively treated in-situ disease, other solid tumors curatively treated, or contralateral breast cancer.
- 15 Previous treatment with anti-HER2 therapy.
- 16 Prior treatment with antibody drug conjugate that comprised an exatecan derivative that is a topoisomerase I inhibitor.
- 17 A pleural effusion, ascites or pericardial effusion that requires drainage, peritoneal shunt, or Cellfree and Concentrated Ascites Reinfusion Therapy (CART) (Drainage and CART are not allowed within 2 weeks prior to screening assessment).

## Treatments

Table 4 Study Treatments and Duration

| Compound       | Dose               | Route   | Schedule                                                                         |
|----------------|--------------------|---------|----------------------------------------------------------------------------------|
| T-DXd          | 5.4 mg/kg          | IV      | Every 3 weeks                                                                    |
| Capecitabine   | 1000 or 1250 mg/m2 | Oral    | Twice daily orally for 2 weeks followed by a 1-week rest period in 3-week cycles |
| Paclitaxel     | 80 mg/m2           | IV      | Every week in 3-week cycles                                                      |
| Nab-paclitaxel | 100 mg/m2          | IV      | Every week for 3 weeks followed by a 1-week rest period in 4-week cycles         |

## Objectives/endpoints

## Table 5 Objectives and Endpoints

| Objectives                                                                                                                                                                                                                                                                                                                    | Endpoints                                                                                                                                                                   |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Primary                                                                                                                                                                                                                                                                                                                       |                                                                                                                                                                             |
| To assess the efficacy of T-DXd compared with Investigator's choice chemotherapy in terms of PFS by BICR in the hormone receptor-positive, HER2-low (IHC 2+/ISH- and IHC 1+) population.                                                                                                                                      | PFS by BICR in the hormone receptor-positive, HER2-low population                                                                                                           |
| Key Secondary                                                                                                                                                                                                                                                                                                                 |                                                                                                                                                                             |
| To assess the efficacy of T-DXd compared with Investigator's choice chemotherapy in terms of OS in the hormone receptor-positive, HER2-low population. To assess the efficacy of T-DXd compared with Investigator's choice chemotherapy in terms of PFS by BICR and OS in the ITT population (HER2 IHC > 0 < 1+ and HER2-low) | OS in the hormone receptor-positive. HER2-low population PFS by BICR according to RECIST 1.1 in the ITT population (HER2 IHC >0 < 1+ and HER2-low) OS in the ITT Population |

<div style=\"page-break-after: always\"></div>

| Other Secondary                                                                                                                                                                                                                              | Other Secondary                                                                                                                                                                                                                                          |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| To further assess the efficacy of T-DXd compared with Investigator's choice chemotherapy in terms of PFS by Investigator assessment, ORR, and DoR by BICR and Investigator assessment in the hormone receptor-positive, HER2-low population. | PFS by Investigator assessment according to RECIST 1.1 in the hormone receptor-positive, HER2-low population. ORR and DoR by BICR and by Investigator assessment according to RECIST 1.1 in the hormone receptor-positive, HER2-low population.          |
| To further assess the efficacy of T-DXd compared with Investigator's choice chemotherapy in terms of ORR and DoR by BICR and Investigator assessment in the ITT population                                                                   | ORR and DoR by BICR and by Investigator assessment in the ITT population (HER2 IHC >0 < 1+ and HER2-low)                                                                                                                                                 |
| To compare the effect of T-DXd with Investigator's choice chemotherapy in terms of PFS2 according to Investigator assessment, TFST, and TSST in the hormone receptor-positive, HER2-low population and the ITT population                    | PFS2 in the hormone receptor-positive, HER2-low population and the ITT population. TFST in the hormone receptor-positive, HER2-low population and the ITT population. TSST in the hormone receptor-positive, HER2-low population and the ITT population. |
| To assess the safety and tolerability profile of T-DXd compared with Investigator's choice chemotherapy                                                                                                                                      | AEs, changes from baseline in laboratory findings, ECHO/MUGA scans, ECGs, and vital signs                                                                                                                                                                |
| To assess the PK of T-DXd                                                                                                                                                                                                                    | T-DXd total anti-HER2 antibody and MAAA-118la concentrations in serum                                                                                                                                                                                    |
| To assess symptoms, functioning, and HRQoL in patients treated with T-DXd compared with Investigator's choice single-agent chemotherapy                                                                                                      | Change from baseline in EORTC QLQ- C30 and EORTC QLQ-BR45 scale scores. Time to deterioration in EORTC QLQ-C30 scale scores                                                                                                                              |
| To investigate the immunogenicity of T-DXd                                                                                                                                                                                                   | Number and percentage of patients who develop ADAs for T-DXd                                                                                                                                                                                             |

## Sample size

Approximately 850 patients were planned to be randomized in this study: 700 HER2-low (IHC 2+/ISHand IHC 1+) patients and 150 HER2 IHC &gt; 0 &lt; 1+ patients. To ensure adequate representation of each subgroup of the HER2-low population, at least 240 patients in each HER2 IHC group (IHC 1+ and IHC 2+/ISH-) were planned to be randomized across both treatment arms (approximately 120 patients per arm).

To ensure that the majority of patients had received prior CDK4/6i therapy in the HER2-low population, no more than 343 patients (49% of 700 patients) who had not received prior therapy with CDK4/6i (e.g. palbociclib, abemaciclib, or ribociclib) were planned to be randomized; a similar proportion of patients who had not received prior CDK4/6 therapy were planned to be randomized in the HER2 IHC &gt; 0 &lt; 1+ population.

The study was powered to show statistical significance for the primary study endpoint of PFS. Based on a 2-sided significance level of 5%, a total of 456 PFS events (65% maturity) would provide at least 95% power to detect a hazard ratio of 0.55 (increase in median PFS from 5.5 to 10 months) in the HER2 low population, assuming an exponential distribution for both treatment groups.

<div style=\"page-break-after: always\"></div>

The study was also powered to demonstrate a statistically significant difference in OS in the HER2-low population.

## Randomisation

Patients were randomly assigned using IRT in a 1:1 ratio to treatment with T-DXd 5.4 mg/kg or Investigator's choice single-agent chemotherapy (capecitabine, paclitaxel or nab-paclitaxel). Patients were stratified according to prior CDK4/6i use (yes vs no), HER2 IHC expression (IHC 2+/ISH- vs IHC 1+ vs IHC &gt; 0 &lt; 1+) by central testing and prior taxane use in the non-metastatic setting (yes vs no).

## Blinding (masking)

This was an open-label study for personnel at study sites. However, the study was conducted 'sponsor-blind' and specific treatment assignment was via an IRT. To maintain the integrity of the study, sponsor personnel involved in the study did not undertake or have access to efficacy data aggregated by treatment arm prior to final data readout for the primary endpoint.

## Statistical methods

The estimand framework has not been applied by the MAH.

## Efficacy analyses sets:

FAS: The ITT population, also termed as FAS, included all randomized patients. Treatment arms were compared on the basis of randomized study treatment, regardless of the study treatment actually received. Patients who were randomized but did not subsequently go on to receive study treatment were included in the analysis in the treatment arm to which they were randomized.

HER2-low : The HER2-low population comprised the subset of patients included in the ITT population with HER2 IHC 2+/ISH- and IHC 1+ as determined by central laboratory testing.

HER2-ultra-low: The HER2 IHC &gt;0 &lt;1+ population comprised the subset of patients included in the ITT population with HER2 IHC &gt;0 &lt;1+ as determined by central laboratory testing and who were randomized ≥ 24 weeks prior to interim futility DCO.

## Analysis methods :

Primary endpoint : PFS by BICR in the hormone receptor-positive, HER2-low population.

PFS distribution was compared between T-DXd and Investigator's choice chemotherapy using a stratified log-rank test adjusting for prior CDK4/6 inhibitor use (yes vs. no), and HER2 IHC expression (IHC 1+ vs. IHC 2+/ISH-).

The HR (T-DXd vs. Investigator's choice chemotherapy) and its CI were estimated from a stratified Cox proportional hazards model, based on the same stratification variables as for the log-rank test.

KM plots of PFS were presented by treatment group. Summaries of the number and percentage of patients experiencing a PFS event, the type of event (RECIST 1.1 progression or death) and the number and percentage of censored patients and detailed reason for censoring were provided along with median PFS and its CI for each treatment.

Of note, assumptions (proportional hazards within strata) for utilizing stratified log-rank test and stratified Cox analysis have been thoroughly investigated according to the SAP.

<div style=\"page-break-after: always\"></div>

## Definition of PFS, including censoring rules:

PFS was defined as the time from date of randomization until the date of objective radiological disease progression by BICR according to RECIST 1.1 or death (by any cause in the absence of progression). Patients who had not progressed or died at the time of analysis were censored at the time of the latest date of assessment from their last evaluable RECIST 1.1 assessment. However, if the patient had disease progression or died immediately after 2 or more consecutive missed visits, the patient was censored at the time of the latest evaluable RECIST 1.1 assessment prior to the 2 missed visits (note: not evaluable visit is not considered as missed visit). Given the scheduled visit assessment scheme (i.e. Q6W for the first 48 weeks, then Q9W thereafter), the definition of 2 missed visits (allowing for early and late visits) will change over time).

## Sensitivity analyses for primary endpoint:

Evaluation-time bias that may be introduced if scans are not performed at the protocol-scheduled time points. The midpoint between the time of progression and the previous evaluable RECIST assessment (using the final date of the assessment) were to be analyzed using a stratified log-rank test, as described for the primary analysis of PFS.

Attrition bias were assessed by repeating the PFS analysis except that the actual PFS event times, rather than the censored times, of patients who progressed or died in the absence of progression immediately following two or more missed tumour assessments were included. Within the same sensitivity analysis, patients who took subsequent therapy (note that for this analysis radiotherapy is not considered a subsequent anti-cancer therapy) prior to their last evaluable RECIST assessment or progression or death were censored at their last evaluable assessment prior to taking the subsequent therapy.

Ascertainment bias was assessed by analyzing Investigator-reported data. The stratified log-rank test was repeated on the programmatically derived PFS using the Investigator-reported data based upon RECIST. The HR and its CI were presented.

Of note, this analysis is to investigate coherence between BICR and investigator assessment.

Deviation bias was assessed by repeating the PFS analysis excluding patients with deviations that may affect the efficacy of trial therapy.

Tipping point analysis : To assess the potential impact of imbalanced censoring due to withdrawal of consent (6 treatment vs 17 chemotherapy) on the PFS results, a tipping point analysis was conducted by assuming a reduced risk for the chemotherapy arm patients who were censored due to withdrawal of consent compared to those still in follow-up (Jackson et al. 2014).

Lastly, a number of subgroup analyses were conducted.

Key secondary efficacy endpoints: PFS by BICR in ITT population, OS in HER2-low population, OS in ITT population.

PFS in the ITT population was treated similarly to PFS in the HER2-low population described above. This also applies for the sensitivity analyses.

## Definition of OS:

OS was defined as the time from the date of randomization until death due to any cause regardless of whether the patient withdrew from randomized therapy or received another anticancer therapy (i.e. date of death or censoring - date of randomization + 1). Any patient not known to have died at the time of analysis was censored based on the last recorded date on which the patient was known to be alive.

<div style=\"page-break-after: always\"></div>

Analysis of OS in the HER2-low population is similar to analysis of PFS.

## Multiple Testing Strategy

In order to strongly control the family-wise Type I error rate at the 5% 2-sided alpha level, a multiple testing procedure (MTP) with gatekeeping strategy was used across the primary and key secondary endpoints, as shown in the figure below.

The final analyses of PFS (DCO: 18 March 2024) was conducted after 457 BICR PFS events were reported between the combined T-DXd and chemotherapy arms (64% maturity) in the HER2-low population. The PFS HR favored T-DXd treatment and was statistically significant at the 5% alpha level.

Therefore, per MTP, the 5% alpha was recycled and split to test PFS in the ITT Population (alpha: 1.5%) and OS in the HER2-low population (alpha: 3.5%).

The PFS HR in the ITT population favored the T-DXd treatment and was statistically significant at the 1.5% alpha level. Therefore, per MTP, the 1.5% alpha was recycled to test OS in the HER2-low population at 5% level.

The OS data in the HER2-low population were immature with a total of 282 events (39.6% maturity; 54% information fraction [282/521 OS events]). While OS in the HER2-low population indicated a trend favoring T-DXd treatment, it did not cross the pre-specified threshold of statistical significance. The OS data will be followed up further.

Per MTP, OS in the ITT population was not tested.

Figure 3 Multiple Testing Procedure

<!-- image -->

## Timing of subsequent OS analyses:

The second interim OS analysis will occur when approximately 392 OS events have been observed in the HER2-low population (56% maturity or 80% information fraction). This was anticipated to occur

<div style=\"page-break-after: always\"></div>

approximately 44 months after the first patient was randomized. It was expected that 477 OS events will be observed in the ITT population at this time.

The final OS analysis will be performed when approximately 489 OS events have been observed in the HER2-low population (70% maturity), which was expected to occur approximately 57 months after the first patient was randomized. At that time, it was estimated that 594 OS events will be  observed in the ITT population.

Multiplicity due to interim analyses : For each hypothesis in OS (HER2-low population and ITT population) Lan DeMets spending function that approximates the O'Brien-Fleming alpha-spending approach (Lan and DeMets, 1983) was used to determine the significance level. Since a total of 282 OS events in the HER2-low population were observed at the time of DCO, the p-value boundary was 0.0046. The p-value boundary for the next interim analysis and the final analysis would have been determined based on the actual information fraction observed.

Other secondary endpoints: PFS by Investigator assessment, PFS2, ORR, DoR, TFST, TSST, HRQoL.

Note, of these endpoints only PFS by Investigator assessment, PFS2, ORR (and cORR) and DoR will be commented on below.

PFS by Investigator assessment: This was treated similarly to the primary endpoint, PFS (by BICR) in the HER2-low population.

ORR: ORR was defined as the percentage of patients with at least one visit response of complete or partial response (using RECIST 1.1). Data obtained up until progression, or last evaluable assessment in the absence of progression, was to be included in the assessment of ORR. However, patients who receive subsequent anticancer therapy (note that for this analysis radiotherapy is not considered a subsequent anticancer therapy) after discontinuing study treatment without progression and then respond were not included as responders in the ORR.

cORR: A confirmed response of CR/PR meant that a response of CR/PR was recorded at 1 visit and confirmed by repeat imaging not less than 4 weeks after the visit when the response was first observed with no evidence of progression between the initial and CR/PR confirmation visit.

ORR and cORR were analyzed by logistic regression in the HER2-low population, the ITT population and HER2-ultralow population.

DoR: For patients who achieved at least one visit response of CR or PR per RECIST 1.1, DoR was defined as the time from the date of first documented response until date of documented progression (using RECIST 1.1) or death in the absence of disease progression (i.e. date of PFS event or censoring - date of first response + 1). The end of response should coincide with the date of progression or death from any cause used for the PFS endpoint. The time of the initial response was defined as the latest of the dates contributing towards the first visit response of PR or CR.

Medians in the different subgroups (HER2-low, ITT and HER2 ultra-low) were calculated using KaplanMeier technique.

PFS2 : Time from randomization to second progression or death (PFS2) was analyzed in the HER2-low and ITT populations using identical methods as outlined for the primary endpoint and adjusting for the same set of covariates, but no subgroup analysis were to be performed. The HR for the treatment effect together with its CI was presented. Medians and KM plots will be presented to support the analysis.

<div style=\"page-break-after: always\"></div>

## Interim futility analysis

An interim futility analysis was carried out after 70 patients have been randomized in the HER2 IHC &gt;0 &lt;1+ subgroup (approximately 35 per treatment group) and have had at least 24 weeks of follow-up from the point of randomization, have discontinued from study treatment or withdrawn from the study. A non-binding stopping boundary was applied to guide the decision of whether to limit recruitment to the HER2-low subgroup only. Confirmed ORR by Investigator assessments according to RECIST 1.1 in the HER2 IHC &gt;0 &lt;1+ analysis set was used in the interim futility analysis.

## Results

## Participant flow

Figure 4 Patient Disposition -Study DB-06 (All Patients)

<!-- image -->

Percentages are calculated from the number of randomized patients.

Percentages are calculated from the number of patients who received treatment.

<div style=\"page-break-after: always\"></div>

Table 6 Patient Disposition -All patients

|                                        | Number (&) of patients   | Number (&) of patients   | Number (&) of patients   | Number (&) of patients   | Number (&) of patients   |
|----------------------------------------|--------------------------|--------------------------|--------------------------|--------------------------|--------------------------|
|                                        | T-DXd                    |                          | Chemotherapy             | Total                    | Total                    |
| Patients enrolled                      |                          |                          |                          | 2311                     |                          |
| Patients randomizedb                   | 436 ( 18.9)              |                          | 430 (18.6)               | 866                      | 37.5)                    |
| Patients who were not randomized       |                          |                          |                          | 1445                     | 62.5)                    |
| Death                                  |                          |                          |                          | 13                       | 0.6)                     |
| Lost to follow-up                      |                          |                          |                          | 0                        |                          |
| Screen failure                         |                          |                          |                          | 1347                     | (58.3)                   |
| Study terminated by Sponsor            |                          |                          |                          | 0                        |                          |
| Withdrawal by subject                  |                          |                          |                          | 72                       | 3.1)                     |
| Other                                  |                          |                          |                          | 13                       | 0.6)                     |
| ITT population*                        | 436 (100.0)              |                          | 430 (100.0)              |                          | 866 (100.0)              |
| Patients who received treatment\"       | 434                      | 99.5)                    | 417 ( 97.0) 13           | 851                      | 98.3)                    |
| Patients who did not receive treatment | 2                        | 0.5)                     | 3.0)                     | 15                       | 1.7)                     |
| Death                                  | 1                        | 0.2)                     | 1 0.2)                   | 2                        | 0.2)                     |
| Lost to follow-up                      | 0                        |                          | 0                        | 0                        |                          |
| Study terminated by Sponsor            | 0                        |                          | 0                        | 0                        |                          |
| Withdrawal by subject                  | 1                        | 0.2)                     | 11 2.6)                  | 12                       | 1.4)                     |
| Other                                  | 0                        |                          | 0                        | 0                        |                          |
| Unknown                                | 0                        |                          | 0.2)                     |                          | 0.1)                     |

|                                                   | Number (&) of patients   | Number (&) of patients   | Number (&) of patients   | Number (&) of patients   | Number (&) of patients   | Number (&) of patients   |
|---------------------------------------------------|--------------------------|--------------------------|--------------------------|--------------------------|--------------------------|--------------------------|
|                                                   | T-DXd                    |                          | Chemotherapy             | Chemotherapy             | Total                    | Total                    |
| Patients ongoing study treatment at data cut-offd |                          | 89 ( 20.5)               | 30                       | 7.2)                     |                          | 119 (14.0)               |
| Patients who discontinued treatmentd              | 345                      | (79.5)                   | 387                      | 92.8)                    | 732                      | 86.0)                    |
| Subject decision                                  | 19                       | 4.4)                     | 34                       | 8.2)                     | 53                       | 6.2)                     |
| Adverse event                                     | 61                       | (14.1)                   | 39                       | 9.4)                     | 100                      | (11.8)                   |
| Severe non-compliance to protocol                 | 0                        |                          | 1                        | 0.2)                     | 1                        | 0.1)                     |
| Objective disease progression                     | 248                      | 57.1)                    | 292                      | 70.0)                    | 540                      | 63.5)                    |
| Subject lost to follow-up                         | 0                        |                          | 0                        |                          | 0                        |                          |
| Pregnancy                                         | 0                        |                          | 0                        |                          | 0                        |                          |
| Other                                             | 17                       | 3.9)                     | 21                       | 5.0)                     | 38                       | 4.5)                     |
| Death                                             | 5                        | 1.2)                     | 4                        | 1.0)                     | 9                        | 1.1)                     |
| Patients ongoing in study                         | 265                      | 60.8)                    | 223                      | 51.9)                    | 488                      | 56.4)                    |
| Patients who terminated studye                    | 171                      | 39.2)                    | 207                      | 48.1)                    | 378                      | 43.6)                    |
| Death                                             | 160                      | (36.7)                   | 166                      | 38.6)                    | 326                      | 37.6)                    |
| Lost to follow-up                                 | 0                        |                          | 0                        |                          | 0                        |                          |
| Study terminated by Sponsor                       | 0                        |                          | 0                        |                          | 0                        |                          |
| Withdrawal by subject                             | 10                       | 2.3)                     | 40                       | 9.3)                     | 50                       | 5.8)                     |
| Other                                             |                          | 0.2)                     | 1                        | 0.2)                     | 2                        | 0.2)                     |

ITT population - all randomized patients.

T-Dxd= trastuzumab deruxtecan.

Table 7 Main Reasons for Screen Failures in Study DB-06 Patients Who Were Not Randomised

| ReasonforScreenFailure                                | ReasonforScreenFailure                                                                                                                                                                                              |   Number of Patients |
|-------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------|
| Number of screen failed patients                      | Number of screen failed patients                                                                                                                                                                                    |                  483 |
| Patients did not satisfyinclusion/exclusion criteriaa | Patients did not satisfyinclusion/exclusion criteriaa                                                                                                                                                               |                  434 |
| Inclusion 01                                          | Male or female patients:(a)≥ 18 years of age applicable for all countries participating in the study except Japan, (b)≥20yearsofageapplicableforJapanonly                                                           |                    1 |
| Inclusion 02                                          | Pathologicallydocumentedbreastcancer(advancedormetastatic/historyofHER2-lowornegativeexpression/HER2-low or HER2 IHC > 0<1 expression by central lab/never previously reported as HER2-positive/documented as HR+). |                  192 |
| Inclusion 03                                          | Musthave an adequate tumortissuesample availableforassessmentofHER2by central laboratory andother exploratorybiomarkeranalyses                                                                                      |                   31 |
| Inclusion 04                                          | ECoGperformancestatusof0or1                                                                                                                                                                                         |                   19 |
| Inclusion 05                                          | Radiologicorobjectiveevidenceofdiseaseprogressiononorafterthelastsystemictherapypriortostarting study treatment                                                                                                     |                    1 |
| Inclusion 06                                          | treatment or(b)atleast2previous lines of ETwith orwithouta targeted therapy.                                                                                                                                        |                    8 |
| Inclusion 07                                          | adjuvant or adjuvant setting are eligible,as long as they have had a disease-free interval of >12 m.                                                                                                                |                   18 |
| Inclusion 08                                          | Lifeexpectancy≥12weeks atscreening                                                                                                                                                                                  |                    4 |
| Inclusion 09                                          | At least 1 lesion, not previously irradiated,that can be measured accurately at baseline as ≥10 mm in the longest diameter.                                                                                         |                   18 |
| Inclusion 10                                          | Left ventricular ejection fraction (LVEF) ≥ 50% within 28 days before randomization.                                                                                                                                |                    6 |
| Inclusion 11                                          | Adequateorganandbonemarrowfunctionwithin14daysbeforerandomization.                                                                                                                                                  |                   51 |

<div style=\"page-break-after: always\"></div>

| ReasonforScreenFailure   | ReasonforScreenFailure                                                                                                                                                                                           |   Number of Patients |
|--------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------|
| Inclusion 12             | Adequatetreatmentwashoutperiodbeforerandomization.                                                                                                                                                               |                    4 |
| Inclusion 13             | Evidenceofpost-menopausalstatusornegativeserumpregnancytestforfemalesofchildbearingpotentialwhoare sexuallyactivewithanon-sterilizedmalepartner.                                                                 |                    1 |
| Inclusion 15             | Non-sterilizedmalepatientswhoaresexuallyactivewithafemalepartnerofchildbearingpotentialmustuseacondom withspermicidefromscreening.                                                                               |                    1 |
| Exclusion 01             | Ineligibleforalloptionsintheinvestigator'schoicechemotherapyarm.Patientswithcontraindicationstocapecitabine, paclitaxel,and nab-paclitaxel treatment cannotbe enrolled tothe study.                              |                    2 |
| Exclusion 02             | Uncontrolled intercurrent illness,such as ongoing or active infection,uncontrolled hypertension,serious chronic gastrointestinalconditions,substantiallyincreaseriskofincurringadverseevents，etc.                |                   11 |
| Exclusion 03             | Uncontrolled or significant cardiovascular disease                                                                                                                                                               |                    7 |
| Exclusion 04             | Has as a history of (non-infectious) interstitial lung disease (ILD)/pneumonitis that required steroids,has current ILD/pneumonitis,orwhere suspected ILD/pneumonitis cannot beruled out byimaging at screening. |                   11 |
| Exclusion 06             | Lung-specific intercurrent clinically significant illnesses including, but not limited to, any underlying pulmonary disorder, and any autoimmune,connective tissue.                                              |                   20 |
| Exclusion 08             | Has spinal cord compression or clinically active central nervous system metastases(untreated and symptomatic, or requiring therapy with corticosteroids or anticonvulsants to control associated symptoms).      |                   29 |
| Exclusion 09             | Activeprimary immunodeficiency,known human immunodeficiency virus(HIv)infection,or activehepatitis B or C infection.                                                                                             |                    4 |
| Exclusion 11             | Has unresolved toxicitiesfrom previous anticancer therapy, defined as toxicities not yet resolved to Grade≤ 1 or baseline.MaybeenrolledwithchronicGrade2toxicities                                               |                    7 |
| Exclusion 12 b           |                                                                                                                                                                                                                  |                    3 |

| ReasonforScreenFailure   | ReasonforScreenFailure                                                               |   Numberof Patients |
|--------------------------|--------------------------------------------------------------------------------------|---------------------|
| Exclusion 15             | Previous treatmentwith anti-HER2therapy                                              |                   6 |
| Exclusion 19             | Has substance abuse or any other medical conditions such as psychological conditions |                   2 |
| Otherc                   |                                                                                      |                  49 |

- Criteria as per the current CSP version.Patients may be counted more than once, if more than 1 criterion was failed.

Any concurrent chemotherapy, investigational product (IP), biologic, or hormonal therapy for cancer treatment' criterion has been removed in CSP Amendment 2 (23 July 2021) due to overlap withInclusion Criterion 12Adequate treatment washout period beforerandomization.

cIncludes patients who exceeded the 28-day re-screening window, died during screening, withdrew consent during the screening or when no randomization slots were available. Source: Table 1

## Recruitment

From 24 July 2020 to 13 April 2023, patients were recruited across Europe, Asia-Pacific, North America, and South America. A total of 866 patients were enrolled at 273 study centres in 28 countries worldwide: 50.8% in Europe, 11.0% in North America, 34.2% in Asia, and 4.0% in the Rest of World. The study population consisted of 713 patients (82.3%) whose tumours were HER2-low (IHC 1+ and IHC 2+/ISH-) per IRT and 152 patients (17.6%) whose tumours were HER2 IHC &gt; 0 &lt; 1+ per central laboratory categorization. The current DCO was at the time of the final analysis of PFS and at the first interim analysis (IA) of overall survival (OS) and safety data at the data cu-toff (DCO) of 18 March 2024.

Median follow-up for OS in the HER2-low population was 19.0 months.

## Conduct of the study

## Protocol amendments

The original clinical study protocol (CSP) (Version 1.0) was dated 20 March 2020. Important protocol amendments to the original CSP, including when those amendments came into effect with respect to the recruitment of patients and details of any associated substantial changes are shown in the below table.

<div style=\"page-break-after: always\"></div>

Table 8 Protocol Amendments Related to Changes in Study Conduct

|                                                                 | Section of CSP (Affected section of this report)                                                                                                                                                                                       | Keydetailsofamendment                                                                                                                                                                                                                                                                                                                                                           | Main reason(s) for amendment                                                                                                                                                                                                                                                                                    |
|-----------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Amendmentsmadebeforethestartofpatientrecruitment                | Amendmentsmadebeforethestartofpatientrecruitment                                                                                                                                                                                       | Amendmentsmadebeforethestartofpatientrecruitment                                                                                                                                                                                                                                                                                                                                | Amendmentsmadebeforethestartofpatientrecruitment                                                                                                                                                                                                                                                                |
| Amendment Number/Date CSP Amendment 1 (Version 2.0) 22 May 2020 | Throughout CSP                                                                                                                                                                                                                         | Updated post-treatment follow-up schedule at 40 days window throughout the CSP from ±7 days to +7 days                                                                                                                                                                                                                                                                          | Amended window for follow-up visit to allow for adequate safety follow-up. given the half-life of T-DXd.                                                                                                                                                                                                        |
| Amendment Number/Date CSP Amendment 1 (Version 2.0) 22 May 2020 | Throughout CSP                                                                                                                                                                                                                         | Guidance added on themanagement of T-DXd in respect to COVID-19 and associated treatments alongwith provision for additional blood samples for exploratory analyses of clinical benefit or safety.                                                                                                                                                                              | Management guidelines,benefit/risk considerations,and additional reporting and sampling procedures were added to help assess potential impact of COVID-19 on data obtained in this study.                                                                                                                       |
| Amendment Number/Date CSP Amendment 1 (Version 2.0) 22 May 2020 | 1.3 Schedule of Assessments 5.1 Inclusion Criteria 6.5 Concomitant Therapy Appendix J (Sections 9.1, 9.3.1, 9.4.5)                                                                                                                     | Specified washout period prior to randomization for related torestrictions and additionalsamplecollectionshould T-DXdpatientsreceive concomitant treatment with chloroquine or hydroxychloroquine.                                                                                                                                                                              | Awashout period and instructions relatedtorestrictions and additional sample collections specified due to a possible interaction between T-DXd and chloroquine/ hydroxychloroquine.                                                                                                                             |
| Amendment Number/Date CSP Amendment 1 (Version 2.0) 22 May 2020 | 5.2 Exclusion Criteria (Section 9.3.2)                                                                                                                                                                                                 | Added exclusion criterionfor patients randomizedin a previous T-DXd study                                                                                                                                                                                                                                                                                                       | Added to discourage early patient withdrawal from earlier line T-DXd studies where patients are assigned to control                                                                                                                                                                                             |
| Amendment Number/Date CSP Amendment 1 (Version 2.0) 22 May 2020 | 5.2 Exclusion Criteria (Section 9.3.2)                                                                                                                                                                                                 | Removal of exclusion criteria 5 (history of clinically significant corneal disease), 11 (infection relating to active tuberculosis [covered by separate criterion excluding ongoing or active infection]), 21 (drainage and CART not allowed within 2 weeks of randomization)                                                                                                   | Removalofexclusion criterion5 based on cumulativereview of clinical data. Exclusion criterion11removed as already covered under exclusion criterion2 Exclusioncriterion21removedas notrelevant forBCindication                                                                                                  |
| Amendment Number/Date CSP Amendment 1 (Version 2.0) 22 May 2020 | 5.2 Exclusion Criteria (Section 9.3.2)                                                                                                                                                                                                 | Amendment of exclusion criterion 6 for prior ILD to remove phrase onrequiring steroid treatment.Patient'spriorILDno                                                                                                                                                                                                                                                             | Updated exclusion criteria to exclude all patients with prior ILD                                                                                                                                                                                                                                               |
| Amendment Number/Date CSP Amendment 1 (Version 2.0) 22 May 2020 |                                                                                                                                                                                                                                        | longerrequirestreatment with corticosteroidforpatient tobe excluded.                                                                                                                                                                                                                                                                                                            | tofurthermitigatetheincidenceof pulmonarytoxicities.                                                                                                                                                                                                                                                            |
| Amendment Number/Date CSP Amendment 1 (Version 2.0) 22 May 2020 | 5.2 Exclusion Criteria (Section 9.3.2)                                                                                                                                                                                                 | Updated exclusion criterion 3 to remove the phrase “unstable angina pectoris, clinically important cardiac arrhythmias, or a recent (<6months)cardiovascular event including,unstable angina pectoris, and stroke and included the provision for a cardiologist consultationfor patientswith troponinlevels above ULN at screening and without any myocardial related symptoms. | Updated toremoveredundant text and include theneedfor cardiologist consultation in patients with elevated troponin levels, as defined by the manufacturer, to rule out any asymptomatic signs of myocardial infarction.                                                                                         |
| Amendment Number/Date CSP Amendment 1 (Version 2.0) 22 May 2020 | 1.3 Schedule ofAssessments 8.2.7Echocardiograms/ Multi-gated Acquisition Scans 8.3.11 Adverse Events of Special Interest 8.3.14.1 Specific Toxicity Management and Dose ModificationInformationfor T-DXd (Section 9.1 and Section 9.7) | Updated ECG and troponin collection frequency.                                                                                                                                                                                                                                                                                                                                  | Updated ECG measurements in line with the observationsfrom aclinical study that showed no clinically meaningful impact of T-DXd on QTc. Data todatehas shown that troponin-T testing is not an indicatorofLVEFdecreaseand therefore troponin will be measured at screening and EOT and as clinically indicated. |
| Amendment Number/Date CSP Amendment 1 (Version 2.0) 22 May 2020 | 1.3 Schedule of Assessments 8.5.2 Immunogenicity Assessments (Section 9.1 and and Section 9.7)                                                                                                                                         | Addition of ADA sample collection after 40-day (+7 day) follow-up for select patients                                                                                                                                                                                                                                                                                           | Provision of additional collection of ADA samples to monitor ADA positive patients at follow-up                                                                                                                                                                                                                 |
| Amendment Number/Date CSP Amendment 1 (Version 2.0) 22 May 2020 | Appendix H Guidance for Management of Patients with Drug-Induced ILD/Pneumonitis and Appendix I Toxicity Management Guidelines for T-DXd (Section 9.1)                                                                                 | UpdatetoILD/pneumonitismanagementguidelines                                                                                                                                                                                                                                                                                                                                     | Further recommendations provided on management of ILD/pneumonitis,in particular, more detailed recommendations around duration of systemicsteroid treatment                                                                                                                                                     |

<div style=\"page-break-after: always\"></div>

| Amendment Number/Date                            | Section of CSP (Affected section of this report)                                                                                                                                                          | Keydetailsofamendment                                                                                                                                                                                                                                                                                                                                                             | Mainreason(s) for amendment                                                                                                                                                                                                                                                                                                                                                                        |
|--------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                  | Appendix I Toxicity Management Guidelines for T-DXd (Section 9.1)                                                                                                                                         | Updates toAST/ALT increased,cardiac toxicity, and QTc prolongation management guidelines and removal of troponin management guidelines.                                                                                                                                                                                                                                           | Management ofAST/ALT increased amendedtoprovide greater clarity in patients with elevated AST/ALT at baseline. ECG QTc prolonged toxicity managementguidelines amended to advise ruling out serum electrolyte related ECG changes. Data to datehas shown that troponintesting isnot anindicator of LVEF decrease. Troponin will only be measured at screening, at EOT and as clinically indicated. |
| Amendmentsmadeqfterthestart ofpatientrecruitment | Amendmentsmadeqfterthestart ofpatientrecruitment                                                                                                                                                          | Amendmentsmadeqfterthestart ofpatientrecruitment                                                                                                                                                                                                                                                                                                                                  | Amendmentsmadeqfterthestart ofpatientrecruitment                                                                                                                                                                                                                                                                                                                                                   |
| CSP Amendment 2 (Version 3.0) 23 July 2021       | 1.1 Synopsis; 1.2 Schema; 2.1 Study Rationale; 2.2.1 Background Information on the Disease to be Treated; 4.1 Overall Design; 5 Study Population; 5.1 Inclusion Criteria (Sections 9.1, 9.2,9.3,9.7, 9.8) | The study population was updated to include patients who progress on first-line ET + CDK4/6i within 6 months of starting therapy.                                                                                                                                                                                                                                                 | To expand study population who have progressed on ET + CDK4/6i and deemed appropriate to receive chemotherapy as next treatment.                                                                                                                                                                                                                                                                   |
| CSP Amendment 2 (Version 3.0) 23 July 2021       | 5.1 Inclusion Criteria (Section 9.3.1)                                                                                                                                                                    | Inclusioncriterion #12updated to addnon-antibodybased immunotherapy washout period.                                                                                                                                                                                                                                                                                               | Added immunotherapy washout period, which was previously omitted by oversight.                                                                                                                                                                                                                                                                                                                     |
| CSP Amendment 2 (Version 3.0) 23 July 2021       | 5.1 Inclusion Criteria; 5.3 Lifestyle Considerations (Section 9.3)                                                                                                                                        | Updated text (Inclusion criteria #14 and 16) regarding females of childbearing potential.                                                                                                                                                                                                                                                                                         | To align with Sponsor standards for the T-DXd program, MHRA and PEI feedback and CTFG guidelines.                                                                                                                                                                                                                                                                                                  |
| CSP Amendment 2 (Version 3.0) 23 July 2021       | 5.1 Inclusion Criteria; 8.3.13.1 Paternal Exposure; Appendix A3                                                                                                                                           | Inclusion criterion #15 updated with text regarding male contraception and added text regarding preservation of sperm.                                                                                                                                                                                                                                                            | To align with Sponsor standards for the T-DXd program, MHRA and PEI feedback and CTFG guidelines.                                                                                                                                                                                                                                                                                                  |
| (Section 9.3)                                    | (Section 9.3)                                                                                                                                                                                             | (Section 9.3)                                                                                                                                                                                                                                                                                                                                                                     | (Section 9.3)                                                                                                                                                                                                                                                                                                                                                                                      |
|                                                  | 5.2 Exclusion Criteria (Section 9.3.2)                                                                                                                                                                    | UpdatedExclusioncriterion#4toexcludepatientswith history of (non-infectious) ILD/pneumonitis that required steroids.                                                                                                                                                                                                                                                              | Updated to allowpatients with prior ILD/pneumonitis that did not requiremanagementwithsteroids to nolongerbe excluded; this is now aligned with Sponsor standards for the T-DXd program.                                                                                                                                                                                                           |
| CSP Amendment 3 (Version 4.0) 27 April 2022      | 1.1 Synopsis; 9.1.1 Multiple Testing Procedure and 9.2 Sample Size Determination (Sections 9.8.3.1,9.8.3.3)                                                                                               | Change in the MTP such that if PFSHER2-low is significant, the 5% alpha will be split between PFS ITT (1.5% alpha) and OS HER2-low (3.5% alpha). Change in the target number of events at the final OS analysis from 489 to521 OSevents in theHER2-lowpopulation; Expected informationfraction at thefirst andsecond interim OS analyses were changed to 41% and 75%respectively. | Toallowimmediateallocationof alpha to PFS ITT if the primary endpoint is significant. Number of OS events in the HER2- low population that will trigger the final OS analysis was increased to achieve 80% power at 3.5% alpha.                                                                                                                                                                    |
| CSP Amendment 3 (Version 4.0) 27 April 2022      | 1.1 Synopsis; 9.1.1 Multiple Testing Procedure; 9.5.1 Interim FutilityAnalysis (Sections 9.8.3.1, 9.8.8)                                                                                                  | Removal of the enrollment pause in the HER2 IHC > 0 < 1+ patient population during the futility analysis.                                                                                                                                                                                                                                                                         | Clinicalevidencefrom theDAISY studyprovidingconfidencefor the efficacy of T-DXd in the HER2 IHC >0 < 1+ population.                                                                                                                                                                                                                                                                                |
| CSP Amendment 3 (Version 4.0) 27 April 2022      | 5.1 Inclusion Criteria (Section 9.3.1)                                                                                                                                                                    | Removal of the requirement for matchedresults between historical/local HER2results and central testresults (Inclusion criterion #2[c] of CSP version 3.0).                                                                                                                                                                                                                        | ToensurethatthecentralHER2test is theprimarydeterminantforstudy eligibility to streamline enrollment procedures and reduce screen failures.                                                                                                                                                                                                                                                        |
| CSP Amendment 3 (Version 4.0) 27 April 2022      | 5.1 Inclusion Criteria (Section 9.3.1)                                                                                                                                                                    | Reduction in the minimum agefor eligible patients inJapan from 20 years to 18 years (Inclusion criterion #1)                                                                                                                                                                                                                                                                      | Revision of Japanese civil code                                                                                                                                                                                                                                                                                                                                                                    |
| CSP Amendment 3 (Version 4.0) 27 April 2022      | 5.2 Exclusion Criteria (Section 9.3.2)                                                                                                                                                                    | Addition of statement that pre-screening for this study while a patient is on-treatment in anotherclinical studyis acceptable (Exclusion criterion #18)                                                                                                                                                                                                                           | Clarification                                                                                                                                                                                                                                                                                                                                                                                      |
| CSP Amendment 3 (Version 4.0) 27 April 2022      | 5.3 Lifestyle Considerations (Section 9.3.3)                                                                                                                                                              | Removal of bilateral tubal ligation as a recognized method of surgical sterilization                                                                                                                                                                                                                                                                                              | Correction                                                                                                                                                                                                                                                                                                                                                                                         |

<div style=\"page-break-after: always\"></div>

| Amendment Number/Date                    | SectionofCSP (Affected section of this report)                                                                                                                                                                                                                                                                                                    | Keydetailsofamendment                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | Main reason(s)for amendment                                                                                   |
|------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------|
|                                          | 5.4 Screen Failures (Section 9.3)                                                                                                                                                                                                                                                                                                                 | Update to clarify allowing rescreening of patients who previously were screen failed due to the local HER2 test result not confirmed by central HER2 testing.                                                                                                                                                                                                                                                                                                                                                      | Changes toInclusion criterion #2.                                                                             |
|                                          | 6.5 Concomitant Therapy (Section 9.4.5)                                                                                                                                                                                                                                                                                                           | Additionoftherecommendationtoadministeracombination regimen of2or 3 anti-emetic agentsprior toeach dose of T-DXd.                                                                                                                                                                                                                                                                                                                                                                                                  | AlignmentwithSponsorstandards for the T-DXd program.                                                          |
|                                          | 6.6.1.1 T-DXd; 8.3.14.1 Specific Toxicity Management and Dose ModificationInformationfor T-DXd (Section 9.1)                                                                                                                                                                                                                                      | Increase in the permitted delay in T-DXd dosing from 49 days to 126 days since the previous dose.                                                                                                                                                                                                                                                                                                                                                                                                                  | Alignment with Sponsor standards for the T-DXd program.                                                       |
|                                          | 8.2.10.1 Pneumonitis (ILD) Investigation; 8.3.11 Adverse Events of Special Interest; 8.3.14.1 Specific Toxicity Management and Dose ModificationInformationfor T-DXd (Section 9.1)                                                                                                                                                                | Addition of the requirement for patients with suspected ILD/pneumonitis to undergo a SARS-CoV-2 (COVID-19) test.                                                                                                                                                                                                                                                                                                                                                                                                   | IDMC request                                                                                                  |
|                                          | 9.5.1 Interim Futility Analysis (Section 9.8.8)                                                                                                                                                                                                                                                                                                   | Additionoftreatmentrecommendationsforpatientswith HER2 IHC >0 < 1+ in the event that recruitment in that subgroup is stopped                                                                                                                                                                                                                                                                                                                                                                                       | Clarification                                                                                                 |
|                                          | Appendix I (Section 9.1)                                                                                                                                                                                                                                                                                                                          | IncreaseinthetimeafterwhichT-DXdshouldbediscontinued in the case of Grade1 ILD/pneumonitis occurringbeyond cycleDay22from49daysto126dayssincetheprevious dose                                                                                                                                                                                                                                                                                                                                                      | Alignment with Sponsor standards for the T-DXd program                                                        |
|                                          | 1.1 Synopsis, 1.3.2 Treatment Period, 1.3.3 Follow-up Period, 4.1 Overall Design, 7.1.2 Procedures forDiscontinuation of Study Treatment,                                                                                                                                                                                                         | Clarified the mandatory requirement to perform an additional imaging assessment following Investigator-determined RECIST progression. Addedrequirementforsubmission of any availablesubsequent tumor assessment scans for central review until the primary                                                                                                                                                                                                                                                         | To reduce informative censoring in PFSbyBICRwhenInvestigator has assessed progressionbutBICRdoes not agree    |
|                                          | 8.1.1 RECIST 1.1 Assessments, Appendix G, GuidelinesforEvaluation of Objective Tumor Response using RECIST 1.1 Criteria (Response Evaluation Criteria in Solid Tumors) (Sections 9.1, 9.5.1 and 9.8.3.2)                                                                                                                                          | PFS analysisDCOoruntil theSponsornotifies the site to discontinue (whichever is earlier). Added that subsequent imaging assessments should include brainscans forparticipants enrolled with stablebrain metastases or if clinicallyindicated.                                                                                                                                                                                                                                                                      |                                                                                                               |
| CSPAmendment 4 (Version 5.0) 23 May 2023 | 1.1 Synopsis, 1.3.2 Treatment Period, 1.3.3 Follow-up Period, 4.1 Overall Design, 7.1.2 Procedures forDiscontinuation of Study Treatment, 8.1.1 RECIST 1.1 Assessments, Appendix G, GuidelinesforEvaluationof Objective Tumor Response using RECIST 1.1 Criteria (Response Evaluation Criteria in Solid Tumors) (Sections 9.1, 9.5.1 and 9.8.3.2) | Clarified the mandatory requirement toperform an additional imaging assessmentfollowingInvestigator-determined RECIST progression. Added requirement for submission of any available subsequent tumor assessment scans for central review until the primary PFS analysis DCO or until the Sponsor notifies the site to discontinue (whichever is earlier). Added that subsequent imaging assessments should include brain scans for participants enrolled with stable brain metastases or if clinically indicated. | Toreduceinformative censoringin PFSbyBICR when Investigator has assessed progression, but BICR does not agree |
| CSPAmendment 4 (Version 5.0) 23 May 2023 | 2.3.1 Potential Risks of T-DXd 2.3.4 OverallBenefit/Risk Conclusion (Sections 9.2, 9.8.5)                                                                                                                                                                                                                                                         | Added text onhigherincidence ofILDinpatientswith baselinemoderaterenalimpairmentand increasedILD education requirements for these patients                                                                                                                                                                                                                                                                                                                                                                         | To provide guidance to Investigators regarding ILD education expectations                                     |
| CSPAmendment 4 (Version 5.0) 23 May 2023 | 1.3.2 Treatment Period                                                                                                                                                                                                                                                                                                                            | Added clarifications to wording on identification, evaluation andmanagement ofILD                                                                                                                                                                                                                                                                                                                                                                                                                                  | To align with Sponsor standards for the T-DXd program                                                         |

<div style=\"page-break-after: always\"></div>

| Amendment Number/Date   | SectionofCSP (Affectedsectionofthis report)                                                      | Keydetailsofamendment                                                                                                              | Mainreason(s)foramendment                                             |
|-------------------------|--------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------|
|                         | 8.2.10 OtherSafety Assessments Appendix H Toxicity ManagementGuidelinesfor T-DXd (Section 9.8.5) |                                                                                                                                    |                                                                       |
|                         | 9.4StatisticalAnalyses (Section 9.8.3)                                                           | Clarifiedthatadditional analysestobeperformed atthetime ofthePFSandOSanalysesfortheHER2IHC>0<1+ populationwill bespecifiedintheSAP | Toclarifythetimingof additional analyses intheHER2IHC>0<1+ population |

## Changes to planned analyses

Table 9 Changes to Planned Analyses

| Key details of change                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Reason forchange                                                                                                                                                                                                                  |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| A revision to the MTP of the study to allow immediate allocation of alpha to PFS ITT if the primary endpoint is significant. Specifically, if PFS HER2-low was significant, the 5% alpha would be split between PFS ITT (1.5% alpha) and OS HER2-low (3.5% alpha). To achieve80%power for OSHER2-low at 3.5% alpha, the final OS analysis will be events had been observed in the HER2-low population. Expected information fraction at the first and second interim OS analyses were changed to 41% and 75% respectively. | To allow immediate allocation of alpha to PFS ITT if the primary endpoint is significant. Number of OS events in the HER2-low population that will trigger the final OS analysis was increased to achieve 80% power at 3.5% alpha |

## Protocol deviations

Table 10 Important Protocol Deviations (ITT Population)

|                                                                                               | Number (%) of Patients   | Number (%) of Patients   | Number (%) of Patients   |
|-----------------------------------------------------------------------------------------------|--------------------------|--------------------------|--------------------------|
| Important protocol deviation a                                                                | T-DXd (N = 436)          | Chemotherapy (N = 430)   | Total (N = 866)          |
| Number of patients with at least 1 important deviation                                        | 53 (12.2)                | 64 (14.9)                | 117 (13.5)               |
| Inclusion criteria deviations                                                                 | 22 (5.0)                 | 34 (7.9)                 | 56 (6.5)                 |
| Exclusion criteria deviations                                                                 | 1 (0.2)                  | 1 (0.2)                  | 2 (0.2)                  |
| Deviations related to study procedure                                                         | 13 (3.0)                 | 17 (4.0)                 | 30 (3.5)                 |
| Discontinuation criteria for study product met but patient not withdrawn from study treatment | 9 (2.1)                  | 3 (0.7)                  | 12 (1.4)                 |
| Excludedmedications taken                                                                     | 3 (0.7)                  | 4 (0.9)                  | 7 (0.8)                  |
| Investigational product deviation                                                             | 2 (0.5)                  | 8 (1.9)                  | 10 (1.2)                 |
| Other important deviations                                                                    | 7 (1.6)                  | 7 (1.6)                  | 14 (1.6)                 |

Note that the same patient may have had more than 1 IPD. The final count of patients with IPDs is to be decreased by 2 patients; 1 from \"inclusion criteria deviations\" category (inclusion criteria #6 IPD for patient E7807003 on chemotherapy arm was inactivated post DBL) and 1 from \"discontinuation criteria for study product met but patient not withdrawn from study treatment\" category (treatment through RECIST progression IPD for patient E4904003 on T-DXd arm was inactivated post DBL).

<div style=\"page-break-after: always\"></div>

## Baseline data

Table 11 Demographic Characteristics -Study DB-06

|                         |                                  | ITT Population   | ITT Population   | HER2-low Population   | HER2-low Population   | HER2 IHC >0 < 1+ Population   | HER2 IHC >0 < 1+ Population   |
|-------------------------|----------------------------------|------------------|------------------|-----------------------|-----------------------|-------------------------------|-------------------------------|
|                         |                                  | T-DXd            | Chemotherapy     | T-DXd                 | Chemotherapy          | T-DXd                         | Chemotherapy                  |
|                         |                                  | (N = 436)        | (N = 430)        | (N = 359)             | (N = 354)             | (N= 76)                       | (N = 76)                      |
| Age (years)             | N                                | 436              | 430              | 359                   | 354                   | 76                            | 76                            |
|                         | Mean                             | 58.2             | 58.2             | 58.1                  | 58.1                  | 58.6                          | 58.5                          |
|                         | SD                               | 11.46            | 10.92            | 11.29                 | 10.90                 | 12.31                         | 11.07                         |
|                         | Median                           | 58.0             | 57.0             | 58.0                  | 57.0                  | 58.0                          | 57.5                          |
|                         | Min                              | 28               | 32               | 28                    | 32                    | 33                            | 34                            |
|                         | Max                              | 87               | 83               | 87                    | 83                    | 85                            | 82                            |
| Age group (years) n (%) | <65                              | 302 (69.3)       | 297 (69.1)       | 252 (70.2)            | 244 (68.9)            | 49 (64.5)                     | 53 (69.7)                     |
|                         | ≥65                              | 134 (30.7)       | 133 (30.9)       | 107 (29.8)            | 110 (31.1)            | 27 (35.5)                     | 23 (30.3)                     |
| Sex n (%)               | Male                             | 0                | 1 (0.2)          | 0                     | 1 (0.3)               |                               | 二                             |
|                         | Female                           | 436 (100)        | 429 (99.8)       | 359 (100)             | 353 (99.7)            | 76 (100)                      | 76 (100)                      |
| Race n (%)              | Black or African- American       | 4 (0.9)          | 3 (0.7)          | 1 (0.3)               | 3 (0.8)               | 3 (3.9)                       | ¥0                            |
|                         | American Indian or Alaska Native | 1 (0.2)          | 0                | 1 (0.3)               | 0                     | 0                             | 0                             |
|                         | Asian                            | 154 (35.3)       | 151 (35.1)       | 122 (34.0)            | 127 (35.9)            | 32 (42.1)                     | 24 (31.6)                     |
|                         | White                            | 231 (53.0)       | 230 (53.5)       | 194 (54.0)            | 186 (52.5)            | 36 (47.4)                     | 44 (57.9)                     |
|                         | Other                            | 7 (1.6)          | 12 (2.8)         | 6 (1.7)               | 10 (2.8)              | 1 (1.3)                       | 2 (2.6)                       |
|                         | Not reported                     | 39 (8.9)         | 34 (7.9)         | 35 (9.7)              | 28 (7.9)              | 4 (5.3)                       | 6 (7.9)                       |

Age calculated at randomization.

Table 12 Baseline Disease Characteristics -Study DB-06

|                                                          |                        | Number (%) of patients   | Number (%) of patients   | Number (%) of patients   | Number (%) of patients   | Number (%) of patients   | Number (%) of patients   |
|----------------------------------------------------------|------------------------|--------------------------|--------------------------|--------------------------|--------------------------|--------------------------|--------------------------|
|                                                          |                        | ITT Population           | ITT Population           | HER2-lowPopulation       | HER2-lowPopulation       | HER2IHC>0<1+ Population  | HER2IHC>0<1+ Population  |
|                                                          |                        | T-DXd                    | Chemotherapy             | T-DXd                    | Chemotherapy             | T-DXd                    | Chemotherapy             |
|                                                          |                        | (N = 436)                | (N = 430)                | (N = 359)                | (N =354)                 | (N = 76)                 | (N = 76)                 |
| AJCC stage at diagnosis of breast cancer n (%)           | Stage IV               | 133 (30.5)               | 132 (30.7)               | 111 (30.9)               | 104 (29.4)               | 22 (28.9)                | 28 (36.8)                |
| ER expression at baseline n (%)a                         | <1%                    | 4 (0.9)                  | 2 (0.5)                  | 3 (0.8)                  | 2 (0.6)                  | 1 (1.3)                  | 0                        |
|                                                          | 1-10%                  | 17 (3.9)                 | 12 (2.8)                 | 15 (4.2)                 | 11 (3.1)                 | 2 (2.6)                  | 1 (1.3)                  |
|                                                          | >10%                   | 364 (83.5)               | 355 (82.6)               | 301 (83.8)               | 288 (81.4)               | 62 (81.6)                | 67 (88.2)                |
|                                                          | Negativeb              |                          |                          | -                        |                          |                          |                          |
|                                                          | Positiveb              | 51 (11.7)                | 61 (14.2)                | 40 (11.1)                | 53 (15.0)                | 11 (14.5)                | 8 (10.5)                 |
| ER and PgR expression at baseline, combined n (%)a c     | ER-,PR-                | 1 (0.2)                  | 0                        |                          |                          | 1 (1.3)                  | 0                        |
|                                                          | ER+,PR-                | 167 (38.3)               | 181 (42.1)               | 141 (39.3)               | 152 (42.9)               | 26 (34.2)                | 29 (38.2)                |
|                                                          | ER-, PR+               | 3 (0.7)                  | 2 (0.5)                  | 3 (0.8)                  | 2 (0.6)                  |                          |                          |
|                                                          | ER+, PR+               | 253 (58.0)               | 237 (55.1)               | 206 (57.4)               | 193 (54.5)               | 46 (60.5)                | 44 (57.9)                |
|                                                          | ER+, PR missing        | 12 (2.8)                 | 10 (2.3)                 | 9 (2.5)                  | 7 (2.0)                  | 3 (3.9)                  | 3 (3.9)                  |
|                                                          | ER missing, PR+        |                          |                          |                          |                          |                          |                          |
|                                                          | ER missing, PR missing |                          |                          |                          |                          |                          | -                        |
| HER2 expression at baseline by central laboratory n (%)d | IHC 0                  | 1 (0.2)                  | 1 (0.2)                  | 1 (0.3)                  | 1 (0.3)                  |                          |                          |
|                                                          | IHC >0 < 1+            | 76 (17.4)                | 76 (17.7)                |                          |                          | 76 (100.0)               | 76 (100.0)               |
|                                                          | IHC 1+                 | 239 (54.8)               | 234 (54.4)               | 238 (66.3)               | 234 (66.1)               |                          |                          |

<div style=\"page-break-after: always\"></div>

|                                                                |                                               | Number(%)ofpatients   | Number(%)ofpatients   | Number(%)ofpatients   | Number(%)ofpatients   | Number(%)ofpatients     | Number(%)ofpatients     |
|----------------------------------------------------------------|-----------------------------------------------|-----------------------|-----------------------|-----------------------|-----------------------|-------------------------|-------------------------|
|                                                                |                                               | ITT Population        | ITT Population        | HER2-low Population   | HER2-low Population   | HER2IHC>0<1+ Population | HER2IHC>0<1+ Population |
|                                                                |                                               | T-DXd                 | Chemotherapy          | T-DXd                 | Chemotherapy          | T-DXd                   | Chemotherapy            |
|                                                                |                                               | (N = 436)             | (N = 430)             | (N =359)              | (N =354)              | (N = 76)                | (N = 76)                |
|                                                                | IHC 2+/ISH-                                   | 117 (26.8)            | 118 (27.4)            | 117 (32.6)            | 118 (33.3)            |                         |                         |
|                                                                | IHC 2+                                        | 3 (0.7)               | 1 (0.2)               | 3 (0.8)               | 1 (0.3)               | -                       |                         |
| Measurabledisease atbaseline by BICRe n (%)                    | Yes                                           | 393 (90.1)            | 389 (90.5)            | 326 (90.8)            | 324 (91.5)            | 67 (88.2)               | 65 (85.5)               |
|                                                                | No                                            | 43 (9.9)              | 41 (9.5)              | 33 (9.2)              | 30 (8.5)              | 9 (11.8)                | 11 (14.5)               |
| Measurable disease atbaseline by Investigator assessment n (%) | Yes                                           | 426 (97.7)            | 419 (97.4)            | 350 (97.5)            | 344 (97.2)            | 75 (98.7)               | 75 (98.7)               |
|                                                                | No                                            | 10 (2.3)              | 11 (2.6)              | 9 (2.5)               | 10 (2.8)              | 1 (1.3)                 | 1 (1.3)                 |
| Bone-onlydisease atbaseline by Investigator assessmentn (%)    | Yes                                           | 13 (3.0)              | 13 (3.0)              | 11 (3.1)              | 10 (2.8)              | 2 (2.6)                 | 3 (3.9)                 |
|                                                                | No                                            | 423 (97.0)            | 417 (97.0)            | 348 (96.9)            | 344 (97.2)            | 74 (97.4)               | 73 (96.1)               |
| Endocrine resistance at baselineh n (%)                        | Primary                                       | 128 (29.4)            | 140 (32.6)            | 105 (29.2)            | 116 (32.8)            | 23 (30.3)               | 24 (31.6)               |
|                                                                | Secondary                                     | 308 (70.6)            | 288 (67.0)            | 254 (70.8)            | 236 (66.7)            | 53 (69.7)               | 52 (68.4)               |
|                                                                | Missing                                       | 0                     | 2 (0.5)               | 0                     | 2 (0.6)               |                         |                         |
| ECOG performance status at screeningi                          | (0) Normal activity                           | 252 (57.8)            | 257 (59.8)            | 207 (57.7)            | 218 (61.6)            | 44 (57.9)               | 39 (51.3)               |
|                                                                | (1) Restricted activity                       | 178 (40.8)            | 163 (37.9)            | 148 (41.2)            | 128 (36.2)            | 30 (39.5)               | 35 (46.1)               |
|                                                                | (2) In bed less than or equalto50%of the time | 1 (0.2)               | 1 (0.2)               | 1 (0.3)               | 0                     | 0                       | 1 (1.3)                 |
|                                                                | Missing                                       | 5 (1.1)               | 9 (2.1)               | 3 (0.8)               | 8 (2.3)               | 2 (2.6)                 | 1 (1.3)                 |

3

Themostrecentresults availableatstudy entry aresummarized.

b 'Positive'and'Negative'categories used when thepercentage of tumor cells demonstratingpositive nuclear staining was not availablefor ER/PR.

c ER/PR+ correspond to the results\"1 to 10%\",\"&gt;10%\"and\"Positive'and ER/PR-correspond to the results'&lt;1%²and\"Negative\".

- P In 4 patients with HER2IHC 2+,ISH was not evaluable per central lab.In 2 patients the final baseline HER2 IHC score per central lab was HER2IHC 0; IPDs were reported for all 6 patients.
- Measurable disease defined as having at least one measurable lesion, not previously irradiated, which is ≥ 10 mm in the longest diameter (LD) (except lymph nodes which must have short axis ≥15 mm), with CT or MRI and which is suitable for accurate repeated measurements by BICR.
- Measurable disease defined ashaving at least one measurable lesion,not previously irradiated,which is&gt;10 mm in thelongest diameter (LD)(except lymph nodes which must have short axis ≥15 mm),with CT or MRI and which is suitable for accurate repeated measurements by Investigator assessment.
- “Bone and locomotor’as only site of disease,withBone’as the only anatomical location of target and non-target lesions by Investigator assessment.
- h Primary endocrine resistance was defined as: relapse while on the first 2 years of adjuvant endocrine therapy, or progressive disease within first 6 months of first line endocrine therapy for metastatic breast cancer,while on endocrine therapy.Secondary (acquired) endocrine resistance was defined as:relapse while on adjuvant endocrine therapy but after the first 2 years,or relapse within12 months of completing adjuvant endocrine therapy, orPD&gt;6 months afterinitiating endocrine therapyformetastatic breast cancer,while on endocrine therapy(EsO-ESMOABC Guidelines)
- ECOGperformancestatusat screeningis derived as thelastobservedmeasurementpriortoor onrandomization.All14patientswithmissingECOGstatus atbaselinehadECOG0or1recordedintheeCRFwithin6daysofrandomization.

<div style=\"page-break-after: always\"></div>

Table 13 Previous Disease Related Treatment Modalities -Study DB-06

|                                                                                                 | Number(%)of patients   | Number(%)of patients   | Number(%)of patients   | Number(%)of patients   | Number(%)of patients        | Number(%)of patients        |
|-------------------------------------------------------------------------------------------------|------------------------|------------------------|------------------------|------------------------|-----------------------------|-----------------------------|
|                                                                                                 | ITT Population         | ITT Population         | HER2-low Population    | HER2-low Population    | HER2 IHC >0 < 1+ Population | HER2 IHC >0 < 1+ Population |
|                                                                                                 | T-DXd                  | Chemotherapy           | T-DXd                  | Chemotherapy           | T-DXd                       | Chemotherapy                |
| Previoustreatmentmodalities                                                                     | (N = 436)              | (N = 430)              | (N = 359)              | (N =354)               | (N = 76)                    | (N = 76)                    |
| Median (range) number of prior lines of ET in the metastatic setting                            | 2.0 (1 - 4)            | 2.0 (1 - 5)            | 2.0 (1 - 5)            | 2.0 (1 - 5)            | 2.0 (1 - 4)                 | 2.0 (1 - 5)                 |
| Number of patients with at least one prior line of endocrine therapy in the metastatic settinga | 435 (99.8)             | 428 (99.5)             | 358 (99.7)             | 352 (99.4)             | 76 (100)                    | 76 (100)                    |
| Number of prior lines of ET in the metastatic setting                                           |                        |                        |                        |                        |                             |                             |
| 1                                                                                               | 65 (14.9)              | 82 (19.2)              | 54 (15.1)              | 67 (19.0)              | 11 (14.5)                   | 15 (19.7)                   |
| 1 prior line and time to progression from start ofET+ CDK4/6i≤6 months                          | 37 (8.5)               | 40 (9.3)               | 33 (9.2)               | 33 (9.4)               | 4 (5.3)                     | 7 (9.2)                     |
| Remaining patients with1 prior line                                                             | 28 (6.4)               | 42 (9.8)               | 21 (5.9)               | 34 (9.7)               | 7 (9.2)                     | 8 (10.5)                    |
| 2                                                                                               | 295 (67.8)             | 288 (67.3)             | 242 (67.6)             | 236 (67.0)             | 52 (68.4)                   | 52 (68.4)                   |
| ≥3                                                                                              | 75 (17.2)              | 58 (13.6)              | 62 (17.3)              | 49 (13.9)              | 13 (17.1)                   | 9 (11.8)                    |
| Number of patients with at least one prior line of ET + CDK4/6i in the metastatic setting       | 388 (89.0)             | 385 (89.5)             | 318 (88.6)             | 316 (89.3)             | 69 (90.8)                   | 69 (90.8)                   |
| Number of prior lines of ET + CDK4/6i in the metastatic settingb                                |                        |                        |                        |                        |                             |                             |
| 0                                                                                               | 48 (11.0)              | 44 (10.3)              | 41 (11.4)              | 37 (10.5)              | 7 (9.2)                     | 7 (9.2)                     |
| 1                                                                                               | 353 (81.0)             | 358 (83.4)             | 292 (81.3)             | 293 (83.0)             | 60 (78.9)                   | 65 (85.5)                   |
| 2                                                                                               | 35 (8.0)               | 27 (6.3)               | 26 (7.2)               | 23 (6.5)               | 9 (11.8)                    | 4 (5.3)                     |
| Hormonal therapy + targeted therapy (other than CDK4/6i)                                        | 143 (32.8)             | 127 (29.5)             | 120 (33.4)             | 105 (29.7)             | 22 (28.9)                   | 22 (28.9)                   |
| Hormonal therapy + mTORi                                                                        | 104 (23.9)             | 102 (23.7)             | 89 (24.8)              | 81 (22.9)              | 15 (19.7)                   | 21 (27.6)                   |
| Hormonal therapy + PIK3CAi                                                                      | 24 (5.5)               | 12 (2.8)               | 19 (5.3)               | 11 (3.1)               | 5 (6.6)                     | 1 (1.3)                     |
| Hormonal therapy + PARPi                                                                        | 3 (0.7)                | 5 (1.2)                | 2 (0.6)                | 5 (1.4)                | 0                           | 0                           |
| Hormonal therapy + Other                                                                        | 16 (3.7)               | 11 (2.6)               | 14 (3.9)               | 11 (3.1)               | 2 (2.6)                     | 0                           |
| Adjuvant/Neoadjuvant setting prior treatment(s)c                                                | 291 (66.7)             | 281 (65.3)             | 240 (66.9)             | 237 (66.9)             | 51 (67.1)                   | 44 (57.9)                   |
| Hormonal therapy                                                                                | 275 (63.1)             | 256 (59.5)             | 227 (63.2)             | 218 (61.6)             | 48 (63.2)                   | 38 (50.0)                   |
| Cytotoxic chemotherapy                                                                          | 228 (52.3)             | 234 (54.4)             | 192 (53.5)             | 196 (55.4)             | 36 (47.4)                   | 38 (50.0)                   |
| Taxane                                                                                          | 179 (41.1)             | 177 (41.2)             | 151 (42.1)             | 151 (42.7)             | 28 (36.8)                   | 26 (34.2)                   |
| Anthracycline                                                                                   | 197 (45.2)             | 206 (47.9)             | 167 (46.5)             | 173 (48.9)             | 30 (39.5)                   | 33 (43.4)                   |
| Cyclophosphamide                                                                                | 203 (46.6)             | 213 (49.5)             | 175 (48.7)             | 178 (50.3)             | 28 (36.8)                   | 35 (46.1)                   |
| 5-FU                                                                                            | 79 (18.1)              | 73 (17.0)              | 68 (18.9)              | 56 (15.8)              | 11 (14.5)                   | 17 (22.4)                   |
| Capecitabine                                                                                    | 4 (0.9)                | 2 (0.5)                | 3 (0.8)                | 2 (0.6)                | 1 (1.3)                     | 0                           |
| Other                                                                                           | 33 (7.6)               | 20 (4.7)               | 25 (7.0)               | 15 (4.2)               | 8 (10.5)                    | 5 (6.6)                     |

3 Percentages have been computed on the number of patients with at least one prior line of endocrine therapy in the metastatic setting

Therapies reported are not mutually exclusive.

b Percentages have been computed on the number of patients with at least one prior line in the metastatic seting.

<div style=\"page-break-after: always\"></div>

Table 14 Previous disease-related treatment modalities ITT population

|                                                                                                | Number (&)of patients   | Number (&)of patients   | Number (&)of patients   |
|------------------------------------------------------------------------------------------------|-------------------------|-------------------------|-------------------------|
| Previous treatment modalities                                                                  | T-DXd (N=436)           | Chemotherapy (N=430)    | Total (N=866)           |
| Median (Range) number of prior lines in the metastatic setting                                 | 2.0 (1 -5)              | 2.0 (1 -6)              | 2.0 (1 -6)              |
| Number of patients with at least one prior line in the metastatic setting                      | 436 (100.0)             | 429 (99.8)              | 865 (99.9)              |
| Number of prior lines in the metastatic setting                                                |                         |                         |                         |
| 1                                                                                              | 60 (13.8)               | 78 (18.2)               | 138 (16.0)              |
| 2                                                                                              | 294 (67.4)              | 286 (66.7)              | 580 (67.1)              |
| >=3                                                                                            | 82 (18.8)               | 65 (15.2)               | 147 (17.0)              |
| Median (Range) number of prior lines of endocrine therapy in the metastatic setting            | 2.0 (1 - 4)             | 2.0 (1 -5)              | 2.0 (1 -5)              |
| Number of patients with at least one prior line of endocrine therapy in the metastatic setting | 435 ( 99.8)             | 428 (99.5)              | 863 (99.7)              |
| Number of prior lines of endocrine therapy in the metastatic settingb                          |                         |                         |                         |
| 1                                                                                              | 65 (14.9)               | 82 (19.2)               | 147 (17.0)              |
| 1 prior line and time to progression from start of ET + CDK4/6 inhibitors <= 6 months          | 37 8.5)                 | 40 ( 9.3)               | 77 (8.9)                |
| Remaining patients with l prior line                                                           | 28 6.4)                 | 42 (9.8)                | 70 (8.1)                |
| 2                                                                                              | 295 (67.8)              | 288 (67.3)              | 583 (67.6)              |
| >=3                                                                                            | 75 (17.2)               | 58 (13.6)               | 133 (15.4)              |
| Number ofpatients withatleast onepriorline ofET+CDK4/6iin the metastatic setting               | 388 (89.0)              | 385 (89.5)              | 773 (89.3)              |

Patients treated with Hormonal therapy and GnRH are summarized under Hormonal therapy.

ET = endocrine therapy. CDK = cyclin-dependent kinase. T-DXd = trastuzumab deruxtecan.

## Numbers analysed

## Table 15 Analysis Sets

|                                                   | Number of Patients   | Number of Patients   | Number of Patients   |
|---------------------------------------------------|----------------------|----------------------|----------------------|
|                                                   | T-DXd                | Chemotherapy         | Total                |
| Patients randomized                               | 436                  | 430                  | 866                  |
| Patients included in FAS (ITT population)         | 436                  | 430                  | 866                  |
| Patients included in HER2-low population          | 359                  | 354                  | 713                  |
| Patients included in HER2 IHC > 0 < 1+ population | 76                   | 76                   | 152                  |
| Patients included in SAF                          | 434                  | 417                  | 851                  |
| Patients excluded from SAF                        |                      |                      | 15                   |
| Did not receive treatment                         |                      |                      | 15                   |
| Patients included in HER2-low SAF                 | 357                  | 343                  | 700                  |
| Patients excludedfromHER2-lowSAF                  |                      |                      | 13                   |
| Did not receive treatment                         |                      |                      | 13                   |
| Patients included in PK analysis set              | 432                  |                      | 432                  |
| Patients excluded from PK analysis set            |                      |                      | 434                  |
| Did not receive T-DXd                             |                      |                      | 432                  |
| Had deviation considered to have impact upon PK   |                      |                      | 1                    |
| No post-dose data                                 |                      |                      | 1                    |
| Patients included in ADA evaluable set            | 433                  |                      | 433                  |
| PatientsexcludedfromADAevaluableset               |                      |                      | 433                  |
| Did not receive T-DXd                             |                      |                      | 432                  |
| Nobaseline and/orpost-baselineADAdata             |                      |                      | 1                    |

HER2-low population - all patients in the ITT population with HER2 IHC 2+/ISH- and IHC 1+ as determined per the IRT data for the HER2 IHC expression.

HER2-low SAFfor the HER2 IHC expression.

HER2 IHC &gt; 0 &lt; 1+ population - all patients in the ITT population with HER2 IHC &gt; 0 &lt; 1+ as determined by central laboratory testing.

An earlier DCO date of 29 November 2023 was applied to ADA and PK data.

setting.

<div style=\"page-break-after: always\"></div>

## Outcomes and estimation

## Primary endpoint - PFS by BICR (HER2-low population)

## Table 16 Progression-free Survival by BICR (HER2-low population)

|                                                                    | T-DXd (N = 359)   | Chemotherapy (N = 354)   |
|--------------------------------------------------------------------|-------------------|--------------------------|
| Total events a , n (%)                                             | 225 (62.7)        | 232 (65.5)               |
| RECIST progression                                                 | 212 (59.1)        | 219 (61.9)               |
| Death in the absence of progression                                | 13 (3.6)          | 13 (3.7)                 |
| Censored patients, n (%)                                           | 134 (37.3)        | 122 (34.5)               |
| Censored RECIST progression b                                      | 6 (1.7)           | 9 (2.5)                  |
| Censored death c                                                   | 24 (6.7)          | 25 (7.1)                 |
| Progression-free at time of analysis                               | 98 (27.3)         | 71 (20.1)                |
| Lost to follow-up                                                  | 0                 | 0                        |
| Withdrawn consent                                                  | 6 (1.7)           | 17 (4.8)                 |
| Other                                                              | 0                 | 0                        |
| Median progression-free survival (months) d                        | 13.2              | 8.1                      |
| 95% CI for median progression-free survival d                      | 11.4, 15.2        | 7.0, 9.0                 |
| Hazard ratio e                                                     | 0.62              |                          |
| 95% CI for hazard ratio e                                          | 0.52, 0.75        |                          |
| 2-sided p-value f                                                  | <0.0001           |                          |
| Median (range) duration of follow-up in censored patients (months) | 15.4 (0.0, 36.2)  | 8.1 (0.0, 36.0)          |

a Patients who had not progressed or died were censored at the latest evaluable RECIST assessment. Patients who progressed or died after two or more missed visits were censored at the latest evaluable RECIST assessment before the two missed visits. If there were no evaluable visits or no baseline assessment (unless the patient died within two visits of baseline), patients were censored at Day 1 (randomization).

b RECIST progression event occurred after two or more missed visits.

c Death which occurred after two or more missed visits in the absence of RECIST progression.

d Calculated using the KM technique. CI for median was derived based on Brookmeyer-Crowley method.

e The HR and confidence interval were calculated using a stratified Cox proportional hazards model, adjusting for prior CDK4/6i use (yes vs. no) and HER2 IHC expression (IHC 1+ vs. IHC 2+/ISH-) and ties handled by Efron approach. A HR &lt; 1 favours T-DXd to be associated with a longer progressionfree survival than Investigator's choice chemotherapy.

f The p-value was calculated using a stratified log-rank test, adjusting for prior CDK4/6i use (yes vs. no)and HER2 IHC expression (IHC 1+ vs. IHC 2+/ISH-). A p-value &lt; 0.05 is significant.

<div style=\"page-break-after: always\"></div>

Figure 5 Progression-free Survival by BICR, Kaplan-Meier plot (HER2-low Population)

<!-- image -->

Circle indicates a censored observation. 2-sided p-value. A p-value &lt; 0.05 is significant

## Secondary endpoint - OS (HER2-low population)

Table 17 Overall Survival, Primary Analysis (HER2-low Population)

|                                                                    | Number (%) of patients   | Number (%) of patients   |
|--------------------------------------------------------------------|--------------------------|--------------------------|
|                                                                    | T-DXd                    | Chemotherapy             |
|                                                                    | (N = 359)                | (N = 354)                |
| Death, n (%)                                                       | 136 (37.9)               | 146 (41.2)               |
| Censored patients, n (%)                                           | 223 (62.1)               | 208 (58.8)               |
| Still in survival follow up a                                      | 215 (59.9)               | 182 (51.4)               |
| Terminated prior to death b                                        | 8 (2.2)                  | 26 (7.3)                 |
| Lost to follow-up                                                  | 0                        | 0                        |
| Withdrawn consent                                                  | 8 (2.2)                  | 26 (7.3)                 |
| Other                                                              | 0                        | 0                        |
| Median overall survival (months) c                                 | 28.9                     | 27.1                     |
| 95% CI for median overall survival c                               | 25.7, 33.7               | 23.5, 29.9               |
| Hazard ratio d                                                     | 0.83                     |                          |
| 95% CI for hazard ratio d                                          | 0.66, 1.05               |                          |
| 99.54% CI for hazard ratio e                                       | 0.59, 1.17               |                          |
| 2-sided p-value f                                                  | 0.1299                   |                          |
| Median (range) duration of follow-up in all patients (months)      | 19.0 (0.1, 40.5)         | 18.3 (0.0, 42.9)         |
| Median (range) duration of follow-up in censored patients (months) | 21.1 (0.1, 40.5)         | 20.3 (0.0, 42.9)         |

<div style=\"page-break-after: always\"></div>

- k Based on Lan DeMets alpha spending function with O'Brien -Fleming type boundary given the actual number of events observed.
- l The p-value was calculated using a log-rank test with no stratification factors. A p-value &lt; 0.0046 is significant.

Figure 6 Overall Survival, Kaplan-Meier Plot (HER2-low Population)

<!-- image -->

## Secondary endpoint - PFS by BICR (ITT population)

Table 18 Progression-free Survival by BICR (ITT Population)

|                                                                    | T-DXd (N = 436)   | Chemotherapy (N = 430)   |
|--------------------------------------------------------------------|-------------------|--------------------------|
| Total events a , n (%)                                             | 269 (61.7)        | 271 (63.0)               |
| RECIST progression                                                 | 254 (58.3)        | 257 (59.8)               |
| Death in the absence of progression                                | 15 (3.4)          | 14 (3.3)                 |
| Censored patients, n (%)                                           | 167 (38.3)        | 159 (37.0)               |
| Median progression-free survival (months) b                        | 13.2              | 8.1                      |
| 95% CI for median progression-free survival b                      | 12.0, 15.2        | 7.0, 9.0                 |
| Hazard ratio c                                                     | 0.64              |                          |
| 95% CI for hazard ratio c                                          | 0.54, 0.76        |                          |
| 2-sided p-value d                                                  | <0.0001           |                          |
| Median (range) duration of follow-up in censored patients (months) | 15.3 (0.0, 36.2)  | 7.2 (0.0, 36.0)          |

- a Patients who had not progressed or died were censored at the latest evaluable RECIST assessment. Patients who progressed or died after two or more missed visits were censored at the latest evaluable RECIST assessment before the two missed visits. If there were no evaluable visits or no baseline assessment (unless the patient died within two visits of baseline), patients were censored at Day 1 (randomization).

c The HR and CI were calculated using a Cox proportional hazards model with no stratification factors.

d The p-value was calculated using a log-rank test with no stratification factors

.

<div style=\"page-break-after: always\"></div>

Figure 7 Progression-free Survival by BICR, Kaplan-Meier Plot -Study DB-06 (ITT Population)

<!-- image -->

2-sided p-value. A p-value &lt; 0.015 is significant.

Progression was determined by BICR according to RECIST 1.1.

## Secondary endpoint - OS (ITT population)

As the efficacy data for OS in the HER2-low population was not statistically significant per the MTP, the OS analysis in the ITT population was not tested.

Figure 8 Overall survival, Kaplan-Meier Plot (ITT Population)

<!-- image -->

<div style=\"page-break-after: always\"></div>

The interim results of OS in the ITT population showed that the median OS was 28.9 months (95%CI: 26.4, 32.7) for T-DXd and 27.4 months (95%CI: 23.9, 29.9) for chemotherapy, HR: 0.81 [95%CI: 0.66, 1.01]).

Table 19 Overall survival, secondary analysis ITT population

|                                                                    | Number （&)of patients   | Number （&)of patients   | Number （&)of patients   |
|--------------------------------------------------------------------|-------------------------|-------------------------|-------------------------|
|                                                                    | T-DXd (N=436)           | Chemotherapy (N=430)    | Total (N=866)           |
| Death, n (8)                                                       | 161 (36.9)              | 174 (40.5)              |                         |
| Censored patients, n (8)                                           | 275 (63.1)              | 256 (59.5)              |                         |
| Still in survival follow-upa                                       | 265 (60.8)              | 223 (51.9)              |                         |
| Terminated prior to deathb                                         | 10 (2.3)                | 33 (7.7)                |                         |
| Lost tofollow-up                                                   |                         | 0                       |                         |
| Withdrawn consent                                                  | 10 (2.3)                | 33 (7.7)                |                         |
| Other                                                              | 0                       | 0                       |                         |
| Median overall survival (months)*                                  | 28.9                    | 27.4                    |                         |
| 958 CI for median overall survivalc                                | 26.4,32.7               | 23.9,29.9               |                         |
| Hazard ratiod                                                      | 0.81                    |                         |                         |
| 95s CI for hazardratiod                                            | 0.66, 1.01              |                         |                         |
| Median (range) duration of follow-up in all patients (months)      | 18.6 (0.1,40.5)         | 17.8( (0.0，42.9)        | 18.2 (0.0, 42.9)        |
| Median (range) duration of follow-up in censored patients (months) | 20.6 (0.1, 40.5)        | 19.8 (0.0,42.9)         |                         |
| Percentage (95s CI) of patients alive at 12 months                 | 87.0( (83.5,89.9)       | 81.1 (77.0,84.6)        |                         |
| Percentage (95& CI) of patients alive at 18 months                 | 74.8 (70.3, 78.8)       | 68.7 (63.8,73.1)        |                         |

<div style=\"page-break-after: always\"></div>

## Secondary endpoint - PFS by INV (HER2-low population)

Table 20 Progression-free Survival by Investigator Assessment (HER2-low Population)

|                                                                    | T-DXd            | Chemotherapy    |
|--------------------------------------------------------------------|------------------|-----------------|
| Total events a , n (%)                                             | 263 (73.3)       | 284 (80.2)      |
| RECIST progression                                                 | 246 (68.5)       | 275 (77.7)      |
| Death in the absence of progression                                | 17 (4.7)         | 9 (2.5)         |
| Censored patients, n (%)                                           | 96 (26.7)        | 70 (19.8)       |
| Median progression-free survival (months) b                        | 12.8             | 7.0             |
| 95% CI for median progression-free survival b                      | 11.1, 13.2       | 6.4, 7.5        |
| Hazard ratio c                                                     | 0.50             |                 |
| 95% CI for hazard ratio c                                          | 0.42, 0.60       |                 |
| 2-sided p-value d                                                  | <0.0001          |                 |
| Median (range) duration of follow-up in censored patients (months) | 19.2 (0.0, 37.9) | 6.2 (0.0, 36.0) |

- a Patients who had not progressed or died were censored at the latest evaluable RECIST assessment. Patients who progressed or died after two or more missed visits were censored at the latest evaluable RECIST assessment before the two missed visits. If there were no evaluable visits or no baseline assessment (unless the patient died within two visits of baseline), patients are censored at Day 1 (randomization).
- b Calculated using the KM technique. CI for median was derived based on Brookmeyer-Crowley method.
- c The HR and CI were calculated using a stratified Cox proportional hazards model, adjusting for prior CDK4/6i use (yes vs. no) and HER2 IHC expression (IHC 1+ vs. IHC 2+/ISH-) and ties handled by Efron approach. A HR &lt; 1 favors T-DXd to be associated with a longer event time than Investigator's choice chemotherapy.
- d The p-value was calculated using a stratified log-rank test, adjusting for prior CDK4/6i use (yes vs. no) and HER2 IHC expression (IHC 1+ vs. IHC 2+/ISH-).

Figure 9 Progression-free Survival by BICR, Kaplan-Meier plot (HER2 IHC &gt; 0 &lt; 1+ Population)

<!-- image -->

Progression was determined by BICR according to RECIST 1.1.

<div style=\"page-break-after: always\"></div>

## Secondary endpoint - ORR + DoR (HER2-low population)

Table 21 Objective response rate by BICR and Investigator assessment, logistic regression model HER2low population

|                                        |                    |         |                                     |                                     |                          | Comparison between groups   | Comparison between groups   | Comparison between groups   |
|----------------------------------------|--------------------|---------|-------------------------------------|-------------------------------------|--------------------------|-----------------------------|-----------------------------|-----------------------------|
| Endpoint                               | Group              | N       | Number （&)of patients with response | Number （&)of patients with response | 958CIc                   | Odds ratio                  | 958CI                       | 2-sided p-value             |
| ORR by BICRab                          | T-DXd Chemotherapy | 359 354 | 217 134                             | (60.4) (37.9)                       | (55.2,65.5) (32.8,43.1)  | 2.51                        | 1.86,3.41                   | <0.0001                     |
| ORR byInvestigator Assessment          | T-DXd Chemotherapy | 359 354 | 217 143                             | (60.4) (40.4)                       | (55.2,65.5) (35.2,45.7)  | 2.26                        | 1.68,3.05                   | <0.0001                     |
| Confirmed ORR by BICR                  | T-DXd Chemotherapy | 359 354 | 203 114                             | (56.5) (32.2)                       | (51.2, 61.7) (27.4,37.3) | 2.74                        | 2.02,3.73                   | <0.0001                     |
| Confirmed ORRbyInvestigator Assessment | T-DXd Chemotherapy | 359 354 | 203 115                             | (56.5) (32.5)                       | (51.2,61.7) (27.6, 37.6) | 2.71                        | 2.00,3.68                   | <0.0001                     |

Table 22 Duration of objective response (confirmed response) by BICR HER2-low population, patients with objective response ( confirmed response) by BICRT

|                                                          | T-DXd (N=203)   | Chemotherapy (N=114)   |
|----------------------------------------------------------|-----------------|------------------------|
| Number of responders who subsequently progressed or died | 119             | 74                     |
| Duration of response from onset of response (months)ab   |                 |                        |
| 25th percentile                                          | 6.9             | 4.2                    |
| Median                                                   | 14.1            | 8.6                    |
| 75th percentile                                          | 25.5            | 15.9                   |
| Percentage remaining in responseb                        |                 |                        |
| At 3 months                                              | 93.5            | 92.8                   |
| At 6 months                                              | 78.8            | 63.8                   |
| At 9 months                                              | 67.0            | 48.0                   |
| At 12 months                                             | 55.4            | 36.4                   |
| At 15 months                                             | 48.2            | 28.5                   |
| At18 months                                              | 37.5            | 16.8                   |
| At 2l months                                             | 33.1            | 13.4                   |
| At 24months                                              | 27.3            | 13.4                   |
| At 27 months                                             | 19.9            | NE                     |
| At 30 months                                             | 19.9            | NE                     |

<div style=\"page-break-after: always\"></div>

Figure 10 Duration of Objective Response by BICR, Kaplan-Meier Plot (HER2-low Population)

<!-- image -->

Responses include unconfirmed responses.

## Secondary endpoint - ORR +DoR (ITT population)

Table 23 Objective response rate by BICR and Investigator assessment, logistic regression model, patients with measurable disease at baseline ITT population

|                                       |                    |         |                                      |                                      |                           | Comparison between groups   | Comparison between groups   | Comparison between groups   |
|---------------------------------------|--------------------|---------|--------------------------------------|--------------------------------------|---------------------------|-----------------------------|-----------------------------|-----------------------------|
| Endpoint                              | Group              | N       | Number (&) of patients with response | Number (&) of patients with response | 958CIc                    | Odds ratio                  | 958CI                       | 2-sided p-value             |
| ORR by BICRab                         | T-DXd Chemotherapy | 436 430 | 268 158                              | (61.5) (36.7)                        | (56.7, 66.1) (32.2, 41.5) | 2.76                        | 2.10,3.64                   | <0.0001                     |
| ORR by Investigator Assessment        | T-DXd Chemotherapy | 436 430 | 268 167                              | (61.5) (38.8)                        | (56.7, 66.1) (34.2, 43.6) | 2.52                        | 1.92,3.32                   | <0.0001                     |
| Confirmed ORR by BICR                 | T-DXd Chemotherapy | 436 430 | 250 134                              | (57.3) (31.2)                        | (52.5， 62.0) (26.8,35.8)  | 2.98                        | 2.26,3.94                   | <0.0001                     |
| ConfirmedORRbyInvestigator Assessment | T-DXd Chemotherapy | 436 430 | 245 132                              | (56.2) (30.7)                        | (51.4, 60.9) (26.4,35.3)  | 2.91                        | 2.20,3.85                   | <0.0001                     |

<div style=\"page-break-after: always\"></div>

Table 24 Duration of objective response (confirmed response) by BICR ITT population, patients with objective response (confirmed response) by BICR

|                                                          | T-DXd (N=250)   | Chemotherapy (N=134)   |
|----------------------------------------------------------|-----------------|------------------------|
| Number of responders who subsequently progressed or died | 142             | 83                     |
| Duration of response from onset of response (months)ab   |                 |                        |
| 25th percentile                                          | 7.0             | 4.4                    |
| Median                                                   | 14.3            | 8.6                    |
| 75th percentile                                          | 25.5            | 17.6                   |
| Percentage remaining in responseb                        |                 |                        |
| At 3months                                               | 93.6            | 93.1                   |
| At 6 months                                              | 79.9            | 65.0                   |
| At 9 months                                              | 67.3            | 49.9                   |
| At 12 months                                             | 56.9            | 38.8                   |
| At 15 months                                             | 48.5            | 30.4                   |
| At 18 months                                             | 38.5            | 19.1                   |
| At 21 months                                             | 32.6            | 15.9                   |
| At 24 months                                             | 27.4            | 15.9                   |
| At 27 months                                             | 21.1            | NE                     |
| At 30 months                                             | 21.1            | NE                     |

Figure 11 Duration of Objective Response by BICR, Kaplan-Meier plot (ITT Population)

<!-- image -->

Responses include unconfirmed responses.

<div style=\"page-break-after: always\"></div>

## Secondary endpoint - PFS 2 (HER-2 low population)

Table 25 Time from randomization to second progression or death HER2- low population

|                                                                          | T-DXd (N=359)   | Chemotherapy (N=354)   |
|--------------------------------------------------------------------------|-----------------|------------------------|
| Total events\", n (8)                                                     | 191 (53.2)      | 239 (67.5)             |
| Second progression                                                       | 122 (34.0)      | 172 (48.6)             |
| Objective radiologicalprogression                                        | 106 (29.5)      | 148 (41.8)             |
| Symptomatic progression in absence of objective radiological progression | 12 (3.3)        | 17 (4.8)               |
| Other                                                                    | 4 (1.1)         | 7 (2.0)                |
| Death in the absence of second progression                               | 69 (19.2)       | 67 (18.9)              |
| Censored patients, n (&)                                                 | 168 (46.8)      | 115 (32.5)             |
| Second progression-free at time of analysis                              | 163 (45.4)      | 96 (27.1)              |
| Lost to follow-up                                                        | 0               | 0                      |
| Withdrawn consent                                                        | 5 1.4)          | 19 (5.4)               |
| Otherb                                                                   | 0               | 0                      |
| Median time to second progression or death （months)*                     | 20.0            | 14.5                   |
| 95& CI for median time to second progression or deathe                   | 18.9, 23.8      | 12.9, 15.5             |
| Hazard ratiod                                                            | 0.59            |                        |
| 958 CI for hazard ratiod                                                 | 0.49,0.72       |                        |
| 2-sided p-value                                                          | <0.0001         |                        |

- Patients alive and for whom a second disease progression has not been observed are censored at the earliest of: date of study termination, date last kmown alive, data cut-off or, if a patient has not had a first subsequent therapy, the date last known not to have received a first subsequent therapy.
- b other category includes patients discontinued the study for any other reason.
- 4 The hazard ratio and confidence intervals were calculated using a Cox proportional hazards model with no stratification factors and ties handled by Efron approach.A hazard ratio&lt;l favours T-Dxd to be associated with a longer event-free survival than Investigator's choice chemotherapy.
- Second progressionis determined by the Investigator according to localstandard clinical practice. 1 month = 30.4375 days.
- e The p-value was calculated using a log-rank test, with no stratification factors.
- CI= confidence interval.HER2 =human epidermal growth factor receptor 2.T-DXd =trastuzumab deruxtecan.

Figure 12 Time from Randomization to Second Progression or Death, KaplanMeier plot (HER2-low Population)

<!-- image -->

## 2-sided p-value.

Second progression was determined by the Investigator according to local standard clinical practice.

<div style=\"page-break-after: always\"></div>

## Secondary endpoint - PFS 2 (ITT population)

Table 26 Time from randomization to second progression or death ITT population

|                                                                          | T-DXd (N=436)   | Chemotherapy (N=430)   |
|--------------------------------------------------------------------------|-----------------|------------------------|
| Total events\",n (8)                                                      | 228 (52.3)      | 278 (64.7)             |
| Second progression                                                       | 149 (34.2)      | 201 (46.7)             |
| Objective radiological progression                                       | 128 (29.4)      | 175 (40.7)             |
| Symptomatic progression in absence of objective radiological progression | 16 (3.7)        | 19 (4.4)               |
| Other                                                                    | 5 (1.1)         | 7 (1.6)                |
| Death in the absence of second progression                               | 79 (18.1)       | 77 (17.9)              |
| Censored patients, n (&)                                                 | 208 (47.7)      | 152 (35.3)             |
| Second progression-free at time of analysis                              | 201 (46.1)      | 127 (29.5)             |
| Lost to follow-up                                                        | 0               | 0                      |
| Withdrawn consent                                                        | 7 (1.6)         | 25 (5.8)               |
| Otherb                                                                   | 0               | 0                      |
| Median time to second progression or death （months)                      | 20.3            | 14.7                   |
| 958 CI for median time to secondprogression or deathe                    | 18.9,23.8       | 13.5, 15.9             |
| Hazard ratiod                                                            | 0.62            |                        |
| 95CI for hazard ratiod                                                   | 0.52,0.74       |                        |
| 2-sided p-value\"                                                         | <0.0001         |                        |

Figure 13 Time from Randomization to Second Progression or Death, Kaplan-Meier plot (ITT Population)

2-sided p-value.

<!-- image -->

Second progression was determined by the Investigator according to local standard clinical practice.

<div style=\"page-break-after: always\"></div>

## Secondary endpoint - TFST and TSST (ITT population)

## Table 27 Time from randomization to first subsequent therapy or death ITT population

|                                                             | PXC-L (N=436)   | Chemotherapy (N=430)   |
|-------------------------------------------------------------|-----------------|------------------------|
| Total eventsa,n (%)                                         | 329(75.5)       | 367 (85.3)             |
| First subsequent therapy                                    | 284(65.1)       | 329 (76.5)             |
| Death in the absence of subsequent therapy                  | 45 (10.3)       | 38(8.8)                |
| Censored patients, n (%)                                    | 107 (24.5)      | 63 (14.7)              |
| Alive and with no subsequent therapy at time of analysis    | 103 (23.6)      | 4 5 (10.5)             |
| Lost to follow-up                                           | 0               | 0                      |
| Withdrawn consent                                           | 4 (0.9)         | 1 8 (4.2)              |
| Otherb                                                      | 0               | 0                      |
| Median time to first subsequent therapy or death (months)c  | 12 .5           | 7.6                    |
| 95$ CI for median time to first subsequent therapy or death | 11.5, 13.9      | 6.9,8.2                |
| Hazard ratiod                                               | 0.54            |                        |
| 95gCI for hazardratiod                                      | 0.46,0.63       |                        |
| 2-sided p-value*                                            | <0.0001         |                        |

- a Patients alive and not known to have had a first subsequent anti-cancer therapy are censored at the earliest of: date of study termination, date last known alive, data cut-off or the last date that the patient was known not to have received a first subsequent anti-cancer therapy.
- b Other category includes patients discontinued the study for any other reason.
- c Calculated using the Kaplan-Meier technique. CI for median is derived based on Brookmeyer-Crowley method.
- d The hazard ratio and confidence interval were calculated using a stratified Cox proportional hazards model, adjusting for prior CDK4/6 inhibitor use (yes vs. no) and HER2 IHC expression (IHC &gt;0 &lt;1+ vs. IHC 1+ vs. IHC 2+/ISH-) and ties handled by Efron approach. A hazard ratio &lt; 1 favours T-DXd to be associated with a longer event-free survival than Investigator's choice chemotherapy.
- e The p-value was calculated using a stratified log-rank test, adjusting for prior CDK4/6 inhibitor use (yes vs. no) and HER2 IHC expression (IHC &gt;0 &lt;1+ vs. IHC 1+ vs. IHC 2+/ISH-). 1 month = 30.4375 days. CDK = cyclindependent kinase. CI = confidence interval. HER2 = human epidermal growth factor receptor 2. IHC = immunohistochemistry. ISH = in situ hybridization. T-DXd = trastuzumab deruxtecan.

## Table 28 Time from randomization to second subsequent therapy or death ITT population

|                                                                 | PXO-L (N=436)   | Chemotherapy (N=430)   |
|-----------------------------------------------------------------|-----------------|------------------------|
| Total events,n (%)                                              | 223 (51.1)      | 276 (64.2)             |
| Secondsubsequenttherapy                                         | 129(29.6)       | 191 (44 . 4)           |
| Death in the absence of second subsequent therapy               | 94 (21.6)       | 85 (19.8)              |
| Censored patients, n (%)                                        | 213 (48.9)      | 15 4 (35.8)            |
| Alive and with no second subsequent therapy at time of analysis | 209(47.9)       | 136 (31.6)             |
| Lost to follow-up                                               | 0               | 0                      |
| Withdrawn consent                                               | 4 (0.9)         | 1 8 (4.2)              |
| Otherb                                                          | 0               | 0                      |
| Median time to second subsequent therapy or death (months)c     | 21.4            | 14 .9                  |
| 95CI for median time to second subsequent therapy or deathc     | 19.2, 23.8      | 13.5, 16.1             |
| Hazard ratiod                                                   | 0.60            |                        |
| 95% CI for hazard ratiod                                        | 0.50,0.71       |                        |
| 2-sided p-value*                                                | <0.0001         |                        |

- a Patients alive and not known to have had a second subsequent anti-cancer therapy are censored at the earliest of: date of study termination, date last known alive, data cut-off or the last date that the patient was known not to have received a second subsequent anti-cancer therapy.
- b Other category includes patients discontinued the study for any other reason.
- c Calculated using the Kaplan-Meier technique. CI for median is derived based on Brookmeyer-Crowley method.
- d The hazard ratio and confidence intervals were calculated using a Cox proportional hazards model with no stratification factors and ties handled by Efron approach. A hazard ratio &lt; 1 favours T-DXd to be associated with a longer event-free survival than Investigator's choice chemotherapy.
- e The p-value was calculated using a log-rank test, with no stratification factors. 1 month = 30.4375 days. CI = confidence interval. T-DXd = trastuzumab deruxtecan.

## Patient-reported outcomes - EORTC QLQ-C30 and EORTC QLQ-BR45

As secondary outcome measures in the ITT population, PRO variables, as measured by EORTC QLQC30 and EORTC QLQ-BR45 PRO questionnaires, showed no differences in change from baseline over the first 7 months between the T-DXd arm and the chemotherapy arm in GHS/QoL and functioning,

<div style=\"page-break-after: always\"></div>

but some differences were observed in symptoms. An improvement from baseline in pain was reported by patients in the T-DXd arm compared to chemotherapy, while a worsening of GI symptoms (nausea/vomiting, appetite loss and constipation) were reported by patients in the T-DXd arm compared to chemotherapy. A worsening of skin mucosis symptoms from baseline was reported by patients in the chemotherapy arm compared to the T-DXd arm. T-DXd also reduced the risk of deterioration for all pre-specified scales of physical functioning (by 28%), role functioning (by 25%) and pain (by 49%), compared to chemotherapy. The risk of deterioration in GHS/QoL was similar between the 2 arms. Results in the HER2-low population were consistent with the ITT population.

Figure 14 EORTC QLQ-C30, Time to Deterioration of Selected Scales, Kaplan-Meier Plot (HER2-low Population)

<!-- image -->

Physical Functioning

<!-- image -->

<div style=\"page-break-after: always\"></div>

Role Functioning

<!-- image -->

For the Pain scale: The hazard ratio and confidence interval were calculated using a stratified Cox proportional hazards model, adjusting for prior CDK4/6 inhibitor use (yes vs. no) and HER2 IHC expression (IHC 1+ vs. IHC 2+/ISH-) and ties handled by Efron approach. The p-value was calculated using a stratified log-rank test, adjusting for the same factors.

For other scales, the hazard ratios and confidence intervals were calculated using a Cox proportional hazards model with no stratification factors and ties handled by Efron approach. The p-value was calculated using a log-rank test, with no stratification factors.

A clinically meaningful deterioration is defined as a decrease from baseline ≥10 points in functional scales and GHS/QoL and as an increase from baseline ≥10 in symptom scales

## Ancillary analyses

Figure 15 Forest Plot of Progression-free Survival by BICR, by Sensitivity Analyses (HER2-low Population)

<!-- image -->

|                                               | Number of patients with event (%)   | Number of patients with event (%)   | Number of patients with event (%)   | Median PFS[Months]   | Median PFS[Months]   | Hazard ratio             | Hazard ratio   |
|-----------------------------------------------|-------------------------------------|-------------------------------------|-------------------------------------|----------------------|----------------------|--------------------------|----------------|
|                                               | T-DXd                               | Chemotherapy                        |                                     | T-DXd                | Chemotherapy         | [95%CI] p-value          |                |
| Primary analysis [a]                          |                                     | 225/359(62.78)                      | 232/354(65.5%)                      | 13.2                 | 8.1                  | 0.62[0.52,0.75]<0.0001   |                |
| Sensitivity analysis evaluation-time bias [b] |                                     | 225/359(62.7%)                      | 232/354(65.5%)                      | 12.3                 | 7.5                  | 0.63 [0.52,0.76] <0.0001 |                |
| Sensitivity analysis attrition bias [c]       | 197/359(54.9%)                      |                                     | 202/354(57.1%)                      | 13.2                 | 8.1                  | 0.57[0.47,0.70]<0.0001   |                |
| Sensitivity analysis ascertainment bias [d]   | 263/359(73.3%)                      |                                     | 284/354(80.2%)                      | 12.8                 | 7.0                  | 0.50[0.42,0.60]<0.0001   |                |

- a Patients who had not progressed or died were censored at the latest evaluable RECIST assessment. Patients who progressed or died after two or more missed visits were censored at the latest evaluable RECIST assessment before the two missed visits. If there were no evaluable visits or no baseline assessment (unless the

<div style=\"page-break-after: always\"></div>

patient died within two visits of baseline), patients were censored at Day 1 (randomization). Progression was determined by BICR according to RECIST 1.1.

- b In case of RECIST progression, the midpoint between the time of progression and the previous evaluable RECIST assessment was considered. For patients whose death was treated as a PFS event, the date of death was used. Progression was determined by BICR according to RECIST 1.1.
- c The actual PFS event times, rather than the censored times, of patients who progressed or died in the absence of progression immediately following two or more missed tumor assessments were included. Also, patients who took subsequent anti-cancer therapy (for this analysis radiotherapy was not considered a subsequent anticancer therapy) prior to their last evaluable RECIST assessment or progression or death were censored at their last evaluable assessment prior to taking the subsequent therapy. Progression was determined by BICR according to RECIST 1.1.
- d Progression was determined by Investigator assessment according to RECIST 1.1.

HR (T-DXd: Investigator's choice chemotherapy), 95% CI for HR.

A HR &lt; 1 favors T-DXd and is associated with a longer progression-free survival than Investigator's choice chemotherapy.

Grey band represents the 95% CI for the HR in the primary analysis.

The HR and CI were calculated using a stratified Cox proportional hazards model, adjusting for prior CDK4/6i use (yes vs. no) and HER2 IHC expression (IHC 1+ vs. IHC 2+/ISH-) and ties handled by Efron approach. The p-value was calculated using a stratified log-rank test, adjusting for prior CDK4/6i use (yes vs. no) and HER2 IHC expression (IHC 1+ vs. IHC 2+/ISH-).

Table 29 PFS by BICR, Sensitivity Analysis Without Applying Two Missed Visits Censoring Rule

|                                | T-DXd             | Chemotherapy    |
|--------------------------------|-------------------|-----------------|
| HER2-low population            |                   |                 |
| Number of patients             | 359               | 354             |
| Total events, n (%) a          | 255 (71.0)        | 266 (75.1)      |
| Censored patients              | 104 (29.0)        | 88 (24.9)       |
| Median PFS, months, (95% CI) b | 13.1 (11.3, 15.2) | 8.2 (7.1, 9.6)  |
| Hazard ratio (95% CI) c        | 0.65 (0.55, 0.78) |                 |
| 2-sided p-value d              | < 0.0001          |                 |
| ITT population                 |                   |                 |
| Number of patients             | 436               | 430             |
| Total events, n (%) a          | 306 (70.2)        | 314 (73.0)      |
| Censored patients              | 130 (29.8)        | 116 (27.0)      |
| Median PFS, months, (95% CI) b | 13.1 (11.4, 15.1) | 8.3 (7.2, 9.6)  |
| Hazard ratio (95% CI) e        | 0.66 (0.56, 0.77) |                 |
| 2-sided p-value f              | < 0.0001          |                 |
| HER2 IHC > 0 < 1+ population   |                   |                 |
| Number of patients             | 76                | 76              |
| Total events, n (%) a          | 51 (67.1)         | 48 (63.2)       |
| Censored patients              | 25 (32.9)         | 28 (36.8)       |
| Median PFS, months, (95% CI) b | 13.1 (9.8, 17.1)  | 9.5 (6.5, 11.6) |
| Hazard ratio (95% CI) e        | 0.74 (0.50, 1.11) |                 |
| 2-sided p-value f              | 0.1455            |                 |

<div style=\"page-break-after: always\"></div>

Table 30 Concordance of Local and Central HER2 status in DB-06

| HER2 Local       | HER2 central             | HER2 central                         | HER2 central   | HER2 central   | HER2 central   | HER2 central   | HER2 central   |
|------------------|--------------------------|--------------------------------------|----------------|----------------|----------------|----------------|----------------|
|                  | IHC 0                    | IHC 0                                | IHC 1+         | IHC 2+ /ISH-   | IHC 2+ /ISH+   | IHC 3+         | Total          |
|                  | Absent membrane staining | With membrane staining HER2-ultralow |                |                |                |                |                |
|                  |                          |                                      | HER2-low       | HER2-low       |                |                |                |
|                  |                          | (IHC > 0 < 1+)                       |                |                |                |                |                |
| IHC 0            | 123                      | 140                                  | 70             | 15             | 1              | 0              | 349            |
| IHC 1+ HER2- low | 45                       | 146                                  | 534            | 83             | 1              | 1              | 810            |
| IHC 2+ / ISH-    | 20                       | 50                                   | 146            | 236            | 6              | 2              | 460            |
| IHC 2+/ ISH+     | 0                        | 2                                    | 3              | 3              | 0              | 0              | 8              |
| IHC 3+           | 1                        | 1                                    | 0              | 0              | 0              | 0              | 2              |
| Total            | 189                      | 339                                  | 753            | 337            | 8              | 3              | 1629           |

Table 31 Disagreements between Investigator and Central Reviews of RECIST Progression (ITT Population)

|                                                                           | Number (%) of patients   | Number (%) of patients   | Difference T-DXd vs Chemotherapy   |
|---------------------------------------------------------------------------|--------------------------|--------------------------|------------------------------------|
|                                                                           | T-DXd                    | Chemotherapy             |                                    |
|                                                                           | (N = 436)                | (N = 430)                |                                    |
| RECIST progression? declared by:                                          |                          |                          |                                    |
| Investigator and central review                                           | 241 (55.3)               | 257 (59.8)               | NA                                 |
| Progression date agreement (within 2 weeks)                               | 106 (24.3)               | 128 (29.8)               | NA                                 |
| Progression date ≥ 2 weeks earlier by central review than by Investigator | 97 (22.2)                | 89 (20.7)                | NA                                 |
| Progression date ≥ 2 weeks earlier by Investigator than by central review | 38 (8.7)                 | 40 (9.3)                 | NA                                 |
| RECIST progression disagreements                                          | 102 (23.4)               | 98 (22.8)                | NA                                 |
| Investigator but not central review                                       | 74 (17.0)                | 84 (19.5)                | NA                                 |
| Central review but not Investigator                                       | 28 (6.4)                 | 14 (3.3)                 | NA                                 |
| No Progression by both                                                    | 93 (21.3)                | 75 (17.4)                | NA                                 |
| Early Discrepancy Rateb                                                   | 0.36                     | 0.36                     | -0.01c                             |
| Late Discrepancy Rated                                                    | 0.53                     | 0.45                     | 0.07                               |

Patients who had not progressed or died were censored at the latest evaluable RECIST assessment. Patients who progressed or died after two or more missed visits were censored at the latest evaluable RECIST assessment before the two missed visits. If there were no evaluable visits or no baseline assessment (unless the patient died within two visits of baseline), patients were censored at Day 1 (randomization).

Early Discrepancy Rate was the frequency of Investigator-declared progressions before central review as a proportion of all Investigator progressions.

Difference was calculated prior to rounding.

d Late Discrepancy Rate was the frequency of Investigator declared progressions after central review as a proportion of all discrepancies. Progression was determined according to RECIST 1.1.

<div style=\"page-break-after: always\"></div>

Figure 16 Tipping Point Analysis -Change in the Estimated HR (ITT Population)

<!-- image -->

Figure 17 Tipping Point Analysis -Change in the Estimated HR (HER2-low Population)

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Subgroup analysis

## Figure 18 Forest Plot of Progression-free Survival by BICR by Subgroup (ITT Population)

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

| Subgroup                                           |         | Number of events T-DXd Chemotherapy   | T-DXd                            | Median [Months, 95& CI] Chemotherapy   | Hazard ratio [95CI]   |
|----------------------------------------------------|---------|---------------------------------------|----------------------------------|----------------------------------------|-----------------------|
| Endocrine resistance: Primary                      | 80/128  | 98/140                                | 12.4 [10.3,15.2]                 | 6.6 [5.4, 7.4]                         | 0.57 [0.42,0.77]      |
| Endocrine resistance:Secondary                     | 189/308 | 172/288                               | 13.2 [12.0,15.5]                 | 9.5 [8.0,11.1]                         | 0.68 [0.55,0.84]      |
| Prior anthracycline use: Yes                       | 121/199 | 128/208                               | 13.1 [11.1,15.3]                 | 8.0[6.4,9.8]                           | 0.66 [0.51,0.85]      |
| Prior anthracycline use:No                         | 148/237 | 143/222                               | 14.5 [11.3,15.6]                 | 8.3[7.0,9.7]                           | 0.61 [0.49,0.77]      |
| Investigator's choice chemotherapy:Capecitabine    | 159/266 | 159/257                               | 13.3 [11.4,15.4]                 | 8.5 [7.0,11.3]                         | 0.66 [0.53,0.82]      |
| Investigator's choice chemotherapy: Nab-paclitaxel | 68/103  | 63/105                                | 12.9 [8.4,15.2]                  | 8.3 [7.2,11.0]                         | 0.80 [0.57,1.14]      |
| Investigator's choice chemotherapy:Paclitaxel      | 42/67   | 49/ 68                                | 16.1 [11.1,19.1]                 | 6.3 [5.0,6.9]                          | 0.35 [0.22,0.54]      |
| Liver metastases: Yes                              | 195/296 | 192/283                               | 12.2 [10.4,13.5]                 | 7.0[6.4,8.1]                           | 0.59 [0.48,0.72]      |
| Liver metastases: No                               | 74/140  | 79/147                                | 16.5 [13.2,19.4] 11.3 [8.3,15.2] |                                        | 0.70 [0.51,0.96]      |

Hazard ratio (T-DXd: Investigator's choice chemotherapy), 95% CI for HR.

A hazard ratio &lt; 1 favors T-DXd and is associated with a longer progression-free survival than Investigator's choice chemotherapy.

For the analysis on all patients, the hazard ratio and confidence interval were calculated using a stratified Cox proportional hazards model, adjusting for prior CDK4/6i use (yes vs no), and HER2 IHC expression (IHC &gt; 0 &lt; 1+ vs IHC 1+ vs IHC 2+/ISH-) and ties handled by Efron approach.

For the analysis in each subgroup, the hazard ratio and confidence interval were calculated using a Cox proportional hazards model with no stratification and ties handled by Efron approach.

Hazard ratio was not calculated in case of less than 20 events across both treatment groups in a subgroup.

Size of circle is proportional to the number of events.

Grey band represents the 95% confidence interval for the overall (all patients) hazard ratio.

Progression was determined by BICR according to RECIST 1.1.

Primary endocrine resistance was defined as: relapse while on the first 2 years of adjuvant endocrine therapy, or progressive disease within first 6 months of first line endocrine therapy for metastatic breast cancer, while on endocrine therapy. Secondary (acquired) endocrine resistance was defined as: relapse while on adjuvant endocrine therapy but after the first 2 years, or relapse within 12 months of completing adjuvant endocrine therapy, or PD &gt; 6 months after initiating endocrine therapy for metastatic breast cancer, while on endocrine therapy.

<div style=\"page-break-after: always\"></div>

Table 32 Summary of Efficacy Outcome Variables in Study DB-06 (ITT Population)

|                                             | ITT Population                              | ITT Population                      | HER2-low Population   | HER2-low Population                 | HER2-ultralowPopulation   | HER2-ultralowPopulation   |
|---------------------------------------------|---------------------------------------------|-------------------------------------|-----------------------|-------------------------------------|---------------------------|---------------------------|
|                                             | T-DXd                                       | Chemotherapy                        | T-DXd                 | Chemotherapy                        | T-DXd                     | Chemotherapy              |
|                                             | (N = 436)                                   | (N = 430)                           | (N = 359)             | (N = 354)                           | (N = 76)                  | (N = 76)                  |
| Median duration of follow-up (range)        | 18.6 (0.1, 40.5)                            | 17.8 (0.0, 42.9)                    | 19.0 (0.1, 40.5)      | 18.3 (0.0, 42.9)                    | 17.2 (3.4, 32.7)          | 16.1 (0.0, 38.1)          |
| PFS by BICR                                 |                                             |                                     |                       |                                     |                           |                           |
| Total progression events, n (%)             | 269 (61.7)                                  | 271 (63.0)                          | 225 (62.7)            | 232 (65.5)                          | 44 (57.9)                 | 39 (51.3)                 |
| Median PFS (95% CI) (months)                | 13.2 (12.0, 15.2)                           | 8.1 (7.0, 9.0)                      | 13.2 (11.4, 15.2)     | 8.1 (7.0, 9.0)                      | 13.2 (9.8, 17.3)          | 8.3 (5.8, 15.2)           |
| HR (95% CI)                                 | 0.64 (0.54, 0.76)b                          | 0.64 (0.54, 0.76)b                  | 0.62 (0.52, 0.75)c    | 0.62 (0.52, 0.75)c                  | 0.78 (0.50, 1.21)b        | 0.78 (0.50, 1.21)b        |
| P-value (2-sided)                           | <0.0001d                                    | <0.0001d                            | <0.0001e              | <0.0001e                            | NA                        | NA                        |
| PFS by Investigator                         |                                             |                                     |                       |                                     |                           |                           |
| Total progression events, n (%)             | 315 (72.2)                                  | 341 (79.3)                          | 263 (73.3)            | 284 (80.2)                          | 52 (68.4)                 | 57 (75.0)                 |
| Median PFS (95% CI) (months)                | 13.1 (11.2, 13.4)                           | 7.0 (6.3, 7.5)                      | 12.8 (11.1, 13.2)     | 7.0 (6.4, 7.5)                      | 14.6 (9.5, 15.4)          | 6.8 (4.6, 9.4)            |
| HR (95% CI)                                 | 0.51 (0.44, 0.60) b                         | 0.51 (0.44, 0.60) b                 | 0.50 (0.42, 0.60)c    | 0.50 (0.42, 0.60)c                  | 0.60 (0.41, 0.88) b       | 0.60 (0.41, 0.88) b       |
| P-value (2-sided) [nominal]                 | <0.0001d                                    | <0.0001d                            | <0.0001f              | <0.0001f                            | NA                        | NA                        |
| Interim Os                                  |                                             |                                     |                       |                                     |                           |                           |
| Total death events, n (%)                   | 161 (36.9)                                  | 174 (40.5)                          | 136 (37.9)            | 146 (41.2)                          | 25 (32.9)                 | 28 (36.8)                 |
| Median OS (95% CI) (months)*                |                                             | 28.9 (26.4, 32.7) 27.4 (23.9, 29.9) |                       | 28.9 (25.7, 33.7) 27.1 (23.5, 29.9) | 29.5 (27.9, NE)           | 27.4 (19.4, NE)           |
| HR (95% CI)b                                | 0.81 (0.66, 1.01)                           | 0.81 (0.66, 1.01)                   | 0.83 (0.66, 1.05)     | 0.83 (0.66, 1.05)                   | 0.75 (0.43, 1.29)         | 0.75 (0.43, 1.29)         |
| P-value (2-sided)                           | NA                                          | NA                                  | 0.1299                | 0.1299                              | NA                        | NA                        |
| Overall survival rate at 12 months (%)      | 87.0                                        | 81.1                                | 87.6                  | 81.7                                | 84.0                      | 78.7                      |
| Overall survival rate at 18 months (%)      | 74.8                                        | 68.7                                | 74.0                  | 69.6                                | 79.5                      | 63.9                      |
| ORR by BICR, Logistic Regression Model      | ORR by BICR, Logistic Regression Model      |                                     |                       |                                     |                           |                           |
| Number (%) of patients with response h      | 268 (61.5)                                  | 158 (36.7)                          | 217 (60.4)            | 134 (37.9)                          | 51 (67.1)                 | 24 (31.6)                 |
| Odds ratio (95% CI)i                        | 2.76 (2.10, 3.64)                           | 2.76 (2.10, 3.64)                   | 2.51 (1.86, 3.41)     | 2.51 (1.86, 3.41)                   | 4.42 (2.27, 8.86)         | 4.42 (2.27, 8.86)         |
| P-value (2-sided) [nominal]                 | <0.0001                                     | <0.0001                             | <0.0001               | <0.0001                             | NA                        | NA                        |
| Confirmed ORRbyBICR,LogisticRegressionModel | Confirmed ORRbyBICR,LogisticRegressionModel |                                     |                       |                                     |                           |                           |
| Number (%) of patients with response j      | 250 (57.3)                                  | 134 (31.2)                          | 203 (56.5)            | 114 (32.2)                          | 47 (61.8)                 | 20 (26.3)                 |
| Odds ratio (95% CI)i                        | 2.98 (2.26, 3.94)                           | 2.98 (2.26, 3.94)                   | 2.74 (2.02, 3.73)     | 2.74 (2.02, 3.73)                   | 4.54 (2.31, 9.20)         | 4.54 (2.31, 9.20)         |
| P-value (2-sided) [nominal]                 | <0.0001                                     | <0.0001                             | <0.0001               | <0.0001                             | NA                        | NA                        |
| DoR by BICR k                               |                                             |                                     |                       |                                     |                           |                           |
| Median (months)                             | 13.7                                        | 7.3                                 | 13.6                  | 7.3                                 | 13.7                      | 11.4                      |
| PFS21                                       |                                             |                                     |                       |                                     |                           |                           |
| Number of events (%) m                      | 228 (52.3)                                  | 278 (64.7)                          | 191 (53.2)            | 239 (67.5)                          | 37 (48.7)                 | 39 (51.3)                 |
| Median PFS2 (95% CI) (months) a             | 20.3 (18.9, 23.8)                           | 14.7 (13.5, 15.9)                   |                       | 20.0 (18.9, 23.8) 14.5 (12.9, 15.5) | 20.3 (16.8, 27.9)         | 16.4 (12.8, 32.3)         |
| HR (95% CI)b                                | 0.62 (0.52, 0.74)                           | 0.62 (0.52, 0.74)                   | 0.59 (0.49, 0.72)     | 0.59 (0.49, 0.72)                   | 0.81 (0.52, 1.28)         | 0.81 (0.52, 1.28)         |
| P-value (2-sided) [nominal]                 | <0.0001d                                    | <0.0001d                            | <0.0001d              | <0.0001d                            | NA                        | NA                        |

b The HR and CI were calculated using a Cox proportional hazards model with no stratificationfactors.

2 Calculated using theKaplan-Meier technique.CI formedianisderivedbased onBrookmeyer-Crowleymethod.

The HR and CI were calculated using a stratified Cox proportional hazards model, adjusting for prior CDK 4/6 inhibitor use (yes vs no) and, HER2 IHC expression (IHC 1+ vs IHC 2+/ISH-) and ties handled by Efron approach. A HR &lt;1 favors T-DXd to be associated with a longer event time than investigator's choice chemotherapy.

- e The p-value was calculated using a stratified log-rank test, adjusting for prior CDK 4/6 inhibitor use (yes vs no) and HER2 IHC expression (IHC 1+ vs IHC 2+/ISH-). A p-value &lt;0.05 is significant.

d The p-value was calculated using a log-rank test, with no stratification factors.

- f The p-value was calculated using a stratified log-rank text, adjusting for prior CDK 4/6 inhibitor use (yes vs no), HER2 IHC expression (IHC 1+ vs IHC 2+/ISH-).
- h Responsesinclude unconfirmedresponses.

Responsesincludeconfirmedresponses only.

- i An odds ratio &gt;1 favors T-DXd.The odds ratio in the ITT and HER2-low populations and CI were calculated using a logistic regression model adjusting for prior CDK 4/6 inhibitor use (yes vs no) and HER2 IHC expression (IHC &gt;0&lt; 1+ vs IHC 1+ vs IHC 2+/ISH- for ITT, IHC 1+ vs IHC 2+/ISH- for HER2-low) as covariates in the mode1. No covariates were included for HER2-ultralow population.
- k DoR is the time from the first documentation of CR/PR (including unconfirmed response) until the date of first documented progression, or death in the absence of progression.Patients who havenot progressed or died are censored at their PFS censoring date.Median calculated using Kaplan-Meier technique.
- m Patients alive and for whom a second disease progression has not been observed are censored at the earliest of: date of study termination, date last known alive, DCO or, if a patient has not had a first subsequent therapy, the date last known not to have received a first subsequent therapy.
- 1 Second progression is determined by theinvestigator according to local standard clinical practice.

1 month = 30.4375 days.

<div style=\"page-break-after: always\"></div>

In the HER2-ultralow population, the median duration of response in study DB-06 was 14.3 months (95% CI: 9.2, 20.7) and 14.1 months (95% CI: 5.9, not estimable) in patients randomised to Enhertu and chemotherapy, respectively.

Figure 19 Progression-free Survival by BICR, Kaplan-Meier plot in the HER2-ultralow Population of Study DB-06

<!-- image -->

Figure 20 Progression-free Survival by BICR Forest Plot by Renal and Hepatic Impairment Subgroup (HER2-low Population)

<!-- image -->

Hazard ratio (T-DXd : investigator's choice chemotherapy), 95% CI for HR. A hazard ratio &lt; 1 favors T-DXd to be associated with a longer PFS than investigator's choice chemotherapy.

For the analysis in each subgroup, the hazard ratio and confidence interval were calculated using a Cox proportional hazards model with no stratification and ties handled by Efron approach.

Hazard ratio is not calculated in case of less than 20 events across both treatment groups in a subgroup. Size of circle is proportional to the number of events.

Grey band represents the 95% confidence interval for the all patients hazard ratio. Progression is determined by BICR according to RECIST 1.1.

<div style=\"page-break-after: always\"></div>

Figure 21 Progression-free Survival by BICR Forest Plot by Renal and Hepatic Impairment Subgroup (ITT Population)

<!-- image -->

Hazard ratio (T-DXd : investigator's choice chemotherapy), 95% CI for HR. A hazard ratio &lt; 1 favors T-DXd to be associated with a longer PFS than investigator's choice chemotherapy.

For the analysis in each subgroup, the hazard ratio and confidence interval were calculated using a Cox proportional hazards model with no stratification and ties handled by Efron approach.

Hazard ratio is not calculated in case of less than 20 events across both treatment groups in a subgroup. Size of circle is proportional to the number of events.

Grey band represents the 95% confidence interval for the all patients hazard ratio. Progression is determined by BICR according to RECIST 1.1.

Figure 22 Overall survival, Kaplan-Meier plot (HER2-ultralow Population)

<!-- image -->

<div style=\"page-break-after: always\"></div>

Figure 23 Overall Survival Forest Plot by Renal and Hepatic Impairment Subgroup (HER2-low Population)

<!-- image -->

Hazard ratio (T-DXd : investigator's choice chemotherapy), 95% CI for HR. A hazard ratio &lt; 1 favors T-DXd to be associated with a longer overall survival than investigator's choice chemotherapy.

For the analysis in each subgroup, the hazard ratio and confidence interval were calculated using a Cox proportional hazards model with no stratification and ties handled by Efron approach.

Hazard ratio is not calculated in case of less than 20 events across both treatment groups in a subgroup. Size of circle is proportional to the number of events.

Grey band represents the 95% confidence interval for the all patients hazard ratio.

Figure 24 Overall Survival Forest Plot by Renal and Hepatic Impairment Subgroup (ITT Population)

<!-- image -->

Hazard ratio (T-DXd : investigator's choice chemotherapy), 95% CI for HR. A hazard ratio &lt; 1 favors T-DXd to be associated with a longer overall survival than investigator's choice chemotherapy.

For the analysis in each subgroup, the hazard ratio and confidence interval were calculated using a Cox proportional hazards model with no stratification and ties handled by Efron approach.

Hazard ratio is not calculated in case of less than 20 events across both treatment groups in a subgroup. Size of circle is proportional to the number of events.

Grey band represents the 95% confidence interval for the all patients hazard ratio.

<div style=\"page-break-after: always\"></div>

## Summary of main study

The following table summarises the efficacy results from the main study supporting the present application. These summaries should be read in conjunction with the discussion on clinical efficacy as well as the benefit risk assessment (see later sections).

## Table 33 Summary of Efficacy for trial DB-06

| Title: A Phase 3, Randomized, multicenter, Open-label Study of Trastuzumab Deruxtecan (T- DXd) Versus Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor-Positive Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy in the Metastatic Setting (DESTINY-Breast06)   | Title: A Phase 3, Randomized, multicenter, Open-label Study of Trastuzumab Deruxtecan (T- DXd) Versus Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor-Positive Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy in the Metastatic Setting (DESTINY-Breast06)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | Title: A Phase 3, Randomized, multicenter, Open-label Study of Trastuzumab Deruxtecan (T- DXd) Versus Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor-Positive Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy in the Metastatic Setting (DESTINY-Breast06)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | Title: A Phase 3, Randomized, multicenter, Open-label Study of Trastuzumab Deruxtecan (T- DXd) Versus Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor-Positive Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy in the Metastatic Setting (DESTINY-Breast06)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                                                                                                                                                                        | Study Code: D9670C00001 EudraCT number: 2019-004493-26 NCT Number: NCT04494425                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Study Code: D9670C00001 EudraCT number: 2019-004493-26 NCT Number: NCT04494425                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Study Code: D9670C00001 EudraCT number: 2019-004493-26 NCT Number: NCT04494425                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Design                                                                                                                                                                                                                                                                                                  | Study DESTINY-Breast06 (DB-06) was a Phase III, open-label, multi-centre, randomised study to assess the efficacy and safety of trastuzumab deruxtecan (T-DXd) compared with investigator's choice single-agent chemotherapy (capecitabine, paclitaxel, or nab-paclitaxel), in patients with advanced or metastatic breast cancer (BC) with hormone receptor positive, HER2-low or HER2- ultralow expression, and whose disease had progressed after 2 or more lines of prior endocrine therapy in the metastatic setting or after one prior line of endocrine therapy in the metastatic setting, if they progressed within 24 months of the start of adjuvant endocrine therapy or within 6 months of starting first line endocrine therapy in combination with a cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor in the metastatic setting. | Study DESTINY-Breast06 (DB-06) was a Phase III, open-label, multi-centre, randomised study to assess the efficacy and safety of trastuzumab deruxtecan (T-DXd) compared with investigator's choice single-agent chemotherapy (capecitabine, paclitaxel, or nab-paclitaxel), in patients with advanced or metastatic breast cancer (BC) with hormone receptor positive, HER2-low or HER2- ultralow expression, and whose disease had progressed after 2 or more lines of prior endocrine therapy in the metastatic setting or after one prior line of endocrine therapy in the metastatic setting, if they progressed within 24 months of the start of adjuvant endocrine therapy or within 6 months of starting first line endocrine therapy in combination with a cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor in the metastatic setting. | Study DESTINY-Breast06 (DB-06) was a Phase III, open-label, multi-centre, randomised study to assess the efficacy and safety of trastuzumab deruxtecan (T-DXd) compared with investigator's choice single-agent chemotherapy (capecitabine, paclitaxel, or nab-paclitaxel), in patients with advanced or metastatic breast cancer (BC) with hormone receptor positive, HER2-low or HER2- ultralow expression, and whose disease had progressed after 2 or more lines of prior endocrine therapy in the metastatic setting or after one prior line of endocrine therapy in the metastatic setting, if they progressed within 24 months of the start of adjuvant endocrine therapy or within 6 months of starting first line endocrine therapy in combination with a cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor in the metastatic setting. |
| Design                                                                                                                                                                                                                                                                                                  | Duration of main phase: Duration of Run-in phase: Duration of Extension phase:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Duration of main phase: Duration of Run-in phase: Duration of Extension phase:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Treatment until progressive disease, unacceptable toxicity, or withdrawal of consent Not applicable Not applicable                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Hypothesis                                                                                                                                                                                                                                                                                              | Superiority: Significant benefit of PFS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Superiority: Significant benefit of PFS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Superiority: Significant benefit of PFS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Treatments groups                                                                                                                                                                                                                                                                                       | T-DXd (N=436)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | T-DXd (N=436)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | T-DXd: 5.4 mg/kg IV infusion Q3W                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Treatments groups                                                                                                                                                                                                                                                                                       | Investigator Choice Chemotherapy (N=430)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | Investigator Choice Chemotherapy (N=430)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | Paclitaxel: 80 mg/m 2 IV every week in 3-week cycles Capecitabine: 1000 or 1250 mg/m 2 twice daily orally for 2 weeks followed by a 1-week rest period in 3- week cycles Nab-paclitaxel: 100 mg/m 2 IV every week for 3 weeks followed by a 1-week rest period in 4-week cycles                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Endpoints and definitions                                                                                                                                                                                                                                                                               | Primary endpoint                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | PFS by BICR in the HER2-low population                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Progression-free survival defined as the time from date of randomisation until the date of objective radiological disease progression by BICR according to RECIST 1.1 or death (by any cause in the absence of progression)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Endpoints and definitions                                                                                                                                                                                                                                                                               | Key Secondary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | PFS by BICR in the ITT population                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Progression-free survival defined as the time from date of randomisation until the date of objective radiological disease progression by BICR according to RECIST 1.1 or death (by any cause in the absence of progression)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Endpoints and definitions                                                                                                                                                                                                                                                                               | Key Secondary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | OS in the HER2-low population                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Overall survival defined as the time from the date of randomization until death due to any cause regardless of whether the patient withdrew from randomized therapy or received another anticancer therapy (ie,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Endpoints and definitions                                                                                                                                                                                                                                                                               | Key Secondary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | OS in the ITT population                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | date of death or censoring - date of randomisation + 1).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Endpoints and definitions                                                                                                                                                                                                                                                                               | Other Secondary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | ORR by BICR                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Objective response rate defined as the percentage of patients with at least one visit response of CR or PR by BICR using RECIST 1.1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |

<div style=\"page-break-after: always\"></div>

|                                                 | Other Secondary                                                                                                                                                                                                                                                   | DOR by BICR                                                                                                                                                                                                                                                       | Duration of response rate defined as the time from date of first detection of objective response until the date of objective radiological disease progression by BICR, per RECIST 1.1 or death in the absence of progression                                      | Duration of response rate defined as the time from date of first detection of objective response until the date of objective radiological disease progression by BICR, per RECIST 1.1 or death in the absence of progression                                      |
|-------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Database lock                                   | DCO 18 March 2024 for PFS FA/OS IA                                                                                                                                                                                                                                | DCO 18 March 2024 for PFS FA/OS IA                                                                                                                                                                                                                                | DCO 18 March 2024 for PFS FA/OS IA                                                                                                                                                                                                                                | DCO 18 March 2024 for PFS FA/OS IA                                                                                                                                                                                                                                |
| Results and Analysis                            | Results and Analysis                                                                                                                                                                                                                                              | Results and Analysis                                                                                                                                                                                                                                              | Results and Analysis                                                                                                                                                                                                                                              | Results and Analysis                                                                                                                                                                                                                                              |
| Analysis description                            | Primary Analysis                                                                                                                                                                                                                                                  | Primary Analysis                                                                                                                                                                                                                                                  | Primary Analysis                                                                                                                                                                                                                                                  | Primary Analysis                                                                                                                                                                                                                                                  |
| Analysis population and time point description  | All efficacy analyses were performed on the FAS (ITT) population* which includes the hormone receptor-positive, HER2-low (IHC 2+/ISH- and IHC 1+) and HER2-ultralow (HER2 IHC > 0 < 1+) population; all randomized patients, including those randomized in error. | All efficacy analyses were performed on the FAS (ITT) population* which includes the hormone receptor-positive, HER2-low (IHC 2+/ISH- and IHC 1+) and HER2-ultralow (HER2 IHC > 0 < 1+) population; all randomized patients, including those randomized in error. | All efficacy analyses were performed on the FAS (ITT) population* which includes the hormone receptor-positive, HER2-low (IHC 2+/ISH- and IHC 1+) and HER2-ultralow (HER2 IHC > 0 < 1+) population; all randomized patients, including those randomized in error. | All efficacy analyses were performed on the FAS (ITT) population* which includes the hormone receptor-positive, HER2-low (IHC 2+/ISH- and IHC 1+) and HER2-ultralow (HER2 IHC > 0 < 1+) population; all randomized patients, including those randomized in error. |
| Descriptive statistics and estimate variability | Treatment group                                                                                                                                                                                                                                                   | Treatment group                                                                                                                                                                                                                                                   | T-DXd                                                                                                                                                                                                                                                             | Investigator's Choice Chemotherapy                                                                                                                                                                                                                                |
| Descriptive statistics and estimate variability | ITT Population                                                                                                                                                                                                                                                    | ITT Population                                                                                                                                                                                                                                                    | N=436                                                                                                                                                                                                                                                             | N=430                                                                                                                                                                                                                                                             |
| Descriptive statistics and estimate variability | Number of events for PFS                                                                                                                                                                                                                                          | Number of events for PFS                                                                                                                                                                                                                                          | 269                                                                                                                                                                                                                                                               | 271                                                                                                                                                                                                                                                               |
| Descriptive statistics and estimate variability | Number of events for OS                                                                                                                                                                                                                                           | Number of events for OS                                                                                                                                                                                                                                           | 161                                                                                                                                                                                                                                                               | 174                                                                                                                                                                                                                                                               |
| Descriptive statistics and estimate variability | PFS by BICR median (95% CI); months                                                                                                                                                                                                                               | PFS by BICR median (95% CI); months                                                                                                                                                                                                                               | 13.2 (12.0, 15.2)                                                                                                                                                                                                                                                 | 8.1 (7.0, 9.0)                                                                                                                                                                                                                                                    |
| Descriptive statistics and estimate variability | HR (95%CI)                                                                                                                                                                                                                                                        | HR (95%CI)                                                                                                                                                                                                                                                        | 0.64 (0.54, 0.76)                                                                                                                                                                                                                                                 | 0.64 (0.54, 0.76)                                                                                                                                                                                                                                                 |
| Descriptive statistics and estimate variability | OS median (95%CI); months                                                                                                                                                                                                                                         | OS median (95%CI); months                                                                                                                                                                                                                                         | 28.9 (26.4 - 32.7)                                                                                                                                                                                                                                                | 27.4 (23.9 - 29.9)                                                                                                                                                                                                                                                |
| Descriptive statistics and estimate variability | HR (95%CI)                                                                                                                                                                                                                                                        | HR (95%CI)                                                                                                                                                                                                                                                        | 0.81 (0.66, 1.01))                                                                                                                                                                                                                                                | 0.81 (0.66, 1.01))                                                                                                                                                                                                                                                |
| Descriptive statistics and estimate variability | Confirmed ORR by BICR N (%) (95%CI)                                                                                                                                                                                                                               | Confirmed ORR by BICR N (%) (95%CI)                                                                                                                                                                                                                               | 250 57.3% (52.5%, 62.0%)                                                                                                                                                                                                                                          | 134 31.2% (26.8%, 35.8%)                                                                                                                                                                                                                                          |
| Descriptive statistics and estimate variability | Confirmed DOR by BICR Median, months (95% CI)                                                                                                                                                                                                                     | Confirmed DOR by BICR Median, months (95% CI)                                                                                                                                                                                                                     | 14.3 (12.5, 15.9)                                                                                                                                                                                                                                                 | 8.6 (6.9, 11.5)                                                                                                                                                                                                                                                   |
| Notes                                           | *Results are only shown for the ITT population, since this is the target population for the sought indication                                                                                                                                                     | *Results are only shown for the ITT population, since this is the target population for the sought indication                                                                                                                                                     | *Results are only shown for the ITT population, since this is the target population for the sought indication                                                                                                                                                     | *Results are only shown for the ITT population, since this is the target population for the sought indication                                                                                                                                                     |

## Clinical studies in special populations

## Table 34 Clinical studies in special populations

|                               | Controlled Trials ITT Population Subjects number /total number (%)   |   Non-controlled trials. |
|-------------------------------|----------------------------------------------------------------------|--------------------------|
| Renal impairment a            | 114/866 (13.2)                                                       |                        0 |
| Hepatic impairment patients b | 4/866 (0.5)                                                          |                        0 |
| Paediatric patients <18 years | 0/866                                                                |                        0 |
| Age 18-64                     | 599/866 (69.2)                                                       |                        0 |

<div style=\"page-break-after: always\"></div>

|             | Controlled Trials ITT Population Subjects number /total number (%)   |   Non-controlled trials. |
|-------------|----------------------------------------------------------------------|--------------------------|
| Age 65-74   | 195/866 (22.5)                                                       |                        0 |
| Age 75-84   | 69/866 (8.0)                                                         |                        0 |
| Age 85+     | 3/866 (0.3)                                                          |                        0 |
| Missing Age | 0/866                                                                |                        0 |

- a  Including moderate and severe renal impairment where moderate renal impairment is serum creatinine clearance ≥ 30 but &lt; 60 mL.min (Stage 3) and severe renal impairment is ≥ 15 but &lt;30 mL/min (Stage 4 and Stage5).

b  Including moderate and severe hepatic impairment where moderate hepatic impairment is total bilirubin

≥ 1.5 × ULN, ≤ 3.0 × ULN and any AST except for patients with Gilbert syndrome and severe hepatic impairment is total bilirubin ≥ 3.0 × ULN and any AST regardless of Gilbert syndrome

## Supportive study

Not applicable.

## In vitro biomarker test for patient selection for efficacy

To be eligible for the DB-06 study, patients had to have a history of HER2-negative status (IHC 0 [ISHor untested], IHC 1+ [ISH- or untested] or IHC 2+/ISH-). However, the inclusion and randomization of patients in study DB-06 was based on prospective central laboratory assessment of HER2-ultralow (IHC &gt; 0 &lt; 1+) or HER2-low (IHC 1+ and IHC 2+/ISH-) status using the PATHWAY/VENTANA antiHER2 (4B5) IUO assay and an approved HER2 ISH assay per manufacturers requirements for IHC 2+ cases.

The overall historical (local) versus central HER2 concordance data were summarized for cases which had both valid local HER2 test results in the eCRF, and central test results reported and is provided in the below table. HER2 IHC 0 scoring was separated into 2 categories ('IHC 0 absent membrane staining' or 'IHC 0 with membrane staining, described as IHC &gt; 0 &lt; 1+ in DB-06') for central test results but not for local test results since this is not currently part of standard clinical practice though these 2 categories are described within IHC 0 category in ASCO/CAP guidelines (Wolff et al. 2023). Therefore, concordance between local and central scoring for HER2-ultralow (IHC 0 with membrane staining) cannot be provided. Among cases that had a prior historical (local) HER2-low (IHC 1+ or IHC 2+/ISH-) result, 78.7% (999/1270) of cases were determined as HER2-low by central HER2 testing, and this is consistent with what was observed in DB-04 screening as 77.6% (Garrido et al. 2023). Differences in testing methodologies, lack of local pathologist training for determination of HER2 scores in the lower expression end, and intra-patient tumour heterogeneity can contribute to the observed differences between local and central assessment of HER2 expression.

Based on experience with HER2 testing following trastuzumab approval, where local versus central concordance for HER2-positivity scoring showed marked improvements over time (initial discordance for HER2 status of 52.4% was reduced to 8.4% in later studies) (Pfitzner et al. 2018), improvements in HER2-low and HER2-ultralow scoring is anticipated as more pathologists receive training and education, and HER2-low and HER2-ultralow assessment becomes standard routine clinical practice and is included in guidelines. Consistent with this, a study found improvements in HER2-low scoring after training (Ruschoff et al. 2023).

<div style=\"page-break-after: always\"></div>

Table 35 Concordance of Local and Central HER2 status in DB-06

| HER2 Local    | HER2 Local   | HER2 central             | HER2 central                         | HER2 central   | HER2 central   | HER2 central   | HER2 central   | HER2 central   |
|---------------|--------------|--------------------------|--------------------------------------|----------------|----------------|----------------|----------------|----------------|
|               |              | IHC 0                    | IHC 0                                | IHC 1+         | IHC 2+ /ISH-   | IHC 2+ /ISH+   | IHC 3+         | Total          |
|               |              | Absent membrane staining | With membrane staining HER2-ultralow |                |                |                |                |                |
|               |              |                          | (IHC                                 | HER2-low       | HER2-low       |                |                |                |
|               |              |                          | > 0 < 1+)                            |                |                |                |                |                |
| IHC 0         | IHC 0        | 123                      | 140                                  | 70             | 15             | 1              | 0              | 349            |
| IHC 1+        | HER2- low    | 45                       | 146                                  | 534            | 83             | 1              | 1              | 810            |
| IHC 2+ / ISH- |              | 20                       | 50                                   | 146            | 236            | 6              | 2              | 460            |
| IHC 2+/ ISH+  | IHC 2+/ ISH+ | 0                        | 2                                    | 3              | 3              | 0              | 0              | 8              |
| IHC 3+        | IHC 3+       | 1                        | 1                                    | 0              | 0              | 0              | 0              | 2              |
| Total         | Total        | 189                      | 339                                  | 753            | 337            | 8              | 3              | 1629           |

During the evaluation, the MAH further clarified the background for the HER2-testing.

Scientific rationale for the choice of the predictive in vitro biomarker test (including the prevalence) and cut-point selection

The primary population of the DESTINY-Breast06 (DB-06) study is the HER2-low population and the MAH therefore decided to use the same in vitro biomarker test i.e. PATHWAY/VENTANA anti-HER2 (4B5) assay, as used in the DESTINY-Breast04 study to select HER2-low BC patients. No substantial molecular differences have been demonstrated between HER2-low and HER2 IHC 0 BC tumours (including both absent membrane staining and with membrane staining cases). It is described in the ESMO expert consensus statement that HER2-low should not be considered a distinct molecular entity (Tarantino et al. 2023). The MAH therefore did not consider HER2-ultralow (IHC 0 with membrane staining), which is part of the HER2 IHC 0 BC tumours, as a distinct molecular entity either, and rather part of a heterogeneous group of tumours with a continuum of different HER2 expression levels from HER2-low to HER2 IHC 0 absent membrane staining, and that these groups can be distinguished by the use of PATHWAY/VENTANA anti-HER2 (4B5) assay.

Regarding the level of HER2 expression detected by the in vitro test, HER2 IHC assays used in clinical practice, including the PATHWAY/VENTANA anti-HER2 (4B5) assay, are optimized to detect overexpression of HER2 and not to detect basal levels of HER2 expression in normal breast tissue. Therefore, any staining detected with the PATHWAY/VENTANA anti-HER2 (4B5) assay, including HER2ultralow (IHC 0 with membrane staining) indicates higher HER2 expression than in normal breast tissue.

Available clinical data were taken into consideration when selecting the cut-point for HER2 testing. At the time of study DB-06 design, there was limited clinical data on patients treated with T-DXd and classified as IHC 0 (both absent membrane staining and with membrane staining cases), but it was hypothesized that any detectable HER2 expression above that of normal breast tissue, including HER2ultralow (IHC 0 with membrane staining), was required for a positive benefit/risk balance of T-DXd treatment. Based on the same rationale, those patients with no detectable HER2 staining (IHC 0

<div style=\"page-break-after: always\"></div>

absent membrane staining) were not eligible for the study, and the MAH selected the HER2-ultralow cut-off as part of the DB-06 design.

A summary of HER2-low and HER2-ultralow prevalence from literature and screening data from study DB-06 is detailed in the below table. Among studies of primary or metastatic HR+ HER2- BC, approximately 20% to 25% were HER2-ultralow (Chen et al. 2023, Mehta 2024, Viale et al. 2023).

Table 36 HER2-ultralow and HER2-low Prevalence in HER2-negative BC

| Data(n)/publication                                     | IHC 0                         | IHC 0                         | IHC 1+ and 2+/ISH-   |
|---------------------------------------------------------|-------------------------------|-------------------------------|----------------------|
|                                                         | Absent Membrane Staining      | HER2-ultralow a               | HER2-low             |
| DB-06 Screening Datab HR+/HER2-negative BC b (n = 1742) | 12.1%                         | 21.8%                         | 65.4%                |
| HR+/HER2-negative BC (n = 1156) (Chen et al 2023)       | 5.4%                          | 27.7%                         | 66.9%                |
| HER2-negative BC (n = 300) (Mehta 2024)                 | 14% to 16% c of HER2-negative | 21% to 24% c of HER2-negative | Not applicable       |
| HR+/HER2-negative BC (n = 554) (Viale et al 2023)       | 17.5%                         | 11.4%                         | 71.1%                |

## Analytical method including analytical and clinical validation strategy

Ventana has performed extensive analytical validation of the 4B5 assay for the detection of HER2ultralow expression, specifically addressing the assay's analytical sensitivity, specificity, and robustness, as well as intra- and inter-instrument, reagent lot, pathologist, and laboratory precision and/or reproducibility for the HER2-ultralow IHC cut-off. All analytical studies, including the reproducibility studies, met Ventana's prespecified acceptance criteria.

In addition, Ventana also conducted tissue characterization studies to evaluate the impact of tumour heterogeneity on the assay performance, including i) a case heterogeneity study to characterize within-case heterogeneity by evaluating staining outcome from multiple blocks from the same subject case, ii) a block heterogeneity study to characterize within-block heterogeneity by evaluating staining outcome from multiple samples from the same tissue block, and iii) a primary vs metastatic tumour comparison study to characterize staining performance of the assay on the primary tumour versus subject-matched metastatic tumour sample.

Validation of the assay in relation to HER2-ultralow also considered sample preparation, including specimen type acceptability, and pre-analytical sample processing. Prior to participating in the study, all clinical sites were provided with guidance on appropriate sample preparation, this guidance was aligned with the VENTANA HER2 (4B5) package insert. The device package insert also detailed the compatible platform and scoring criteria. The clinical validity of the assay was demonstrated by assessing its performance in determining subject eligibility for enrolment in the DB-06 study.

<div style=\"page-break-after: always\"></div>

In conclusion, the MAH has sufficiently clarified the scientific rationale for HER2 testing.

## 2.4.3. Discussion on clinical efficacy

## Design and conduct of clinical studies

The efficacy assessment of the applied extension of indication is based on the pivotal study DESTINYBreast06 (DB-06), which is a phase III randomised open-label two-arm study comparing trastuzumab deruxtecan (T-DXd) head to head with the current SoC in patients who were chemo-naïve and had received 1-2 lines of endocrine therapy (ET) +/- a CDK4/6 Inhibitor or had recurred within 24 months of starting adjuvant treatment. The proposed dosing regimen of 5.4 mg/kg IV Q3W is the same used for T-DXd in the approved breast cancer indications. Single-agent chemotherapy of Physician's choice (capecitabine, nab-paclitaxel or paclitaxel) used in the control arm is considered acceptable. Patients were randomised 1:1 to receive either T-DXd 5.4 mg/kg (N=436) IV Q3W or physician's choice of single-agent chemotherapy (N=430, capecitabine 60%, nab-paclitaxel 24%, or paclitaxel 16%). According to the MAH, anthracyclines were not considered an appropriate choice for the comparator arm due to the cumulative risk of cardiotoxicity associated with these agents, which limits treatment duration. Moreover, given the DB-06 study design, which entails treatment continuation until progression of disease, and the use of anthracyclines in the neoadjuvant/adjuvant setting, which also limits their use in the metastatic setting, it was considered that the use of anthracyclines as a choice of comparator would not be appropriate due to the maximum lifetime cumulative dose cap of these agents, potentially excluding patients from enrolling into the trial according to the MAH. Considering that baseline characteristics from the pivotal study showed that ~45-47% of the included patients have had prior anthracyclines (see section 5.1 of the SmPC), this precautionary measure of precluding this option may not have been necessary as more than half of patients could have received anthracyclines without safety concerns. The beneficial effect of T-DXd in patients who did not yet receive anthracyclines in the (neo-) adjuvant setting remains therefore uncertain. However, the MAH's justification is acknowledged. The study excluded patients with prior chemotherapy for advanced or metastatic disease, patients with a history of ILD/pneumonitis requiring treatment with steroids or ILD/pneumonitis at screening, uncontrolled or significant cardiovascular disease, untreated and symptomatic brain metastases, or ECOG performance status &gt;1. The exclusion criteria are similar to previous Enhertu studies and adequately described in section 5.1 of the SmPC.

T-DXd remains approved under a conditional marketing authorisation with the outstanding specific obligations to be fulfilled pertaining to of the approved indications in the gastric cancer and NSCLC setting. As the data submitted with the current variation application are considered comprehensive, no new specific obligation is being imposed.

A sample size of 866 patients randomized 1:1 to the two treatment arms is considered acceptable.

The current DCO was at the time of the final analysis of PFS and at the first interim analysis (IA) of overall survival (OS).

After the initial release (v1.0, 20 March 2020), and although the study protocol was amended 4 times, the protocol amendments do not appear to have had a major impact on the study outcome.

Baseline characteristics showed that the median age was ~58 years with ~69% of the patients being less than 65 years old and ~31% of the patients were ≥65 years, which is reflective of the targeted patient population. One male patient was included in the control arm (chemotherapy), which is acceptable since breast cancer is rare in men. The results from the pivotal trial are considered extrapolatable to men with HER2-low and ultralow metastatic breast cancer based on the common

<div style=\"page-break-after: always\"></div>

biological and pharmacological rationale and in line with previous EMA decisions for T-DXd and other HER2-targeted treatments (e.g. trastuzumab). Most patients were White (~53%) or Asian (~35%), which was equally distributed between the arms. Hence, the fraction of patients representative of the EU population is considered acceptable for interpretation of the study results. Patients were most often of good ECOG Performance status (PS), and either of ECOC PS 0 (~60%) or ECOG PS 1, and the majority had tumours with HER2 expression on ICH of 1+ (~54%) or IHC2+/ISH- (~27%), which are both categorised as HER2-low, while only 17% were HER2-ultralow (IHC&gt;0&lt;1+). Approximately one third of patients had tumours with primary endocrine resistance, while the remaining had secondary endocrine resistance. 67% of patients had liver metastases, 32% had lung metastases, 8% had brain metastases, and 3% had bone-only metastases.

Prior lines of therapy were equally distributed between the treatment arms and in line with the inclusion criteria and the wording of the claimed therapeutic indication i.e. ' Enhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic HR+ HER2-low or HER2ultralow breast cancer who have received at least one endocrine therapy in the metastatic setting and who are not considered suitable for endocrine therapy as the next line of treatment (see sections 4.2 and 5.1)' ). Overall, the eligibility criteria adequately define the target population in need for chemotherapy, with the general note that the clinical trial population is considered healthier than the population treated in clinical practice. The wording of the indication initially applied for generally reflected the included study population, except for the additional specifications on rapid progression in case patients received only 1 line of ET in the metastatic setting. Due to concern that patients could be treated with Enhertu after only one line of ET in the metastatic setting in a broader sense, the wording of the indication was amended during the evaluation to include patients who are not considered suitable for endocrine therapy (ET) as the next line of treatment.

The primary objective of study DB-06 was to compare PFS benefit by blinded independent review (BICR) in the HER2-low population, and in the ITT population. OS in the HER2-low population and in the ITT population were secondary endpoints. The ITT comprises both the HER2-low and the HER2ultralow populations. Other secondary efficacy endpoints were ORR, DoR, PFS by investigator and PFS2. The primary and secondary endpoints are considered acceptable and established in the current disease setting.

## Efficacy data and additional analyses

The primary endpoint of PFS by BICR assessment in the HER2-low population was met and showed a statistically significant and clinically relevant improvement of 5.1 months from 8.1 months with chemotherapy to 13.2 months with T-DXd, HR 0.62 (95%CI: 0.52; 0.75). The data is considered mature with more than 60% events in both arms after a median duration of follow up of 19 months in the T-DXd arm and 18.3 months in the chemotherapy arm. The KM curves for PFS by BICR separates early and stay separated, so further updates are unlikely to change the benefit significantly due to the high number of events in both arms, although a third of the patients are censored. The sensitivity analyses provided support the primary analysis of PFS by BIRC.

The performance of the control arm is considered in line with what can be expected, as the median PFS with single-agent chemotherapy is approximately 6 to 7 months in patients who received 0 to 1 prior lines of chemotherapy in patients with advanced breast cancer, who has progressed on multiple lines of endocrine therapy +/- targeted therapy or has progressed rapidly on prior adjuvant or first-line endocrine therapy (O'Shaughnessy at al 2021, Robert at al. 2011). All of the included patients were chemotherapy-naïve in the metastatic setting and were less pre-treated, therefore the performance of the control arm is considered acceptable in this context.

<div style=\"page-break-after: always\"></div>

The secondary endpoint of OS in the HER2-low population showed that, with ~40% of events at the time the first IA ,the median OS was 28.9 months in the T-DXd arm vs 27.1 months in the control arm; HR of 0.83 (95%CI: 0.66; 1.05). The KM curves for OS do not clearly separate but there is no sign of a detrimental effect. Considering that the targeted patient population are likely to have a relatively long OS and will receive further lines of treatment, this OS result is considered sufficient to grant an approval in the claimed indication as any future detriment on OS is considered unlikely. The interim results of OS in the ITT population were comparable to that of the HER2-low population, i.e. the median OS was 28.9 months (95%CI: 26.4, 32.7) for T-DXd and 27.4 months (95%CI: 23.9, 29.9) for chemotherapy (HR: 0.81; 95%CI: 0.66, 1.01). The next IA of OS is planned at 75% events and is expected around April 2025. The MAH is recommended to submit the results of the next interim OS analysis data as well as the final OS analysis data from study DB-06 when available (Recommendation (REC)).

PFS by BICR assessment in the ITT population also showed a statistically significant and clinically relevant improvement of 5.1 months from 8.1 months with chemotherapy to 13.2 months with T-DXd, HR 0.64 (95%CI: 0.54, 0.76). The KM curves also separates early and stay separated, so these results support the claimed indication for the ITT population, which includes both the HER2-low and the HER2ultralow populations.

Since OS in the HER2-low population was not statistically significant, the OS analysis in the ITT population was not tested according to the testing hierarchy, which is considered acceptable. PFS by INV assessment in the HER2-low population showed slightly better results than for the ITT population.

Confirmed ORR by BICR in the HER2-low population , which was clinically and statistically significantly improved from 32.2% in the control arm to 56.5% with T-DXd. Complete responses (CR by BICR) were observed in 2.5% of the patients in the T-DXd arm and 0 patients in the chemotherapy arm, while the partial response (PR) was observed in 54.0% on T-DXd vs 32.2% for chemotherapy. The median duration of response (DoR) by BICR was longer for patients in the T-DXd arm i.e. 14.1 months vs 8.6 months with chemotherapy. These results are in line with the primary analysis of PFS and the improved ORR and DoR results are considered clinically relevant as a higher chance of a durable response is a key goal in the management of the targeted patient population with advanced progressive disease.

Confirmed ORR by BICR in the ITT population was clinically and statistically significantly improved from 31.2% in the control arm to 57.3% with T-DXd. CR was observed in 3.0% of the patients with TDXd and 0 patients in the chemotherapy arm, while the rate of PR was 54.4% with T-DXd vs 31.2% in the chemotherapy arm. The median DoR by BICR was also longer for patients in the T-DXd arm i.e. 14.3 months vs 8.6 months with chemotherapy, which is in line with the primary analysis of PFS and the improved ORR and DoR results in the ITT population are considered supportive of the claimed indication.

In the absence of fully mature OS data, the provided PFS2 results from the ITT population are considered clinically important. The median PFS2 in the T-DXd arm was 20.3 months vs 14.7 months in the chemotherapy arm, HR 0.61 (95%CI: 0.51; 0.73), with the KM curves separating early and staying separated, so the patients on T-DXd have a longer time to the second progression on next-line therapy. This is considered reassuring and indicates that any detriment on OS is unlikely.

Considering the open-label design of the pivotal DB-06 study, the patient-reported outcomes should be interpreted with caution and are therefore not reflected in section 5.1 of the SmPC. No firm conclusion can be drawn and the conclusions in the safety section are considered more important in relation to the tolerability of T-DXd.

<div style=\"page-break-after: always\"></div>

The subgroup analyses of PFS by BIRC in the ITT population are considered the most relevant for the sought indication, considering that the primary endpoint was PFS by BICR in the HER2-low population. The ITT population consists of both the HER2-low and the HER2-ultralow populations, and the subgroup analysis for both populations combined show that all of the point estimates are on the right side of one except for a small subgroup of those who were from the region of North America (HR 1.02 (95%CI: 0.60;1.74), N=80). This is not concerning as the point estimate is very close to one, no detrimental effect is observed and this may be due to a chance finding. Overall, the PFS benefit observed across the following prespecified subgroups, including HER2 expression, prior CDK4/6 inhibitor use (yes or no), prior taxane use in the non-metastatic setting (yes or no), and number of prior lines of endocrine therapy in the metastatic setting was in line with the primary analysis. Subgroup analyses based on renal and hepatic impairment have also been provided during the evaluation and these analyses support a beneficial effect independent of renal/hepatic impairment. No patients with severe renal impairment or moderate/severe hepatic impairment were included in the study.

The subgroup analysis of the HER2-ultralow population showed a median PFS of 13.2 months in patients who had T-DXd (N=76) versus 8.3 months in the control arm, HR 0.78 (95%CI: 0.50, 1.21). It is acknowledged that although this result is not statistically significant, the difference in PFS benefit observed is very similar to the primary analysis of the primary endpoint, and the numerical difference of 4.9 months is considered clinically relevant. The limited sample size of the HER2-ultralow population of 152 patients in total hampers the robustness of the results and is considered the reason for the not statistically significant results. However, the efficacy results from this subgroup is considered clinically relevant and the close similarity to the PFS, ORR and DoR and the PFS results from the HER2-low and the ITT populations are considered compelling, it is therefore concluded that T-DXd has similar and clinically relevant efficacy in the HER2-ultralow population as well. To conclude, it is considered acceptable to grant an indication of T-DXd for both the HER2-low and the HER2-ultralow populations, meaning the ITT population in study DB-06.

## 2.4.4. Conclusions on the clinical efficacy

The results from the pivotal study DB-06 show a statistically significant and clinically relevant superior efficacy of trastuzumab deruxtecan (T-DXd) compared to singleagent chemotherapy of Physician's choice regarding PFS by BIRC and INV, response rate, duration of response in the ITT population. Partly mature OS and PFS2 data indicates that any detriment on OS is unlikely and more mature OS data will be provided post-approval (REC).

To conclude, the efficacy of Enhertu as monotherapy is considered established for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-low or HER2-ultralow breast cancer who have received at least one endocrine therapy in the metastatic setting and who are not considered suitable for endocrine therapy as the next line of treatment.

## 2.5. Clinical safety

## Introduction

The current safety assessment is based on data from the pivotal study DESTINY-Breast06 (DB-06) (n=434 received T-DXd) and 2 safety pools: a BC Pool, comprising 1741 patients exposed to T-DXd from 7 studies. All Tumour Type (ATT) Pool, comprising 2335 patients exposed to T-DXd from 11

<div style=\"page-break-after: always\"></div>

studies. The studies included in both pools evaluated safety and tolerability of T-DXd 5.4 mg/kg Q3W across stage and line of treatment.

The used data cut-off date for study DB-06 was 18 March 2024. Median (range) duration of follow-up of censored patients in the ITT population was 15.3 months in the T-DXd and 7.2 months in the chemotherapy arm.

Table 37 Summary of Clinical Studies constituting the All Tumour Type (ATT) Pool

| Study Number (Study Name) Phase Status a                      | Data Cut- off Date   | Study Title                                                                                                                                                                                                                                                                                                       | Number of Patients Treated with T-DXd 5.4 mg/kg or Active Control   |
|---------------------------------------------------------------|----------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------|
| Breast Cancer                                                 | Breast Cancer        | Breast Cancer                                                                                                                                                                                                                                                                                                     | Breast Cancer                                                       |
| D9670C00001 (DESTINY- Breast06; DB-06) Phase III Completed    | 18 Mar 2024          | A Phase 3, Randomized, Multi-center, Open-label Study of Trastuzumab Deruxtecan (TDXd) Versus Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor- positive Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy in the Metastatic Setting                                       | 434 T-DXd 417 Chemotherapy                                          |
| DS8201-A-U201 (DESTINY- Breast01; DB- 01) Phase II Completed  | 08 Jun 2020          | A Phase 2, Multicenter, Open-label Study of DS-8201a, an Anti-HER2-antibody Drug Conjugate (ADC), for HER2- positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated with T-DM1                                                                                                         | 184 T-DXd                                                           |
| DS8201-A-U301 (DESTINY- Breast02; DB- 02) Phase III Completed | 30 Jun 2022          | A Phase 3, Multicenter, Randomized, Open-label, Active- controlled Study of Trastuzumab Deruxtecan (DS-8201A), an Anti-HER2-antibody Drug Conjugate, versus Treatment of Investigator's Choice for HER2 -positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated with T-DM1            | 404 T-DXd 195 TPC                                                   |
| DS8201-A-U302 (DESTINY- Breast03; DB- 03) Phase III Completed | 25 Jul 2022          | A Phase 3, Multicenter, Randomized, Open-label, Active- controlled Study of Trastuzumab Deruxtecan (DS-8201a), an Anti-HER2-antibody Drug Conjugate, versus Trastuzumab Emtansine (T-DM1) for HER2-positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated with Trastuzumab and Taxane | 257 T-DXd 261 T-DM1                                                 |
| DS8201-A-U303 (DESTINY- Breast04; DB- 04) Phase III Completed | 11 Apr 2022          | A Phase 3, Multicenter, Randomized, Open-label, Active- controlled Trial of Trastuzumab Deruxtecan (T-DXd), an Anti-HER2-antibody Drug Conjugate (ADC), versus Treatment of Physician's Choice for HER2 -low, Unresectable and/or Metastatic Breast Cancer Subjects                                               | 371 T-DXd 172 TPC                                                   |
| NSCLC                                                         | NSCLC                | NSCLC                                                                                                                                                                                                                                                                                                             | NSCLC                                                               |
| DS8201-A-U204 (DESTINY- Lung01; DL-01) Phase II Completed     | 03 Dec 2021          | A Phase 2, Multicenter, Open-label, 2-cohort Study of Trastuzumab Deruxtecan (DS-8201a), an Anti-HER2- antibody Drug Conjugate (ADC), for HER2-overexpressing or -mutated, Unresectable and/or Metastatic Non-small Cell Lung Cancer (NSCLC)                                                                      | 41 T-DXd                                                            |

<div style=\"page-break-after: always\"></div>

Table 37 Summary of Clinical Studies constituting the All Tumour Type (ATT) Pool

| Study Number (Study Name) Phase Status a                     | Data Cut- off Date   | Study Title                                                                                                                                                                                                              | Number of Patients Treated with T-DXd 5.4 mg/kg or Active Control   |
|--------------------------------------------------------------|----------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------|
| DS8201-A-U206 (DESTINY- Lung02; DL-02) Phase II Completed    | 23 Dec 2022          | A Phase 2, Multicenter, Randomized Study of Trastuzumab Deruxtecan in Subjects with HER2-mutated Metastatic Non- small cell Lung Cancer (NSCLC)                                                                          | 101 T-DXd                                                           |
| Solid Tumors                                                 |                      |                                                                                                                                                                                                                          |                                                                     |
| DS8201-A-J101 Phase I Completed                              | 01 Aug 2019          | Phase 1, Two-part, Multicenter, Non-randomized, Open- label, Multiple-dose, First-in-human Study of DS-8201a, in Subjects with Advanced Solid Malignant Tumors                                                           | 91 T-DXd                                                            |
| D967MC00001 (DESTINY- PanTumor01; DP-01) Phase II Completed  | 25 Jan 2023          | A Phase 2, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of T-DXd for the Treatment of Unresectable and/or Metastatic Solid Tumors Harboring HER2-activating Mutations Regardless of Tumor Histology | 102 T-DXd                                                           |
| D967VC00001 (DESTINY- PanTumor02; DP-02) Phase III Completed | 08 Jun 2023          | A Phase 2, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of T-DXd (DS-8201a) for the Treatment of Selected HER2-expressing Tumors                                                                    | 267 T-DXd                                                           |
| Colorectal Cancer                                            | Colorectal Cancer    | Colorectal Cancer                                                                                                                                                                                                        | Colorectal Cancer                                                   |
| DS8201-A-U207 (DESTINY- CRC02; DC-02) Phase II Completed     | 01 Nov 2022          | A Phase 2, Multicenter, Randomized Study of Trastuzumab Deruxtecan in Subjects with HER2-overexpressing Locally Advanced, Unresectable or Metastatic Colorectal Cancer                                                   | 83 T-DXd                                                            |

A study was defined as completed if the analyses for the primary objective had been performed.

Table 38 Number of Patients in the Safety Pools

| Study   | Number of Patients Treated   | Number of Patients Treated           |
|---------|------------------------------|--------------------------------------|
|         | T-DXd 5.4 mg/kg All BC Pool  | T-DXd 5.4 mg/kg All Tumor Types Pool |
| Total   | 1741                         | 2335                                 |
| DB-06   | 434                          | 434                                  |
| DB-01   | 184                          | 184                                  |
| DB-02   | 404                          | 404                                  |
| DB-03   | 257                          | 257                                  |
| DB-04   | 371                          | 371                                  |
| DL-01   | NA                           | 41                                   |
| DL-02   | NA                           | 101                                  |

<div style=\"page-break-after: always\"></div>

Table 38 Number of Patients in the Safety Pools

| Study   | Number of Patients Treated   | Number of Patients Treated           |
|---------|------------------------------|--------------------------------------|
|         | T-DXd 5.4 mg/kg All BC Pool  | T-DXd 5.4 mg/kg All Tumor Types Pool |
| DP-01   | 20                           | 102                                  |
| DP-02   | NA                           | 267                                  |
| J101    | 71                           | 91                                   |
| DC-02   | NA                           | 83                                   |

## Patient exposure

## Table 39 Summary of Exposure (Safety Analysis Set)

|                                         | Number (%) of Patients    | Number (%) of Patients   | Number (%) of Patients             | Number (%) of Patients                          |
|-----------------------------------------|---------------------------|--------------------------|------------------------------------|-------------------------------------------------|
|                                         | Study DB-06               | Study DB-06              | Supportive Safety Pools            | Supportive Safety Pools                         |
|                                         | T-DXd 5.4 mg/kg (N = 434) | Chemotherapy (N = 417)   | T-DXd 5.4 mg/kg BC Pool (N = 1741) | T-DXd 5.4 mg/kg All Tumor Types Pool (N = 2335) |
| Duration of treatment (months) a        |                           |                          |                                    |                                                 |
| Mean                                    | 12.12                     | 7.58                     | 12.96                              | 11.49                                           |
| Std Dev                                 | 7.636                     | 6.312                    | 9.166                              | 8.865                                           |
| Median                                  | 11.02                     | 5.62                     | 10.58                              | 8.97                                            |
| Minimum, maximum                        | 0.4, 39.6                 | 0.1, 35.9                | 0.2, 45.1                          | 0.2, 45.1                                       |
| Duration of treatment category, n (%) a |                           |                          |                                    |                                                 |
| 0 to ≤ 3 months                         | 48 (11.1)                 | 121 (29.0)               | 212 (12.2)                         | 406 (17.4)                                      |
| > 3 to ≤ 6 months                       | 63 (14.5)                 | 100 (24.0)               | 263 (15.1)                         | 391 (16.7)                                      |
| > 6 to ≤ 9 months                       | 61 (14.1)                 | 71 (17.0)                | 267 (15.3)                         | 375 (16.1)                                      |
| > 9 to ≤ 12 months                      | 62 (14.3)                 | 37 (8.9)                 | 217 (12.5)                         | 273 (11.7)                                      |
| > 12 to ≤ 18 months                     | 114 (26.3)                | 53 (12.7)                | 304 (17.5)                         | 370 (15.8)                                      |
| > 18 to ≤ 24 months                     | 50 (11.5)                 | 26 (6.2)                 | 245 (14.1)                         | 273 (11.7)                                      |
| > 24 months                             | 36 (8.3)                  | 9 (2.2)                  | 233 (13.4)                         | 247 (10.6)                                      |
| Number of cycles                        |                           |                          |                                    |                                                 |
| Mean                                    | 16.6                      | 9.9                      | 17.7                               | 15.7                                            |
| Std Dev                                 | 10.48                     | 8.49                     | 12.49                              | 12.06                                           |
| Median                                  | 15.0                      | 8.0                      | 14.0                               | 12.0                                            |
| Minimum, maximum                        | 1, 56                     | 1, 49                    | 1, 60                              | 1, 60                                           |
| Number of cycles category, n (%)        |                           |                          |                                    |                                                 |
| ≤ 6 cycles                              | 83 (19.1)                 | 182 (43.6)               | 347 (19.9)                         | 619 (26.5)                                      |
| > 6 to ≤ 12 cycles                      | 91 (21.0)                 | 116 (27.8)               | 398 (22.9)                         | 553 (23.7)                                      |
| > 12 to- ≤ 18 cycles                    | 85 (19.6)                 | 55 (13.2)                | 298 (17.1)                         | 384 (16.4)                                      |
| > 18 to ≤ 24 cycles                     | 84 (19.4)                 | 33 (7.9)                 | 225 (12.9)                         | 265 (11.3)                                      |
| > 24 to ≤ 30 cycles                     | 43 (9.9)                  | 15 (3.6)                 | 177 (10.2)                         | 200 (8.6)                                       |
| > 30 cycles                             | 48 (11.1)                 | 16 (3.8)                 | 296 (17.0)                         | 314 (13.4)                                      |
| Total patient-years of exposure b       | 438.5                     | 263.5                    | 1880.2                             | 2235.2                                          |
| Relative dose intensity (%) c           |                           |                          |                                    |                                                 |

<div style=\"page-break-after: always\"></div>

|                                         | Number (%) of Patients    | Number (%) of Patients   | Number (%) of Patients             | Number (%) of Patients                          |
|-----------------------------------------|---------------------------|--------------------------|------------------------------------|-------------------------------------------------|
|                                         | Study DB-06               | Study DB-06              | Supportive Safety Pools            | Supportive Safety Pools                         |
|                                         | T-DXd 5.4 mg/kg (N = 434) | Chemotherapy (N = 417)   | T-DXd 5.4 mg/kg BC Pool (N = 1741) | T-DXd 5.4 mg/kg All Tumor Types Pool (N = 2335) |
| Mean                                    | 92.90                     | 87.54                    | 96.87                              | 96.01                                           |
| Std Dev                                 | 11.072                    | 15.494                   | 8.057                              | 9.155                                           |
| Median                                  | 97.76                     | 91.50                    | 99.70                              | 99.48                                           |
| Minimum, maximum                        | 45.1, 111.3               | 39.1, 131.9              | 45.1, 111.3                        | 45.1, 199.6                                     |
| Relative dose intensity category, n (%) |                           |                          |                                    |                                                 |
| ≥ 90%                                   | 312 (71.9)                | 216 (51.8)               | 1542 (88.6)                        | 1977 (84.7)                                     |
| < 90% to ≥ 80%                          | 66 (15.2)                 | 66 (15.8)                | 105 (6.0)                          | 189 (8.1)                                       |
| < 80% to ≥ 60%                          | 46 (10.6)                 | 106 (25.4)               | 77 (4.4)                           | 148 (6.3)                                       |
| < 60%                                   | 10 (2.3)                  | 23 (5.5)                 | 17 (1.0)                           | 21 (0.9)                                        |

a Duration of treatment (months) = (date of the last dose - date of the first dose + 1+ C days) / 30.44, where C = (scheduled number of days between doses - 1) and. 1 month = 365.25 / 12 = 30.44 days.

b Total patient-years of exposure = sum of duration of treatment (months) / 12.

c RDI derivation/definition for each study follows the study convention specified in CSR SAPs. RDI is the percentage of the actual dose intensity delivered relative to the intended dose intensity through treatment discontinuation. Actual treatment duration = total treatment duration, excluding duration of dose delays.

Percentages are calculated using the number of patients in the Safety Analysis Set as the denominator.

The pooled analysis group is based on tumor type and first dose received for patients in each study.

<div style=\"page-break-after: always\"></div>

## Adverse events

## Table 40 Overview of Treatment-emergent Adverse Events (Safety Analysis Set)

|                                                              | Number (%) of Patients    | Number (%) of Patients   | Number (%) of Patients             | Number (%) of Patients                          |
|--------------------------------------------------------------|---------------------------|--------------------------|------------------------------------|-------------------------------------------------|
|                                                              | Study DB-06               | Study DB-06              | Supportive Safety Pools            | Supportive Safety Pools                         |
|                                                              | T-DXd 5.4 mg/kg (N = 434) | Chemotherapy (N = 417)   | T-DXd 5.4 mg/kg BC Pool (N = 1741) | T-DXd 5.4 mg/kg All Tumor Types Pool (N = 2335) |
| Patients with any TEAE                                       | 429 (98.8)                | 397 (95.2)               | 1730 (99.4)                        | 2317 (99.2)                                     |
| TEAE with CTCAE Grade ≥ 3                                    | 229 (52.8)                | 185 (44.4)               | 941 (54.0)                         | 1280 (54.8)                                     |
| TEAE associated with an outcome of death                     | 11 (2.5)                  | 6 (1.4)                  | 56 (3.2)                           | 96 (4.1)                                        |
| TEAE associated with study drug discontinuation              | 62 (14.3)                 | 39 (9.4)                 | 307 (17.6)                         | 376 (16.1)                                      |
| TEAE associated with study drug interruption                 | 210 (48.4)                | 160 (38.4)               | 794 (45.6)                         | 1039 (44.5)                                     |
| TEAE associated with dose reduction                          | 107 (24.7)                | 161 (38.6)               | 417 (24.0)                         | 532 (22.8)                                      |
| Drug-related TEAE                                            | 417 (96.1)                | 373 (89.4)               | 1689 (97.0)                        | 2208 (94.6)                                     |
| Drug-related TEAE with CTCAE Grade ≥ 3                       | 176 (40.6)                | 131 (31.4)               | 750 (43.1)                         | 971 (41.6)                                      |
| Drug-related TEAE associated with an outcome of death        | 5 (1.2)                   | 0                        | 20 (1.1)                           | 28 (1.2)                                        |
| Drug-related TEAE associated with study drug discontinuation | 56 (12.9)                 | 33 (7.9)                 | 266 (15.3)                         | 317 (13.6)                                      |
| Drug-related TEAE associated with study drug interruption    | 127 (29.3)                | 103 (24.7)               | 563 (32.3)                         | 688 (29.5)                                      |
| Drug-related TEAE associated with dose reduction             | 94 (21.7)                 | 155 (37.2)               | 383 (22.0)                         | 489 (20.9)                                      |
| Treatment-emergent SAE                                       | 88 (20.3)                 | 67 (16.1)                | 429 (24.6)                         | 652 (27.9)                                      |
| SAE with CTCAE Grade ≥ 3                                     | 68 (15.7)                 | 54 (12.9)                | 332 (19.1)                         | 522 (22.4)                                      |
| SAE associated with an outcome of death                      | 11 (2.5)                  | 6 (1.4)                  | 56 (3.2)                           | 96 (4.1)                                        |
| SAE associated with study drug discontinuation               | 24 (5.5)                  | 11 (2.6)                 | 105 (6.0)                          | 134 (5.7)                                       |
| SAE associated with study drug interruption                  | 24 (5.5)                  | 27 (6.5)                 | 133 (7.6)                          | 203 (8.7)                                       |
| SAE associated with dose reduction                           | 12 (2.8)                  | 8 (1.9)                  | 48 (2.8)                           | 73 (3.1)                                        |
| Drug-related SAE                                             | 46 (10.6)                 | 24 (5.8)                 | 208 (11.9)                         | 281 (12.0)                                      |
| Drug-related SAE with CTCAE Grade ≥ 3                        | 35 (8.1)                  | 19 (4.6)                 | 144 (8.3)                          | 203 (8.7)                                       |
| Drug-related SAE associated with an outcome of death         | 5 (1.2)                   | 0                        | 20 (1.1)                           | 28 (1.2)                                        |
| Drug-related SAE associated with study drug discontinuation  | 21 (4.8)                  | 7 (1.7)                  | 81 (4.7)                           | 94 (4.0)                                        |
| Drug-related SAE associated with study drug interruption     | 8 (1.8)                   | 6 (1.4)                  | 46 (2.6)                           | 62 (2.7)                                        |
| Drug-related SAE associated with dose reduction              | 10 (2.3)                  | 6 (1.4)                  | 38 (2.2)                           | 60 (2.6)                                        |

Percentages are calculated using the number of patients in the Safety Analysis Set as the denominator.

<div style=\"page-break-after: always\"></div>

Table 41 Adverse Events Reported in ≥ 10% of Patients in Either Treatment Arm of Study DB-06, by Preferred Term (Safety Analysis Set)

|                                               | Number (%) of Patients    | Number (%) of Patients   | Number (%) of Patients             | Number (%) of Patients                          |
|-----------------------------------------------|---------------------------|--------------------------|------------------------------------|-------------------------------------------------|
|                                               | Study DB-06               | Study DB-06              | Supportive Safety Pools            | Supportive Safety Pools                         |
|                                               | T-DXd 5.4 mg/kg (N = 434) | Chemotherapy (N = 417)   | T-DXd 5.4 mg/kg BC Pool (N = 1741) | T-DXd 5.4 mg/kg All Tumor Types Pool (N = 2335) |
| Patients with any TEAE                        | 429 (98.8)                | 397 (95.2)               | 1730 (99.4)                        | 2317 (99.2)                                     |
| Nausea                                        | 303 (69.8)                | 126 (30.2)               | 1294 (74.3)                        | 1660 (71.1)                                     |
| Alopecia                                      | 210 (48.4)                | 87 (20.9)                | 729 (41.9)                         | 844 (36.1)                                      |
| Anaemia                                       | 159 (36.6)                | 107 (25.7)               | 598 (34.3)                         | 825 (35.3)                                      |
| Diarrhoea                                     | 148 (34.1)                | 114 (27.3)               | 529 (30.4)                         | 703 (30.1)                                      |
| Vomiting                                      | 146 (33.6)                | 49 (11.8)                | 713 (41.0)                         | 870 (37.3)                                      |
| Constipation                                  | 137 (31.6)                | 62 (14.9)                | 594 (34.1)                         | 741 (31.7)                                      |
| Aspartate aminotransferase increased          | 117 (27.0)                | 44 (10.6)                | 394 (22.6)                         | 476 (20.4)                                      |
| Fatigue                                       | 117 (27.0)                | 83 (19.9)                | 587 (33.7)                         | 753 (32.2)                                      |
| Decreased appetite                            | 114 (26.3)                | 48 (11.5)                | 529 (30.4)                         | 715 (30.6)                                      |
| COVID-19                                      | 106 (24.4)                | 52 (12.5)                | 209 (12.0)                         | 282 (12.1)                                      |
| Asthenia                                      | 99 (22.8)                 | 71 (17.0)                | 342 (19.6)                         | 462 (19.8)                                      |
| Neutrophil count decreased                    | 99 (22.8)                 | 66 (15.8)                | 397 (22.8)                         | 506 (21.7)                                      |
| Alanine aminotransferase increased            | 93 (21.4)                 | 48 (11.5)                | 317 (18.2)                         | 388 (16.6)                                      |
| White blood cell count decreased              | 79 (18.2)                 | 53 (12.7)                | 324 (18.6)                         | 384 (16.4)                                      |
| Neutropenia                                   | 76 (17.5)                 | 63 (15.1)                | 264 (15.2)                         | 343 (14.7)                                      |
| Headache                                      | 74 (17.1)                 | 42 (10.1)                | 319 (18.3)                         | 370 (15.8)                                      |
| Cough                                         | 69 (15.9)                 | 38 (9.1)                 | 262 (15.0)                         | 325 (13.9)                                      |
| Platelet count decreased                      | 61 (14.1)                 | 15 (3.6)                 | 296 (17.0)                         | 385 (16.5)                                      |
| Stomatitis                                    | 57 (13.1)                 | 37 (8.9)                 | 228 (13.1)                         | 287 (12.3)                                      |
| Hypokalaemia                                  | 56 (12.9)                 | 15 (3.6)                 | 201 (11.5)                         | 271 (11.6)                                      |
| Pyrexia                                       | 52 (12.0)                 | 30 (7.2)                 | 223 (12.8)                         | 293 (12.5)                                      |
| Dysgeusia                                     | 51 (11.8)                 | 24 (5.8)                 | 157 (9.0)                          | 182 (7.8)                                       |
| Dyspepsia                                     | 50 (11.5)                 | 20 (4.8)                 | 202 (11.6)                         | 245 (10.5)                                      |
| Blood alkaline phosphatase increased          | 48 (11.1)                 | 17 (4.1)                 | 165 (9.5)                          | 193 (8.3)                                       |
| Abdominal pain                                | 45 (10.4)                 | 35 (8.4)                 | 199 (11.4)                         | 266 (11.4)                                      |
| Epistaxis                                     | 44 (10.1)                 | 15 (3.6)                 | 187 (10.7)                         | 213 (9.1)                                       |
| Oedema peripheral                             | 36 (8.3)                  | 59 (14.1)                | 146 (8.4)                          | 186 (8.0)                                       |
| Arthralgia                                    | 32 (7.4)                  | 45 (10.8)                | 188 (10.8)                         | 223 (9.6)                                       |
| Peripheral sensory neuropathy                 | 12 (2.8)                  | 49 (11.8)                | 82 (4.7)                           | 100 (4.3)                                       |
| Palmar-plantar erythro- dysaesthesia syndrome | 4 (0.9)                   | 146 (35.0)               | 25 (1.4)                           | 28 (1.2)                                        |

Percentages are calculated using the number of patients in the Safety Analysis Set as the denominator.

<div style=\"page-break-after: always\"></div>

Table 42 Adverse Events of CTCAE Grade 3 or Higher Reported in ≥ 5% of Patients in Either Treatment Arm in Study DB-06, by Preferred Term (Safety Analysis Set)

|                                                | Number (%) of Patients    | Number (%) of Patients   | Number (%) of Patients             | Number (%) of Patients                          |
|------------------------------------------------|---------------------------|--------------------------|------------------------------------|-------------------------------------------------|
|                                                | Study DB-06               | Study DB-06              | Supportive Safety Pools            | Supportive Safety Pools                         |
|                                                | T-DXd 5.4 mg/kg (N = 434) | Chemotherapy (N = 417)   | T-DXd 5.4 mg/kg BC Pool (N = 1741) | T-DXd 5.4 mg/kg All Tumor Types Pool (N = 2335) |
| Patients with any TEAE Grade ≥ 3               | 229 (52.8)                | 185 (44.4)               | 941 (54.0)                         | 1280 (54.8)                                     |
| Neutrophil count decreased                     | 60 (13.8)                 | 36 (8.6)                 | 208 (11.9)                         | 268 (11.5)                                      |
| Anaemia                                        | 38 (8.8)                  | 18 (4.3)                 | 158 (9.1)                          | 245 (10.5)                                      |
| Neutropenia                                    | 37 (8.5)                  | 35 (8.4)                 | 122 (7.0)                          | 160 (6.9)                                       |
| White blood cell count decreased               | 25 (5.8)                  | 20 (4.8)                 | 102 (5.9)                          | 117 (5.0)                                       |
| Palmar- plantar erythro- dysaesthesia syndrome | 0                         | 31 (7.4)                 | 1 (0.1)                            | 1 (0.0)                                         |

Percentages are calculated using the number of patients in the Safety Analysis Set as the denominator. The pooled analysis group is based on first dose received for patients in each study.

PTs are sorted by descending frequency in the Study DB-06 T-DXd 5.4 mg/kg treatment arm.

If a patient had multiple occurrences of the same PT, the patient is counted once for the specific PT.

If a patient had multiple PTs, the patient is counted in each of the different PTs.

## Adverse Drug Reactions

As ADR determination methodology, the MAH analysed systematically all-causality TEAEs from study DB-06. The MAH applied quantitative criteria to look for an imbalance in the incidence of TEAEs between treatment groups, examined pre-existing ADRs for changes in characteristics, and performed medical review of all ADR candidates including rare or life-threatening events. Events that were already identified as a T-DXd program-wide ADR continued to be classified as an ADR and TEAEs from study DB-06 were initially classified into 3 categories by incidence. Any imbalances observed between the T-DXd and Chemotherapy arms were meticulously assessed. In addition, the MAH reviewed laboratory and clinical measurements for any additional ADRs by looking at aspects such as trends, medians, means, and range of values. Through these various considerations, the MAH determined which TEAEs are considered an ADR. Relevant safety data from nonclinical studies, other clinical studies, class-effects, and AESIs (ILD/pneumonitis and LV dysfunction) were examined as well. This determination process was subjected to individual assessment based on frequency and severity of the events and/or evaluation of confounding factors and causality.

As a consequence of the updated All Tumour Type (ATT) Pool, the frequency of the following ADRs has been revised in section 4.8 of the SmPC: for lymphopenia, dizziness, dyspnoea and epistaxis from 'very common' to 'common', and for febrile neutropenia from 'uncommon' to 'common'.

<div style=\"page-break-after: always\"></div>

Figure 25 Methodology of Adverse Drug reaction Determination in Study DB-06

<!-- image -->

Determination was based on the review for individual events.

- a Comparators grouped to determine AE incidence (SoC = standard of care).
- b Individual assessment if ADR not listed as an ADR for comparator.
- C Product labels of each comparator assessed.
- d If evidence suggest that the event is due to the underlying disease/alternative etiology, it may be determined as not as an ADR
- If there is reasonable possibility of a causal relationship between the event and study drug. it may be determined as an ADR.

Table 43 Common Adverse Drug Reactions Reported in ≥ 10% of Patients with Any Event or ≥ 2% of Patients with Events of Grade 3 or 4 in the TDXd Arm of Study DB06, by MedDRA System Organ Class and Preferred Term/Grouped Term in Study DB06 (Safety Analysis Set)

| MedDRA System Organ Class Preferred Term/Grouped Term   | T-DXd 5.4 mg/kg (N = 434)            | T-DXd 5.4 mg/kg (N = 434)            | T-DXd 5.4 mg/kg (N = 434)            | T-DXd 5.4 mg/kg (N = 434)            | T-DXd 5.4 mg/kg (N = 434)            | Chemotherapy (N = 417)               | Chemotherapy (N = 417)               | Chemotherapy (N = 417)               | Chemotherapy (N = 417)               | Chemotherapy (N = 417)               |
|---------------------------------------------------------|--------------------------------------|--------------------------------------|--------------------------------------|--------------------------------------|--------------------------------------|--------------------------------------|--------------------------------------|--------------------------------------|--------------------------------------|--------------------------------------|
| MedDRA System Organ Class Preferred Term/Grouped Term   | Frequency a                          | Number (%) of Subjects               | Number (%) of Subjects               | Number (%) of Subjects               | Number (%) of Subjects               | Frequency a                          | Number (%) of Subjects               | Number (%) of Subjects               | Number (%) of Subjects               | SAE                                  |
| MedDRA System Organ Class Preferred Term/Grouped Term   | Frequency a                          | CTCAE Grade                          | CTCAE Grade                          | CTCAE Grade                          | SAE                                  | Frequency a                          | CTCAE Grade                          | CTCAE Grade                          | CTCAE Grade                          | SAE                                  |
| MedDRA System Organ Class Preferred Term/Grouped Term   | Frequency a                          | All Grades                           | Grade 3 or 4                         | Grade 5                              | SAE                                  | Frequency a                          | All Grades                           | Grade 3 or 4                         | Grade 5                              | SAE                                  |
| Patients with any ADR                                   | --                                   | 428 (98.6)                           | 193 (44.5)                           | 3 (0.7)                              | 39 (9.0)                             | --                                   | 370 (88.7)                           | 118 (28.3)                           | 0                                    | 20 (4.8)                             |
| Blood and lymphatic system disorders                    | Blood and lymphatic system disorders | Blood and lymphatic system disorders | Blood and lymphatic system disorders | Blood and lymphatic system disorders | Blood and lymphatic system disorders | Blood and lymphatic system disorders | Blood and lymphatic system disorders | Blood and lymphatic system disorders | Blood and lymphatic system disorders | Blood and lymphatic system disorders |
| Neutropenia b                                           | Very Common                          | 169 (38.9)                           | 96 (22.1)                            | 0                                    | 1 (0.2)                              | Very Common                          | 128 (30.7)                           | 71 (17.0)                            | 0                                    | 0                                    |
| Anemia b                                                | Very Common                          | 162 (37.3)                           | 38 (8.8)                             | 0                                    | 3 (0.7)                              | Very Common                          | 110 (26.4)                           | 18 (4.3)                             | 0                                    | 1 (0.2)                              |
| Leukopenia b                                            | Very Common                          | 105 (24.2)                           | 31 (7.1)                             | 0                                    | 0                                    | Very Common                          | 70 (16.8)                            | 25 (6.0)                             | 0                                    | 0                                    |
| Thrombocytopenia b                                      | Very Common                          | 86 (19.8)                            | 20 (4.6)                             | 0                                    | 1 (0.2)                              | Common                               | 21 (5.0)                             | 1 (0.2)                              | 0                                    | 0                                    |
| Lymphopenia b                                           | Very Common                          | 47 (10.8)                            | 14 (3.2)                             | 0                                    | 0                                    | Common                               | 16 (3.8)                             | 2 (0.5)                              | 0                                    | 0                                    |
| Gastrointestinal disorders                              | Gastrointestinal disorders           | Gastrointestinal disorders           | Gastrointestinal disorders           | Gastrointestinal disorders           | Gastrointestinal disorders           | Gastrointestinal disorders           | Gastrointestinal disorders           | Gastrointestinal disorders           | Gastrointestinal disorders           | Gastrointestinal disorders           |
| Nausea                                                  | Very Common                          | 303 (69.8)9                          | (2.1)                                | 0                                    | 3 (0.7)                              | Very Common                          | 126 (30.2)2                          | (0.5)                                | 0                                    | 1 (0.2)                              |
| Diarrhoea                                               | Very Common                          | 148 (34.1)                           | 10 (2.3)                             | 0                                    | 1 (0.2)                              | Very Common                          | 114 (27.3)                           | 11 (2.6)                             | 0                                    | 3 (0.7)                              |

<div style=\"page-break-after: always\"></div>

| MedDRA System Organ Class Preferred                  | T-DXd 5.4 mg/kg (N = 434)                            | T-DXd 5.4 mg/kg (N = 434)                            | T-DXd 5.4 mg/kg (N = 434)                            | T-DXd 5.4 mg/kg (N = 434)                            | T-DXd 5.4 mg/kg (N = 434)                            | Chemotherapy (N = 417)                               | Chemotherapy (N = 417)                               | Chemotherapy (N = 417)                               | Chemotherapy (N = 417)                               | Chemotherapy (N = 417)                               |
|------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|
| Term/Grouped Term                                    | Frequency a                                          | Number (%) of Subjects                               | Number (%) of Subjects                               | Number (%) of Subjects                               | Number (%) of Subjects                               | Frequency                                            | Number (%) of Subjects                               | Number (%) of Subjects                               | Number (%) of Subjects                               | Number (%) of Subjects                               |
|                                                      |                                                      | CTCAE Grade All Grades                               | Grade 3 or 4                                         | Grade 5                                              | SAE                                                  | a                                                    | CTCAE All Grades                                     | Grade Grade 3 or 4                                   | Grade 5                                              | SAE                                                  |
| Vomiting                                             | Very Common                                          | 146 (33.6)6                                          | (1.4)                                                | 0                                                    | 3 (0.7)                                              | Very Common                                          | 49 (11.8)                                            | 1 (0.2)                                              | 0                                                    | 1 (0.2)                                              |
| Constipation                                         | Very Common                                          | 137 (31.6)3                                          | (0.7)                                                | 0                                                    | 1 (0.2)                                              | Very Common                                          | 62 (14.9)                                            | 2 (0.5)                                              | 0                                                    | 2 (0.5)                                              |
| Abdominal pain b                                     | Very Common                                          | 86 (19.8)                                            | 2 (0.5)                                              | 0                                                    | 0                                                    | Very Common                                          | 58 (13.9)                                            | 1 (0.2)                                              | 0                                                    | 1 (0.2)                                              |
| Stomatitis b                                         | Very Common                                          | 64 (14.7)                                            | 0                                                    | 0                                                    | 0                                                    | Very Common                                          | 46 (11.0)                                            | 2 (0.5)                                              | 0                                                    | 0                                                    |
| Dyspepsia                                            | Very Common                                          | 50 (11.5)                                            | 0                                                    | 0                                                    | 0                                                    | Common                                               | 20 (4.8)                                             | 0                                                    | 0                                                    | 0                                                    |
| General disorders and administration site conditions | General disorders and administration site conditions | General disorders and administration site conditions | General disorders and administration site conditions | General disorders and administration site conditions | General disorders and administration site conditions | General disorders and administration site conditions | General disorders and administration site conditions | General disorders and administration site conditions | General disorders and administration site conditions | General disorders and administration site conditions |
| Fatigue b                                            | Very Common                                          | 229 (52.8)                                           | 19 (4.4)                                             | 0                                                    | 1 (0.2)                                              | Very Common                                          | 166 (39.8)                                           | 10 (2.4)                                             | 0                                                    | 0                                                    |
| Pyrexia                                              | Very Common                                          | 52 (12.0)                                            | 1 (0.2)                                              | 0                                                    | 0                                                    | Common                                               | 30 (7.2)                                             | 0                                                    | 0                                                    | 2 (0.5)                                              |
| Hepatobiliary disorders                              | Hepatobiliary disorders                              | Hepatobiliary disorders                              | Hepatobiliary disorders                              | Hepatobiliary disorders                              | Hepatobiliary disorders                              | Hepatobiliary disorders                              | Hepatobiliary disorders                              | Hepatobiliary disorders                              | Hepatobiliary disorders                              | Hepatobiliary disorders                              |
| Transaminases increased b                            | Very Common                                          | 159 (36.6)                                           | 18 (4.1)                                             | 0                                                    | 1 (0.2)                                              | Very Common                                          | 63 (15.1)                                            | 2 (0.5)                                              | 0                                                    | 0                                                    |
| Infections and infestations                          | Infections and infestations                          | Infections and infestations                          | Infections and infestations                          | Infections and infestations                          | Infections and infestations                          | Infections and infestations                          | Infections and infestations                          | Infections and infestations                          | Infections and infestations                          | Infections and infestations                          |
| Upper respiratory tract infection b                  | Very Common                                          | 81 (18.7)                                            | 0                                                    | 0                                                    | 0                                                    | Common                                               | 39 (9.4)                                             | 0                                                    | 0                                                    | 0                                                    |
| Investigations                                       | Investigations                                       | Investigations                                       | Investigations                                       | Investigations                                       | Investigations                                       | Investigations                                       | Investigations                                       | Investigations                                       | Investigations                                       | Investigations                                       |
| Blood alkaline phosphatase increased                 | Very Common                                          | 48 (11.1)                                            | 2 (0.5)                                              | 0                                                    | 0                                                    | Common                                               | 17 (4.1)                                             | 1 (0.2)                                              | 0                                                    | 0                                                    |
| Metabolism and nutrition disorders                   | Metabolism and nutrition disorders                   | Metabolism and nutrition disorders                   | Metabolism and nutrition disorders                   | Metabolism and nutrition disorders                   | Metabolism and nutrition disorders                   | Metabolism and nutrition disorders                   | Metabolism and nutrition disorders                   | Metabolism and nutrition disorders                   | Metabolism and nutrition disorders                   | Metabolism and nutrition disorders                   |
| Decreased appetite                                   | Very Common                                          | 114 (26.3)6                                          | (1.4)                                                | 0                                                    | 2 (0.5)                                              | Very Common                                          | 48 (11.5)                                            | 2 (0.5)                                              | 0                                                    | 1 (0.2)                                              |
| Hypokalaemia b                                       | Very Common                                          | 57 (13.1)                                            | 20 (4.6)                                             | 0                                                    | 5 (1.2)                                              | Common                                               | 17 (4.1)                                             | 6 (1.4)                                              | 0                                                    | 1 (0.2)                                              |
| Musculoskeletal and connective tissue disorders      | Musculoskeletal and connective tissue disorders      | Musculoskeletal and connective tissue disorders      | Musculoskeletal and connective tissue disorders      | Musculoskeletal and connective tissue disorders      | Musculoskeletal and connective tissue disorders      | Musculoskeletal and connective tissue disorders      | Musculoskeletal and connective tissue disorders      | Musculoskeletal and connective tissue disorders      | Musculoskeletal and connective tissue disorders      | Musculoskeletal and connective tissue disorders      |
| Musculoskeletal pain b                               | Very Common                                          | 102 (23.5)                                           | 2 (0.5)                                              | 0                                                    | 3 (0.7)                                              | Very Common                                          | 94 (22.5)                                            | 8 (1.9)                                              | 0                                                    | 4 (1.0)                                              |
| Nervous system disorders                             | Nervous system disorders                             | Nervous system disorders                             | Nervous system disorders                             | Nervous system disorders                             | Nervous system disorders                             | Nervous system disorders                             | Nervous system disorders                             | Nervous system disorders                             | Nervous system disorders                             | Nervous system disorders                             |
| Headache b                                           | Very Common                                          | 76 (17.5)                                            | 2 (0.5)                                              | 0                                                    | 0                                                    | Very Common                                          | 43 (10.3)                                            | 0                                                    | 0                                                    | 0                                                    |
| Dysgeusia                                            | Very Common                                          | 51 (11.8)                                            | 1 (0.2)                                              | 0                                                    | 0                                                    | Common                                               | 24 (5.8)                                             | 0                                                    | 0                                                    | 0                                                    |
| Respiratory, thoracic and mediastinal disorders      | Respiratory, thoracic and mediastinal disorders      | Respiratory, thoracic and mediastinal disorders      | Respiratory, thoracic and mediastinal disorders      | Respiratory, thoracic and mediastinal disorders      | Respiratory, thoracic and mediastinal disorders      | Respiratory, thoracic and mediastinal disorders      | Respiratory, thoracic and mediastinal disorders      | Respiratory, thoracic and mediastinal disorders      | Respiratory, thoracic and mediastinal disorders      | Respiratory, thoracic and mediastinal disorders      |
| Cough                                                | Very Common                                          | 69 (15.9)                                            | 0                                                    | 0                                                    | 0                                                    | Common                                               | 38 (9.1)                                             | 0                                                    | 0                                                    | 0                                                    |
| Interstitial lung disease c                          | Very Common                                          | 49 (11.3)                                            | 3 (0.7)                                              | 3 (0.7)                                              | 11 (2.5)                                             | Uncommon                                             | 1 (0.2)                                              | 0                                                    | 0                                                    | 0                                                    |
| Epistaxis                                            | Very Common                                          | 44 (10.1)                                            | 0                                                    | 0                                                    | 0                                                    | Common                                               | 15 (3.6)                                             | 1 (0.2)                                              | 0                                                    | 0                                                    |
| Skin and subcutaneous tissue disorders               | Skin and subcutaneous tissue disorders               |                                                      |                                                      |                                                      |                                                      |                                                      |                                                      |                                                      |                                                      |                                                      |

<div style=\"page-break-after: always\"></div>

| MedDRA System Organ Class   | T-DXd 5.4 mg/kg (N = 434)   | T-DXd 5.4 mg/kg (N = 434)   | T-DXd 5.4 mg/kg (N = 434)   | T-DXd 5.4 mg/kg (N = 434)   | T-DXd 5.4 mg/kg (N = 434)   | Chemotherapy (N = 417)   | Chemotherapy (N = 417)   | Chemotherapy (N = 417)   | Chemotherapy (N = 417)   | Chemotherapy (N = 417)   |
|-----------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|--------------------------|--------------------------|--------------------------|--------------------------|--------------------------|
| Preferred Term/Grouped Term | Frequency a                 | Number (%) of Subjects      | Number (%) of Subjects      | Number (%) of Subjects      | Number (%) of Subjects      | Frequency a              | Number (%) of Subjects   | Number (%) of Subjects   | Number (%) of Subjects   | Number (%) of Subjects   |
|                             |                             | CTCAE Grade                 | CTCAE Grade                 | CTCAE Grade                 | SAE                         |                          | CTCAE Grade              | CTCAE Grade              | CTCAE Grade              | SAE                      |
|                             |                             | All                         | Grade Grade                 | Grade Grade                 |                             |                          | All                      | Grade Grade              | Grade Grade              |                          |
|                             |                             | Grades                      | 3 or 4                      | 5                           |                             |                          | Grades                   | 3 or 4                   | 5                        |                          |
| Alopecia                    | Very                        | 210                         | 0                           | 0                           | 0                           | Very                     | 87 (20.9)                | 2 (0.5)                  | 0                        | 0                        |
|                             | Common                      | (48.4)                      |                             |                             |                             | Common                   |                          |                          |                          |                          |

a Within each pool, frequency was defined as follows: Very Common ≥ 1/10 subjects; Common ≥ 1/100 to

&lt; 1/10

patients; Uncommon ≥

&lt; 1/10000 patients.

The PTs included in each grouped term are listed in Table 43.

Interstitial lung disease (AESI) includes PTs of bronchiectasis, interstitial lung disease, lower respiratory tract infection, pneumonia, pneumonia bacterial, pneumonitis, and pulmonary toxicity. These events were adjudicated as ILD and related to use of TDX-d.

System organ classes are presented by alphabetic order. PTs/grouped terms are presented by descending frequency in the Study DB-06 All Grades column .

If a subject had multiple occurrences of the same ADR, the patient was counted once for that specific ADR.

Table 44 All Adverse Drug reactions in T-DXd 5.4 mg/kg breast cancer pool and T-DXd 5.4 mg/kg all tumour types pool, by MedDRA System Organ Class, Preferred Term/Grouped Term and Frequency (Safety Analysis Set)

| MedDRA Systeim Organ Class           | T-DXd5.4mg/kgbreastcancerpool (N = 1741)   | T-DXd5.4mg/kgbreastcancerpool (N = 1741)   | T-DXd5.4mg/kgbreastcancerpool (N = 1741)   | T-DXd5.4mg/kgbreastcancerpool (N = 1741)   | T-DXd5.4mg/kgbreastcancerpool (N = 1741)   | T-DXd 5.4 mg/kg all tumor types pool (N= 2335)   | T-DXd 5.4 mg/kg all tumor types pool (N= 2335)   | T-DXd 5.4 mg/kg all tumor types pool (N= 2335)   | T-DXd 5.4 mg/kg all tumor types pool (N= 2335)   | T-DXd 5.4 mg/kg all tumor types pool (N= 2335)   |
|--------------------------------------|--------------------------------------------|--------------------------------------------|--------------------------------------------|--------------------------------------------|--------------------------------------------|--------------------------------------------------|--------------------------------------------------|--------------------------------------------------|--------------------------------------------------|--------------------------------------------------|
| PreferredTerm/ Grouped Term          | Frequency 1                                | Number (%) of Subjects CTCAE Grade         | Number (%) of Subjects CTCAE Grade         | Number (%) of Subjects CTCAE Grade         | SAE                                        | Frequency 1                                      | Number (%) of Subjects CTCAE Grade               | Number (%) of Subjects CTCAE Grade               | Number (%) of Subjects CTCAE Grade               | SAE                                              |
| PreferredTerm/ Grouped Term          | Frequency 1                                | All Grades                                 | Gradle 3 or 4                              | Grade 5                                    | SAE                                        | Frequency 1                                      | All Gradles                                      | Grade 3 or 4                                     | Grade 5                                          | SAE                                              |
| Subjects with any ADR                |                                            | 1724 (99.0)                                | 785 (45.1)                                 | 21 (1.2)                                   | 222 (12.8)                                 |                                                  | 2299 (98.5)                                      | 1044 (44.7)                                      | 33 (1.4)                                         | 334 (14.3)                                       |
| Blood and lymphatic system disorders |                                            |                                            |                                            |                                            |                                            |                                                  |                                                  |                                                  |                                                  |                                                  |
| Neutropenia a                        | Very Common                                | 633 (36.4)                                 | 323 (18.6)                                 | 0                                          | 4 (0.2)                                    | Very Common                                      | 819 (35.1)                                       | 420 (18.0)                                       | 0                                                | 8 (0.3)                                          |
| Anemia b                             | Very Common                                | 611 (35.1)                                 | 159 (9.1)                                  | 0                                          | 17 (1.0)                                   | Very Common                                      | 838 (35.9)                                       | 246 (10.5)                                       | 0                                                | 28 (1.2)                                         |
| Leukopenia c                         | Very Common                                | 413 (23.7)                                 | 119 (6.8)                                  | 0                                          | 0                                          | Very Common                                      | 501 (21.5)                                       | 139 (6.0)                                        | 0                                                | 0                                                |
| Thrombocytopenia d                   | Very Common                                | 406 (23.3)                                 | 84 (4.8)                                   | 0                                          | 5 (0.3)                                    | Very Common                                      | 539 (23.1)                                       | 127 (5.4)                                        | 0                                                | 13 (0.6)                                         |
| Lymphopenia                          | Very Common                                | 193 (11.1)                                 | 80 (4.6)                                   | 0                                          | 0                                          | Common                                           | 222 (9.5)                                        | 91 (3.9)                                         | 0                                                | 0                                                |
| Febrile neutropenia                  | Uncommon                                   | 17 (1.0)                                   | 16 (0.9)                                   | 1 (0.1)                                    | 14 (0.8)                                   | Common                                           | 24 (1.0)                                         | 22 (0.9)                                         | 1 (0.0)                                          | 19 (0.8)                                         |
| Eye disorders                        |                                            |                                            |                                            |                                            |                                            |                                                  |                                                  |                                                  |                                                  |                                                  |
| Dry eye                              | Common                                     | 104 (6.0)                                  | 2 (0.1)                                    | 0                                          | 0                                          | Common                                           | 116 (5.0)                                        | 2 (0.1)                                          | 0                                                | 0                                                |
| Vision blurred f                     | Common                                     | 82 (4.7)                                   | 0                                          | 0                                          | 0                                          | Common                                           | 95 (4.1)                                         | 1 (0.0)                                          | 0                                                | 0                                                |
| Gastrointestinaldisorders            |                                            |                                            |                                            |                                            |                                            |                                                  |                                                  |                                                  |                                                  |                                                  |
| Nausea                               | Very Common                                | 1294 (74.3)                                | 89 (5.1)                                   | 0                                          | 17 (1.0)                                   | Very Common                                      | 1660 (71.1)                                      | 115 (4.9)                                        | 0                                                | 25 (1.1)                                         |
| Vomiting                             | Very Common                                | 713 (41.0)                                 | 42 (2.4)                                   | 0                                          | 23 (1.3)                                   | Very Common                                      | 870 (37.3)                                       | 55 (2.4)                                         | 0                                                | 35 (1.5)                                         |
| Constipation                         | Very Common                                | 594 (34.1)                                 | 8 (0.5)                                    | 0                                          | 5 (0.3)                                    | Very Common                                      | 741 (31.7)                                       | 15 (0.6)                                         | 0                                                | 8 (0.3)                                          |
| Diarrhoea                            | Very Common                                | 529 (30.4)                                 | 36 (2.1)                                   | 0                                          | 5 (0.3)                                    | Very Common                                      | 703 (30.1)                                       | 58 (2.5)                                         | 0                                                | 12 (0.5)                                         |
| Abdominalpain                        | Very Common                                | 355 (20.4)                                 | 16 (0.9)                                   | 0                                          | 5 (0.3)                                    | Very C Common                                    | 455 (19.5)                                       | 24 (1.0)                                         | 0                                                | 13 (0.6)                                         |
| Stomatitis h                         | Very Common                                | 259 (14.9)                                 | 10 (0.6)                                   | 0                                          | 2 (0.1)                                    | Very Common                                      | 325 (13.9)                                       | 11 (0.5)                                         | 0                                                | 2 (0.1)                                          |
| Dyspepsia                            | Very Common                                | 202 (11.6)                                 | 0                                          | 0                                          | 0                                          | Very Common                                      | 245 (10.5)                                       | 1 (0.0)                                          | 0                                                | 0                                                |
| Abdominal distension                 | Common                                     | 73 (4.2)                                   | 0                                          | 0                                          | 0                                          | Common                                           | 89 (3.8)                                         | 1 (0.0)                                          | 0                                                | 1 (0.0)                                          |
| Flatulence                           | Common                                     | 36 (2.1)                                   | 0                                          | 0                                          | 0                                          | Common                                           | 45 (1.9)                                         | 0                                                | 0                                                | 0                                                |

1/1000 to &lt;

1/100 patients; Rare ≥

1/10000 to &lt; 1/1000 patients; Very rare

<div style=\"page-break-after: always\"></div>

| MedDRASystemOrganClass                               | T-DXd5.4mg/kgbreastcancerpool (N =1741)   | T-DXd5.4mg/kgbreastcancerpool (N =1741)   | T-DXd5.4mg/kgbreastcancerpool (N =1741)   | T-DXd5.4mg/kgbreastcancerpool (N =1741)   | T-DXd5.4mg/kgbreastcancerpool (N =1741)   | T-DXd 5.4 mg/kg all tumor types pool (N = 2335)   | T-DXd 5.4 mg/kg all tumor types pool (N = 2335)   | T-DXd 5.4 mg/kg all tumor types pool (N = 2335)   | T-DXd 5.4 mg/kg all tumor types pool (N = 2335)   | T-DXd 5.4 mg/kg all tumor types pool (N = 2335)   |
|------------------------------------------------------|-------------------------------------------|-------------------------------------------|-------------------------------------------|-------------------------------------------|-------------------------------------------|---------------------------------------------------|---------------------------------------------------|---------------------------------------------------|---------------------------------------------------|---------------------------------------------------|
| Preferred Term/ GroupedTerm                          | Frequency1                                | Number (%) of Subjects CTCAE Grade        | Number (%) of Subjects CTCAE Grade        | Number (%) of Subjects CTCAE Grade        | SAE                                       | Frequency 1                                       | Number (%) of Subjects CTCAE Grade                | Number (%) of Subjects CTCAE Grade                | Number (%) of Subjects CTCAE Grade                | SAE                                               |
| Preferred Term/ GroupedTerm                          | Frequency1                                | All Grades                                | Graile 3or 4                              | Gradle 5                                  | SAE                                       | Frequency 1                                       | All Grades                                        | Grade 3 or 4                                      | Grade 5                                           | SAE                                               |
| Gastritis                                            | Common                                    | 32 (1.8)                                  | 2 (0.1)                                   | 0                                         | 1 (0.1)                                   | Common                                            | 38 (1.6)                                          | 3 (0.1)                                           | 0                                                 | 1 (0.0)                                           |
| General disorders and administration site conditions |                                           |                                           |                                           |                                           |                                           |                                                   |                                                   |                                                   |                                                   |                                                   |
| Fatigue i                                            | Very Common                               | 990 (56.9)                                | 130 (7.5)                                 | 0                                         | 10 (0.6)                                  | Very Common                                       | 1292 (55.3)                                       | 182 (7.8)                                         | 0                                                 | 21 (0.9)                                          |
| Pyrexia                                              | Very Common                               | 223 (12.8)                                | 6 (0.3)                                   | 0                                         | 11 (0.6)                                  | Very Common                                       | 293 (12.5)                                        | 10 (0.4)                                          | 0                                                 | 16 (0.7)                                          |
| Oedema peripheral                                    | *NA                                       | *NA                                       | *NA                                       | *NA                                       | *NA                                       | Common                                            | 186 (8.0)                                         | 3 (0.1)                                           | 0                                                 | 3 (0.1)                                           |
| Hepatobiliarydisorders                               |                                           |                                           |                                           |                                           |                                           |                                                   |                                                   |                                                   |                                                   |                                                   |
| Transaminases increasedj                             | VeryCommon                                | 518 (29.8)                                | 67 (3.8)                                  | 0                                         | 3 (0.2)                                   | Very Common                                       | 622 (26.6)                                        | 81 (3.5)                                          | 0                                                 | 3 (0.1)                                           |
| Infectionsandinfestations                            |                                           |                                           |                                           |                                           |                                           |                                                   |                                                   |                                                   |                                                   |                                                   |
| Upper respiratory tract infection k                  | Very Common                               | 339 (19.5)                                | 3 (0.2)                                   | 0                                         | 4 (0.2)                                   | Very Common                                       | 380 (16.3)                                        | 3 (0.1)                                           | 0                                                 | 4 (0.2)                                           |
| Pneumonia                                            | *NA                                       | *NA                                       | *NA                                       | *NA                                       | *NA                                       | Common                                            | 126 (5.4)                                         | 31 (1.3)                                          | 7 (0.3)                                           | 43 (1.8)                                          |
| Injury,poisoningandprocedural                        |                                           |                                           |                                           |                                           |                                           |                                                   |                                                   |                                                   |                                                   |                                                   |
| complications                                        |                                           |                                           |                                           |                                           |                                           |                                                   |                                                   |                                                   |                                                   |                                                   |
| Infusionrelated reaction                             | Common                                    | 22 (1.3)                                  | 1 (0.1)                                   | 0                                         | 1 (0.1)                                   | Common                                            | 25 (1.1)                                          | 1 (0.0)                                           | 0                                                 | 1 (0.0)                                           |
| Investigations                                       |                                           |                                           |                                           |                                           |                                           |                                                   |                                                   |                                                   |                                                   |                                                   |
| Ejectionfraction decreasedt                          | Very Common                               | 269 (15.5)                                | 19 (1.1)                                  | 0                                         | 3 (0.2)                                   | Very Common                                       | 325 (13.9)                                        | 24 (1.0)                                          | 0                                                 | 5 (0.2)                                           |
| Weight decreased                                     | Very Common                               | 246 (14.1)                                | 8 (0.5)                                   | 0                                         | 1 (0.1)                                   | Very Common                                       | 300 (12.8)                                        | 12 (0.5)                                          | 0                                                 | 1 (0.0)                                           |
| Blood alkalinephosphataseincreased                   | Common                                    | 165 (9.5)                                 | 7 (0.4)                                   | 0                                         | 0                                         | Common                                            | 193 (8.3)                                         | 11 (0.5)                                          | 0                                                 | 0                                                 |
| Blood bilirubin increased !                          | Common                                    | 142 (8.2)                                 | 14 (0.8)                                  | 0                                         | 5 (0.3)                                   | Common                                            | 176 (7.5)                                         | 20 (0.9)                                          | 0                                                 | 6 (0.3)                                           |
| Blood creatinineincreased                            | Common                                    | 46 (2.6)                                  | 5 (0.3)                                   | 0                                         | 1 (0.1)                                   | Common                                            | 85 (3.6)                                          | 7 (0.3)                                           | 0                                                 | 2 (0.1)                                           |
| Metabolism andnutritiondisorders                     |                                           |                                           |                                           |                                           |                                           |                                                   |                                                   |                                                   |                                                   |                                                   |
| Decreased appetite                                   | Very Common                               | 529 (30.4)                                | 29 (1.7)                                  | 0                                         | 4 (0.2)                                   | Very Common                                       | 715 (30.6)                                        | 42 (1.8)                                          | 0                                                 | 7 (0.3)                                           |
| Hypokalaemia m                                       | [Very Common                              | 208 (11.9)                                | 63 (3.6)                                  | 0                                         | 12 (0.7)                                  | [Very Common                                      | 279 (11.9)                                        | 89 (3.8)                                          | 0                                                 | 13 (0.6)                                          |
| Dehydration                                          | Common                                    | 46 (2.6)                                  | 7 (0.4)                                   | 0                                         | 5 (0.3)                                   | Common                                            | 58 (2.5)                                          | 8 (0.3)                                           | 0                                                 | 5 (0.2)                                           |
| Musculoskeletalandconnectivetissue                   |                                           |                                           |                                           |                                           |                                           |                                                   |                                                   |                                                   |                                                   |                                                   |
| disorders                                            |                                           |                                           |                                           |                                           |                                           |                                                   |                                                   |                                                   |                                                   |                                                   |
| Musculoskeletal pain \"                               | Very Common                               | 456 (26.2)                                | 15 (0.9)                                  | 0                                         |                                           | 14 (0.8) Very Common                              | 551 (23.6)                                        | 21 (0.9)                                          | 0                                                 | 19 (0.8)                                          |
| Nervous system disorders                             |                                           |                                           |                                           |                                           |                                           |                                                   |                                                   |                                                   |                                                   |                                                   |
| Headache °                                           | Very Common                               | 329 (18.9)                                | 5 (0.3)                                   | 0                                         | 2 (0.1)                                   | Very Common                                       | 381 (16.3)                                        | 5 (0.2)                                           | 0                                                 | 3 (0.1)                                           |
| Dizziness                                            | Common                                    | 170 (9.8)                                 | 4 (0.2)                                   | 0                                         | 1 (0.1)                                   | Common                                            | 211 (9.0)                                         | 5 (0.2)                                           | 0                                                 | 1 (0.0)                                           |
| Dysgeusia                                            | Common                                    | 157 (9.0)                                 | 1 (0.1)                                   | 0                                         | 0                                         | Common                                            | 182 (7.8)                                         | 1 (0.0)                                           | 0                                                 | 0                                                 |
| Respiratory, thoracic andmediastinal                 |                                           |                                           |                                           |                                           |                                           |                                                   |                                                   |                                                   |                                                   |                                                   |
| disorders                                            |                                           |                                           |                                           |                                           |                                           |                                                   |                                                   |                                                   |                                                   |                                                   |
| Cough                                                | Very Common                               | 262 (15.0)                                | 1 (0.1)                                   | 0                                         | 1 (0.1)                                   | Very Common                                       | 325 (13.9)                                        | 2 (0.1)                                           | 0                                                 | 1 (0.0)                                           |
| Interstitial lung disease$                           | Very Common                               | 226 (13.0)                                | 15 (0.9)                                  | 18 (1.0)                                  | 64 (3.7)                                  | Very Common                                       | 286 (12.2)                                        | 18 (0.8)                                          | 25 (1.1)                                          | 80 (3.4)                                          |
| Epistaxis                                            | Very Common                               | 187 (10.7)                                | 0                                         | 0                                         | 0                                         | Common                                            | 213 (9.1)                                         | 2 (0.1)                                           | 0                                                 | 1 (0.0)                                           |
| Dyspnoea                                             | Common                                    | 168 (9.6)                                 | 12 (0.7)                                  | 0                                         | 11 (0.6)                                  | Common                                            | 219 (9.4)                                         | 21 (0.9)                                          | 1 (0.0)                                           | 20 (0.9)                                          |
| Skinandsubcutaneoustissuedisorders                   |                                           |                                           |                                           |                                           |                                           |                                                   |                                                   |                                                   |                                                   |                                                   |
| Alopecia                                             | Very Common                               | 729 (41.9)                                | 3 (0.2)                                   | 0                                         | 0                                         | Very Common                                       | 844 (36.1)                                        | 3 (0.1)                                           | 0                                                 | 0                                                 |
| Rash P                                               | Common                                    | 170 (9.8)                                 | 2 (0.1)                                   | 0                                         | 1 (0.1)                                   | Common                                            | 197 (8.4)                                         | 3 (0.1)                                           | 0                                                 | 1 (0.0)                                           |
| Pruritus                                             | Common                                    | 86 (4.9)                                  | 1 (0.1)                                   | 0                                         | 0                                         | Common                                            | 111 (4.8)                                         | 1 (0.0)                                           | 0                                                 | 0                                                 |
| Skin hyperpigmentation q                             | Common                                    | 68 (3.9)                                  | 0                                         | 0                                         | 1 (0.1)                                   | Common                                            | 81 (3.5)                                          | 0                                                 | 0                                                 | 1 (0.0)                                           |

Percentageswere calculated using the number of subjects in theSafetyAnalysisSet as the denominator.

ADR= adverse drug reaction; CTCAE =CommonTerminology Criteria forAdverseEvents,version5.0; MedDRA=Medical Dictionary for RegulatoryActivities,version 26.1; N = total number of subjects treated; NA =not applicable; PT=preferred term; SAE = serious adverse event; T-DXd = trastuzumab deruxtecan.

If a subject hadmultiple occurrences ofthe same ADR,the subject was counted oncefor that specific ADR.

- Neutropenia (grouped term) includes PTs of Neutrophil count decreased, Neutropenia.
- 1 Within each pool, frequency was defined as follows: Very Common &gt;=1/10 subjects; Common &gt;=1/100 to &lt;1/10 subjects; Uncommon &gt;=1/1000 to &lt;1/100 subjects; Rare &gt;=1/10000 to &lt;1/1000 subjects; Very rare&lt;1/10000 subjects.
- bAnemia (grouped term) includes PTs ofHaemoglobin decreased,Red blood cell count decreased,Anaemia,Haematocrit decreased.
- d Thrombocytopenia (grouped term) includes PTs of Platelet count decreased, Thrombocytopenia.
- (Leukopenia (grouped term) includes PTs of White blood cell count decreased, Leukopenia.
- Lymphopenia (grouped term) includes PTs of Lymphocyte count decreased, Lymphopenia.
- Abdominal pain(grouped term)includesPTs ofAbdominal discomfort,Abdominal pain,Abdominal pain lower,Abdominal pain upper,Gastrointestinal pain.

f Vision blurred (grouped term) includesPTs of Vision blurred, Visual impairment.

- Stomatiis (grouped tem) includes PTs ofStomatitis, Aphthous ulcer, Mouth ulceration, Oral mucosa erosion, Oral mucosal blistering, Oral mucosal eruption.
- iTransaminases increased (grouped term) includes PTs of Transaminases increased,Aspartate aminotransferase increased, Alanine aminotransferase increased, Gamma-glutamyltransferase increased,Liverfunction test abnormal,Hepaticfunction abnormal,Liverfunctiontestincreased,Hypertransaminasaemia.
- iFatigue (grouped term) includes PIs of Fatigue, Asthenia, Malaise, Lethargy.
- Blood bilirubinincreased(grouped term)includesPTs ofBloodbilirubinincreased,HyperbilirubinaemiaBilirubinconjugated increasedBlood bilirubinunconjugated increased.
- mHypokalaemia (grouped term) includes PTs of Hypokalaemia, Blood potassium decreased.
- Limb discomfort.
- PRash(grouped term)includesPTs ofRash,Rash pustular,Rashmaculo-papular,Rashpapular,Rash macular,Rash pruritic.
- Headache (grouped term)includes PTs of Migraine,Headache,Sinus headache.
- q Skin hyperpigmentation (grouped term) includes PTs of Skin hyperpigmentation, Skin discolouration, Pigmentation disorder.
- Infusion related reaction (grouped term) includes PTs of Hypersensitivity (n=2), Infusion related reaction (n=23)..
- Idiopathic interstitial pneumonia (n=1), Interstitial lung disease (n=109), Lower respiratory tract infection (n=1), Lung disorder (n=1), Lung infiltration (n=1), Lung opacity (n=4), Lymphangitis (n=1), Organising pneumonia (n=9), Pneumonia (n=9), Pneumonia bacterial (n=2), Pneumonia fungal (n=1), Pneumonitis (n=136), Pulmonary fibrosis (n=2), Pulmonary mass
- Ejection fraction decreased(grouped term)includes Laboratory parameters ofLVEF decrease(n=312) and PTs of Cardiacfailure(n=5),Cardiacfailure acute(n=1),Cardiac failure chronic (n=1),Cardiac failure congestive(n=1),Ejection fraction decreased (n=99),Left ventricular dysfunction(n=3).
- (n=1),Pulmonary toxicity (n=3),Radiation pneumonitis (n=4),Respiratory failure (n=5). These events were adjudicated as ILD.

<div style=\"page-break-after: always\"></div>

Table 45 Common Adverse Drug Reactions Reported in ≥ 10% of Patients with Any Event or ≥ 2% of Patients with Events of Grade 3 or 4 in the T-DXd 5.4 mg/kg Breast Cancer Pool or the T-DXd 5.4 mg/kg All Tumor Types Pool, by MedDRA System Organ Class and Preferred Term/Grouped Term (Safety Analysis Set)

| MedDRA System Organ Class Preferred                  | T-DXd 5.4 mg/kg BC Pool (N = 1741)                   | T-DXd 5.4 mg/kg BC Pool (N = 1741)                   | T-DXd 5.4 mg/kg BC Pool (N = 1741)                   | T-DXd 5.4 mg/kg BC Pool (N = 1741)                   | T-DXd 5.4 mg/kg BC Pool (N = 1741)                   | T-DXd 5.4 mg/kg All Tumor Types Pool (N = 2335)      | T-DXd 5.4 mg/kg All Tumor Types Pool (N = 2335)      | T-DXd 5.4 mg/kg All Tumor Types Pool (N = 2335)      | T-DXd 5.4 mg/kg All Tumor Types Pool (N = 2335)      | T-DXd 5.4 mg/kg All Tumor Types Pool (N = 2335)      |
|------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|
| Term/Grouped Term                                    | Frequen cy a                                         | Number (%) of Subjects                               | Number (%) of Subjects                               | Number (%) of Subjects                               | Number (%) of Subjects                               | Frequency a                                          | Number (%) of Subjects                               | Number (%) of Subjects                               | Number (%) of Subjects                               | SAE                                                  |
| Term/Grouped Term                                    | Frequen cy a                                         | CTCAE Grade                                          | CTCAE Grade                                          | CTCAE Grade                                          | SAE                                                  | Frequency a                                          | CTCAE Grade                                          | CTCAE Grade                                          | CTCAE Grade                                          | SAE                                                  |
| Term/Grouped Term                                    | Frequen cy a                                         | All Grades                                           | Grade 3 or 4                                         | Grade 5                                              | SAE                                                  | Frequency a                                          | All Grades                                           | Grade 3 or 4                                         | Grade 5                                              | SAE                                                  |
| Patients with any ADR                                | --                                                   | 1721 (98. 9)                                         | 776 (44. 6)                                          | 20 (1. 1)                                            | 220 (12.6)                                           | --                                                   | 2294 (98. 2)                                         | 1032 (44. 2)                                         | 32 (1. 4)                                            | 330 (14. 1)                                          |
| Blood and lymphatic system disorders                 | Blood and lymphatic system disorders                 | Blood and lymphatic system disorders                 | Blood and lymphatic system disorders                 | Blood and lymphatic system disorders                 | Blood and lymphatic system disorders                 | Blood and lymphatic system disorders                 | Blood and lymphatic system disorders                 | Blood and lymphatic system disorders                 | Blood and lymphatic system disorders                 | Blood and lymphatic system disorders                 |
| Neutropenia b                                        | Very Common                                          | 633 (36.4)                                           | 323 (18.6)                                           | 0                                                    | 4 (0.2)                                              | Very Common                                          | 819 (35.1)                                           | 420 (18.0)                                           | 0                                                    | 8 (0.3)                                              |
| Anemia b                                             | Very Common                                          | 611 (35.1)                                           | 159 (9.1)                                            | 0                                                    | 17 (1.0)                                             | Very Common                                          | 838 (35.9)                                           | 246 (10.5)                                           | 0                                                    | 28 (1.2)                                             |
| Leukopenia b                                         | Very Common                                          | 413 (23.7)                                           | 119 (6.8)                                            | 0                                                    | 0                                                    | Very Common                                          | 501 (21.5)                                           | 139 (6.0)                                            | 0                                                    | 0                                                    |
| Thrombocytop enia b                                  | Very Common                                          | 406 (23.3)                                           | 84 (4.8)                                             | 0                                                    | 5 (0.3)                                              | Very Common                                          | 539 (23.1)                                           | 127 (5.4)                                            | 0                                                    | 13 (0.6)                                             |
| Lymphopenia b                                        | Very Common                                          | 193 (11.1)                                           | 80 (4.6)                                             | 0                                                    | 0                                                    | Common                                               | 222 (9.5)                                            | 91 (3.9)                                             | 0                                                    | 0                                                    |
| Gastrointestinal disorders                           | Gastrointestinal disorders                           | Gastrointestinal disorders                           | Gastrointestinal disorders                           | Gastrointestinal disorders                           | Gastrointestinal disorders                           | Gastrointestinal disorders                           | Gastrointestinal disorders                           | Gastrointestinal disorders                           | Gastrointestinal disorders                           | Gastrointestinal disorders                           |
| Nausea                                               | Very Common                                          | 1294 (74.3)                                          | 89 (5.1)                                             | 0                                                    | 17 (1.0)                                             | Very Common                                          | 1660 (71.1)                                          | 115 (4.9)                                            | 0                                                    | 25 (1.1)                                             |
| Vomiting                                             | Very Common                                          | 713 (41.0)                                           | 42 (2.4)                                             | 0                                                    | 23 (1.3)                                             | Very Common                                          | 870 (37.3)                                           | 55 (2.4)                                             | 0                                                    | 35 (1.5)                                             |
| Constipation                                         | Very Common                                          | 594 (34.1)                                           | 8 (0.5)                                              | 0                                                    | 5 (0.3)                                              | Very Common                                          | 741 (31.7)                                           | 15 (0.6)                                             | 0                                                    | 8 (0.3)                                              |
| Diarrhoea                                            | Very Common                                          | 529 (30.4)                                           | 36 (2.1)                                             | 0                                                    | 5 (0.3)                                              | Very Common                                          | 703 (30.1)                                           | 58 (2.5)                                             | 0                                                    | 12 (0.5)                                             |
| Abdominal pain b                                     | Very Common                                          | 355 (20.4)                                           | 16 (0.9)                                             | 0                                                    | 5 (0.3)                                              | Very Common                                          | 455 (19.5)                                           | 24 (1.0)                                             | 0                                                    | 13 (0.6)                                             |
| Stomatitis b                                         | Very Common                                          | 259 (14.9)                                           | 10 (0.6)                                             | 0                                                    | 2 (0.1)                                              | Very Common                                          | 325 (13.9)                                           | 11 (0.5)                                             | 0                                                    | 2 (0.1)                                              |
| Dyspepsia                                            | Very Common                                          | 202 (11.6)                                           | 0                                                    | 0                                                    | 0                                                    | Very Common                                          | 245 (10.5)                                           | 1 (0.0)                                              | 0                                                    | 0                                                    |
| General disorders and administration site conditions | General disorders and administration site conditions | General disorders and administration site conditions | General disorders and administration site conditions | General disorders and administration site conditions | General disorders and administration site conditions | General disorders and administration site conditions | General disorders and administration site conditions | General disorders and administration site conditions | General disorders and administration site conditions | General disorders and administration site conditions |
| Fatigue b                                            | Very Common                                          | 990 (56.9)                                           | 130 (7.5)                                            | 0                                                    | 10 (0.6)                                             | Very Comm on                                         | 1292 (55.3)                                          | 182 (7.8)                                            | 0                                                    | 21 (0.9)                                             |
| Pyrexia                                              | Very Common                                          | 223 (12.8)                                           | 6 (0.3)                                              | 0                                                    | 11 (0.6)                                             | Very Common                                          | 293 (12.5)                                           | 10 (0.4)                                             | 0                                                    | 16 (0.7)                                             |
| Hepatobiliary disorders                              | Hepatobiliary disorders                              | Hepatobiliary disorders                              | Hepatobiliary disorders                              | Hepatobiliary disorders                              | Hepatobiliary disorders                              | Hepatobiliary disorders                              | Hepatobiliary disorders                              | Hepatobiliary disorders                              | Hepatobiliary disorders                              | Hepatobiliary disorders                              |
| Transaminases increased b                            | 518 (29.8)                                           | 67 (3.8)                                             | 0                                                    | 3 (0.2)                                              | Very Common                                          | 622 (26.6)                                           | 81 (3.5)                                             | 0                                                    | 3 (0.1)                                              | 0                                                    |
| Infections and infestations                          | Infections and infestations                          | Infections and infestations                          | Infections and infestations                          | Infections and infestations                          | Infections and infestations                          | Infections and infestations                          | Infections and infestations                          | Infections and infestations                          | Infections and infestations                          | Infections and infestations                          |
| Upper respiratory tract infection b                  | 339 (19.5)                                           | 3 (0.2)                                              | 0                                                    | 4 (0.2)Very                                          | Comm on                                              | 380 (16.3)                                           | 3 (0.1)                                              | 0                                                    | 4 (0.2)                                              | 0                                                    |

<div style=\"page-break-after: always\"></div>

| MedDRA System Organ Class                       | T-DXd 5.4 mg/kg BC Pool (N = 1741)              | T-DXd 5.4 mg/kg BC Pool (N = 1741)              | T-DXd 5.4 mg/kg BC Pool (N = 1741)              | T-DXd 5.4 mg/kg BC Pool (N = 1741)              | T-DXd 5.4 mg/kg BC Pool (N = 1741)              | T-DXd 5.4 mg/kg All Tumor Types Pool (N = 2335)   | T-DXd 5.4 mg/kg All Tumor Types Pool (N = 2335)   | T-DXd 5.4 mg/kg All Tumor Types Pool (N = 2335)   | T-DXd 5.4 mg/kg All Tumor Types Pool (N = 2335)   | T-DXd 5.4 mg/kg All Tumor Types Pool (N = 2335)   |
|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|---------------------------------------------------|---------------------------------------------------|---------------------------------------------------|---------------------------------------------------|---------------------------------------------------|
| Preferred Term/Grouped Term                     | Frequen cy a                                    | Number (%) of Subjects                          | Number (%) of Subjects                          | Number (%) of Subjects                          | Number (%) of Subjects                          | Frequency a                                       | Number (%) of Subjects                            | Number (%) of Subjects                            | Number (%) of Subjects                            | Number (%) of Subjects                            |
| Preferred Term/Grouped Term                     | Frequen cy a                                    | CTCAE Grade                                     | CTCAE Grade                                     | CTCAE Grade                                     | SAE                                             | Frequency a                                       | CTCAE Grade                                       | CTCAE Grade                                       | CTCAE Grade                                       | SAE                                               |
| Preferred Term/Grouped Term                     | Frequen cy a                                    | All Grades                                      | Grade 3 or 4                                    | Grade 5                                         | SAE                                             | Frequency a                                       | All Grades                                        | Grade 3 or 4                                      | Grade 5                                           | SAE                                               |
| Weight decreased                                | Very Common                                     | 246 (14.1)                                      | 8 (0.5)                                         | 0                                               | 1 (0.1)                                         | Very Common                                       | 300 (12.8)                                        | 12 (0.5)                                          | 0                                                 | 1 (0.0)                                           |
| Metabolism and nutrition disorders              | Metabolism and nutrition disorders              | Metabolism and nutrition disorders              | Metabolism and nutrition disorders              | Metabolism and nutrition disorders              | Metabolism and nutrition disorders              | Metabolism and nutrition disorders                | Metabolism and nutrition disorders                | Metabolism and nutrition disorders                | Metabolism and nutrition disorders                | Metabolism and nutrition disorders                |
| Decreased appetite                              | Very Common                                     | 529 (30.4)                                      | 29 (1.7)                                        | 0                                               | 4 (0.2)                                         | Very Common                                       | 715 (30.6)                                        | 42 (1.8)                                          | 0                                                 | 7 (0.3)                                           |
| Hypokalaemia b                                  | Very Common                                     | 208 (11.9)                                      | 63 (3.6)                                        | 0                                               | 12 (0.7)                                        | Very Common                                       | 279 (11.9)                                        | 89 (3.8)                                          | 0                                                 | 13 (0.6)                                          |
| Musculoskeletal and connective tissue disorders | Musculoskeletal and connective tissue disorders | Musculoskeletal and connective tissue disorders | Musculoskeletal and connective tissue disorders | Musculoskeletal and connective tissue disorders | Musculoskeletal and connective tissue disorders | Musculoskeletal and connective tissue disorders   | Musculoskeletal and connective tissue disorders   | Musculoskeletal and connective tissue disorders   | Musculoskeletal and connective tissue disorders   | Musculoskeletal and connective tissue disorders   |
| Musculoskelet al pain b                         | Very Common                                     | 456 (26.2)                                      | 15 (0.9)                                        | 0                                               | 14 (0.8)                                        | Very Comm on                                      | 551 (23.6)                                        | 21 (0.9)                                          | 0                                                 | 19 (0.8)                                          |
| Nervous system disorders                        | Nervous system disorders                        | Nervous system disorders                        | Nervous system disorders                        | Nervous system disorders                        | Nervous system disorders                        | Nervous system disorders                          | Nervous system disorders                          | Nervous system disorders                          | Nervous system disorders                          | Nervous system disorders                          |
| Headache b                                      | Very Common                                     | 329 (18.9)                                      | 5 (0.3)                                         | 0                                               | 2 (0.1)                                         | Very Common                                       | 381 (16.3)                                        | 5 (0.2)                                           | 0                                                 | 3 (0.1)                                           |
| Respiratory, thoracic and mediastinal disorders | Respiratory, thoracic and mediastinal disorders | Respiratory, thoracic and mediastinal disorders | Respiratory, thoracic and mediastinal disorders | Respiratory, thoracic and mediastinal disorders | Respiratory, thoracic and mediastinal disorders | Respiratory, thoracic and mediastinal disorders   | Respiratory, thoracic and mediastinal disorders   | Respiratory, thoracic and mediastinal disorders   | Respiratory, thoracic and mediastinal disorders   | Respiratory, thoracic and mediastinal disorders   |
| Cough                                           | Very Common                                     | 262 (15.0)                                      | 1 (0.1)                                         | 0                                               | 1 (0.1)                                         | Very Common                                       | 325 (13.9)                                        | 2 (0.1)                                           | 0                                                 | 1 (0.0)                                           |
| Interstitial lung disease c                     | Very Common                                     | 217 (12.5)                                      | 14 (0.8)                                        | 16 (0. 9)                                       | 61 (3.5)                                        | Very Common                                       | 276 (11.8)                                        | 17 (0.7)                                          | 23 (1. 0)                                         | 77 (3.3)                                          |
| Epistaxis                                       | Very Common                                     | 187 (10.7)                                      | 0                                               | 0                                               | 0                                               | Common                                            | 213 (9.1)                                         | 2 (0.1)                                           | 0                                                 | 1 (0.0)                                           |
| Skin and subcutaneous tissue disorders          | Skin and subcutaneous tissue disorders          | Skin and subcutaneous tissue disorders          | Skin and subcutaneous tissue disorders          | Skin and subcutaneous tissue disorders          | Skin and subcutaneous tissue disorders          | Skin and subcutaneous tissue disorders            | Skin and subcutaneous tissue disorders            | Skin and subcutaneous tissue disorders            | Skin and subcutaneous tissue disorders            | Skin and subcutaneous tissue disorders            |
| Alopecia                                        | Very Common                                     | 729 (41.9)                                      | 3 (0.2)                                         | 0                                               | 0                                               | Very Common                                       | 844 (36.1)                                        | 3 (0.1)                                           | 0                                                 | 0                                                 |

a Within each pool, frequency was defined as follows: Very Common ≥ 1/10 subjects; Common ≥ 1/100 to &lt; 1/10 patients; Uncommon ≥ 1/1000 to &lt; 1/100 patients; Rare ≥ 1/10000 to &lt; 1/1000 patients; Very rare &lt; 1/10000 patients.

b The PTs included in each grouped term are listed in Table.

c Interstitial lung disease (AESI) includes PTs of bronchiectasis, interstitial lung disease, lower respiratory tract infection, pneumonia, pneumonia bacterial, pneumonitis, and pulmonary toxicity. These events were adjudicated as ILD and related to use of T-DXd.

System organ classes are presented by alphabetic order. PTs/grouped terms are presented by descending frequency in the T-DXd 5.4 mg/kg BC Pool column .

If a subject had multiple occurrences of the same ADR, the patient was counted once for that specific ADR.

Table 46 Time to onset of Hematological Grouped Term ≥Grade 3 TEAEs in DB -06

|                                             | T-DXd (N = 434)   | Chemotherapy (N = 417)   |
|---------------------------------------------|-------------------|--------------------------|
| Selected TEAE: Hematological grouped term a |                   |                          |
| Time to first onset (Days) b                |                   |                          |
| n                                           | 143               | 81                       |
| Mean                                        | 72.9              | 62.4                     |
| Standard deviation                          | 116.07            | 112.53                   |
| Median                                      | 22.0              | 15.0                     |
| Minimum, maximum                            | -12, 855 c        | 0, 716                   |
| Selected TEAE: Neutropenia d                |                   |                          |
| Time to first onset (Days) b                |                   |                          |
| n                                           | 70                | 48                       |

<div style=\"page-break-after: always\"></div>

|                                                      | T-DXd (N = 434)   | Chemotherapy (N = 417)   |
|------------------------------------------------------|-------------------|--------------------------|
| Mean                                                 | 54.6              | 51.6                     |
| Standard deviation                                   | 111.61            | 113.09                   |
| Median                                               | 21.0              | 15.0                     |
| Minimum, maximum                                     | 0, 855            | 7, 716                   |
| Selected TEAE: Anemia e Time to first onset (Days) b |                   |                          |
| n                                                    | 33                | 16                       |
| Mean                                                 | 99.5              | 75.4                     |
| Standard deviation                                   | 130.18            | 105.98                   |
| Median                                               | 64.0              | 14.0                     |
| Minimum, maximum                                     | -12, 572 c        | 0, 371                   |
| Selected TEAE: Leukopenia f                          |                   |                          |
| Time to first onset (Days) b n                       | 18                | 15                       |
| Mean                                                 | 59.5              | 71.8                     |
| Standard deviation                                   | 95.80             | 118.07                   |
| Median                                               | 15.0              | 22.0                     |
| Minimum, maximum                                     | 6, 391            | 7, 461                   |
| Selected TEAE: Thrombocytopenia g                    |                   |                          |
| n                                                    | 12                | 1                        |
| Mean                                                 | 89.9              | 258.0                    |
| Standard deviation                                   | 131.31            | NA                       |
| Median                                               | 19.5              | 258.0                    |
| Minimum, maximum                                     | 1, 372            | 258, 258                 |
| Selected TEAE: Lymphopenia h                         |                   |                          |
| n                                                    | 10                | 1                        |
| Mean                                                 | 117.1             | 42.0                     |
| Standard deviation                                   | 101.36            | NA                       |
| Median                                               | 74.0              | 42.0                     |
| Minimum, maximum                                     | 14, 254           | 42, 42                   |

a Hematological grouped term includes grouped terms neutropenia, anemia, leukopenia, thrombocytopenia, lymphopenia.

b Time to first onset (Days) = date of onset of the patient's first selected TEAE - date of the first dose + 1.

c Negative values indicate event start date before dosing and worsening of the same event after dosing.

d Includes the PTs of neutropenia and neutrophil count decreased.

e Includes the PTs of anaemia, haemoglobin decreased, haematocrit decreased, and red blood cell count decreased.

f Includes the PTs of leukopenia and white blood cell count decreased.

g Includes the PTs of platelet count decreased and thrombocytopenia.

h Includes the PTs of lymphopenia and lymphocyte count decreased.

A TEAE is defined as an adverse event that occurs, having been absent before the first dose of study drug, or has worsened in severity or seriousness after initiating the study drug until the 40-day (+ 7 days) safety follow-up visit

In the All Tumour Type (ATT) Pool, for the ADR neutropenia, median time to onset was 42 days (range: 1 day  to  31.9 months),  and  median  duration  of  the  first  event  was  21 days  (range:  1 day  to 17.1 months).

<div style=\"page-break-after: always\"></div>

## Serious adverse event/deaths/other significant events

Table 47 Primary Cause of Any Deaths and On-treatment Deaths (Safety Analysis Set)

|                             | Number (%) of Patients    | Number (%) of Patients   | Number (%) of Patients             | Number (%) of Patients                          |
|-----------------------------|---------------------------|--------------------------|------------------------------------|-------------------------------------------------|
|                             | Study DB-06               | Study DB-06              | Supportive Safety Pools            | Supportive Safety Pools                         |
|                             | T-DXd 5.4 mg/kg (N = 434) | Chemotherapy (N = 417)   | T-DXd 5.4 mg/kg BC Pool (N = 1741) | T-DXd 5.4 mg/kg All Tumor Types Pool (N = 2335) |
| Any death                   | 160 (36.9)                | 171 (41.0)               | 634 (36.4)                         | 960 (41.1)                                      |
| Adverse event               | 10 (2.3)                  | 7 (1.7)                  | 41 (2.4)                           | 64 (2.7)                                        |
| Disease progression         | 0                         | 0                        | 373 (21.4)                         | 447 (19.1)                                      |
| Disease under investigation | 136 (31.3)                | 150 (36.0)               | 140 (8.0)                          | 342 (14.6)                                      |
| Unknown a                   | 1 (0.2)                   | 2 (0.5)                  | 44 (2.5)                           | 61 (2.6)                                        |
| Other                       | 13 (3.0)                  | 12 (2.9)                 | 36 (2.1)                           | 46 (2.0)                                        |
| On-treatment death b        | 12 (2.8)                  | 13 (3.1)                 | 52 (3.0)                           | 123 (5.3)                                       |
| Adverse event               | 8 (1.8)                   | 6 (1.4)                  | 29 (1.7)                           | 49 (2.1)                                        |
| Disease progression         | 0                         | 0                        | 15 (0.9)                           | 34 (1.5)                                        |
| Disease under investigation | 4 (0.9)                   | 6 (1.4)                  | 4 (0.2)                            | 32 (1.4)                                        |
| Unknown                     | 0                         | 0                        | 2 (0.1)                            | 3 (0.1)                                         |
| Other                       | 0                         | 1 (0.2)                  | 2 (0.1)                            | 5 (0.2)                                         |

a In Study DB06 the 'unknown' category consists of patients with missing primary cause of death on the eCRF.

b On-treatment death is defined as death occurred between first dose and 28 days following the last dose of study drug and before the initiation of the first subsequent anticancer therapy (whichever occurred first) for Study J101 and 47 days following the last dose of study treatment and before the initiation of the first subsequent anticancer therapy (whichever occurred first) for all other studies.

Percentages are calculated using the number of patients in the Safety Analysis Set as the denominator. The pooled analysis group is based on tumor type and first dose received for patients in each study. In Study DB06, the reason for death of 'disease under investigation' includes any death due to disease progression.

Table 48 Adverse Events Associated with an Outcome of Death Reported in a Least One Patient in Either Treatment Arm of Study DB-06, by Preferred Term (Safety Analysis Set)

|                                                            | Number (%) of Patients    | Number (%) of Patients   | Number (%) of Patients             | Number (%) of Patients                          |
|------------------------------------------------------------|---------------------------|--------------------------|------------------------------------|-------------------------------------------------|
|                                                            | Study DB-06               | Study DB-06              | Supportive Safety Pools            | Supportive Safety Pools                         |
|                                                            | T-DXd 5.4 mg/kg (N = 434) | Chemotherapy (N = 417)   | T-DXd 5.4 mg/kg BC Pool (N = 1741) | T-DXd 5.4 mg/kg All Tumor Types Pool (N = 2335) |
| Patients with any TEAE associated with an outcome of death | 11 (2.5)                  | 6 (1.4)                  | 56 (3.2)                           | 96 (4.1)                                        |
| Interstitial lung disease                                  | 2 (0.5)                   | 0                        | 3 (0.2)                            | 3 (0.1)                                         |
| Sepsis                                                     | 2 (0.5)                   | 1 (0.2)                  | 4 (0.2)                            | 6 (0.3)                                         |
| COVID-19 pneumonia                                         | 1 (0.2)                   | 0                        | 1 (0.1)                            | 3 (0.1)                                         |
| Cerebrovascular accident                                   | 1 (0.2)                   | 0                        | 1 (0.1)                            | 3 (0.1)                                         |
| Death                                                      | 1 (0.2)                   | 1 (0.2)                  | 2 (0.1)                            | 7 (0.3)                                         |
| General physical health deterioration                      | 1 (0.2)                   | 0                        | 3 (0.2)                            | 3 (0.1)                                         |
| Meningoencephalitis bacterial                              | 1 (0.2)                   | 0                        | 1 (0.1)                            | 1 (0.0)                                         |
| Neutropenic sepsis                                         | 1 (0.2)                   | 0                        | 1 (0.1)                            | 2 (0.1)                                         |
| Peritonitis                                                | 1 (0.2)                   | 0                        | 1 (0.1)                            | 1 (0.0)                                         |
| Cardiac arrest                                             | 0                         | 1 (0.2)                  | 0                                  | 2 (0.1)                                         |

<div style=\"page-break-after: always\"></div>

|                          | Number (%) of Patients    | Number (%) of Patients   | Number (%) of Patients             | Number (%) of Patients                          |
|--------------------------|---------------------------|--------------------------|------------------------------------|-------------------------------------------------|
|                          | Study DB-06               | Study DB-06              | Supportive Safety Pools            | Supportive Safety Pools                         |
|                          | T-DXd 5.4 mg/kg (N = 434) | Chemotherapy (N = 417)   | T-DXd 5.4 mg/kg BC Pool (N = 1741) | T-DXd 5.4 mg/kg All Tumor Types Pool (N = 2335) |
| Haemorrhage intracranial | 0                         | 1 (0.2)                  | 0                                  | 0                                               |
| Pleural effusion         | 0                         | 1 (0.2)                  | 1 (0.1)                            | 1 (0.0)                                         |
| Pulmonary embolism       | 0                         | 1 (0.2)                  | 0                                  | 1 (0.0)                                         |

Percentages are calculated using the number of patients in the Safety Analysis Set as the denominator.

The pooled analysis group is based on first dose received for patients in each study.

PTs are sorted by descending frequency in the Study DB-06 T-DXd 5.4 mg/kg treatment arm.

If a patient had multiple occurrences of the same PT, the patient is counted once for the specific PT.

If a patient had multiple PTs, the patient is counted in each of the different PTs.

Table 49 Serious Adverse Events Reported in at Least 2 Patients in Either Treatment Arm in Study DB-06, by Preferred Term (Safety Analysis Set)

|                                       | Number (%) of Patients    | Number (%) of Patients   | Number (%) of Patients             | Number (%) of Patients                          |
|---------------------------------------|---------------------------|--------------------------|------------------------------------|-------------------------------------------------|
|                                       | Study DB-06               | Study DB-06              | Supportive Safety Pools            | Supportive Safety Pools                         |
|                                       | T-DXd 5.4 mg/kg (N = 434) | Chemotherapy (N = 417)   | T-DXd 5.4 mg/kg BC Pool (N = 1741) | T-DXd 5.4 mg/kg All Tumor Types Pool (N = 2335) |
| Patients with any TEAE                | 88 (20.3)                 | 67 (16.1)                | 429 (24.6)                         | 652 (27.9)                                      |
| Interstitial lung disease             | 8 (1.8)                   | 0                        | 27 (1.6)                           | 30 (1.3)                                        |
| Pneumonitis                           | 8 (1.8)                   | 0                        | 33 (1.9)                           | 43 (1.8)                                        |
| COVID-19                              | 7 (1.6)                   | 1 (0.2)                  | 23 (1.3)                           | 32 (1.4)                                        |
| Febrile neutropenia                   | 5 (1.2)                   | 2 (0.5)                  | 14 (0.8)                           | 19 (0.8)                                        |
| Hypokalaemia                          | 5 (1.2)                   | 1 (0.2)                  | 12 (0.7)                           | 13 (0.6)                                        |
| Anaemia                               | 3 (0.7)                   | 1 (0.2)                  | 17 (1.0)                           | 28 (1.2)                                        |
| General physical health deterioration | 3 (0.7)                   | 0                        | 7 (0.4)                            | 12 (0.5)                                        |
| Nausea                                | 3 (0.7)                   | 1 (0.2)                  | 17 (1.0)                           | 25 (1.1)                                        |
| Pulmonary embolism                    | 3 (0.7)                   | 3 (0.7)                  | 6 (0.3)                            | 9 (0.4)                                         |
| Vomiting                              | 3 (0.7)                   | 1 (0.2)                  | 23 (1.3)                           | 35 (1.5)                                        |
| Decreased appetite                    | 2 (0.5)                   | 1 (0.2)                  | 4 (0.2)                            | 7 (0.3)                                         |
| Hypercalcaemia                        | 2 (0.5)                   | 2 (0.5)                  | 7 (0.4)                            | 7 (0.3)                                         |
| Liver injury                          | 2 (0.5)                   | 0                        | 3 (0.2)                            | 3 (0.1)                                         |
| Pneumocystis jirovecii pneumonia      | 2 (0.5)                   | 0                        | 6 (0.3)                            | 7 (0.3)                                         |
| Pneumothorax                          | 2 (0.5)                   | 0                        | 4 (0.2)                            | 5 (0.2)                                         |
| Pyelonephritis                        | 2 (0.5)                   | 1 (0.2)                  | 6 (0.3)                            | 6 (0.3)                                         |
| Sepsis                                | 2 (0.5)                   | 2 (0.5)                  | 12 (0.7)                           | 25 (1.1)                                        |
| Cellulitis                            | 1 (0.2)                   | 5 (1.2)                  | 10 (0.6)                           | 11 (0.5)                                        |
| Constipation                          | 1 (0.2)                   | 2 (0.5)                  | 5 (0.3)                            | 8 (0.3)                                         |
| Diarrhoea                             | 1 (0.2)                   | 3 (0.7)                  | 5 (0.3)                            | 12 (0.5)                                        |
| Pneumonia                             | 1 (0.2)                   | 3 (0.7)                  | 26 (1.5)                           | 43 (1.8)                                        |
| Back pain                             | 0                         | 2 (0.5)                  | 3 (0.2)                            | 4 (0.2)                                         |
| Cardiac failure                       | 0                         | 2 (0.5)                  | 1 (0.1)                            | 2 (0.1)                                         |
| Cholangitis                           | 0                         | 3 (0.7)                  | 0                                  | 4 (0.2)                                         |
| Colitis                               | 0                         | 3 (0.7)                  | 3 (0.2)                            | 4 (0.2)                                         |

<div style=\"page-break-after: always\"></div>

|                  | Number (%) of Patients    | Number (%) of Patients   | Number (%) of Patients             | Number (%) of Patients                          |
|------------------|---------------------------|--------------------------|------------------------------------|-------------------------------------------------|
|                  | Study DB-06               | Study DB-06              | Supportive Safety Pools            | Supportive Safety Pools                         |
|                  | T-DXd 5.4 mg/kg (N = 434) | Chemotherapy (N = 417)   | T-DXd 5.4 mg/kg BC Pool (N = 1741) | T-DXd 5.4 mg/kg All Tumor Types Pool (N = 2335) |
| Femur fracture   | 0                         | 3 (0.7)                  | 1 (0.1)                            | 1 (0.0)                                         |
| Pleural effusion | 0                         | 5 (1.2)                  | 8 (0.5)                            | 16 (0.7)                                        |
| Pyrexia          | 0                         | 2 (0.5)                  | 11 (0.6)                           | 16 (0.7)                                        |

Percentages are calculated using the number of patients in the Safety Analysis Set as the denominator.

The pooled analysis group is based on first dose received for patients in each study.

PTs are sorted by descending frequency in the Study DB-06 T-DXd 5.4 mg/kg treatment arm.

If a patient had multiple occurrences of the same PT, the patient is counted once for the specific PT.

If a patient had multiple PTs, the patient is counted in each of the different PTs.

Table 50 Overview of Adjudicated Drug-related ILD (Safety Analysis Set)

| Adjudication Result and CTCAE Grade by Adjudication Committee   | Number (%) of Patients              | Number (%) of Patients              | Number (%) of Patients              | Number (%) of Patients                           |
|-----------------------------------------------------------------|-------------------------------------|-------------------------------------|-------------------------------------|--------------------------------------------------|
| Adjudication Result and CTCAE Grade by Adjudication Committee   | Study DB-06                         | Study DB-06                         | Supportive Safety Pools             | Supportive Safety Pools                          |
| Adjudication Result and CTCAE Grade by Adjudication Committee   | T-DXd 5.4 mg/k g (N = 434 )         | Chemotherap y (N = 417)             | T-DXd 5.4 mg/k g BC Pool (N = 1741) | T-DXd 5.4 mg/k g All Tumor Types Pool (N = 2335) |
| Total number of patients with events adjudicated by the ILD AC  | 75 (17.3)                           | 5 (1.2)                             | 299 (17.2)                          | 379 (16.2)                                       |
| Adjudicated as ILD                                              |                                     |                                     |                                     |                                                  |
| Any grade                                                       | 52 (12.0)                           | 1 (0.2)                             | 226 (13.0)                          | 286 (12.2)                                       |
| 1                                                               | 10 (2.3)                            | 0                                   | 54 (3.1)                            | 68 (2.9)                                         |
| 2                                                               | 36 (8.3)                            | 1 (0.2)                             | 139 (8.0)                           | 175 (7.5)                                        |
| 3                                                               | 3 (0.7)                             | 0                                   | 14 (0.8)                            | 17 (0.7)                                         |
| 4                                                               | 0                                   | 0                                   | 1 (0.1)                             | 1 (0.0)                                          |
| 5                                                               | 3 (0.7)                             | 0                                   | 18 (1.0)                            | 25 (1.1)                                         |
| ≥ 3                                                             | 6 (1.4)                             | 0                                   | 33 (1.9)                            | 43 (1.8)                                         |
| Adjudicated as drug-related ILD                                 | Adjudicated as drug-related ILD     | Adjudicated as drug-related ILD     | Adjudicated as drug-related ILD     | Adjudicated as drug-related ILD                  |
| Any grade                                                       | 49 (11.3)                           | 1 (0.2)                             | 217 (12.5)                          | 276 (11.8)                                       |
| 1                                                               | 7 (1.6)                             | 0                                   | 51 (2.9)                            | 65 (2.8)                                         |
| 2                                                               | 36 (8.3)                            | 1 (0.2)                             | 136 (7.8)                           | 171 (7.3)                                        |
| 3                                                               | 3 (0.7)                             | 0                                   | 14 (0.8)                            | 17 (0.7)                                         |
| 4                                                               | 0                                   | 0                                   | 0                                   | 0                                                |
| 5                                                               | 3 (0.7)                             | 0                                   | 16 (0.9)                            | 23 (1.0)                                         |
| ≥ 3                                                             | 6 (1.4)                             | 0                                   | 30 (1.7)                            | 40 (1.7)                                         |
| Adjudicated as not drug-related ILD                             | Adjudicated as not drug-related ILD | Adjudicated as not drug-related ILD | Adjudicated as not drug-related ILD | Adjudicated as not drug-related ILD              |
| Any grade                                                       | 3 (0.7)                             | 0                                   | 9 (0.5)                             | 10 (0.4)                                         |
| 1                                                               | 3 (0.7)                             | 0                                   | 4 (0.2)                             | 4 (0.2)                                          |
| 2                                                               | 0                                   | 0                                   | 3 (0.2)                             | 4 (0.2)                                          |
| 3                                                               | 0                                   | 0                                   | 0                                   | 0                                                |
| 4                                                               | 0                                   | 0                                   | 0                                   | 0                                                |
| 5                                                               | 0                                   | 0                                   | 2 (0.1)                             | 2 (0.1)                                          |

<div style=\"page-break-after: always\"></div>

| Adjudication Result and CTCAE Grade by Adjudication Committee   | Number (%) of Patients      | Number (%) of Patients    | Number (%) of Patients              | Number (%) of Patients                           |
|-----------------------------------------------------------------|-----------------------------|---------------------------|-------------------------------------|--------------------------------------------------|
| Adjudication Result and CTCAE Grade by Adjudication Committee   | Study DB-06                 | Study DB-06               | Supportive Safety Pools             | Supportive Safety Pools                          |
| Adjudication Result and CTCAE Grade by Adjudication Committee   | T-DXd 5.4 mg/k g (N = 434 ) | Chemotherap y (N = 417)   | T-DXd 5.4 mg/k g BC Pool (N = 1741) | T-DXd 5.4 mg/k g All Tumor Types Pool (N = 2335) |
| ≥ 3                                                             | 0                           | 0                         | 2 (0.1)                             | 2 (0.1)                                          |
| Adjudicated as not ILD                                          | 23 (5.3)                    | 4 (1.0)                   | 72 (4.1)                            | 92 (3.9)                                         |
| Pending adjudication a, b                                       | Pending adjudication a, b   | Pending adjudication a, b | Pending adjudication a, b           | Pending adjudication a, b                        |
| Any grade                                                       | 0                           | 0                         | 1 (0.1)                             | 1 (0.0)                                          |
| 1                                                               | 0                           | 0                         | 0                                   | 0                                                |
| 2                                                               | 0                           | 0                         | 0                                   | 0                                                |
| 3                                                               | 0                           | 0                         | 1 (0.1)                             | 1 (0.0)                                          |
| 4                                                               | 0                           | 0                         | 0                                   | 0                                                |
| 5                                                               | 0                           | 0                         | 0                                   | 0                                                |
| ≥ 3                                                             | 0                           | 0                         | 1 (0.1)                             | 1 (0.0)                                          |

a The CTCAE grade is based on investigator assessed grade.

b Patient 34050001 in Study U201 had an ILD case pending for adjudication.

Percentages are calculated using the number of patients in the Safety Analysis Set as the denominator.

The pooled analysis group is based on first dose received for patients in each study.

This table includes all events that were submitted to the ILD Adjudication Committee for adjudication.

Each patient is counted only in one of the last 4 summary blocks. For patients having ILD cases across the last 4 blocks, the patient is counted in the block according to the preceding order presented in the table. If a patient had multiple ILD events, the CTCAE grade is shown for the event with the worst grade. If a patient has both missing and non-missing CTCAE grades for a TEAE, the worst CTCAE grade is based on non-missing grade.

## Adverse Events of Special Interest

Table 51 Preferred Terms in Adverse Events of Special Interest

| Category                     | Preferred Terms                                                                                                                                                                                                                                                                                                                                            |
|------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| ILD/pneumonitis              | Events of ILD/pneumonitis from PTs triggering adjudication, based on the current study MedDRA version for the narrow ILD SMQ, selected terms from the broad ILD SMQ, and PTs of respiratory failure and acute respiratory failure                                                                                                                          |
| Left ventricular dysfunction | Acute left ventricular failure Acute right ventricular failure Cardiac failure Cardiac failure acute Cardiac failure chronic Cardiac failure congestive Chronic left ventricular failure Chronic right ventricular failure Ejection fraction decreased Left ventricular dysfunction Left ventricular failure Right ventricular failure Ventricular failure |

<div style=\"page-break-after: always\"></div>

Astrazeneca

## · ILD/Pneumonitis T-DXd Integrated Safety Summary

Table 2.7.4.2.1.4.a Drug Related ILD/Pneumonitis by Preferred Term

Table 52 Drug Related ILD ILD/Pneumonitis by Preferred Terms (Safety Analysis Set) (Safety Analysis Set)

|                               | Number (%) of Patients        | Number (%) of Patients                      | Number (%) of Patients                      | Number (%) of Patients                        |
|-------------------------------|-------------------------------|---------------------------------------------|---------------------------------------------|-----------------------------------------------|
|                               | D9670C00001(DESTINY-Breast06) | D9670C00001(DESTINY-Breast06)               | Supportive Safety Pools                     | Supportive Safety Pools                       |
| MedDRA Preferred Term         | T-DXd 5.4 mg/kg (N=434)       | Investigator choice of chemotherapy (N=417) | T-DXd 5.4 mg/kg breast cancer pool (N=1741) | T-DXd 5.4 mg/kg all tumor types pool (N=2335) |
| Patients with ILD/Pneumonitis | 58 (13.4)                     | 2 (0.5)                                     | 234 (13.4)                                  | 290 (12.4)                                    |
| Interstitial lung disease     | 30 (6.9)                      | 2 (0.5)                                     | 101 (5.8)                                   | 119 (5.1)                                     |
| Pneumonitis                   | 28 (6.5)                      | 0                                           | 133 (7.6)                                   | 171 (7.3)                                     |

Table 53 Treatment-Emergent ILD/Pneumonitis by Grouped Term, Preferred Term and Worst NCI CTCAE Grade (Safety Analysis Set)

Table 54 Analysis of ILD/Organising pneumonitis/Acute interstitial pneumonitis (Safety Analysis Set)

|                                        | Number (%) of Patients        | Number (%) of Patients                      | Number (%) of Patients                      | Number (%) of Patients                        |
|----------------------------------------|-------------------------------|---------------------------------------------|---------------------------------------------|-----------------------------------------------|
|                                        | D9670C00001(DESTINY-Breast06) | D9670C00001(DESTINY-Breast06)               | Supportive Safety Pools                     | Supportive Safety Pools                       |
|                                        | T-DXd 5.4 mg/kg (N=434)       | Investigator choice of chemotherapy (N=417) | T-DXd 5.4 mg/kg breast cancer pool (N=1741) | T-DXd 5.4 mg/kg all tumor types pool (N=2335) |
| Selected TEAE: ILD/Pneumonitis         |                               |                                             |                                             |                                               |
| Any selected TEAE                      | 60 (13.8)                     | 2 (0.5)                                     | 243 (14.0)                                  | 301 (12.9)                                    |
| Worst NCI CTCAE Grade                  |                               |                                             |                                             |                                               |
| 1                                      | 37 (8.5)                      | 1 (0.2)                                     | 147 (8.4)                                   | 183 (7.8)                                     |
| 2                                      | 15 (3.5)                      | 1 (0.2)                                     | 63 (3.6)                                    | 76 (3.3)                                      |
| 3                                      | 5 (1.2)                       | 0                                           | 21 (1.2)                                    | 27 (1.2)                                      |
| 4                                      | 1 (0.2)                       | 0                                           | 3 (0.2)                                     | 3 (0.1)                                       |
| 5                                      | 2 (0.5)                       | 0                                           | 9 (0.5)                                     | 12 (0.5)                                      |
| >=3                                    | 8 (1.8)                       | 0                                           | 33 (1.9)                                    | 42 (1.8)                                      |
| Outcome of the worst selected TEAE [1] |                               |                                             |                                             |                                               |
| Fatal                                  | 2 (3.3)                       | 0                                           | 9 (3.7)                                     | 13 (4.3)                                      |
| Not Recovered/Not Resolved             | 25 (41.7)                     | 0                                           | 61 (25.1)                                   | 85 (28.2)                                     |
| Ongoing                                | 0                             | 0                                           | 1 (0.4)                                     | 1 (0.3)                                       |
| Recovering/Resolving                   | 4 (6.7)                       | 0                                           | 16 (6.6)                                    | 20 (6.6)                                      |
| Recovered/Resolved with Sequelae       | 4 (6.7)                       | 0                                           | 13 (5.3)                                    | 14 (4.7)                                      |
| Recovered/Resolved                     | 25 (41.7)                     | 2 (100)                                     | 138 (56.8)                                  | 163 (54.2)                                    |
| Missing/Unknown                        | 0                             | 0                                           | 5 (2.1)                                     | 5 (1.7)                                       |

<!-- formula-not-decoded -->

<!-- image -->

|                                                                                                      | Number （&)of Patients         | Number （&)of Patients                       | Number （&)of Patients                     | Number （&)of Patients   |
|------------------------------------------------------------------------------------------------------|-------------------------------|---------------------------------------------|-------------------------------------------|-------------------------|
|                                                                                                      | D9670C00001(DESTINY-BreaSt06) | D9670C00001(DESTINY-BreaSt06)               | SupportiveSafetyPools                     | SupportiveSafetyPools   |
|                                                                                                      | T-DXd5.4mg/kg (N=434)         | Investigator choice of chemotherapy (N=417) | T-DXd5.4mg/kg breast cancer pool (N=1741) | T-DXd5.4mg/kg (N=2335)  |
| Selected TEAE:ILD/Pneumonitis/Organising pneumonitis/Acute interstitialpneumonitis Any selected TEAE | 60 (13.8)                     | 2 (0.5)                                     | 250 (14.4)                                | 310 (13.3)              |

Please refer to Table 50 Overview of Adjudicated Drug-related ILD (Safety Analysis Set) above.

Table 55 Overview of Investigator-reported ILD/Pneumonitis

|                                           | Number (%) of Patients    | Number (%) of Patients   | Number (%) of Patients             | Number (%) of Patients                          |
|-------------------------------------------|---------------------------|--------------------------|------------------------------------|-------------------------------------------------|
|                                           | Study DB-06               | Study DB-06              | Supportive Safety Pools            | Supportive Safety Pools                         |
|                                           | T-DXd 5.4 mg/kg (N = 434) | Chemotherapy (N = 417)   | T-DXd 5.4 mg/kg BC Pool (N = 1741) | T-DXd 5.4 mg/kg All Tumor Types Pool (N = 2335) |
| Patients with ILD/pneumonitis (any grade) | 60 (13.8)                 | 2 (0.5)                  | 243 (14.0)                         | 301 (12.9)                                      |
| 1                                         | 37 (8.5)                  | 1 (0.2)                  | 147 (8.4)                          | 183 (7.8)                                       |
| 2                                         | 15 (3.5)                  | 1 (0.2)                  | 63 (3.6)                           | 76 (3.3)                                        |
| 3                                         | 5 (1.2)                   | 0                        | 21 (1.2)                           | 27 (1.2)                                        |
| 4                                         | 1 (0.2)                   | 0                        | 3 (0.2)                            | 3 (0.1)                                         |
| 5                                         | 2 (0.5)                   | 0                        | 9 (0.5)                            | 12 (0.5)                                        |

Page 1 of 1

<div style=\"page-break-after: always\"></div>

|                                                    | Number (%) of Patients    | Number (%) of Patients   | Number (%) of Patients             | Number (%) of Patients                          |
|----------------------------------------------------|---------------------------|--------------------------|------------------------------------|-------------------------------------------------|
|                                                    | Study DB-06               | Study DB-06              | Supportive Safety Pools            | Supportive Safety Pools                         |
|                                                    | T-DXd 5.4 mg/kg (N = 434) | Chemotherapy (N = 417)   | T-DXd 5.4 mg/kg BC Pool (N = 1741) | T-DXd 5.4 mg/kg All Tumor Types Pool (N = 2335) |
| ≥ 3                                                | 8 (1.8)                   | 0                        | 33 (1.9)                           | 42 (1.8)                                        |
| Serious ILD/pneumonitis                            | 16 (3.7)                  | 0                        | 60 (3.4)                           | 73 (3.1)                                        |
| ILD/pneumonitis leading to study                   | 38 (8.8)                  | 0                        | 172 (9.9)                          | 212 (9.1)                                       |
| ILD/pneumonitis leading to study drug interruption | 10 (2.3)                  | 0                        | 50 (2.9)                           | 61 (2.6)                                        |

If a patient has multiple occurrences of the same preferred term, the patient is counted once for the specific preferred term. If a patient has more than one event per grouped term, the patient is counted once at the Grouped Term level. Within the same grouped term, if a patient has multiple preferred terms, the patient is counted in each of the different preferred terms.

Table 56 Investigator Assessment and ILD Adjudication Committee Assessment of Fatal ILD Events

| Patient Description,   | T-DXd Administration and Death Dates                             | Investigator Assessment                                                                                                                                                                     | Adjudication Committee Assessment                                                                        |
|------------------------|------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------|
| Female, 79 White,      | Received 7 doses of T-DXd; last dose on Day 128 Died on Day 170  | Grade 1 ILD on Day 127 Maximum Grade 5 ILD Primary cause of death: AE of ILD                                                                                                                | Adjudicated as Grade 1 drug-related ILD at onset Maximum Grade 5 drug-related ILD per AC                 |
| Female, 57 White,      | Received 6 doses of T-DXd; last dose on Day 114 Died on Day 246  | Grade 2 ILD on Day 125 Maximum Grade 3 ILD Primary cause of death: disease under investigation                                                                                              | Adjudicated as Grade 3 drug-related ILD at onset Maximum Grade 5 drug-related ILD per AC                 |
| Female, 76 Asian,      | Received 10 doses of T-DXd; last dose on Day 196 Died on Day 210 | Grade 3 bacterial pneumonia on Day 207; Grade 1 cytomegalovirus infection on Day 208; Grade 3 ILD on Day 209 Primary cause of death: disease under investigation                            | Adjudicated as Grade 3 drug related ILD at onset Maximum Grade 5 drug-related ILD per AC                 |
| Female, 82 Asian,      | Received 6 doses of T-DXd; last dose on Day 113 Died on Day 138  | Grade 1 ILD on Day 127, Maximum Grade 5 ILD Grade 4 COVID-19 on Day 130; Grade 4 Pneumocystis jirovecii pneumonia on Day 132 Primary cause of death: ILD Secondary cause of death: COVID-19 | Adjudicated as not ILD. The ILD adjudication committee considered that this event was COVID-19 pneumonia |

<div style=\"page-break-after: always\"></div>

Table 57 Adjudicated Drug-Related Interstitial Lung Disease by Preferred Term and Worst NCI CTCAE Grade (Safety Analysis Set)

|                                     | Number (%) of Patients         | Number (%) of Patients              | Number (%) of Patients             | Number (%) of Patients               |
|-------------------------------------|--------------------------------|-------------------------------------|------------------------------------|--------------------------------------|
|                                     | D9670C00001 (DESTINY-Breast06) | D9670C00001 (DESTINY-Breast06)      | Supportive Safety Pools            | Supportive Safety Pools              |
| AESI Category MedDRA Preferred Term | T-DXd 5.4 mg/kg                | Investigator choice of chemotherapy | T-DXd 5.4 mg/kg breast cancer pool | T-DXd 5.4 mg/kg all tumor types pool |
| CTCAE Grade                         | (N=434)                        |                                     | (N=1741)                           |                                      |
|                                     |                                | (N=417)                             |                                    | (N=2335)                             |
| Adjudicated Drug-related ILD        | 49 (11.3)                      | 1 (0.2)                             | 217 (12.5)                         | 276 (11.8)                           |
| 1                                   | 7 (1.6)                        | 0                                   | 51 (2.9)                           | 65 (2.8)                             |
| 2                                   | 36 (8.3)                       | 1 (0.2)                             | 136 (7.8)                          | 171 (7.3)                            |
| 3                                   | 3 (0.7)                        | 0                                   | 14 (0.8)                           | 17 (0.7)                             |
| 4                                   | 0                              | 0                                   | 0                                  | 0                                    |
| 5                                   | 3 (0.7)                        | 0                                   | 16 (0.9)                           | 23 (1.0)                             |
| >=3                                 | 6 (1.4)                        | 0                                   | 30 (1.7)                           | 40 (1.7)                             |
| Interstitial lung disease           | 24 (5.5)                       | 1 (0.2)                             | 93 (5.3)                           | 107 (4.6)                            |
| 1                                   | 6 (1.4)                        | 0                                   | 22 (1.3)                           | 27 (1.2)                             |
| 2                                   | 14 (3.2)                       | 1 (0.2)                             | 63 (3.6)                           | 72 (3.1)                             |
| 3                                   | 1 (0.2)                        | 0                                   | 3 (0.2)                            | 3 (0.1)                              |
| 4                                   | 0                              | 0                                   | 0                                  | 0                                    |
| 5                                   | 3 (0.7)                        | 0                                   | 5 (0.3)                            | 5 (0.2)                              |
| >=3                                 | 4 (0.9)                        | 0                                   | 8 (0.5)                            | 8 (0.3)                              |

Table 58 Adjudicated Drug-related Interstitial Lung Disease by Preferred Term and Worst NCI CTCAE Grade (Safety Analysis Set)

|                                     | Number (&)of Patients         | Number (&)of Patients               | Number (&)of Patients              | Number (&)of Patients                |
|-------------------------------------|-------------------------------|-------------------------------------|------------------------------------|--------------------------------------|
|                                     | D9670C00001(DESTINY-BreaSt06) | D9670C00001(DESTINY-BreaSt06)       | Supportive Safety Pools            | Supportive Safety Pools              |
| AESI Category MedDRA Preferred Term | T-DXd 5.4 mg/kg (N=434)       | Investigator choice of chemotherapy | T-DXd 5.4 mg/kg breast cancer pool | T-DXd 5.4 mg/kg all tumor types pool |
| CTCAE Grade                         |                               | (N=417)                             | (N=1741)                           | (N=2335)                             |
| Pneumonitis                         | 20 (4.6)                      | 0                                   | 101 (5.8)                          | 134 (5.7)                            |
| 1                                   | 1 (0.2)                       | 0                                   | 22 (1.3)                           | 27 (1.2)                             |
| 2                                   | 17 (3.9)                      | 0                                   | 64 (3.7)                           | 85 (3.6)                             |
| 3                                   | 2 (0.5)                       | 0                                   | 8 (0.5)                            | 10 (0.4)                             |
| 4                                   | 0                             | 0                                   | 1 (0.1)                            | 1 (0.0)                              |
| 5                                   | 0                             | 0                                   | 6 (0.3)                            | 11 (0.5)                             |
| >=3                                 | 2 (0.5)                       | 0                                   | 15 (0.9)                           | 22 (0.9)                             |
| Bronchiectasis                      | 1 (0.2)                       | 0                                   | 1  (0.1)                           | 1 (0.0)                              |
| 1                                   | 0                             | 0                                   | 0                                  | 0                                    |
| 2                                   | 1 (0.2)                       | 0                                   | 1 (0.1)                            | 1 (0.0)                              |
| 3                                   | 0                             | 0                                   | 0                                  | 0                                    |
| 4                                   | 0                             | 0                                   | 0                                  | 0                                    |
| 5                                   | 0                             | 0                                   | 0                                  | 0                                    |
| >=3                                 | 0                             | 0                                   | 0                                  | 0                                    |

Note: Percentages are calculated using the number of patients in the Safety Analysis Set as the denominator.

Adjudicated ILD events include all adjudicated and considered study drug related events by adjudication committee.

CTCAE grade for adjudicated ILD is the adjudicated ILD grade.

Adverse Events are coded using MedDRA Version 26.1 and graded per CTcAE 5.0.

If a patient has multiple occurrences of the same preferred term,the patient is counted once for the specific preferred term by worst adjudicated drug-related ILD grade.

If a patient has multiple preferred terms, the patient is counted in each of the different preferred terms.

DC02(N=83)，DP01(N=102)，DP02(N=267)

Date of Data cut-off: T-DXd 5.4 mg/kg breast cancer pool from studies J101 (01Aug2019), DB01 (08Jun2020), DB02 (30Jun2022), DB03 (25Jul2022), DB04(11Apr2022)，DB06(18MAR2024)，DP01(25Jan2023)

T-DXd 5.4 mg/kg all tumor types cancer pool from J101 (01Aug2019)， DB01 (08Jun2020)， DB02 (30Jun2022)， DB03 (25Jul2022)， DB04 (11Apr2022),

<div style=\"page-break-after: always\"></div>

Table 59 Characteristics of Events of ILD Adjudicated as Drug-related ILD (Safety Analysis Set)

|                                                                                            | Number (%) of Patients                                                                     | Number (%) of Patients                                                                     | Number (%) of Patients                                                                     | Number (%) of Patients                                                                     |
|--------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------|
|                                                                                            | Study DB-06                                                                                | Study DB-06                                                                                | Supportive Safety Pools                                                                    | Supportive Safety Pools                                                                    |
|                                                                                            | T-DXd 5.4 mg/kg (N = 434)                                                                  | Chemotherapy (N = 417)                                                                     | T-DXd 5.4 mg/kg BC Pool (N = 1741)                                                         | T-DXd 5.4 mg/kg All Tumor Types Pool (N = 2335)                                            |
| Time to first onset of adjudicated drug-related ILD (days) a                               | Time to first onset of adjudicated drug-related ILD (days) a                               | Time to first onset of adjudicated drug-related ILD (days) a                               | Time to first onset of adjudicated drug-related ILD (days) a                               | Time to first onset of adjudicated drug-related ILD (days) a                               |
| n                                                                                          | 49                                                                                         | 1                                                                                          | 217                                                                                        | 276                                                                                        |
| Mean                                                                                       | 242.4                                                                                      | 121.0                                                                                      | 229.9                                                                                      | 214.0                                                                                      |
| Std Dev                                                                                    | 205.17                                                                                     | NA                                                                                         | 179.03                                                                                     | 175.37                                                                                     |
| Median                                                                                     | 141.0                                                                                      | 121.0                                                                                      | 170.0                                                                                      | 166.5                                                                                      |
| Minimum, maximum                                                                           | 37, 835                                                                                    | 121, 121                                                                                   | 26, 960                                                                                    | 26, 960                                                                                    |
| Time to first onset of investigator-reported ILD for adjudicated drug-related ILD (days) b | Time to first onset of investigator-reported ILD for adjudicated drug-related ILD (days) b | Time to first onset of investigator-reported ILD for adjudicated drug-related ILD (days) b | Time to first onset of investigator-reported ILD for adjudicated drug-related ILD (days) b | Time to first onset of investigator-reported ILD for adjudicated drug-related ILD (days) b |
| n                                                                                          | 49                                                                                         | 1                                                                                          | 217                                                                                        | 276                                                                                        |
| Mean                                                                                       | 264.3                                                                                      | 121.0                                                                                      | 266.3                                                                                      | 246.1                                                                                      |
| Std Dev                                                                                    | 223.25                                                                                     | NA                                                                                         | 199.66                                                                                     | 192.24                                                                                     |
| Median                                                                                     | 168.0                                                                                      | 121.0                                                                                      | 212.0                                                                                      | 204.0                                                                                      |
| Minimum, maximum                                                                           | 38, 892                                                                                    | 121, 121                                                                                   | 26, 1163                                                                                   | 19, 1163                                                                                   |
| Duration of first ILD event (days) c, d                                                    | Duration of first ILD event (days) c, d                                                    | Duration of first ILD event (days) c, d                                                    | Duration of first ILD event (days) c, d                                                    | Duration of first ILD event (days) c, d                                                    |
| n                                                                                          | 22                                                                                         | 1                                                                                          | 136                                                                                        | 173                                                                                        |
| Mean                                                                                       | 92.5                                                                                       | 33.0                                                                                       | 88.0                                                                                       | 79.9                                                                                       |
| Std Dev                                                                                    | 64.62                                                                                      | NA                                                                                         | 86.97                                                                                      | 80.80                                                                                      |
| Median                                                                                     | 81.5                                                                                       | 33.0                                                                                       | 50.0                                                                                       | 48.0                                                                                       |
| Minimum, maximum                                                                           | 7, 226                                                                                     | 33, 33                                                                                     | 1, 395                                                                                     | 1, 395                                                                                     |
| Outcome of the worst ILD event e                                                           | Outcome of the worst ILD event e                                                           | Outcome of the worst ILD event e                                                           | Outcome of the worst ILD event e                                                           | Outcome of the worst ILD event e                                                           |
| Not Recovered/Not Resolved                                                                 | 23 (46.9)                                                                                  | 0                                                                                          | 61 (28.1)                                                                                  | 83 (30.1)                                                                                  |
| Recovered/Resolved                                                                         | 20 (40.8)                                                                                  | 1 (100)                                                                                    | 117 (53.9)                                                                                 | 146 (52.9)                                                                                 |
| Recovering/Resolving                                                                       | 3 (6.1)                                                                                    | 0                                                                                          | 12 (5.5)                                                                                   | 14 (5.1)                                                                                   |
| Recovered/Resolved with Sequelae                                                           | 2 (4.1)                                                                                    | 0                                                                                          | 10 (4.6)                                                                                   | 10 (3.6)                                                                                   |
| Fatal                                                                                      | 1 (2.0) f                                                                                  | 0                                                                                          | 11 (5.1)                                                                                   | 16 (5.8)                                                                                   |
| Ongoing                                                                                    | 0                                                                                          | 0                                                                                          | 1 (0.5)                                                                                    | 1 (0.4)                                                                                    |
| Missing/Unknown                                                                            | 0                                                                                          | 0                                                                                          | 5 (2.3)                                                                                    | 6 (2.2)                                                                                    |

c Time to first onset of adjudicated drug-related ILD (days) = onset date of first ILD adjudicated as drug related - first dose date + 1.

d Time to first onset of investigator-reported ILD (days) = onset date of first investigator-reported ILD adjudicated as drug related - first dose date + 1.

e Duration of first ILD = investigator-reported end date -investigator-reported onset date + 1. End date is censored for ongoing ILDs.

f Descriptive statistics are based on patients with AE start and end dates. Partial date is imputed per the SAP.

g The denominator for outcome of the worst ILD event is number of patients with adjudicated drug-related ILD.

h Outcome of death as recorded by the investigator on the AE eCRF.

Percentages are calculated using the number of patients in the Safety Analysis Set as the denominator.

The pooled analysis group is based on first dose received for patients in each study. Adjudicated ILD events include all events that were adjudicated and considered drug related by the Adjudication Committee.

<div style=\"page-break-after: always\"></div>

## Supplementary data on recovery from ILD/pneumonitis:

A detailed summary of the 23 patients in study DB-06 who had not recovered from ILD at the time of DCO is provided below:

- 8 patients died prior to DCO, (6 patients died of BC progression and 2 patients died of other reasons post study safety follow-up period) and for all those patients, the investigator confirmed that ILD was ongoing at the time of death.
- 1 patient fully withdrew consent and the investigator confirmed that per the last scan prior to withdrawal of consent the event of ILD was ongoing.
- The ILD event outcome for the above 9 patients can be considered final with a status of ILD not recovered.
- 14 patients were alive at the time of DCO:
- o 4 patients were receiving study treatment at the time of DCO and for all these patients ILD outcome was changed to recovered after the primary analysis database lock.
- o 10 patients had discontinued study treatment at the time of DCO. The ILD outcome was changed to recovered for 5 patients after the primary analysis database lock and 5 patients are still in follow up by the investigator with a current outcome of not recovered.

Overall, out of 23 patients who had not recovered from ILD at the time of DCO, 9 are now recovered, leading to a lower percentage of patients who have not recovered, more in line with what was observed in both pools.

## Table 60 Summary of Follow Up Duration for Patients Who Had Not Resolved/Not Recovered Worst ILD

|                                                           | Study DB-06                                               | SupportiveSafetyPools                                     | SupportiveSafetyPools                                     |
|-----------------------------------------------------------|-----------------------------------------------------------|-----------------------------------------------------------|-----------------------------------------------------------|
|                                                           | T-Dxd5.4mg/kg （N=434)                                     | T-Dxd5.4mg/kg Breast Cancer Pool (N = 1741)               | T-DXd5.4mg/kg All Jumor Types Pool （N =2335)              |
| Follow-up duration from adjudicated ILD onset date (days) | Follow-up duration from adjudicated ILD onset date (days) | Follow-up duration from adjudicated ILD onset date (days) | Follow-up duration from adjudicated ILD onset date (days) |
| n                                                         | 23                                                        | 61                                                        | 83                                                        |
| Mean                                                      | 277.2                                                     | 352.6                                                     | 322.8                                                     |
| Standard deviation                                        | 222.25                                                    | 245.83                                                    | 240.68                                                    |
| Median                                                    | 235.0                                                     | 278.0                                                     | 276.0                                                     |
| Minimum,maximum                                           | 4,886                                                     | 3,1183                                                    | -286,1183 a                                               |

<div style=\"page-break-after: always\"></div>

Table 61 Analysis of ILD/Pneumonitis (Safety Analysis Set)

|                                    | Number （$)of Patients         | Number （$)of Patients                       | Number （$)of Patients                       | Number （$)of Patients                         |
|------------------------------------|-------------------------------|---------------------------------------------|---------------------------------------------|-----------------------------------------------|
|                                    | D9670C00001(DESTINY-Breast06) | D9670C00001(DESTINY-Breast06)               | Supportive Safety Pools                     | Supportive Safety Pools                       |
|                                    | T-DXd 5.4 mg/kg (N=434)       | Investigator choice of chemotherapy (N=417) | T-DXd 5.4 mg/kg breast cancer pool (N=1741) | T-DXd 5.4 mg/kg [0od sadA4 xoum4 TIB (N=2335) |
| Selected TEAE: ILD/Pneumonitis     |                               |                                             |                                             |                                               |
| Time to first onset (Days) [2]     |                               |                                             |                                             |                                               |
| n                                  | 60                            | 2                                           | 201                                         | 259                                           |
| Mean                               | 244.8                         | 99.0                                        | 247.6                                       | 229.7                                         |
| Std Dev                            | 192.66                        | 31.11                                       | 186.11                                      | 177.99                                        |
| Median                             | 173.0                         | 99.0                                        | 204.0                                       | 174.0                                         |
|                                    | 38,892                        | 77, 121                                     | 26,1163                                     | 19, 1163                                      |
| Duration of first event (Days) [3] | 118.0                         | 42.0                                        | 76.0                                        | 66.0                                          |
| Median (95+ CI) [4]                | (69.0, 152.0)                 | (33.0, 51.0)                                | (55.0, 104.0)                               | (50.0, 84.0)                                  |
| Patients with Censored Duration    | 31                            | 0                                           | 70                                          | 91                                            |
| n [5]                              | 29                            | 2                                           | 131                                         | 168                                           |
| Mean                               | 99.4                          | 42.0                                        | 89.6                                        | 78.7                                          |
| Std Dev                            | 73.46                         | 12.73                                       | 88.02                                       | 81.64                                         |
| Median                             | 84.0                          | 42.0                                        | 52.0                                        | 46.5                                          |
| X 'UT                              | 7, 260                        | 33,51                                       | 1, 395                                      | 1, 395                                        |

Table 62 Characteristics of ILD by the ILD Adjudication Committee and Investigator (Safety Analysis Set)

|                                                     | Number （&) of Patients        | Number （&) of Patients                      | Number （&) of Patients                      | Number （&) of Patients                        |
|-----------------------------------------------------|-------------------------------|---------------------------------------------|---------------------------------------------|-----------------------------------------------|
|                                                     | D9670C00001(DESTINY-Breast06) | D9670C00001(DESTINY-Breast06)               | Supportive Safety Pools                     | Supportive Safety Pools                       |
|                                                     | T-DXd 5.4 mg/kg (N=434)       | Investigator choice of chemotherapy (N=417) | T-DXd 5.4 mg/kg breast cancer pool (N=1741) | T-DXd 5.4 mg/kg all tumor types pool (N=2335) |
| Time to first onset of Adjudicated ILD (Days) [l] n | 52                            | 1                                           | 226                                         | 286                                           |
| Mean                                                | 242.9                         | 121.0                                       | 226.4                                       | 212.0                                         |
| Std Dev                                             | 204.62                        | NA                                          | 178.96                                      | 174.93                                        |
| Median                                              | 144.5                         | 121.0                                       | 168.0                                       | 166.0                                         |
|                                                     | -7,835                        | 121, 121                                    | -9, 960                                     | -9,960                                        |

Note: Percentages are calculated using the number of patients in the Safety Analysis Set as the denominator.

AdjudicatedILDevents include alladjudicated as ILDevents by adjudication committee.

[1] Time to First onset of Adjudicated ILD (Days)= onset date of first ILD adjudicated by AC-first dose date

Std Dev = Standard Deviation

T-DXd 5.4 mg/kg a11 Tumor Types Pool: J101(N=91), DB01 (N=184), DB02(N=404), DB03(N=257), DB04(N=371), DB06 (N=434), DL01(N=41), DL02(N=101), DC02(N=83), DP01(N=102), DP02(N=267)

Date of Data cut-off:T-DXd 5.4 mg/kg breast cancer pool from studies J101 （01Aug2019),DB01 (08Jun2020),DB02 （30Jun2022),DB03 （25Ju12022), DB04(11Apr2022),DB06 (18MAR2024)，DP01(25Jan2023)

T-DXd 5.4 mg/kg a11 tumor types cancer poo1 from J101 (01Aug2019), DB01 (08Jun2020), DB02 (30Jun2022), DB03 (25Jul2022), DB04 (11Apr2022), DB06（18MAR2024)，DL01(03Dec2021)，DL02(23Dec2022)，DC02 （01Nov2022)，DP01（25Jan2023)，DP02 （08Jun2023) Reference:ADAE2

|                                    | Number （8）of Patients         | Number （8）of Patients                       | Number （8）of Patients                       | Number （8）of Patients                         |
|------------------------------------|-------------------------------|---------------------------------------------|---------------------------------------------|-----------------------------------------------|
|                                    | D9670C00001(DESTINY-Breast06) | D9670C00001(DESTINY-Breast06)               | Supportive Safety Pools                     | Supportive Safety Pools                       |
|                                    | T-DXd 5.4 mg/kg (N=434)       | Investigator choice of chemotherapy (N=417) | T-DXd 5.4 mg/kg breast cancer pool (N=1741) | T-DXd 5.4 mg/kg all tumor types pool (N=2335) |
| Outcome of the worst ILD event [1] |                               |                                             |                                             |                                               |
| Fatal                              | (1.9)                         | 0                                           | 13 (5.8)                                    | 18 (6.3)                                      |
| Not Recovered/Not Resolved         | 24 (46.2)                     | 0                                           | 65 (28.8)                                   | 88 (30.8)                                     |
| Ongoing                            | 0                             | 0                                           | 1 (0.4)                                     | 1 (0.3)                                       |
| Recovering/Resolving               | 3 (5.8)                       | 0                                           | 13 (5.8)                                    | 15 (5.2)                                      |
| Recovered/Resolved with Sequelae   | 3 (5.8)                       | 0                                           | 11 (4.9)                                    | 11 (3.8)                                      |
| Recovered/Resolved                 | 21 (40.4)                     | (100)                                       | 118 (52.2)                                  | 147 7(51.4)                                   |
| Missing/Unknown                    | 0                             | 0                                           | 5 (2.2)                                     | 6 (2.1)                                       |

Adjudicated ILD events include all adjudicated events by adjudication committee.

T-DXd 5.4 mg/kg a11 Tumor Types Poo1:J101(N=91),DB01(N=184),DB02(N=404),DB03(N=257),DB04(N=371), DB06(N=434),DL01(N=41),DL02(N=101), DC02(N=83),DP01(N=102),DP02(N=267)

Date of Data cut-off:T-DXd 5.4 mg/kg breast cancer pool from Studies J101 (01Aug2019), DB01 (08Jun2020),DB02 (30Jun2022), DB03 (25Ju12022), DB04 （11Apr2022)，DB06 (18MAR2024)，DP01 （25Jan2023)

DB06 (18MAR2024)，DL01(03Dec2021)，DL02(23Dec2022)，DC02 (01Nov2022),DP01(25Jan2023)，DP02 (08Jun2023)

I-DXd 5.4 mg/kg al1 tumor types cancer poo1 from J101 (01Aug2019), DB01 (08Jun2020), DB02 (30Jun2022), DB03 (25Jul2022), DB04 (11Apr2022),

Reference: ADAE

<div style=\"page-break-after: always\"></div>

## · Left Ventricular Ejection Fraction Decrease

Table 63 Events of Left Ventricular Dysfunction Reported in Any Patient in Either Treatment Arm of Study DB-06 (Safety Analysis Set)

| MedDRA Preferred Term CTCAE Grade   | Number (%) of Patients    | Number (%) of Patients   | Number (%) of Patients             | Number (%) of Patients                          |
|-------------------------------------|---------------------------|--------------------------|------------------------------------|-------------------------------------------------|
| MedDRA Preferred Term CTCAE Grade   | Study DB-06               | Study DB-06              | Supportive Safety Pools            | Supportive Safety Pools                         |
| MedDRA Preferred Term CTCAE Grade   | T-DXd 5.4 mg/kg (N = 434) | Chemotherapy (N = 417)   | T-DXd 5.4 mg/kg BC Pool (N = 1741) | T-DXd 5.4 mg/kg All Tumor Types Pool (N = 2335) |
| Patients with LV dysfunction        | 35 (8.1)                  | 16 (3.8)                 | 89 (5.1)                           | 108 (4.6)                                       |
| 1                                   | 1 (0.2)                   | 0                        | 11 (0.6)                           | 14 (0.6)                                        |
| 2                                   | 31 (7.1)                  | 13 (3.1)                 | 69 (4.0)                           | 80 (3.4)                                        |
| 3                                   | 3 (0.7)                   | 2 (0.5)                  | 9 (0.5)                            | 13 (0.6)                                        |
| 4                                   | 0                         | 1 (0.2)                  | 0                                  | 1 (0.0)                                         |
| 5                                   | 0                         | 0                        | 0                                  | 0                                               |
| ≥ 3                                 | 3 (0.7)                   | 3 (0.7)                  | 9 (0.5)                            | 14 (0.6)                                        |
| Ejection fraction decreased         | 35 (8.1)                  | 12 (2.9)                 | 84 (4.8)                           | 99 (4.2)                                        |
| 1                                   | 1 (0.2)                   | 0                        | 8 (0.5)                            | 10 (0.4)                                        |
| 2                                   | 31 (7.1)                  | 11 (2.6)                 | 68 (3.9)                           | 79 (3.4)                                        |
| 3                                   | 3 (0.7)                   | 1 (0.2)                  | 8 (0.5)                            | 10 (0.4)                                        |
| 4                                   | 0                         | 0                        | 0                                  | 0                                               |
| 5                                   | 0                         | 0                        | 0                                  | 0                                               |
| ≥ 3                                 | 3 (0.7)                   | 1 (0.2)                  | 8 (0.5)                            | 10 (0.4)                                        |
| Left ventricular dysfunction        | 1 (0.2)                   | 1 (0.2)                  | 3 (0.2)                            | 3 (0.1)                                         |
| 1                                   | 0                         | 0                        | 2 (0.1)                            | 2 (0.1)                                         |
| 2                                   | 0                         | 1 (0.2)                  | 0                                  | 0                                               |
| 3                                   | 1 (0.2)                   | 0                        | 1 (0.1)                            | 1 (0.0)                                         |
| 4                                   | 0                         | 0                        | 0                                  | 0                                               |
| 5                                   | 0                         | 0                        | 0                                  | 0                                               |
| ≥ 3                                 | 1 (0.2)                   | 0                        | 1 (0.1)                            | 1 (0.0)                                         |
| Cardiac failure                     | 0                         | 3 (0.7)                  | 3 (0.2)                            | 5 (0.2)                                         |
| 1                                   | 0                         | 0                        | 1 (0.1)                            | 2 (0.1)                                         |
| 2                                   | 0                         | 1 (0.2)                  | 1 (0.1)                            | 1 (0.0)                                         |
| 3                                   | 0                         | 1 (0.2)                  | 1 (0.1)                            | 2 (0.1)                                         |
| 4                                   | 0                         | 1 (0.2)                  | 0                                  | 0                                               |
| 5                                   | 0                         | 0                        | 0                                  | 0                                               |
| ≥ 3                                 | 0                         | 2 (0.5)                  | 1 (0.1)                            | 2 (0.1)                                         |

Percentages are calculated using the number of patients in the Safety Analysis Set as the denominator.

The pooled analysis group is based on first dose received for patients in each study.

PTs are sorted by descending frequency in the Study DB-06 T-DXd 5.4 mg/kg treatment arm.

If a patient had multiple occurrences of the same PT, the patient is counted once for the specific PT by worst CTCAE grade.

If a patient had multiple PTs, the patient is counted in each of the different PTs.

<div style=\"page-break-after: always\"></div>

Table 64 Summary of LVEF Values, Based on ECHO/MUGA Scan Data (Safety Analysis Set)

| LVEF Parameter Criteria                                    | Number (%) of Patients                                    | Number (%) of Patients                                    | Number (%) of Patients                                    | Number (%) of Patients                                    |
|------------------------------------------------------------|-----------------------------------------------------------|-----------------------------------------------------------|-----------------------------------------------------------|-----------------------------------------------------------|
|                                                            | Study DB-06                                               | Study DB-06                                               | Supportive Safety Pools                                   | Supportive Safety Pools                                   |
|                                                            | T-DXd 5.4 mg/kg (N = 434)                                 | Chemotherapy (N = 417)                                    | T-DXd 5.4 mg/kg BC Pool (N = 1741)                        | T-DXd 5.4 mg/kg All Tumor Types Pool (N = 2335)           |
| Patients with worst LVEF CTCAE grade post baseline, n (%)  | Patients with worst LVEF CTCAE grade post baseline, n (%) | Patients with worst LVEF CTCAE grade post baseline, n (%) | Patients with worst LVEF CTCAE grade post baseline, n (%) | Patients with worst LVEF CTCAE grade post baseline, n (%) |
| Nonmissing n a                                             | 396                                                       | 332                                                       | 1617                                                      | 2075                                                      |
| Grade 2                                                    | 58 (14.6)                                                 | 26 (7.8)                                                  | 246 (15.2)                                                | 296 (14.3)                                                |
| Patients with LVEF measurement after worst grade           | 42                                                        | 15                                                        | 188                                                       | 213                                                       |
| Recovered from worst grade to ≥ 90% of baseline, n (%) b,c | 35 (83.3)                                                 | 10 (66.7)                                                 | 146 (77.7)                                                | 164 (77.0)                                                |
| Grade 3                                                    | 3 (0.8)                                                   | 2 (0.6)                                                   | 14 (0.9)                                                  | 15 (0.7)                                                  |
| Patients with LVEF measurement after worst grade           | 2                                                         | 2                                                         | 11                                                        | 12                                                        |
| Recovered from worst grade to ≥ 90% of baseline, n (%) b,c | 2 (100)                                                   | 1 (50.0)                                                  | 7 (63.6)                                                  | 7 (58.3)                                                  |
| LVEF measurements at baseline                              | LVEF measurements at baseline                             | LVEF measurements at baseline                             | LVEF measurements at baseline                             | LVEF measurements at baseline                             |
| n                                                          | 432                                                       | 417                                                       | 1738                                                      | 2332                                                      |
| Mean                                                       | 63.6                                                      | 63.1                                                      | 63.9                                                      | 63.9                                                      |
| Std Dev                                                    | 6.16                                                      | 5.79                                                      | 6.20                                                      | 6.10                                                      |
| Median                                                     | 63.0                                                      | 63.0                                                      | 64.0                                                      | 64.0                                                      |
| Minimum, maximum                                           | 50, 81                                                    | 50, 83                                                    | 50, 86                                                    | 50, 86                                                    |
| 40% to 49%                                                 | 0                                                         | 0                                                         | 0                                                         | 0                                                         |
| 20% to 39%                                                 | 0                                                         | 0                                                         | 0                                                         | 0                                                         |
| < 20%                                                      | 0                                                         | 0                                                         | 0                                                         | 0                                                         |
| Lowest LVEF measurement post baseline                      | Lowest LVEF measurement post baseline                     | Lowest LVEF measurement post baseline                     | Lowest LVEF measurement post baseline                     | Lowest LVEF measurement post baseline                     |
| n                                                          | 398                                                       | 332                                                       | 1620                                                      | 2078                                                      |
| Mean                                                       | 59.6                                                      | 61.2                                                      | 60.1                                                      | 60.3                                                      |
| Std Dev                                                    | 5.49                                                      | 5.41                                                      | 5.70                                                      | 5.74                                                      |
| Median                                                     | 60.0                                                      | 61.0                                                      | 60.0                                                      | 60.0                                                      |
| Minimum, maximum                                           | 24, 79                                                    | 42, 76                                                    | 24, 79                                                    | 24, 80                                                    |
| 40% to 49%                                                 | 11 (2.5)                                                  | 6 (1.4)                                                   | 46 (2.6)                                                  | 52 (2.2)                                                  |
| 20% to 39%                                                 | 1 (0.2)                                                   | 0                                                         | 3 (0.2)                                                   | 3 (0.1)                                                   |
| < 20%                                                      | 0                                                         | 0                                                         | 0                                                         | 0                                                         |
| Change from baseline to lowest post-baseline measurement   | Change from baseline to lowest post-baseline measurement  | Change from baseline to lowest post-baseline measurement  | Change from baseline to lowest post-baseline measurement  | Change from baseline to lowest post-baseline measurement  |
| n                                                          | 396                                                       | 332                                                       | 1617                                                      | 2075                                                      |
| Mean                                                       | -4.0                                                      | -1.9                                                      | -3.9                                                      | -3.7                                                      |
| Std Dev                                                    | 5.63                                                      | 5.42                                                      | 5.53                                                      | 5.48                                                      |

<div style=\"page-break-after: always\"></div>

| LVEF Parameter Criteria                                   | Number (%) of Patients                                    | Number (%) of Patients                                    | Number (%) of Patients                                    | Number (%) of Patients                                    |
|-----------------------------------------------------------|-----------------------------------------------------------|-----------------------------------------------------------|-----------------------------------------------------------|-----------------------------------------------------------|
|                                                           | Study DB-06                                               | Study DB-06                                               | Supportive Safety Pools                                   | Supportive Safety Pools                                   |
|                                                           | T-DXd 5.4 mg/kg (N = 434)                                 | Chemotherapy (N = 417)                                    | T-DXd 5.4 mg/kg BC Pool (N = 1741)                        | T-DXd 5.4 mg/kg All Tumor Types Pool (N = 2335)           |
| Median                                                    | -3.0                                                      | -1.0                                                      | -3.0                                                      | -3.0                                                      |
| Minimum, maximum                                          | -38, 14                                                   | -25, 19                                                   | -38, 18                                                   | -38, 18                                                   |
| 10% to 19% decrease in absolute value                     | 55 (12.7)                                                 | 22 (5.3)                                                  | 228 (13.1)                                                | 275 (11.8)                                                |
| ≥ 20% decrease in absolute value                          | 3 (0.7)                                                   | 2 (0.5)                                                   | 13 (0.7)                                                  | 14 (0.6)                                                  |
| Highest LVEF measurement post-baseline                    | Highest LVEF measurement post-baseline                    | Highest LVEF measurement post-baseline                    | Highest LVEF measurement post-baseline                    | Highest LVEF measurement post-baseline                    |
| n                                                         | 398                                                       | 332                                                       | 1620                                                      | 2078                                                      |
| Mean                                                      | 65.7                                                      | 65.0                                                      | 66.6                                                      | 66.2                                                      |
| Std Dev                                                   | 5.78                                                      | 6.11                                                      | 6.25                                                      | 6.25                                                      |
| Median                                                    | 65.0                                                      | 65.0                                                      | 66.0                                                      | 66.0                                                      |
| Minimum, maximum                                          | 50, 81                                                    | 49, 84                                                    | 43, 90                                                    | 43, 90                                                    |
| Change from baseline to highest post-baseline measurement | Change from baseline to highest post-baseline measurement | Change from baseline to highest post-baseline measurement | Change from baseline to highest post-baseline measurement | Change from baseline to highest post-baseline measurement |
| n                                                         | 396                                                       | 332                                                       | 1617                                                      | 2075                                                      |
| Mean                                                      | 2.1                                                       | 1.9                                                       | 2.6                                                       | 2.3                                                       |
| Std Dev                                                   | 5.63                                                      | 5.42                                                      | 5.75                                                      | 5.73                                                      |
| Median                                                    | 2.0                                                       | 2.0                                                       | 2.0                                                       | 2.0                                                       |
| Minimum, maximum                                          | -27, 22                                                   | -25, 26                                                   | -27, 24                                                   | -27, 24                                                   |
| 10% to 19% increase in absolute value                     | 37 (8.5)                                                  | 19 (4.6)                                                  | 174 (10.0)                                                | 211 (9.0)                                                 |
| ≥ 20% increase in absolute value                          | 2 (0.5)                                                   | 2 (0.5)                                                   | 8 (0.5)                                                   | 9 (0.4)                                                   |

b Nonmissing n is the number of subjects with both baseline and post-baseline data. Percentages are calculated using the nonmissing n as the denominator.

≥ 90% baseline since worst grade is defined as the highest post-baseline LVEF after the measurement with worst grade that is ≥ 90% of the baseline LVEF value.

Percentages are calculated using the number of subjects having worst post-baseline LVEF at the specific grade. If there is no LVEF measurement after the worst grade of LVEF, the subject is not included in the denominator.

The baseline value is defined as the last nonmissing value before initial administration of study treatment.

Percentages are calculated using the number of patients in the Safety Analysis Set as the denominator.

This analysis was based on ECHO/MUGA scan data.

The pooled analysis group is based on first dose received for patients in each study.

Per CTCAE, LVEF was defined as follows: Grade 2 = resting LVEF ≥ 40% to &lt; 50% or a 10% to &lt; 20% decrease from baseline; Grade 3 = resting LVEF ≥ 20% to &lt; 40% or a ≥ 20% decrease from baseline; Grade 4 = resting LVEF &lt; 20%.

<div style=\"page-break-after: always\"></div>

Table 65 Analysis of LVEF (Safety Analysis Set)

|                                              | StudyDB-06      | StudyDB-06             | SupportiveSafetyPools                       | SupportiveSafetyPools                          |
|----------------------------------------------|-----------------|------------------------|---------------------------------------------|------------------------------------------------|
| LVEFParameter Criteria                       | pxa-1 (N = 434) | Chemotherapy (N = 417) | T-Dxd 5.4 mg/kg BreastCancerPool (N = 1741) | T-DXd 5.4 mg/kg All Jumor Types Pool (N =2335) |
| Worstqradepost-baselineLVEF                  |                 |                        |                                             |                                                |
| Non-missing n a                              | 396             | 332                    | 1617                                        | 2075                                           |
| Grade2                                       | 58 (14.6)       | 26 (7.8)               | 246 (15.2)                                  | 296 (14.3)                                     |
| PatientswithLVEFmeasurementsinceworstqrade   | 42              | 15                     | 188                                         | 213                                            |
| ≥ 90% baseline since worst qrade, n(%) bc    | 35 (83.3)       | 10 (66.7)              | 146 (77.7)                                  | 164 (77.0)                                     |
| Time to worst grade                          |                 |                        |                                             |                                                |
| n                                            | 58              | 26                     | 246                                         | 296                                            |
| Mean                                         | 244.0           | 222.7                  | 270.7                                       | 258.7                                          |
| Standard deviation                           | 158.53          | 136.84                 | 204.45                                      | 197.23                                         |
| Median                                       | 173.5           | 190.0                  | 190.5                                       | 185.5                                          |
| Minimum,maximum                              | 78,714          | 51,593                 | 24,1156                                     | 22,1156                                        |
| Time tofirst≥90%baseline sinceworstqrade     |                 |                        |                                             |                                                |
| n                                            | 35              | 10                     | 146                                         | 164                                            |
| Mean                                         | 352.9           | 287.4                  | 356.7                                       | 357.9                                          |
| Standarddeviation                            | 183.58          | 115.40                 | 188.27                                      | 194.18                                         |
| Median                                       | 281.0           | 266.5                  | 320.0                                       | 327.5                                          |
| Minimum,maximum                              | 102,818         | 130,457                | 102,1009                                    | 43,1009                                        |
| Grade 3                                      | 3 (0.8)         | 2 (0.6)                | 14 (0.9)                                    | 15 (0.7)                                       |
| PatientswithLvEFmeasurementsinceworstgrade   | 2               | 2                      | 11                                          | 12                                             |
| ≥ 90% baseline since worst qrade, n (%)bc    | 2(100)          | 1(50.0)                | 7 (63.6)                                    | 7 (58.3)                                       |
| Time to worst qrade(days)                    |                 |                        |                                             |                                                |
| n                                            | 3               | 2                      | 14                                          | 15                                             |
| Mean                                         | 91.0            | 110.0                  | 189.4                                       | 194.6                                          |
| Standarddeviation                            | 11.27           | 1.41                   | 145.40                                      | 141.57                                         |
| Median                                       | 97.0            | 110.0                  | 122.5                                       | 147.0                                          |
| Minimum,maximum                              | 78,98           | 109,111                | 78,532                                      | 78,532                                         |
| Timetofirst≥9o%baselinesinceworstqrade(days) |                 |                        |                                             |                                                |
| n                                            | 2               | 1                      | 7                                           | 7                                              |
| Mean                                         | 129.0           | 126.0                  | 251.0                                       | 251.0                                          |
| Standard deviation                           | 35.36           | NA                     | 190.70                                      | 190.70                                         |
| Median                                       | 129.0           | 126.0                  | 154.0                                       | 154.0                                          |
| Minimum,maximum                              | 104,154         | 126,126                | 104,593                                     | 104,593                                        |

Non-missing n is the number of patients with both baseline and post-baseline data.Percentages are calculated using the non-missing n as denominator.

b ≥90%baseline since worst grade is defined as the highest post-baseline LVEF after the measurement with worst grade that is≥90% of the baseline LVEF value.

Percentages are calculated using thenumber ofpatientshavingworstpost-baseline at the specificgrade.If there isnoLVEFmeasurements after the worstgrade ofLVEF,the patient is not included in the denominator.

This analysis was based on ECHO/MUGA scan data.

Thepooledanalysisgroupisbasedonfirstdosereceivedforpatientsineachstudy.

Per CTCAE5.0,Grade 2 LVEF decrease is defined by a resting ejection fraction of ≥40-&lt;50%, or a 10-&lt;20% drop from baseline.Grade 3 LVEF decrease is defined by a resting ejection fraction of ≥20-&lt;40%,or a≥20% dropfrom baseline.Grade 4 LVEF decrease is defined by aresting ejection fraction&lt;20%.

In the All Tumour Type (ATT) Pool, the ADR left ventricular dysfunction led to treatment interruption in 27/2335 (1.2%) patients. The median time to worst grade LVEF was 4.8 months, and the median time to recovery (≥90% baseline) from worst grade LVEF was 6.3 months.

## · To Immunogenicity

Infusion-related reactions (IRRs) with T-DXd treatment occurred infrequently (n=5 (1.2%)), with an event of Grade ≥ 3 reported in 1 (0.2%) patient, who subsequently discontinued treatment. Of the 22 (5.1%) patients in the T-DXd arm who were identified as having treatment-emergent ADA positive status, no patient experienced an event of IRR.

<div style=\"page-break-after: always\"></div>

## Laboratory findings

Table 66 Summary of Shifts from Baseline to Worst Post-baseline CTCAE Grade in Anemia (Hemoglobin Decrease) (Safety Analysis Set)

|                                                 | Baseline CTCAE   | Number (%) of Patients with Worst Post-Baseline CTCAE Grade   | Number (%) of Patients with Worst Post-Baseline CTCAE Grade   | Number (%) of Patients with Worst Post-Baseline CTCAE Grade   | Number (%) of Patients with Worst Post-Baseline CTCAE Grade   |   Number (%) of Patients with Worst Post-Baseline CTCAE Grade | Number (%) of Patients with Worst Post-Baseline CTCAE Grade   | Number (%) of Patients with Worst Post-Baseline CTCAE Grade   |
|-------------------------------------------------|------------------|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|
|                                                 | Grade            | Normal                                                        | 1                                                             | 2                                                             | 3                                                             |                                                             4 | Total                                                         | Missing                                                       |
| T-DXd 5.4 mg/kg (N = 434)                       | Normal           | 36 (8.4)                                                      | 167 (38.7)                                                    | 39 (9.0)                                                      | 13 (3.0)                                                      |                                                             0 | 255 (59.2)                                                    | 2                                                             |
| T-DXd 5.4 mg/kg (N = 434)                       | 1                | 1 (0.2)                                                       | 75 (17.4)                                                     | 54 (12.5)                                                     | 16 (3.7)                                                      |                                                             0 | 146 (33.9)                                                    | 1                                                             |
| T-DXd 5.4 mg/kg (N = 434)                       | 2                | 0                                                             | 1 (0.2)                                                       | 21 (4.9)                                                      | 8 (1.9)                                                       |                                                             0 | 30 (7.0)                                                      | 0                                                             |
| T-DXd 5.4 mg/kg (N = 434)                       | 3                | 0                                                             | 0                                                             | 0                                                             | 0                                                             |                                                             0 | 0                                                             | 0                                                             |
| T-DXd 5.4 mg/kg (N = 434)                       | 4                | 0                                                             | 0                                                             | 0                                                             | 0                                                             |                                                             0 | 0                                                             | 0                                                             |
| T-DXd 5.4 mg/kg (N = 434)                       | Total            | 37 (8.6)                                                      | 243 (56.4)                                                    | 114 (26.5)                                                    | 37 (8.6)                                                      |                                                             0 | 431 (100)                                                     | 3                                                             |
| T-DXd 5.4 mg/kg (N = 434)                       | Missing          | 0                                                             | 0                                                             | 0                                                             | 0                                                             |                                                             0 | 0                                                             | 0                                                             |
| Chemotherapy (N = 417)                          | Normal           | 68 (16.6)                                                     | 133 (32.4)                                                    | 30 (7.3)                                                      | 5 (1.2)                                                       |                                                             0 | 236 (57.6)                                                    | 4                                                             |
| Chemotherapy (N = 417)                          | 1                | 1 (0.2)                                                       | 84 (20.5)                                                     | 52 (12.7)                                                     | 9 (2.2)                                                       |                                                             0 | 146 (35.6)                                                    | 2                                                             |
| Chemotherapy (N = 417)                          | 2                | 0                                                             | 3 (0.7)                                                       | 18 (4.4)                                                      | 7 (1.7)                                                       |                                                             0 | 28 (6.8)                                                      | 1                                                             |
| Chemotherapy (N = 417)                          | 3                | 0                                                             | 0                                                             | 0                                                             | 0                                                             |                                                             0 | 0                                                             | 0                                                             |
| Chemotherapy (N = 417)                          | 4                | 0                                                             | 0                                                             | 0                                                             | 0                                                             |                                                             0 | 0                                                             | 0                                                             |
| Chemotherapy (N = 417)                          | Total            | 69 (16.8)                                                     | 220 (53.7)                                                    | 100 (24.4)                                                    | 21 (5.1)                                                      |                                                             0 | 410 (100)                                                     | 7                                                             |
| Chemotherapy (N = 417)                          | Missing          | 0                                                             | 0                                                             | 0                                                             | 0                                                             |                                                             0 | 0                                                             | 0                                                             |
| T-DXd 5.4 mg/kg BC Pool (N = 1741)              | Normal           | 245 (14.2)                                                    | 599 (34.6)                                                    | 193 (11.1)                                                    | 56 (3.2)                                                      |                                                             0 | 1093 (63.1)                                                   | 2                                                             |
| T-DXd 5.4 mg/kg BC Pool (N = 1741)              | 1                | 3 (0.2)                                                       | 229 (13.2)                                                    | 234 (13.5)                                                    | 58 (3.4)                                                      |                                                             0 | 524 (30.3)                                                    | 1                                                             |
| T-DXd 5.4 mg/kg BC Pool (N = 1741)              | 2                | 0                                                             | 2 (0.1)                                                       | 78 (4.5)                                                      | 32 (1.8)                                                      |                                                             0 | 112 (6.5)                                                     | 1                                                             |
| T-DXd 5.4 mg/kg BC Pool (N = 1741)              | 3                | 0                                                             | 0                                                             | 2 (0.1)                                                       | 0                                                             |                                                             0 | 2 (0.1)                                                       | 0                                                             |
| T-DXd 5.4 mg/kg BC Pool (N = 1741)              | 4                | 0                                                             | 0                                                             | 0                                                             | 0                                                             |                                                             0 | 0                                                             | 0                                                             |
| T-DXd 5.4 mg/kg BC Pool (N = 1741)              | Total            | 248 (14.3)                                                    | 830 (47.9)                                                    | 507 (29.3)                                                    | 146 (8.4)                                                     |                                                             0 | 1731 (100)                                                    | 4                                                             |
| T-DXd 5.4 mg/kg BC Pool (N = 1741)              | Missing          | 0                                                             | 2                                                             | 1                                                             | 2                                                             |                                                             0 | 5                                                             | 1                                                             |
| T-DXd 5.4 mg/kg All Tumor Types Pool (N = 2335) | Normal           | 285 (12.3)                                                    | 718 (30.9)                                                    | 222 (9.6)                                                     | 68 (2.9)                                                      |                                                             0 | 1293 (55.7)                                                   | 3                                                             |
| T-DXd 5.4 mg/kg All Tumor Types Pool (N = 2335) | 1                | 3 (0.1)                                                       | 357 (15.4)                                                    | 366 (15.8)                                                    | 100 (4.3)                                                     |                                                             0 | 826 (35.6)                                                    | 3                                                             |
| T-DXd 5.4 mg/kg All Tumor Types Pool (N = 2335) | 2                | 0                                                             | 6 (0.3)                                                       | 127 (5.5)                                                     | 68 (2.9)                                                      |                                                             0 | 201 (8.7)                                                     | 1                                                             |
| T-DXd 5.4 mg/kg All Tumor Types Pool (N = 2335) | 3                | 0                                                             | 0                                                             | 2 (0.1)                                                       | 0                                                             |                                                             0 | 2 (0.1)                                                       | 0                                                             |
| T-DXd 5.4 mg/kg All Tumor Types Pool (N = 2335) | 4                | 0                                                             | 0                                                             | 0                                                             | 0                                                             |                                                             0 | 0                                                             | 0                                                             |
| T-DXd 5.4 mg/kg All Tumor Types Pool (N = 2335) | Total            | 288 (12.4)1081 (46.6) 717                                     |                                                               | (30.9)                                                        | 236 (10.2)                                                    |                                                             0 | 2322 (100)                                                    | 7                                                             |
| T-DXd 5.4 mg/kg All Tumor Types Pool (N = 2335) | Missing          | 0                                                             | 2                                                             | 1                                                             | 2                                                             |                                                             0 | 5                                                             | 1                                                             |

Percentages are calculated using the number of patients with both baseline and post-baseline measurements (n in the Total column) as the denominator.

The pooled analysis group is based on first dose received for patients in each study.

The baseline value is defined as the last nonmissing value before initial administration of study treatment.

Table 67 Summary of Shifts from Baseline to Worst Post-baseline CTCAE Grade in Platelet Count (Safety Analysis Set)

|                           | Baseline CTCAE Grade   | Number (%) of Patients with Worst Post-Baseline CTCAE Grade   | Number (%) of Patients with Worst Post-Baseline CTCAE Grade   | Number (%) of Patients with Worst Post-Baseline CTCAE Grade   | Number (%) of Patients with Worst Post-Baseline CTCAE Grade   | Number (%) of Patients with Worst Post-Baseline CTCAE Grade   | Number (%) of Patients with Worst Post-Baseline CTCAE Grade   | Number (%) of Patients with Worst Post-Baseline CTCAE Grade   |
|---------------------------|------------------------|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|
|                           |                        | Normal                                                        | 1                                                             | 2                                                             | 3                                                             | 4                                                             | Total                                                         | Missing                                                       |
| T-DXd 5.4 mg/kg (N = 434) | Normal                 | 216 (50.1)                                                    | 157 (36.4)                                                    | 24 (5.6)                                                      | 12 (2.8)                                                      | 8 (1.9)                                                       | 417 (96.8)                                                    | 2                                                             |
| T-DXd 5.4 mg/kg (N = 434) | 1                      | 0                                                             | 7 (1.6)                                                       | 2 (0.5)                                                       | 4 (0.9)                                                       | 0                                                             | 13 (3.0)                                                      | 1                                                             |
| T-DXd 5.4 mg/kg (N = 434) | 2                      | 0                                                             | 0                                                             | 1 (0.2)                                                       | 0                                                             | 0                                                             | 1 (0.2)                                                       | 0                                                             |

<div style=\"page-break-after: always\"></div>

|                                                 | Baseline CTCAE   | Number (%) of Patients with Worst Post-Baseline CTCAE Grade   | Number (%) of Patients with Worst Post-Baseline CTCAE Grade   | Number (%) of Patients with Worst Post-Baseline CTCAE Grade   | Number (%) of Patients with Worst Post-Baseline CTCAE Grade   | Number (%) of Patients with Worst Post-Baseline CTCAE Grade   | Number (%) of Patients with Worst Post-Baseline CTCAE Grade   | Number (%) of Patients with Worst Post-Baseline CTCAE Grade   |
|-------------------------------------------------|------------------|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|
|                                                 | Grade            | Normal                                                        | 1                                                             | 2                                                             | 3                                                             | 4                                                             | Total                                                         | Missing                                                       |
|                                                 | 3                | 0                                                             | 0                                                             | 0                                                             | 0                                                             | 0                                                             | 0                                                             | 0                                                             |
|                                                 | 4                | 0                                                             | 0                                                             | 0                                                             | 0                                                             | 0                                                             | 0                                                             | 0                                                             |
|                                                 | Total            | 216 (50.1)                                                    | 164 (38.1)                                                    | 27 (6.3)                                                      | 16 (3.7)                                                      | 8 (1.9)                                                       | 431 (100)                                                     | 3                                                             |
|                                                 | Missing          | 0                                                             | 0                                                             | 0                                                             | 0                                                             | 0                                                             | 0                                                             | 0                                                             |
| Chemotherapy (N = 417)                          | Normal           | 292 (71.2)                                                    | 93 (22.7)                                                     | 4 (1.0)                                                       | 2 (0.5)                                                       | 2 (0.5)                                                       | 393 (95.9)                                                    | 7                                                             |
|                                                 | 1                | 1 (0.2)                                                       | 14 (3.4)                                                      | 2 (0.5)                                                       | 0                                                             | 0                                                             | 17 (4.1)                                                      | 0                                                             |
|                                                 | 2                | 0                                                             | 0                                                             | 0                                                             | 0                                                             | 0                                                             | 0                                                             | 0                                                             |
|                                                 | 3                | 0                                                             | 0                                                             | 0                                                             | 0                                                             | 0                                                             | 0                                                             | 0                                                             |
|                                                 | 4                | 0                                                             | 0                                                             | 0                                                             | 0                                                             | 0                                                             | 0                                                             | 0                                                             |
|                                                 | Total            | 293 (71.5)                                                    | 107 (26.1)                                                    | 6 (1.5)                                                       | 2 (0.5)                                                       | 2 (0.5)                                                       | 410 (100)                                                     | 7                                                             |
|                                                 | Missing          | 0                                                             | 0                                                             | 0                                                             | 0                                                             | 0                                                             | 0                                                             | 0                                                             |
| T-DXd 5.4 mg/kg BC Pool (N = 1741)              | Normal           | 785 (45.4)                                                    | 586 (33.9)                                                    | 104 (6.0)                                                     | 52 (3.0)                                                      | 16 (0.9)1543                                                  | (89.2)                                                        | 3                                                             |
|                                                 | 1                | 4 (0.2)                                                       | 107 (6.2)                                                     | 54 (3.1)                                                      | 16 (0.9)                                                      | 3 (0.2)                                                       | 184 (10.6)                                                    | 1                                                             |
|                                                 | 2                | 1 (0.1)                                                       | 0                                                             | 1 (0.1)                                                       | 1 (0.1)                                                       | 0                                                             | 3 (0.2)                                                       | 0                                                             |
|                                                 | 3                | 0                                                             | 0                                                             | 0                                                             | 0                                                             | 0                                                             | 0                                                             | 0                                                             |
|                                                 | 4                | 0                                                             | 0                                                             | 0                                                             | 0                                                             | 0                                                             | 0                                                             | 0                                                             |
|                                                 | Total            | 790 (45.7)                                                    | 693 (40.1)                                                    | 159 (9.2)                                                     | 69 (4.0)                                                      | 19 (1.1)                                                      | 1730 (100)                                                    | 4                                                             |
|                                                 | Missing          | 2                                                             | 4                                                             | 0                                                             | 0                                                             | 0                                                             | 6                                                             | 1                                                             |
| T-DXd 5.4 mg/kg All Tumor Types Pool (N = 2335) | Normal           | 1074 (46.3)                                                   | 764 (32.9)                                                    | 138 (5.9)                                                     | 75 (3.2)                                                      | 27                                                            | (1.2)2078 (89.6)                                              | 6                                                             |
|                                                 | 1                | 8 (0.3)                                                       | 131 (5.6)                                                     | 71 (3.1)                                                      | 23 (1.0)                                                      | 6 (0.3)                                                       | 239 (10.3)                                                    | 1                                                             |
|                                                 | 2                | 1 (0.0)                                                       | 0                                                             | 1 (0.0)                                                       | 1 (0.0)                                                       | 0                                                             | 3 (0.1)                                                       | 0                                                             |
|                                                 | 3                | 0                                                             | 0                                                             | 0                                                             | 0                                                             | 0                                                             | 0                                                             | 0                                                             |
|                                                 | 4                | 0                                                             | 0                                                             | 0                                                             | 0                                                             | 0                                                             | 0                                                             | 0                                                             |
|                                                 | Total            | 1083 (46.7)                                                   | 895 (38.6)                                                    | 210 (9.1)                                                     | 99 (4.3)                                                      | 33 (1.4)                                                      | 2320 (100)                                                    | 7                                                             |
|                                                 | Missing          | 2                                                             | 5                                                             | 0                                                             | 0                                                             | 0                                                             | 7                                                             | 1                                                             |

Percentages are calculated using the number of patients with both baseline and post-baseline measurements (n in the

Total column) as the denominator.

The pooled analysis group is based on first dose received for patients in each study.

The baseline value is defined as the last nonmissing value before initial administration of study treatment.

## Table 68 Summary of Shifts from Baseline to Worst Post-baseline CTCAE Grade in Neutrophil Count (Safety Analysis Set)

|                           | Baseline CTCAE   | Number (%) of Patients with Worst Post-Baseline CTCAE Grade   | Number (%) of Patients with Worst Post-Baseline CTCAE Grade   | Number (%) of Patients with Worst Post-Baseline CTCAE Grade   | Number (%) of Patients with Worst Post-Baseline CTCAE Grade   | Number (%) of Patients with Worst Post-Baseline CTCAE Grade   | Number (%) of Patients with Worst Post-Baseline CTCAE Grade   | Number (%) of Patients with Worst Post-Baseline CTCAE Grade   |
|---------------------------|------------------|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|
|                           | Grade            | Normal                                                        | 1                                                             | 2                                                             | 3                                                             | 4                                                             | Total                                                         | Missing                                                       |
| T-DXd 5.4 mg/kg (N = 434) | Normal           | 106 (24.6)                                                    | 73 (16.9)                                                     | 133 (30.9)                                                    | 91 (21.1)                                                     | 13 (3.0)                                                      | 416 (96.5)                                                    | 3                                                             |
| T-DXd 5.4 mg/kg (N = 434) | 1                | 0                                                             | 0                                                             | 3 (0.7)                                                       | 8 (1.9)                                                       | 0                                                             | 11 (2.6)                                                      | 0                                                             |
| T-DXd 5.4 mg/kg (N = 434) | 2                | 0                                                             | 0                                                             | 1 (0.2)                                                       | 3 (0.7)                                                       | 0                                                             | 4 (0.9)                                                       | 0                                                             |
| T-DXd 5.4 mg/kg (N = 434) | 3                | 0                                                             | 0                                                             | 0                                                             | 0                                                             | 0                                                             | 0                                                             | 0                                                             |
| T-DXd 5.4 mg/kg (N = 434) | 4                | 0                                                             | 0                                                             | 0                                                             | 0                                                             | 0                                                             | 0                                                             | 0                                                             |
| T-DXd 5.4 mg/kg (N = 434) | Total            | 106 (24.6)                                                    | 73 (16.9)                                                     | 137 (31.8)                                                    | 102 (23.7)                                                    | 13 (3.0)                                                      | 431 (100)                                                     | 3                                                             |
| T-DXd 5.4 mg/kg (N = 434) | Missing          | 0                                                             | 0                                                             | 0                                                             | 0                                                             | 0                                                             | 0                                                             | 0                                                             |
|                           | Normal           | 188 (45.9)                                                    | 54 (13.2)                                                     | 83 (20.2)                                                     | 55 (13.4)                                                     | 17 (4.1)                                                      | 397 (96.8)                                                    | 7                                                             |

<div style=\"page-break-after: always\"></div>

|                                                 | Baseline CTCAE   | Number (%) of Patients with Worst Post-Baseline CTCAE Grade   | Number (%) of Patients with Worst Post-Baseline CTCAE Grade   | Number (%) of Patients with Worst Post-Baseline CTCAE Grade   | Number (%) of Patients with Worst Post-Baseline CTCAE Grade   | Number (%) of Patients with Worst Post-Baseline CTCAE Grade   | Number (%) of Patients with Worst Post-Baseline CTCAE Grade   | Number (%) of Patients with Worst Post-Baseline CTCAE Grade   |
|-------------------------------------------------|------------------|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|
| Chemotherapy (N = 417)                          | Grade            | Normal                                                        | 1                                                             | 2                                                             | 3                                                             | 4                                                             | Total                                                         | Missing                                                       |
| Chemotherapy (N = 417)                          | 1                | 1 (0.2)                                                       | 1 (0.2)                                                       | 1 (0.2)                                                       | 8 (2.0)                                                       | 0                                                             | 11 (2.7)                                                      | 0                                                             |
| Chemotherapy (N = 417)                          | 2                | 0                                                             | 1 (0.2)                                                       | 0                                                             | 1 (0.2)                                                       | 0                                                             | 2 (0.5)                                                       | 0                                                             |
| Chemotherapy (N = 417)                          | 3                | 0                                                             | 0                                                             | 0                                                             | 0                                                             | 0                                                             | 0                                                             | 0                                                             |
| Chemotherapy (N = 417)                          | 4                | 0                                                             | 0                                                             | 0                                                             | 0                                                             | 0                                                             | 0                                                             | 0                                                             |
| Chemotherapy (N = 417)                          | Total            | 189 (46.1)                                                    | 56 (13.7)                                                     | 84 (20.5)                                                     | 64 (15.6)                                                     | 17 (4.1)                                                      | 410 (100)                                                     | 7                                                             |
| Chemotherapy (N = 417)                          | Missing          | 0                                                             | 0                                                             | 0                                                             | 0                                                             | 0                                                             | 0                                                             | 0                                                             |
| T-DXd 5.4 mg/kg BC Pool (N = 1741)              | Normal           | 535 (30.9)                                                    | 311 (18.0)                                                    | 497 (28.7)                                                    | 241 (13.9)                                                    | 30 (1.7)                                                      | 1614 (93.3)                                                   | 4                                                             |
| T-DXd 5.4 mg/kg BC Pool (N = 1741)              | 1                | 1 (0.1)                                                       | 9 (0.5)                                                       | 39 (2.3)                                                      | 40 (2.3)                                                      | 9 (0.5)                                                       | 98 (5.7)                                                      | 0                                                             |
| T-DXd 5.4 mg/kg BC Pool (N = 1741)              | 2                | 1 (0.1)                                                       | 1 (0.1)                                                       | 5 (0.3)                                                       | 9 (0.5)                                                       | 0                                                             | 16 (0.9)                                                      | 0                                                             |
| T-DXd 5.4 mg/kg BC Pool (N = 1741)              | 3                | 0                                                             | 2 (0.1)                                                       | 0                                                             | 0                                                             | 0                                                             | 2 (0.1)                                                       | 0                                                             |
| T-DXd 5.4 mg/kg BC Pool (N = 1741)              | 4                | 0                                                             | 0                                                             | 0                                                             | 0                                                             | 0                                                             | 0                                                             | 0                                                             |
| T-DXd 5.4 mg/kg BC Pool (N = 1741)              | Total            | 537 (31.0)                                                    | 323 (18.7)                                                    | 541 (31.3)                                                    | 290 (16.8)                                                    | 39 (2.3)                                                      | 1730 (100)                                                    | 4                                                             |
| T-DXd 5.4 mg/kg BC Pool (N = 1741)              | Missing          | 2                                                             | 0                                                             | 3                                                             | 1                                                             | 0                                                             | 6                                                             | 1                                                             |
| T-DXd 5.4 mg/kg All Tumor Types Pool (N = 2335) | Normal           | 818 (35.3)                                                    | 388 (16.7)                                                    | 616 (26.6)                                                    | 315 (13.6)                                                    | 54 (2.3)                                                      | 2191 (94.5)                                                   | 7                                                             |
| T-DXd 5.4 mg/kg All Tumor Types Pool (N = 2335) | 1                | 1 (0.0)                                                       | 11 (0.5)                                                      | 43 (1.9)                                                      | 43 (1.9)                                                      | 9 (0.4)                                                       | 107 (4.6)                                                     | 0                                                             |
| T-DXd 5.4 mg/kg All Tumor Types Pool (N = 2335) | 2                | 1 (0.0)                                                       | 3 (0.1)                                                       | 5 (0.2)                                                       | 10 (0.4)                                                      | 0                                                             | 19 (0.8)                                                      | 0                                                             |
| T-DXd 5.4 mg/kg All Tumor Types Pool (N = 2335) | 3                | 0                                                             | 2 (0.1)                                                       | 0                                                             | 0                                                             | 0                                                             | 2 (0.1)                                                       | 0                                                             |
| T-DXd 5.4 mg/kg All Tumor Types Pool (N = 2335) | 4                | 0                                                             | 0                                                             | 0                                                             | 0                                                             | 0                                                             | 0                                                             | 0                                                             |
| T-DXd 5.4 mg/kg All Tumor Types Pool (N = 2335) | Total            | 820 (35.4)                                                    | 404 (17.4)                                                    | 664 (28.6)                                                    | 368 (15.9)                                                    | 63 (2.7)                                                      | 2319 (100)                                                    | 7                                                             |
| T-DXd 5.4 mg/kg All Tumor Types Pool (N = 2335) | Missing          | 2                                                             | 0                                                             | 3                                                             | 1                                                             | 0                                                             | 6                                                             | 3                                                             |

Percentages are calculated using the number of patients with both baseline and post-baseline measurements (n in the Total column) as the denominator.

The pooled analysis group is based on first dose received for patients in each study.

The baseline value is defined as the last nonmissing value before initial administration of study treatment.

Table 69 Summary of Shifts from Baseline to Worst Post-baseline CTCAE Grade in Lymphocyte Count (Safety Analysis Set)

|                           | Baseline CTCAE   | Number (%) of Patients with Worst Post-Baseline CTCAE Grade   | Number (%) of Patients with Worst Post-Baseline CTCAE Grade   | Number (%) of Patients with Worst Post-Baseline CTCAE Grade   | Number (%) of Patients with Worst Post-Baseline CTCAE Grade   | Number (%) of Patients with Worst Post-Baseline CTCAE Grade   | Number (%) of Patients with Worst Post-Baseline CTCAE Grade   | Number (%) of Patients with Worst Post-Baseline CTCAE Grade   |
|---------------------------|------------------|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|
|                           | Grade            | Normal                                                        | 1                                                             | 2                                                             | 3                                                             | 4                                                             | Total                                                         | Missing                                                       |
| T-DXd 5.4 mg/kg (N = 434) | Normal           | 114 (26.5)                                                    | 82 (19.0)                                                     | 90 (20.9)                                                     | 40 (9.3)                                                      | 4 (0.9)                                                       | 330 (76.6)                                                    | 2                                                             |
| T-DXd 5.4 mg/kg (N = 434) | 1                | 2 (0.5)                                                       | 6 (1.4)                                                       | 30 (7.0)                                                      | 18 (4.2)                                                      | 1 (0.2)                                                       | 57 (13.2)                                                     | 0                                                             |
| T-DXd 5.4 mg/kg (N = 434) | 2                | 0                                                             | 1 (0.2)                                                       | 20 (4.6)                                                      | 18 (4.2)                                                      | 0                                                             | 39 (9.0)                                                      | 1                                                             |
| T-DXd 5.4 mg/kg (N = 434) | 3                | 0                                                             | 0                                                             | 0                                                             | 5 (1.2)                                                       | 0                                                             | 5 (1.2)                                                       | 0                                                             |
| T-DXd 5.4 mg/kg (N = 434) | 4                | 0                                                             | 0                                                             | 0                                                             | 0                                                             | 0                                                             | 0                                                             | 0                                                             |
| T-DXd 5.4 mg/kg (N = 434) | Total            | 116 (26.9)                                                    | 89 (20.6)                                                     | 140 (32.5)                                                    | 81 (18.8)                                                     | 5 (1.2)                                                       | 431 (100)                                                     | 3                                                             |
| T-DXd 5.4 mg/kg (N = 434) | Missing          | 0                                                             | 0                                                             | 0                                                             | 0                                                             | 0                                                             | 0                                                             | 0                                                             |
| Chemotherapy (N = 417)    | Normal           | 162 (39.5)                                                    | 74 (18.0)                                                     | 51 (12.4)                                                     | 11 (2.7)                                                      | 0                                                             | 298 (72.7)                                                    | 6                                                             |
| Chemotherapy (N = 417)    | 1                | 2 (0.5)                                                       | 12 (2.9)                                                      | 33 (8.0)                                                      | 9 (2.2)                                                       | 1 (0.2)                                                       | 57 (13.9)                                                     | 1                                                             |
| Chemotherapy (N = 417)    | 2                | 2 (0.5)                                                       | 4 (1.0)                                                       | 35 (8.5)                                                      | 8 (2.0)                                                       | 1 (0.2)                                                       | 50 (12.2)                                                     | 0                                                             |
| Chemotherapy (N = 417)    | 3                | 0                                                             | 0                                                             | 2 (0.5)                                                       | 2 (0.5)                                                       | 1 (0.2)                                                       | 5 (1.2)                                                       | 0                                                             |
| Chemotherapy (N = 417)    | 4                | 0                                                             | 0                                                             | 0                                                             | 0                                                             | 0                                                             | 0                                                             | 0                                                             |
| Chemotherapy (N = 417)    | Total            | 166 (40.5)                                                    | 90 (22.0)                                                     | 121 (29.5)                                                    | 30 (7.3)                                                      | 3 (0.7)                                                       | 410 (100)                                                     | 7                                                             |
| Chemotherapy (N = 417)    | Missing          | 0                                                             | 0                                                             | 0                                                             | 0                                                             | 0                                                             | 0                                                             | 0                                                             |

<div style=\"page-break-after: always\"></div>

|                                                 | Baseline CTCAE   | Number (%) of Patients with Worst Post-Baseline CTCAE Grade   | Number (%) of Patients with Worst Post-Baseline CTCAE Grade   | Number (%) of Patients with Worst Post-Baseline CTCAE Grade   | Number (%) of Patients with Worst Post-Baseline CTCAE Grade   | Number (%) of Patients with Worst Post-Baseline CTCAE Grade   | Number (%) of Patients with Worst Post-Baseline CTCAE Grade   | Number (%) of Patients with Worst Post-Baseline CTCAE Grade   |
|-------------------------------------------------|------------------|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|
|                                                 | Grade            | Normal                                                        | 1                                                             | 2                                                             | 3                                                             | 4                                                             | Total                                                         | Missing                                                       |
| T-DXd 5.4 mg/kg BC Pool (N = 1741)              | Normal           | 546 (31.6)                                                    | 237 (13.7)                                                    | 391 (22.6)                                                    | 134 (7.7)                                                     | 13 (0.8)                                                      | 1321 (76.4)                                                   | 2                                                             |
| T-DXd 5.4 mg/kg BC Pool (N = 1741)              | 1                | 6 (0.3)                                                       | 29 (1.7)                                                      | 101 (5.8)                                                     | 61 (3.5)                                                      | 6 (0.3)                                                       | 203 (11.7)                                                    | 0                                                             |
| T-DXd 5.4 mg/kg BC Pool (N = 1741)              | 2                | 6 (0.3)                                                       | 2 (0.1)                                                       | 60 (3.5)                                                      | 95 (5.5)                                                      | 4 (0.2)                                                       | 167 (9.7)                                                     | 2                                                             |
| T-DXd 5.4 mg/kg BC Pool (N = 1741)              | 3                | 0                                                             | 0                                                             | 1 (0.1)                                                       | 31 (1.8)                                                      | 6 (0.3)                                                       | 38 (2.2)                                                      | 0                                                             |
| T-DXd 5.4 mg/kg BC Pool (N = 1741)              | 4                | 0                                                             | 0                                                             | 1 (0.1)                                                       | 0                                                             | 0                                                             | 1 (0.1)                                                       | 0                                                             |
| T-DXd 5.4 mg/kg BC Pool (N = 1741)              | Total            | 558 (32.3)                                                    | 268 (15.5)                                                    | 554 (32.0)                                                    | 321 (18.6)                                                    | 29 (1.7)                                                      | 1730 (100)                                                    | 4                                                             |
| T-DXd 5.4 mg/kg BC Pool (N = 1741)              | Missing          | 3                                                             | 0                                                             | 1                                                             | 2                                                             | 0                                                             | 6                                                             | 1                                                             |
| T-DXd 5.4 mg/kg All Tumor Types Pool (N = 2335) | Normal           | 731 (31.7)                                                    | 294 (12.7)                                                    | 515 (22.3)                                                    | 183 (7.9)                                                     | 20 (0.9)                                                      | 1743 (75.5)                                                   | 3                                                             |
| T-DXd 5.4 mg/kg All Tumor Types Pool (N = 2335) | 1                | 7 (0.3)                                                       | 46 (2.0)                                                      | 133 (5.8)                                                     | 71 (3.1)                                                      | 8 (0.3)                                                       | 265 (11.5)                                                    | 2                                                             |
| T-DXd 5.4 mg/kg All Tumor Types Pool (N = 2335) | 2                | 9 (0.4)                                                       | 2 (0.1)                                                       | 92 (4.0)                                                      | 131 (5.7)                                                     | 7 (0.3)                                                       | 241 (10.4)                                                    | 2                                                             |
| T-DXd 5.4 mg/kg All Tumor Types Pool (N = 2335) | 3                | 0                                                             | 0                                                             | 3 (0.1)                                                       | 46 (2.0)                                                      | 10 (0.4)                                                      | 59 (2.6)                                                      | 0                                                             |
| T-DXd 5.4 mg/kg All Tumor Types Pool (N = 2335) | 4                | 0                                                             | 0                                                             | 1 (0.0)                                                       | 0                                                             | 0                                                             | 1 (0.0)                                                       | 0                                                             |
| T-DXd 5.4 mg/kg All Tumor Types Pool (N = 2335) | Total            | 747 (32.4)                                                    | 342 (14.8)                                                    | 744 (32.2)                                                    | 431 (18.7)                                                    | 45 (1.9)                                                      | 2309 (100)                                                    | 7                                                             |
| T-DXd 5.4 mg/kg All Tumor Types Pool (N = 2335) | Missing          | 3                                                             | 1                                                             | 1                                                             | 2                                                             | 0                                                             | 7                                                             | 12                                                            |

Percentages are calculated using the number of patients with both baseline and post-baseline measurements (n in the

Total column) as the denominator.

The pooled analysis group is based on first dose received for patients in each study.

The baseline value is defined as the last nonmissing value before initial administration of study treatment.

<div style=\"page-break-after: always\"></div>

Table 70 Summary of Shifts (Increase) from Baseline to Worst Post-baseline CTCAE Grade in Serum Creatinine (Safety Analysis Set)

|                                      | Baseline Number (%) of Patients with Worst Post-Baseline CTCAE Grade   | Baseline Number (%) of Patients with Worst Post-Baseline CTCAE Grade   | Baseline Number (%) of Patients with Worst Post-Baseline CTCAE Grade   | Baseline Number (%) of Patients with Worst Post-Baseline CTCAE Grade   | Baseline Number (%) of Patients with Worst Post-Baseline CTCAE Grade   | Baseline Number (%) of Patients with Worst Post-Baseline CTCAE Grade   | Baseline Number (%) of Patients with Worst Post-Baseline CTCAE Grade   | Baseline Number (%) of Patients with Worst Post-Baseline CTCAE Grade   |
|--------------------------------------|------------------------------------------------------------------------|------------------------------------------------------------------------|------------------------------------------------------------------------|------------------------------------------------------------------------|------------------------------------------------------------------------|------------------------------------------------------------------------|------------------------------------------------------------------------|------------------------------------------------------------------------|
|                                      | CTCAE Grade                                                            | Normal                                                                 | 1                                                                      | 2                                                                      | 3                                                                      | 4                                                                      | Total                                                                  | Missing                                                                |
| T-DXd 5.4 mg/kg (N = 434)            | Normal                                                                 | 384 (89.1)                                                             | 12 (2.8)                                                               | 24 (5.6)                                                               | 4 (0.9)                                                                | 0                                                                      | 424 (98.4)                                                             | 3                                                                      |
|                                      | 1                                                                      | 0                                                                      | 2 (0.5)                                                                | 0                                                                      | 3 (0.7)                                                                | 0                                                                      | 5 (1.2)                                                                | 0                                                                      |
|                                      | 2                                                                      | 0                                                                      | 0                                                                      | 1 (0.2)                                                                | 1 (0.2)                                                                | 0                                                                      | 2 (0.5)                                                                | 0                                                                      |
|                                      | 3                                                                      | 0                                                                      | 0                                                                      | 0                                                                      | 0                                                                      | 0                                                                      | 0                                                                      | 0                                                                      |
|                                      | 4                                                                      | 0                                                                      | 0                                                                      | 0                                                                      | 0                                                                      | 0                                                                      | 0                                                                      | 0                                                                      |
|                                      | Total                                                                  | 384 (89.1)                                                             | 14 (3.2)                                                               | 25 (5.8)                                                               | 8 (1.9)                                                                | 0                                                                      | 431 (100)                                                              | 3                                                                      |
|                                      | Missing                                                                | 0                                                                      | 0                                                                      | 0                                                                      | 0                                                                      | 0                                                                      | 0                                                                      | 0                                                                      |
| Chemotherapy (N = 417)               | Normal                                                                 | 371 (90.7)                                                             | 7 (1.7)                                                                | 21 (5.1)                                                               | 4 (1.0)                                                                | 0                                                                      | 403 (98.5)                                                             | 7                                                                      |
|                                      | 1                                                                      | 1 (0.2)                                                                | 4 (1.0)                                                                | 1 (0.2)                                                                | 0                                                                      | 0                                                                      | 6 (1.5)                                                                | 0                                                                      |
|                                      | 2                                                                      | 0                                                                      | 0                                                                      | 0                                                                      | 0                                                                      | 0                                                                      | 0                                                                      | 1                                                                      |
|                                      | 3                                                                      | 0                                                                      | 0                                                                      | 0                                                                      | 0                                                                      | 0                                                                      | 0                                                                      | 0                                                                      |
|                                      | 4                                                                      | 0                                                                      | 0                                                                      | 0                                                                      | 0                                                                      | 0                                                                      | 0                                                                      | 0                                                                      |
|                                      | Total                                                                  | 372 (91.0)                                                             | 11 (2.7)                                                               | 22 (5.4)                                                               | 4 (1.0)                                                                | 0                                                                      | 409 (100)                                                              | 8                                                                      |
|                                      | Missing                                                                | 0                                                                      | 0                                                                      | 0                                                                      | 0                                                                      | 0                                                                      | 0                                                                      | 0                                                                      |
| T-DXd 5.4 mg/kg BC Pool (N = 1741)   | Normal                                                                 | 1435 (82.9)                                                            | 152 (8.8)                                                              | 66 (3.8)                                                               | 7 (0.4)                                                                | 1 (0.1)                                                                | 1661 (96.0)                                                            | 7                                                                      |
|                                      | 1                                                                      | 4 (0.2)                                                                | 49 (2.8)                                                               | 4 (0.2)                                                                | 5 (0.3)                                                                | 0                                                                      | 62 (3.6)                                                               | 0                                                                      |
|                                      | 2                                                                      | 0                                                                      | 1 (0.1)                                                                | 4 (0.2)                                                                | 2 (0.1)                                                                | 0                                                                      | 7 (0.4)                                                                | 0                                                                      |
|                                      | 3                                                                      | 0                                                                      | 0                                                                      | 0                                                                      | 0                                                                      | 0                                                                      | 0                                                                      | 0                                                                      |
|                                      | 4                                                                      | 0                                                                      | 0                                                                      | 0                                                                      | 0                                                                      | 0                                                                      | 0                                                                      | 0                                                                      |
|                                      | Total                                                                  | 1439 (83.2)                                                            | 202 (11.7)                                                             | 74 (4.3)                                                               | 14 (0.8)                                                               | 1 (0.1)                                                                | 1730 (100)                                                             | 7                                                                      |
|                                      | Missing                                                                | 3                                                                      | 0                                                                      | 0                                                                      | 0                                                                      | 0                                                                      | 3                                                                      | 1                                                                      |
| T-DXd 5.4 mg/kg All Tumor Types Pool | Normal                                                                 | 1834 (79.1)                                                            | 223 (9.6)                                                              | 108 (4.7)                                                              | 12 (0.5)                                                               | 1 (0.0)                                                                | 2178 (94.0)                                                            | 11                                                                     |
| (N = 2335)                           | 1                                                                      | 5 (0.2)                                                                | 97 (4.2)                                                               | 17 (0.7)                                                               | 6 (0.3)                                                                | 0                                                                      | 125 (5.4)                                                              | 1                                                                      |
|                                      | 2                                                                      | 0                                                                      | 2 (0.1)                                                                | 8 (0.3)                                                                | 5 (0.2)                                                                | 0                                                                      | 15 (0.6)                                                               | 0                                                                      |
|                                      | 3                                                                      | 0                                                                      | 0                                                                      | 0                                                                      | 0                                                                      | 0                                                                      | 0                                                                      | 0                                                                      |
|                                      | 4                                                                      | 0                                                                      | 0                                                                      | 0                                                                      | 0                                                                      | 0                                                                      | 0                                                                      | 0                                                                      |
|                                      | Total                                                                  | 1839 (79.3)                                                            | 322 (13.9)                                                             | 133 (5.7)                                                              | 23 (1.0)                                                               | 1 (0.0)                                                                | 2318 (100)                                                             | 12                                                                     |
|                                      | Missing                                                                | 4                                                                      | 0                                                                      | 0                                                                      | 0                                                                      | 0                                                                      | 4                                                                      | 1                                                                      |

Percentages are calculated using the number of patients with both baseline and post-baseline measurements (n in the Total column) as the denominator.

The pooled analysis group is based on first dose received for patients in each study.

The baseline value is defined as the last nonmissing value before initial administration of study treatment.

<div style=\"page-break-after: always\"></div>

Table 71 Renal Function Abnormalities (Safety Analysis Set)

| Creatinine clearance (mL/min)   | Number (%) of Patients      | Number (%) of Patients      | Number (%) of Patients             | Number (%) of Patients                          |
|---------------------------------|-----------------------------|-----------------------------|------------------------------------|-------------------------------------------------|
| Creatinine clearance (mL/min)   | Study DB-06                 | Study DB-06                 | Supportive Safety Pools            | Supportive Safety Pools                         |
| Creatinine clearance (mL/min)   | T-DXd 5.4 mg/kg (N = 434)   | Chemotherapy (N = 417)      | T-DXd 5.4 mg/kg BC Pool (N = 1741) | T-DXd 5.4 mg/kg All Tumor Types Pool (N = 2335) |
| Nonmissing n a                  | 431                         | 409                         | 1718                               | 2308                                            |
| Minimum post-baseline value     | Minimum post-baseline value | Minimum post-baseline value | Minimum post-baseline value        | Minimum post-baseline value                     |
| < 30                            | 12 (2.8)                    | 6 (1.5)                     | 32 (1.9)                           | 59 (2.6)                                        |
| 30 to < 60                      | 107 (24.8)                  | 93 (22.7)                   | 403 (23.5)                         | 621 (26.9)                                      |
| 60 to < 90                      | 211 (49.0)                  | 179 (43.8)                  | 807 (47.0)                         | 1032 (44.7)                                     |
| ≥ 90 c                          | 101 (23.4)                  | 131 (32.0)                  | 476 (27.7)                         | 596 (25.8)                                      |

a Nonmissing n is the number of patients with both baseline and post-baseline data.

The pooled analysis group is based on first dose received for patients in each study.

CrCl was computed by the calculation by each site. Percentages are calculated using the nonmissing n as denominator.

<div style=\"page-break-after: always\"></div>

Table 72 Summary of Shifts (Decrease) from Baseline to Worst Post-Baseline CTCAE Grade in Potassium (Hypokalemia) (Safety Analysis Set)

<!-- image -->

|                                                | Baseline CTCAE   | Number (%) of Patients with Worst Post-Baseline CTCAE Grade   | Number (%) of Patients with Worst Post-Baseline CTCAE Grade   | Number (%) of Patients with Worst Post-Baseline CTCAE Grade   | Number (%) of Patients with Worst Post-Baseline CTCAE Grade   | Number (%) of Patients with Worst Post-Baseline CTCAE Grade   | Number (%) of Patients with Worst Post-Baseline CTCAE Grade   | Number (%) of Patients with Worst Post-Baseline CTCAE Grade   |
|------------------------------------------------|------------------|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|
|                                                | Grade            | Normal                                                        | 1                                                             | 2                                                             | 3                                                             | 4                                                             | Total                                                         | Missing                                                       |
| T-DXd 5.4 mg/kg (N = 434)                      | Normal           | 278 (64.5)                                                    | 116 (26.9)                                                    | 0                                                             | 24 (5.6)                                                      | 2 (0.5)                                                       | 420 (97.4)                                                    | 2                                                             |
| T-DXd 5.4 mg/kg (N = 434)                      | 1                | 3 (0.7)                                                       | 1 (0.2)                                                       | 0                                                             | 5 (1.2)                                                       | 2 (0.5)                                                       | 11 (2.6)                                                      |                                                               |
| T-DXd 5.4 mg/kg (N = 434)                      | 2                | 0                                                             | 0                                                             | 0                                                             | 0                                                             | 0                                                             | 0                                                             | 0                                                             |
| T-DXd 5.4 mg/kg (N = 434)                      | 3                | 0                                                             | 0                                                             | 0                                                             | 0                                                             | 0                                                             | 0                                                             | 0                                                             |
| T-DXd 5.4 mg/kg (N = 434)                      | 4                | 0                                                             | 0                                                             | 0                                                             | 0                                                             | 0                                                             | 0                                                             | 0                                                             |
| T-DXd 5.4 mg/kg (N = 434)                      | Total            | 281 (65.2)                                                    | 117 (27.1)                                                    | 0                                                             | 29 (6.7)                                                      | 4 (0.9)                                                       | 431 (100)                                                     |                                                               |
| T-DXd 5.4 mg/kg (N = 434)                      | Missing          | 0                                                             | 0                                                             | 0                                                             | 0                                                             | 0                                                             | 0                                                             | 0                                                             |
| Chemotherapy (N = 417)                         | Normal           | 342 (83.8)                                                    | 48 (11.8)                                                     | 0                                                             | 7 (1.7)                                                       | 4 (1.0)                                                       | 401 (98.3)                                                    | 8                                                             |
| Chemotherapy (N = 417)                         |                  | 1 (0.2)                                                       | 4 (1.0)                                                       | 0                                                             | 1 (0.2)                                                       | 0                                                             | 6 (1.5)                                                       | 0                                                             |
| Chemotherapy (N = 417)                         | 2                | 0                                                             | 0                                                             | 0                                                             | 0                                                             | 0                                                             | 0                                                             | 0                                                             |
| Chemotherapy (N = 417)                         |                  | 0                                                             | 1 (0.2)                                                       | 0                                                             | 0                                                             | 0                                                             | 1 (0.2)                                                       | 0                                                             |
| Chemotherapy (N = 417)                         | 4                | 0                                                             | 0                                                             | 0                                                             | 0                                                             | 0                                                             | 0                                                             | 0                                                             |
| Chemotherapy (N = 417)                         | Total            | 343 (84.1)                                                    | 53 (13.0)                                                     | 0                                                             | 8 (2.0)                                                       | 4 (1.0)                                                       | 408 (100)                                                     | 8                                                             |
| Chemotherapy (N = 417)                         | Missing          | 1                                                             | 0                                                             | 0                                                             | 0                                                             | 0                                                             | 1                                                             | 0                                                             |
| T-DXd 5.4 mg/kg BC Pool (N =1741)              | Normal           | 1151 (66.6)                                                   | 199 (11.5)                                                    | 254 (14.7)                                                    | 67 (3.9)                                                      | 4 (0.2)                                                       | 1675 (97.0)                                                   | 4                                                             |
| T-DXd 5.4 mg/kg BC Pool (N =1741)              | 1                | 5 (0.3)                                                       | 6 (0.3)                                                       | 0                                                             | 6 (0.3)                                                       | 3 (0.2)                                                       | 20 (1.2)                                                      | 1                                                             |
| T-DXd 5.4 mg/kg BC Pool (N =1741)              | 2                | 3 (0.2)                                                       | 0                                                             | 18 (1.0)                                                      | 8 (0.5)                                                       | 2 (0.1)                                                       | 31 (1.8)                                                      | 0                                                             |
| T-DXd 5.4 mg/kg BC Pool (N =1741)              | 3                | 0                                                             | 0                                                             | 0                                                             | 1 (0.1)                                                       | 0                                                             | 1 (0.1)                                                       | 0                                                             |
| T-DXd 5.4 mg/kg BC Pool (N =1741)              | 4                | 0                                                             | 0                                                             | 0                                                             | 0                                                             | 0                                                             | 0                                                             | 0                                                             |
| T-DXd 5.4 mg/kg BC Pool (N =1741)              | Total            | 1159 (67.1)                                                   | 205 (11.9)                                                    | 272 (15.7)                                                    | 82 (4.7)                                                      | 9 (0.5)                                                       | 1727 (100)                                                    |                                                               |
| T-DXd 5.4 mg/kg BC Pool (N =1741)              | Missing          |                                                               | 2                                                             | 1                                                             | 0                                                             | 0                                                             | 8                                                             | 1                                                             |
| T-DXd 5.4mg/kg All Tumor Types Pool (N = 2335) | Normal           | 1537 (66.3)                                                   | 300 (12.9)                                                    | 300 (12.9)                                                    | 95 (4.1)                                                      | 7 (0.3)                                                       | 2239 (96.6)                                                   | 7                                                             |
| T-DXd 5.4mg/kg All Tumor Types Pool (N = 2335) | 1                | 9 (0.4)                                                       | 14 (0.6)                                                      | 0                                                             | 11 (0.5)                                                      | 3 (0.1)                                                       | 37 (1.6)                                                      | 一                                                             |
| T-DXd 5.4mg/kg All Tumor Types Pool (N = 2335) | 2                | 3 (0.1)                                                       | 0                                                             | 20 (0.9)                                                      | 9 (0.4)                                                       | 3 (0.1)                                                       | 35 (1.5)                                                      | 0                                                             |
| T-DXd 5.4mg/kg All Tumor Types Pool (N = 2335) | 3                | 0                                                             | 1 (0.0)                                                       | 2 (0.1)                                                       | 1 (0.0)                                                       | 0                                                             | 4 (0.2)                                                       | 0                                                             |
| T-DXd 5.4mg/kg All Tumor Types Pool (N = 2335) | 4                | 0                                                             | 0                                                             | 0                                                             | 0                                                             |                                                               | 2 (0.1)                                                       | 0                                                             |
| T-DXd 5.4mg/kg All Tumor Types Pool (N = 2335) | Total            |                                                               | 1549 (66.9)315 (13.6)                                         | 322 (13.9)                                                    | 116 (5.0)                                                     | 2 (0.1) 15 (0.6)                                              | 2317 (100)                                                    | 8                                                             |
| T-DXd 5.4mg/kg All Tumor Types Pool (N = 2335) | Missing          | 6                                                             | 2                                                             | 1                                                             | 0                                                             | 0                                                             | 9                                                             | 1                                                             |

Percentages are calculated using the number of patients with both baseline and post-baseline measurements (n in the Total column) as the denominator.

The pooled analysis group is based on first dose received for patients in cach study.

The baseline value is defined as the last nonmissing value before initial administration of study treatment.

Table 73 Hepatic Function Abnormalities (Safety Analysis Set)

|                          | Number (%) of Patients    | Number (%) of Patients   | Number (%) of Patients             | Number (%) of Patients                          |
|--------------------------|---------------------------|--------------------------|------------------------------------|-------------------------------------------------|
|                          | Study DB-06               | Study DB-06              | Supportive Safety Pools            | Supportive Safety Pools                         |
|                          | T-DXd 5.4 mg/kg (N = 434) | Chemotherapy (N = 417)   | T-DXd 5.4 mg/kg BC Pool (N = 1741) | T-DXd 5.4 mg/kg All Tumor Types Pool (N = 2335) |
| Alanine aminotransferase |                           |                          |                                    |                                                 |
| Nonmissing n a           | 431                       | 408                      | 1730                               | 2320                                            |
| Baseline ≥ ULN           | 164 (38.1)                | 142 (34.8)               | 483 (27.9)                         | 577 (24.9)                                      |
| Maximum post baseline    |                           |                          |                                    |                                                 |
| ≥ 3 × ULN                | 86 (20.0)                 | 39 (9.6)                 | 192 (11.1)                         | 243 (10.5)                                      |

<div style=\"page-break-after: always\"></div>

| ≥ 5 × ULN                                                              | 25 (5.8)                                                               | 9 (2.2)                                                                | 44 (2.5)                                                               | 64 (2.8)                                                               |
|------------------------------------------------------------------------|------------------------------------------------------------------------|------------------------------------------------------------------------|------------------------------------------------------------------------|------------------------------------------------------------------------|
| ≥ 6 × ULN                                                              | 7 (1.6)                                                                | 2 (0.5)                                                                | 10 (0.6)                                                               | 19 (0.8)                                                               |
| ≥ 10 × ULN                                                             | 5 (1.2)                                                                | 2 (0.5)                                                                | 7 (0.4)                                                                | 10 (0.4)                                                               |
| ≥ 20 × ULN                                                             | 0                                                                      | 1 (0.2)                                                                | 0                                                                      | 1 (0.0)                                                                |
| Aspartate aminotransferase                                             |                                                                        |                                                                        |                                                                        |                                                                        |
| Nonmissing n a                                                         | 431                                                                    | 409                                                                    | 1729                                                                   | 2319                                                                   |
| Baseline ≥ ULN                                                         | 231 (53.6)                                                             | 212 (51.8)                                                             | 821 (47.5)                                                             | 974 (42.0)                                                             |
| Maximum post baseline                                                  |                                                                        |                                                                        |                                                                        |                                                                        |
| ≥ 3 × ULN                                                              | 95 (22.0)                                                              | 51 (12.5)                                                              | 250 (14.5)                                                             | 311 (13.4)                                                             |
| ≥ 5 × ULN                                                              | 29 (6.7)                                                               | 20 (4.9)                                                               | 67 (3.9)                                                               | 84 (3.6)                                                               |
| ≥ 6 × ULN                                                              | 11 (2.6)                                                               | 7 (1.7)                                                                | 23 (1.3)                                                               | 32 (1.4)                                                               |
| ≥ 10 × ULN                                                             | 8 (1.9)                                                                | 3 (0.7)                                                                | 15 (0.9)                                                               | 19 (0.8)                                                               |
| ≥ 20 × ULN                                                             | 2 (0.5)                                                                | 1 (0.2)                                                                | 5 (0.3)                                                                | 6 (0.3)                                                                |
| ALT or AST                                                             |                                                                        |                                                                        |                                                                        |                                                                        |
| Nonmissing n a                                                         | 431                                                                    | 409                                                                    | 1730                                                                   | 2320                                                                   |
| Baseline ≥ ULN                                                         | 240 (55.7)                                                             | 224 (54.8)                                                             | 856 (49.5)                                                             | 1032 (44.5)                                                            |
| Maximum post-baseline                                                  |                                                                        |                                                                        |                                                                        |                                                                        |
| ≥ 3 × ULN                                                              | 121 (28.1)                                                             | 67 (16.4)                                                              | 319 (18.4)                                                             | 398 (17.2)                                                             |
| ≥ 5 × ULN                                                              | 41 (9.5)                                                               | 22 (5.4)                                                               | 93 (5.4)                                                               | 118 (5.1)                                                              |
| ≥ 6 × ULN                                                              | 14 (3.2)                                                               | 8 (2.0)                                                                | 26 (1.5)                                                               | 38 (1.6)                                                               |
| ≥ 10 × ULN                                                             | 10 (2.3)                                                               | 4 (1.0)                                                                | 17 (1.0)                                                               | 22 (0.9)                                                               |
| ≥ 20 × ULN                                                             | 2 (0.5)                                                                | 2 (0.5)                                                                | 5 (0.3)                                                                | 7 (0.3)                                                                |
| Alkaline phosphatase                                                   |                                                                        |                                                                        |                                                                        |                                                                        |
| Nonmissing n a                                                         | 429                                                                    | 409                                                                    | 1729                                                                   | 2319                                                                   |
| Baseline ≥ ULN                                                         | 111 (25.9)                                                             | 108 (26.4)                                                             | 546 (31.6)                                                             | 773 (33.3)                                                             |
| Maximum post-baseline                                                  |                                                                        |                                                                        |                                                                        |                                                                        |
| ≥ 1.5 × ULN                                                            | 168 (39.2)                                                             | 96 (23.5)                                                              | 701 (40.5)                                                             | 959 (41.4)                                                             |
| ≥ 2 × ULN                                                              | 105 (24.5)                                                             | 67 (16.4)                                                              | 429 (24.8)                                                             | 606 (26.1)                                                             |
| Total bilirubin                                                        |                                                                        |                                                                        |                                                                        |                                                                        |
| Nonmissing n a                                                         | 430                                                                    | 408                                                                    | 1730                                                                   | 2320                                                                   |
| Baseline ≥ ULN                                                         | 7 (1.6)                                                                | 11 (2.7)                                                               | 58 (3.4)                                                               | 80 (3.4)                                                               |
| Maximum post-baseline                                                  |                                                                        |                                                                        |                                                                        |                                                                        |
| ≥ 1.5 × ULN                                                            | 35 (8.1)                                                               | 31 (7.6)                                                               | 134 (7.7)                                                              | 191 (8.2)                                                              |
| ≥ 2 × ULN                                                              | 19 (4.4)                                                               | 11 (2.7)                                                               | 61 (3.5)                                                               | 95 (4.1)                                                               |
| ≥ 3 × ULN                                                              | 8 (1.9)                                                                | 6 (1.5)                                                                | 25 (1.4)                                                               | 42 (1.8)                                                               |
| TBL elevation concurrent with ALT or AST elevation                     | TBL elevation concurrent with ALT or AST elevation                     | b                                                                      |                                                                        |                                                                        |
| Nonmissing n a                                                         | 430                                                                    | 408                                                                    | 1728                                                                   | 2318                                                                   |
| ALT or AST ≥ 3 × ULN and TBL ≥ 2 × ULN                                 | 9 (2.1)                                                                | 6 (1.5)                                                                | 29 (1.7)                                                               | 49 (2.1)                                                               |
| TBL elevation concurrent with ALT or AST elevation and ALP < 2 × ULN b | TBL elevation concurrent with ALT or AST elevation and ALP < 2 × ULN b | TBL elevation concurrent with ALT or AST elevation and ALP < 2 × ULN b | TBL elevation concurrent with ALT or AST elevation and ALP < 2 × ULN b | TBL elevation concurrent with ALT or AST elevation and ALP < 2 × ULN b |
| Nonmissing n a                                                         | 428                                                                    | 408                                                                    | 1725                                                                   | 2315                                                                   |
| ALT or AST ≥ 3 × ULN and TBL ≥ 2 × ULN and ALP < 2 × ULN               | 5 (1.2)                                                                | 3 (0.7)                                                                | 17 (1.0)                                                               | 26 (1.1)                                                               |

Nonmissing n is the number of patients with both baseline and post-baseline data. Percentages are calculated using the nonmissing n as denominator.

d

<div style=\"page-break-after: always\"></div>

e 'Concurrent' is defined as these abnormalities occurred within a 28 -day window.

The pooled analysis group is based on tumor type and first dose received for patients in each study.

The baseline value is defined as the last nonmissing value before initial administration of study treatment.

## ECG

## Table 74 Summary of QT and QTcF Intervals (Safety Analysis Set)

|                                                    | Number (%) of Patients                    | Number (%) of Patients   | Number (%) of Patients             | Number (%) of Patients                          |
|----------------------------------------------------|-------------------------------------------|--------------------------|------------------------------------|-------------------------------------------------|
|                                                    | Study DB-06                               | Study DB-06              | Supportive Safety Pools            | Supportive Safety Pools                         |
|                                                    | T-DXd 5.4 mg/kg (N = 434)                 | Chemotherapy (N = 417)   | T-DXd 5.4 mg/kg BC Pool (N = 1741) | T-DXd 5.4 mg/kg All Tumor Types Pool (N = 2335) |
| QT interval (msec)                                 |                                           |                          |                                    |                                                 |
| Nonmissing n a                                     | 410                                       | 364                      | 1711                               | 2215                                            |
| New > 470 msec (female) or New > 450 msec (male) b | 5 (1.2)                                   | 6 (1.6)                  | 77 (4.5)                           | 91 (4.1)                                        |
| New > 480 msec b                                   | 2 (0.5)                                   | 5 (1.4)                  | 37 (2.2)                           | 43 (1.9)                                        |
| New > 500 msec b                                   | 2 (0.5)                                   | 0                        | 20 (1.2)                           | 20 (0.9)                                        |
| Increase from baseline > 30 msec                   | 112 (27.3)                                | 81 (22.3)                | 719 (42.0)                         | 849 (38.3)                                      |
| Increase from baseline > 60 msec                   | 24 (5.9)                                  | 16 (4.4)                 | 188 (11.0)                         | 218 (9.8)                                       |
| Maximum post-baseline value                        | (msec)                                    |                          |                                    |                                                 |
| n                                                  | 410                                       | 364                      | 1711                               | 2215                                            |
| Mean                                               | 399.96                                    | 395.74                   | 414.42                             | 409.91                                          |
| Std Dev                                            | 30.866                                    | 32.583                   | 33.397                             | 34.687                                          |
| Median                                             | 400.00                                    | 395.00                   | 414.00                             | 410.00                                          |
| Minimum, maximum                                   | 300, 578                                  | 311, 500                 | 300, 610                           | 280, 610                                        |
| Maximum change from baseline value (msec)          | Maximum change from baseline value (msec) |                          |                                    |                                                 |
| n                                                  | 410                                       | 364                      | 1711                               | 2215                                            |
| Mean                                               | 15.96                                     | 10.04                    | 27.66                              | 23.99                                           |
| Std Dev                                            | 28.462                                    | 28.854                   | 29.554                             | 30.818                                          |
| Median                                             | 14.67                                     | 8.00                     | 25.83                              | 22.67                                           |
| Minimum, maximum                                   | -76.7, 148                                | -62, 115                 | -76.7, 248.3                       | -112, 248.3                                     |
| QTcF interval (msec)                               |                                           |                          |                                    |                                                 |
| Nonmissing n a                                     | 410                                       | 364                      | 1711                               | 2213                                            |
| New > 470 msec (female) or New > 450 msec (male) b | 15 (3.7)                                  | 4 (1.1)                  | 157 (9.2)                          | 188 (8.5)                                       |
| New > 480 msec b                                   | 8 (2.0)                                   | 4 (1.1)                  | 91 (5.3)                           | 101 (4.6)                                       |
| New > 500 msec b                                   | 1 (0.2)                                   | 2 (0.5)                  | 32 (1.9)                           | 35 (1.6)                                        |
| Increase from baseline > 30 msec                   | 66 (16.1)                                 | 37 (10.2)                | 459 (26.8)                         | 539 (24.4)                                      |
| Increase from baseline > 60 msec                   | 7 (1.7)                                   | 5 (1.4)                  | 94 (5.5)                           | 107 (4.8)                                       |
| Maximum post-baseline value (msec)                 | Maximum post-baseline value (msec)        |                          |                                    |                                                 |

<div style=\"page-break-after: always\"></div>

|                                           | Number (%) of Patients                    | Number (%) of Patients                    | Number (%) of Patients                    | Number (%) of Patients                          |
|-------------------------------------------|-------------------------------------------|-------------------------------------------|-------------------------------------------|-------------------------------------------------|
|                                           | Study DB-06                               | Study DB-06                               | Supportive Safety Pools                   | Supportive Safety Pools                         |
|                                           | T-DXd 5.4 mg/kg (N = 434)                 | Chemotherapy (N = 417)                    | T-DXd 5.4 mg/kg BC Pool (N = 1741)        | T-DXd 5.4 mg/kg All Tumor Types Pool (N = 2335) |
| n                                         | 410                                       | 364                                       | 1711                                      | 2213                                            |
| Mean                                      | 428.72                                    | 423.85                                    | 438.81                                    | 435.53                                          |
| Std Dev                                   | 22.968                                    | 23.648                                    | 26.775                                    | 27.100                                          |
| Median                                    | 427.00                                    | 422.00                                    | 435.78                                    | 433.10                                          |
| Minimum, maximum                          | 367, 633                                  | 373, 564                                  | 367, 694.4                                | 323, 694.4                                      |
| Maximum change from baseline value (msec) | Maximum change from baseline value (msec) | Maximum change from baseline value (msec) | Maximum change from baseline value (msec) | Maximum change from baseline value (msec)       |
| n                                         | 410                                       | 364                                       | 1711                                      | 2213                                            |
| Mean                                      | 12.73                                     | 8.15                                      | 21.53                                     | 19.07                                           |
| Std Dev                                   | 21.298                                    | 19.814                                    | 26.032                                    | 26.990                                          |
| Median                                    | 12.00                                     | 7.00                                      | 17.66                                     | 15.74                                           |
| Minimum, maximum                          | -40, 183                                  | -48.3, 149                                | -72.5, 277.2                              | -98, 337                                        |

Nonmissing n is the number of patients with both baseline and post-baseline data. Percentages are calculated using the nonmissing n as denominator.

f

g New is defined as an abnormal ECG finding at post-baseline that is not present at baseline.

The pooled analysis group is based on first dose received for patients in each study.

The baseline value is defined as the last nonmissing value before initial administration of study treatment.

If multiple ECG measurements are taken at the baseline, the average of all baseline values will be used as baseline.

## Safety in special populations

## Intrinsic factors

## Table 75 Overall Summary of Treatment-emergent Adverse Events by Age Group (Safety Analysis Set)

| Parameter                        | < 65 years                       | < 65 years                       | < 65 years                           | < 65 years                                        | ≥ 65 years                       | ≥ 65 years                       | ≥ 65 years                          | ≥ 65 years                                       |
|----------------------------------|----------------------------------|----------------------------------|--------------------------------------|---------------------------------------------------|----------------------------------|----------------------------------|-------------------------------------|--------------------------------------------------|
|                                  | Study DB-06                      | Study DB-06                      | Supportive Safety Pools              | Supportive Safety Pools                           | Study DB-06                      | Study DB-06                      | Supportive Safety Pools             | Supportive Safety Pools                          |
|                                  | T-DXd 5.4 mg/ kg (N = 30 2)      | Chemo- therapy (N = 28 6)        | T-DXd 5.4 mg/ kg BC Pool (N = 132 0) | T-DXd 5.4 mg/ kg All Tumor Types Pool (N = 166 1) | T-DXd 5.4 mg/ kg (N = 13 2)      | Chemo- therapy (N = 13 1)        | T-DXd 5.4 mg/ kg BC Pool (N = 42 1) | T-DXd 5.4 mg/ kg All Tumor Types Pool (N = 67 4) |
| Duration of treatment (months) a | Duration of treatment (months) a | Duration of treatment (months) a | Duration of treatment (months) a     | Duration of treatment (months) a                  | Duration of treatment (months) a | Duration of treatment (months) a | Duration of treatment (months) a    | Duration of treatment (months) a                 |
| Median                           | 11.45                            | 5.52                             | 10.82                                | 9.66                                              | 10.50                            | 7.36                             | 9.95                                | 8.10                                             |
| Minimum, maximum                 | 0.7, 33.3                        | 0.1, 26.9                        | 0.2, 44.0                            | 0.2, 44.0                                         | 0.4, 39.6                        | 0.2, 35.9                        | 0.4, 45.1                           | 0.4, 45.1                                        |
| Patients with any TEAE           | 301 (99.7)                       | 272 (95.1)                       | 1313 (99.5)                          | 1651 (99.4)                                       | 128 (97.0)                       | 125 (95.4)                       | 417 (99.0)                          | 666 (98.8)                                       |

<div style=\"page-break-after: always\"></div>

| Parameter                                         | < 65 years                  | < 65 years                | < 65 years                           | < 65 years                                        | ≥ 65 years                  | ≥ 65 years                | ≥ 65 years                          | ≥ 65 years                                       |
|---------------------------------------------------|-----------------------------|---------------------------|--------------------------------------|---------------------------------------------------|-----------------------------|---------------------------|-------------------------------------|--------------------------------------------------|
| Parameter                                         | Study DB-06                 | Study DB-06               | Supportive Safety Pools              | Supportive Safety Pools                           | Study DB-06                 | Study DB-06               | Supportive Safety Pools             | Supportive Safety Pools                          |
| Parameter                                         | T-DXd 5.4 mg/ kg (N = 30 2) | Chemo- therapy (N = 28 6) | T-DXd 5.4 mg/ kg BC Pool (N = 132 0) | T-DXd 5.4 mg/ kg All Tumor Types Pool (N = 166 1) | T-DXd 5.4 mg/ kg (N = 13 2) | Chemo- therapy (N = 13 1) | T-DXd 5.4 mg/ kg BC Pool (N = 42 1) | T-DXd 5.4 mg/ kg All Tumor Types Pool (N = 67 4) |
| TEAEs with worst CTCAE Grade ≥ 3 b                | 154 (51.0)                  | 115 (40.2)                | 686 (52.0)                           | 865 (52.1)                                        | 75 (56.8)                   | 70 (53.4)                 | 255 (60.6)                          | 415 (61.6)                                       |
| Treatment- emergent SAEs                          | 52 (17.2)                   | 38 (13.3)                 | 299 (22.7)                           | 408 (24.6)                                        | 36 (27.3)                   | 29 (22.1)                 | 130 (30.9)                          | 244 (36.2)                                       |
| TEAEs associated with study drug discontinua tion | 38 (12.6)                   | 23 (8.0)                  | 211 (16.0)                           | 244 (14.7)                                        | 24 (18.2)                   | 16 (12.2)                 | 96 (22.8)                           | 132 (19.6)                                       |
| TEAEs associated with study drug interruptio n    | 152 (50.3)                  | 101 (35.3)                | 588 (44.5)                           | 724 (43.6)                                        | 58 (43.9)                   | 59 (45.0)                 | 206 (48.9)                          | 315 (46.7)                                       |
| TEAEs associated with dose reduction              | 75 (24.8)                   | 98 (34.3)                 | 308 (23.3)                           | 371 (22.3)                                        | 32 (24.2)                   | 63 (48.1)                 | 109 (25.9)                          | 161 (23.9)                                       |
| TEAEs associated with an outcome of death c       | 5 (1.7)                     | 2 (0.7)                   | 37 (2.8)                             | 50 (3.0)                                          | 6 (4.5)                     | 4 (3.1)                   | 19 (4.5)                            | 46 (6.8)                                         |
| Patients with any drug- related TEAE d            | 295 (97.7)                  | 256 (89.5)                | 1284 (97.3)                          | 1586 (95.5)                                       | 122 (92.4)                  | 117 (89.3)                | 405 (96.2)                          | 622 (92.3)                                       |
| Drug- related TEAEs with worst CTCAE Grade ≥ 3 b  | 116 (38.4)                  | 82 (28.7)                 | 545 (41.3)                           | 659 (39.7)                                        | 60 (45.5)-                  | 49 (37.4)                 | 205 (48.7)                          | 312 (46.3)                                       |
| Drug- related treatment- emergent SAEs            | 27 (8.9)                    | 14 (4.9)                  | 143 (10.8)                           | 172 (10.4)                                        | 19 (14.4)                   | 10 (7.6)                  | 65 (15.4)                           | 109 (16.2)                                       |

<div style=\"page-break-after: always\"></div>

| Parameter                                                       | < 65 years                  | < 65 years                | < 65 years                           | < 65 years                                        | ≥ 65 years                  | ≥ 65 years                | ≥ 65 years                          | ≥ 65 years                                       |
|-----------------------------------------------------------------|-----------------------------|---------------------------|--------------------------------------|---------------------------------------------------|-----------------------------|---------------------------|-------------------------------------|--------------------------------------------------|
| Parameter                                                       | Study DB-06                 | Study DB-06               | Supportive Safety Pools              | Supportive Safety Pools                           | Study DB-06                 | Study DB-06               | Supportive Safety Pools             | Supportive Safety Pools                          |
| Parameter                                                       | T-DXd 5.4 mg/ kg (N = 30 2) | Chemo- therapy (N = 28 6) | T-DXd 5.4 mg/ kg BC Pool (N = 132 0) | T-DXd 5.4 mg/ kg All Tumor Types Pool (N = 166 1) | T-DXd 5.4 mg/ kg (N = 13 2) | Chemo- therapy (N = 13 1) | T-DXd 5.4 mg/ kg BC Pool (N = 42 1) | T-DXd 5.4 mg/ kg All Tumor Types Pool (N = 67 4) |
| Drug- related TEAEs associated with study drug discontinua tion | 37 (12.3)                   | 19 (6.6)                  | 180 (13.6)                           | 205 (12.3)                                        | 19 (14.4)                   | 14 (10.7)                 | 86 (20.4)                           | 112 (16.6)                                       |
| Drug- related TEAEs associated with study drug interruptio n    | 90 (29.8)                   | 67 (23.4)                 | 412 (31.2)                           | 475 (28.6)                                        | 37 (28.0)                   | 36 (27.5)                 | 151 (35.9)                          | 213 (31.6)                                       |
| Drug- related TEAEs associated with dose reduction              | 65 (21.5)                   | 95 (33.2)                 | 287 (21.7)                           | 347 (20.9)                                        | 29 (22.0)                   | 60 (45.8)                 | 96 (22.8)                           | 142 (21.1)                                       |
| Drug- related TEAEs associated with an outcome of death c       | 2 (0.7)                     | 0                         | 13 (1.0)                             | 14 (0.8)                                          | 3 (2.3)                     | 0                         | 7 (1.7)                             | 14 (2.1)                                         |

c Duration of treatment (months) = (date of the last dose - date of the first dose + a cycle length (day))/30.44. 1 month = 365.25/12 = 30.44 days

d A patient was counted once at the maximum severity.

For specific TEAEs associated with outcome of death, refer to.

If relationship was missing, the TEAE was considered to be related to the drug.

Percentages are calculated using the number of patients in the Safety Analysis Set as the denominator.

Table 76 All Adverse Drug Reactions in At Least 65 Years of Age in T-DXd 5.4 mg/kg breast cancer pool and T-DXd 5.4 mg/kg all tumour types pool, by MedDRA System Organ Class, Preferred Term/Grouped Term and Frequency (Safety Analysis Set)

| MedDRASystemOrganClass   | T-DXd5.4mg/kgbreastcancerpool (N =421)   | T-DXd5.4mg/kgbreastcancerpool (N =421)   | T-DXd5.4mg/kgbreastcancerpool (N =421)   | T-DXd5.4mg/kgbreastcancerpool (N =421)   | T-DXd5.4mg/kgbreastcancerpool (N =421)   | T-DXd5.4mg/kg all tumor typespool (N =674)   | T-DXd5.4mg/kg all tumor typespool (N =674)   | T-DXd5.4mg/kg all tumor typespool (N =674)   | T-DXd5.4mg/kg all tumor typespool (N =674)   | T-DXd5.4mg/kg all tumor typespool (N =674)   |
|--------------------------|------------------------------------------|------------------------------------------|------------------------------------------|------------------------------------------|------------------------------------------|----------------------------------------------|----------------------------------------------|----------------------------------------------|----------------------------------------------|----------------------------------------------|
| PreferredTerm/           |                                          | Number(%)ofSubjects                      | Number(%)ofSubjects                      | Number(%)ofSubjects                      | Number(%)ofSubjects                      | Frequency                                    | Number(%)ofSubjects                          | Number(%)ofSubjects                          | Number(%)ofSubjects                          | Number(%)ofSubjects                          |
|                          | Frequency                                | CTCAEGrade                               | CTCAEGrade                               | CTCAEGrade                               | SAE                                      |                                              | CTCAEGrade                                   | CTCAEGrade                                   | CTCAEGrade                                   | SAE                                          |
| GroupedTerm              |                                          | AlI                                      | Grade                                    | Grade5                                   |                                          |                                              | AlI                                          | Grade 3or4                                   | Grade5                                       |                                              |
|                          |                                          | Grades                                   | 3or4                                     |                                          |                                          |                                              | Grades                                       |                                              |                                              |                                              |
| SubjectswithanyADR       |                                          | 415 (98.6)204 (48.5)                     |                                          | 6 (1.4)                                  | 67 (15.9)                                |                                              | 656 (97.3)322 (47.8)                         |                                              | 16 (2.4)                                     | 133                                          |
|                          |                                          |                                          |                                          |                                          |                                          |                                              |                                              |                                              |                                              | (19.7)                                       |

<div style=\"page-break-after: always\"></div>

Table 77 All Adverse Drug Reactions in Subjects Less than 65 Years in T-DXd 5.4 mg/kg breast cancer pool and T-DXd 5.4 mg/kg all tumour types pool. By MedDRA System Organ Class, Preferred Term/Grouped Term and Frequency (Safety Analysis Set)

<!-- image -->

| MedDRASystemOrganClass   | T-DXd5.4mg/kgbreastcancerpool (N =1320)   | T-DXd5.4mg/kgbreastcancerpool (N =1320)   | T-DXd5.4mg/kgbreastcancerpool (N =1320)   | T-DXd5.4mg/kgbreastcancerpool (N =1320)   | T-DXd5.4mg/kgbreastcancerpool (N =1320)   | T-DXd5.4mg/kg alltumor typespool (N=1661)   | T-DXd5.4mg/kg alltumor typespool (N=1661)   | T-DXd5.4mg/kg alltumor typespool (N=1661)   | T-DXd5.4mg/kg alltumor typespool (N=1661)   | T-DXd5.4mg/kg alltumor typespool (N=1661)   |
|--------------------------|-------------------------------------------|-------------------------------------------|-------------------------------------------|-------------------------------------------|-------------------------------------------|---------------------------------------------|---------------------------------------------|---------------------------------------------|---------------------------------------------|---------------------------------------------|
| PreferredTerm/           | Frequency                                 | Number(%)ofSubjects                       | Number(%)ofSubjects                       | Number(%)ofSubjects                       | Number(%)ofSubjects                       | Frequency                                   | Number(%)ofSubjects                         | Number(%)ofSubjects                         | Number(%)ofSubjects                         | Number(%)ofSubjects                         |
|                          |                                           | CTCAEGrade                                | CTCAEGrade                                | CTCAEGrade                                |                                           |                                             | CTCAEGrade                                  | CTCAEGrade                                  | CTCAEGrade                                  | SAE                                         |
| GroupedTerm              |                                           | All                                       | Grade                                     | Grade5                                    | SAE                                       |                                             | AlI                                         | Grade                                       | Grade5                                      |                                             |
|                          |                                           |                                           | 3or4                                      |                                           |                                           |                                             | Grades                                      | 3or4                                        |                                             |                                             |
|                          |                                           | Grades                                    |                                           |                                           |                                           |                                             |                                             |                                             |                                             |                                             |
| SubjectswithanyADR       |                                           | 1306                                      | 572 (43.3)                                | 14 (1.1)                                  | 153                                       |                                             | 1638                                        | 710 (42.7)                                  | 16 (1.0)                                    | 197                                         |
|                          |                                           | (98.9)                                    |                                           |                                           | (11.6)                                    |                                             | (98.6)                                      |                                             |                                             | (11.9)                                      |

Table 78 AEs by age range

<!-- image -->

|                                                                                           | T-DXd         | T-DXd            | T-DXd            | T-DXd         | Chemotherapy   | Chemotherapy    | Chemotherapy     | Chemotherapy   |
|-------------------------------------------------------------------------------------------|---------------|------------------|------------------|---------------|----------------|-----------------|------------------|----------------|
| MedDRA Terms                                                                              | Age <65 n (%) | Age 65- 74 n (%) | Age 75- 84 n (%) | Age 85+ n (%) | Age <65 n (%)  | Age 65-74 n (%) | Age 75- 84 n (%) | Age 85+ n (%)  |
| Total Subjects Number per Category                                                        | 301           | 97               | 33               | 3             | 285            | 96              | 36               | 0              |
| Total AEs                                                                                 | 300 (99.7)    | 95 (97.9)        | 31 (93.9)        | 3 (100)       | 271 (95.1)     | 90 (93.8)       | 36 (100)         | 0              |
| Serious AEs - Total                                                                       | 52 (17.3)     | 25 (25.8)        | 11 (33.3)        | 0             | 37 (13.0)      | 19 (19.8)       | 11 (30.6)0       |                |
| - Fatal                                                                                   | 5 (1.7)       | 2 (2.1)          | 4 (12.1)         | 0             | 2 (0.7)        | 3 (3.1)         | 1 (2.8)          | 0              |
| - Hospitalization/ prolong existing hospitalization                                       | 49 (16.3)     | 23 (23.7)        | 11 (33.3)        | 0             | 33 (11.6)      | 19 (19.8)       | 11 (30.6)0       |                |
| - Life-threatening                                                                        | 5 (1.7)       | 4 (4.1)          | 3 (9.1)          | 0             | 1 (0.4)        | 4 (4.2)         | 0                | 0              |
| - Disability/incapacity                                                                   | 1 (0.3)       | 0                | 1 (3.0)          | 0             | 2 (0.7)        | 0               | 1(2.8)           | 0              |
| - Other (medically significant)                                                           | 11 (3.7)      | 4 (4.1)          | 0                | 0             | 6 (2.1)        | 5 (5.2)         | 2 (5.6)          | 0              |
| AE leading to treatment discontinuation                                                   | 38 (12.6)     | 14 (14.4)        | 10 (30.3)        | 0             | 23 (8.1)       | 11 (11.5)       | 5 (13.9)         | 0              |
| Psychiatric disorders a                                                                   | 38 (12.6)     | 9 (9.3)          | 6 (18.2)         | 0             | 16 (5.6)       | 9 (9.4)         | 7 (19.4)         | 0              |
| Nervous system disorders a                                                                | 122 (40.5)    | 35 (36.1)        | 11 (33.3)        | 1 (33.3)      | 126 (44.2)     | 45 (46.9)       | 17 (47.2)0       |                |
| Accidents and injuries b                                                                  | 16 (5.3)      | 9 (9.3)          | 4 (12.1)         | 2 (66.7)      | 17 (6.0)       | 10 (10.4)       | 4 (11.1)         | 0              |
| Cardiac disorders a                                                                       | 23 (7.6)      | 8 (8.2)          | 2 (6.1)          | 2 (66.7)      | 14 (4.9)       | 8 (8.3)         | 3 (8.3)          | 0              |
| Vascular disorders a                                                                      | 40 (13.3)     | 18 (18.6)        | 2 (6.1)          | 0             | 32 (11.2)      | 13 (13.5)       | 7 (19.4)         | 0              |
| Cerebrovascular disorders c                                                               | 1 (0.3)       | 0                | 0                | 0             | 1 (0.4)        | 0               | 1 (2.8)          | 0              |
| Infections and infestations a                                                             | 172 (57.1)    | 48 (49.5)        | 12 (36.4)        | 1 (33.3)      | 99 (34.7)      | 45 (46.9)       | 17 (47.2)0       |                |
| Anticholinergic syndrome                                                                  | 0             | 0                | 0                | 0             | 0              | 0               | 0                | 0              |
| Quality of life decreased                                                                 | 0             | 0                | 0                | 0             | 0              | 0               | 0                | 0              |
| Sum of orthostatic hypotension, fall, loss of consciousness, syncope, dizziness, ataxia d | 29 (9.6)      | 10 (10.3)        | 5 (15.2)         | 2 (66.7)      | 21 (7.4)       | 9 (9.4)         | 7 (19.4)         | 0              |

a  MedDRA System Organ Class (SOC).

<div style=\"page-break-after: always\"></div>

b  Accidents and Injuries MedDRA Standardised MedDRA Query (SMQ; narrow search).

- c  Includes central nervous system haemorrhages and cerebrovascular conditions SMQ (narrow search)
- d  Grouped term including PTs of orthostatic hypotension, fall, loss of consciousness, syncope, dizziness, and ataxia. The PT of fracture was removed to avoid duplication given all fractures are included in the Accidents and Injuries SMQ.

Includes AEs with an onset date or worsening on or after the date of first dose and up to and including 47 days following the date of last dose of study medication or before the initiation of the first subsequent cancer therapy (whichever occurs first). MedDRA version 26.1.

Table 79 Subgroup Analysis of Overall Summary of Treatment-Emergent Adverse Events in Patients ≥ 75 (Safety Analysis Set)

Age:&gt;=75 years

|                                                         | Number （&)of Patients         | Number （&)of Patients               | Number （&)of Patients   | Number （&)of Patients                                 |
|---------------------------------------------------------|-------------------------------|-------------------------------------|-------------------------|-------------------------------------------------------|
|                                                         | D9670C00001(DESTINY-Breast06) | D9670C00001(DESTINY-Breast06)       | Supportive Safety Pools | Supportive Safety Pools                               |
|                                                         | T-DXd 5.4mg/kg                | Investigator choice of chemotherapy | T-DXd5.4mg/kg           | T-DXd5.4mg/kg breast cancer pool all tumor types pool |
|                                                         |                               |                                     |                         | (N=147)                                               |
|                                                         | (N=36)                        | (N=36)                              | (N=86)                  |                                                       |
| Treatment-Emergent Adverse Events (TEAE)                | 34(94.4)                      | 36 (100)                            | 84 (97.7)               | 145 (98.6)                                            |
| TEAE with CTCAE Grade>=3                                | 24 (66.7)                     | 20 (55.6)                           | 48 (55.8)               | 90 (61.2)                                             |
| TEAE associated with an outcome of death                | 4 (11.1)                      | 1 (2.8)                             | 4 (4.7)                 | 14 (9.5)                                              |
| TEAE associated with study drug discontinuation         | 10 (27.8)                     | 5 (13.9)                            | 24 (27.9)               | 35 (23.8)                                             |
| TEAE associated with study drug interruption            | 16 (44.4)                     | 12 (33.3)                           | 37 (43.0)               | 67 (45.6)                                             |
| TEAE associated with dose reduction                     | 7(19.4)                       | 20 (55.6)                           | 21 (24.4)               | 31 (21.1)                                             |
| Drug-Related TEAE (Related TEAE)                        | 32 (88.9)                     | 32 (88.9)                           | 82 (95.3)               | 136 (92.5)                                            |
| Related TEAE with CTCAE Grade >=3                       | 22 (61.1)                     | 15 (41.7)                           | 42 (48.8)               | 69 (46.9)                                             |
| Related TEAE associated with an outcome of death        | (8.3)                         | 0                                   | 3 (3.5)                 | 5 (3.4)                                               |
| Related TEAE associated with study drug discontinuation | 10 (27.8)                     | 4 (11.1)                            | 24 (27.9)               | 32 (21.8)                                             |
| Related TEAE associated with study drug interruption    | 10 (27.8)                     | 6 (16.7)                            | 26 (30.2)               | 42 (28.6)                                             |
| Related TEAE associated with dose reduction             | (19.4)                        | 19 (52.8)                           | 17 (19.8)               | 27 (18.4)                                             |

<div style=\"page-break-after: always\"></div>

Table 80 Overall Summary of Treatment-emergent Adverse Events by Race (Safety Analysis Set)

| Parameter                                        | White                       | White                       | White                          | White                                         | Asian                       | Asian                       | Asian                            | Asian                                         | Other                       | Other                       | Other                            | Other                               |
|--------------------------------------------------|-----------------------------|-----------------------------|--------------------------------|-----------------------------------------------|-----------------------------|-----------------------------|----------------------------------|-----------------------------------------------|-----------------------------|-----------------------------|----------------------------------|-------------------------------------|
| Parameter                                        | Study DB-06                 | Study DB-06                 | Supportive Safety Pools        | Supportive Safety Pools                       | Study DB-06                 | Study DB-06                 | Supportive Safety Pools          | Supportive Safety Pools                       | Study DB-06                 | Study DB-06                 | Supportive Safety Pools          | Supportive Safety Pools             |
| Parameter                                        | PXI-L 5.4 mg/kg (N = 231)   | Chemo- therapy (N =223)     | T-DXd 5.4mg/kg BC Pool (N=878) | T-DXd 5.4 mg/kg All Tumor Types Pool (N=1172) | PXG-L 5.4 mg/kg (N = 153)   | Chemo- therapy (N = 147)    | T-DXd 5.4 mg/kg BC Pool (N =681) | PXI-L 5.4 mg/kg All Tumor Types Pool (N= 928) | PXI-L 5.4 mg/kg (N =50)     | Chemo- therapy (N = 477)    | T-DXd 5.4 mg/kg BC Pool (N =178) | PXI-L 5.4 mg/kg Types Pool (N= 231) |
| Durationoftreatment(months)                      | Durationoftreatment(months) | Durationoftreatment(months) | Durationoftreatment(months)    | Durationoftreatment(months)                   | Durationoftreatment(months) | Durationoftreatment(months) | Durationoftreatment(months)      | Durationoftreatment(months)                   | Durationoftreatment(months) | Durationoftreatment(months) | Durationoftreatment(months)      | Durationoftreatment(months)         |
| Median                                           | 10.35                       | 5.59                        | 10.27                          | 8.87                                          | 11.50                       | 7.36                        | 11.04                            | 9.59                                          | 12.22                       | 4.17                        | 11.86                            | 9.66                                |
| Minimum, maximum                                 | 0.4, 37.1                   | 0.1, 26.9                   | 0.2, 39.1                      | 0.2, 39.1                                     | 0.7, 39.6                   | 0.1, 35.9                   | 0.7, 45.1                        | 0.7, 45.1                                     | 0.6, 30.6                   | 0.2, 22.0                   | 0.6, 39.0                        | 0.6, 39.0                           |
| Patientswith anyTEAE                             | 227 (98.3)                  | 214 (96.0)                  | 871 (99.2)                     | 1159 (98.9)                                   | 153 (100)                   | 138 (93.9)                  | 679 (99.7)                       | 925 (99.7)                                    | 49 (98.0)                   | 45 (95.7)                   | 176 (98.9)                       | 229 (99.1)                          |
| TEAEs with worst CTCAE Grade≥3 b                 | 114 (49.4)                  | 110 (49.3)                  | 452 (51.5)                     | 605 (51.6)                                    | 93 (60.8)                   | 59 (40.1)                   | 397 (58.3)                       | 553 (59.6)                                    | 22 (44.0)                   | 16 (34.0)                   | 89 (50.0)                        | 119 (51.5)                          |
| Treatment-emergent SAEs                          | 48 (20.8)                   | 43 (19.3)                   | 227 (25.9)                     | 333 (28.4)                                    | 32 (20.9)                   | 16 (10.9)                   | 160 (23.5)                       | 253 (27.3)                                    | 8 (16.0)                    | 8 (17.0)                    | 40 (22.5)                        | 64 (27.7)                           |
| TEAEs associated with study drug discontinuation | 33 (14.3)                   | 22 (9.9)                    | 143 (16.3)                     | 177 (15.1)                                    | 26 (17.0)                   | 7 (4.8)                     | 133 (19.5)                       | 165 (17.8)                                    | 3 (6.0)                     | 10 (21.3)                   | 31 (17.4)                        | 34 (14.7)                           |
| TEAEs associated with study drug interruption    | 110 (47.6)                  | 95 (42.6)                   | 371 (42.3)                     | 474 (40.4)                                    | 80 (52.3)                   | 51 (34.7)                   | 343 (50.4)                       | 461 (49.7)                                    | 20 (40.0)                   | 14 (29.8)                   | 77 (43.3)                        | 101 (43.7)                          |
| TEAEs associated with dose reduction             | 49 (21.2)                   | 93 (41.7)                   | 187 (21.3)                     | 236 (20.1)                                    | 50 (32.7)                   | 52 (35.4)                   | 189 (27.8)                       | 249 (26.8)                                    | 8 (16.0)                    | 16( 34.0)                   | 39 (21.9)                        | 45 (19.5)                           |
| TEAEs associated with an outcome of deathc       | 7 (3.0)                     | 4 (1.8)                     | 40 (4.6)                       | 61 (5.2)                                      | 2 (1.3)                     | 2 (1.4)                     | 12 (1.8)                         | 28 (3.0)                                      | 2 (4.0)                     | 0                           | 4 (2.2)                          | 7 (3.0)                             |

| Parameter                                                    | White                    | White                    | White                             | White                                           | Asian                     | Asian                    | Asian                             | Asian                                         | Other                   | Other                    | Other                           | Other                                        |
|--------------------------------------------------------------|--------------------------|--------------------------|-----------------------------------|-------------------------------------------------|---------------------------|--------------------------|-----------------------------------|-----------------------------------------------|-------------------------|--------------------------|---------------------------------|----------------------------------------------|
| Parameter                                                    | Study DB-06              | Study DB-06              | Supportive Safety Pools           | Supportive Safety Pools                         | StudyDB-06                | StudyDB-06               | Supportive Safety Pools           | Supportive Safety Pools                       | Study DB-06             | Study DB-06              | Supportive Safety Pools         | Supportive Safety Pools                      |
| Parameter                                                    | PXI-L 5.4 mg/kg (N= 231) | Chemo- therapy (N = 223) | T-DXd 5.4 mg/kg BC Pool (N = 878) | T-DXd 5.4 mg/kg All Tumor Types Pool (N = 1172) | T-DXd 5.4 mg/kg (N = 153) | Chemo- therapy (N = 147) | T-DXd 5.4 mg/kg BC Pool (N = 681) | T-DXd 5.4 mg/kg All Tumor Types Pool (N= 928) | T-DXd 5.4 mg/kg (N =50) | Chemo- therapy (N = 477) | T-DXd 5.4 mg/kg BC Pool (N=178) | T-DXd 5.4 mg/kg AllTumor Types Pool (N= 231) |
| Patients with any drug- related TEAE d                       | 221 (95.7)               | 200 (89.7)               | 847 (96.5)                        | 1096 (93.5)                                     | 151 (98.7)                | 132 (89.8)               | 668 (98.1)                        | 891 (96.0)                                    | 45 (90.0)               | 41 (87.2)                | 170 (95.5)                      | 217 (93.9)                                   |
| Drug-related TEAEs with worst CTCAE Grade ≥3 b               | 79 (34.2)                | 68 (30.5)                | 334 (38.0)                        | 423 (36.1)                                      | 79 (51.6)                 | 50 (34.0)                | 345 (50.7)                        | 461 (49.7)                                    | 18 (36.0)               | 13 (27.7)                | 69 (38.8)                       | 85 (36.8)                                    |
| Drug-related treatment-emergent SAEs                         | 24 (10.4)                | 12 (5.4)                 | 102 (9'11)                        | 134 (11.4)                                      | 18 (11.8)                 | 6 (4.1)                  | 85 (12.5)                         | 611 (12.8)                                    | 4 (8.0)                 | 6 (12.8)                 | 20 (11.2)                       | 27 (11.7)                                    |
| Drug-related TEAEs associatedwith study drug discontinuation | 28 (12.1)                | 18 (8.1)                 | 118 (13.4)                        | 142 (12.1)                                      | 25 (16.3)                 | 6 (4.1)                  | 119 (17.5)                        | 143 (15.4)                                    | 3 (6.0)                 | 9 (19.1)                 | 29 (16.3)                       | 32 (13.9)                                    |
| Drug-related TEAEs associatedwith Snup Apns interruption     | 60 (26.0)                | 58 (26.0)                | 232 (26.4)                        | 271 (23.1)                                      | 55 (35.9)                 | 36 (24.5)                | 276 (40.5)                        | 351 (37.8)                                    | 12 (24.0)               | 9 (19.1)                 | 52 (29.2)                       | 63 (27.3)                                    |
| Drug-related TEAEs associatedwith dose reduction             | 45 (19.5)                | 88 (39.5)                | 166 (18.9)                        | 211 (18.0)                                      | 42 (27.5)                 | 52 (35.4)                | 178 (26.1)                        | 234 (25.2)                                    | 7 (14.0)                | 15 (31.9)                | 37 (20.8)                       | 42 (18.2)                                    |
| Drug-related TEAEs associatedwith an outcome of death        | 3 (1.3)                  | 0                        | 15 (1.7)                          | 19 (1.6)                                        | 2 (1.3)                   | 0                        | 5 (0.7)                           | 7 (0.8)                                       | 0                       | 0                        | 0                               | 2 (0.9)                                      |

PercentagesarecalculatedusingthenumberofpatientsintheSafetyAnalysisSetasthedenominator.

d If relationship was missing, the TEAE was considered to be related to the drug.

<div style=\"page-break-after: always\"></div>

Table 81 Overall Summary of Treatment-emergent Adverse Events by ECOG Performance Status (Safety Analysis Set)

| Parameter                                                     | ECOG PS=0                       | ECOG PS=0                       | ECOG PS=0                         | ECOG PS=0                                      | ECOG PS =1                      | ECOG PS =1                      | ECOG PS =1                       | ECOG PS =1                                     |
|---------------------------------------------------------------|---------------------------------|---------------------------------|-----------------------------------|------------------------------------------------|---------------------------------|---------------------------------|----------------------------------|------------------------------------------------|
| Parameter                                                     | Study DB-06                     | Study DB-06                     | Supportive Safety Pools           | Supportive Safety Pools                        | Study DB-06                     | Study DB-06                     | Supportive Safety Pools          | Supportive Safety Pools                        |
| Parameter                                                     | T-DXd 5.4 mg/kg (N = 251)       | Chemo- therapy (N =246)         | T-DXd 5.4 mg/kg BC Pool (N = 990) | T-DXd 5.4 mg/kg All Tumor Iypes Pool (N =1245) | T-DXd 5.4 mg/kg (N =177)        | Chemo- therapy (N =162)         | T-DXd 5.4 mg/kg BC Pool (N =743) | T-DXd 5.4 mg/kg All Tumor Iypes Pool (N =1080) |
| Duration of treatment (months)a                               | Duration of treatment (months)a | Duration of treatment (months)a | Duration of treatment (months)a   | Duration of treatment (months)a                | Duration of treatment (months)a | Duration of treatment (months)a | Duration of treatment (months)a  | Duration of treatment (months)a                |
| Median                                                        | 11.70                           | 6.24                            | 11.71                             | 10.18                                          | 9.95                            | 5.55                            | 9.66                             | 7.75                                           |
| Minimum, maximum                                              | 0.7, 39.6                       | 0.1, 32.0                       | 0.4, 44.0                         | 0.4, 44.0                                      | 0.4, 32.1                       | 0.1, 35.9                       | 0.2, 45.1                        | 0.2, 45.1                                      |
| Patients with any TEAE                                        | 248 (98.8)                      | 234 (95.1)                      | 982 (99.2)                        | 1235 (99.2)                                    | 175 (98.9)                      | 154 (95.1)                      | 740 (99.6)                       | 1073 (99.4)                                    |
| TEAEs with worst CTCAE Grade ≥3 b                             | 125 (49.8)                      | 101 (41.1)                      | 497 (50.2)                        | 623 (50.0                                      | 101 (57.1)                      | 80 (49.4)                       | 440 (59.2)                       | 653 (60.5)                                     |
| Treatment-emergent SAEs                                       | 41 (16.3)                       | 42 (17.1)                       | 197 (19.9)                        | 271 (21.8)                                     | 46 (26.0)                       | 24 (14.8)                       | 230 (31.0)                       | 379 (35.1)                                     |
| TEAEs associated with study drug discontinuation              | 31 (12.4)                       | 19 (7.7)                        | 171 (17.3)                        | 203 (16.3)                                     | 31 (17.5)                       | 20 (12.3)                       | 136 (18.3)                       | 173 (16.0)                                     |
| TEAEs associated with study drug interruption                 | 124 (49.4)                      | 92 (37.4)                       | 452 (45.7)                        | 549 (44.1)                                     | 83 (46.9)                       | 62 (38.3)                       | 339 (45.6)                       | 486 (45.0)                                     |
| TEAEs associated with dose reduction                          | 60 (23.9)                       | 101 (41.1)                      | 202 (20.4)                        | 258 (20.7)                                     | 45 (25.4)                       | 58 (35.8)                       | 213 (28.7)                       | 272 (25.2)                                     |
| TEAEs associated with an outcome of death c                   | 5 (2.0)                         | 5 (2.0)                         | 21 (2.1)                          | 26 (2.1)                                       | 6 (3.4)                         | 1 (0.6)                         | 34 (4.6)                         | 69 (6.4)                                       |
| Patients with any drug-related TEAE d                         | 241 (96.0)                      | 218 (88.6)                      | 964 (97.4)                        | 1193 (95.8)                                    | 171 (96.6)                      | 147 (90.7)                      | 718 (96.6)                       | 1007 (93.2)                                    |
| Drug-related TEAEs with worst CTCAE Grade ≥3 b                | 91 (36.3)                       | 74 (30.1)                       | 400 (40.4)                        | 492 (39.5)                                     | 83 (46.9)                       | 54 (33.3)                       | 347 (46.7)                       | 476 (44.1)                                     |
| Drug-related treatment- emergent SAEs                         | 20 (8.0)                        | 15 (6.1)                        | 97 (9.8)                          | 128 (10.3)                                     | 26 (14.7)                       | 9 (5.6)                         | 111 (14.9)                       | 153 (14.2)                                     |
| Drug-related TEAEs associated with study drug discontinuation | 28 (11.2)                       | 17 (6.9)                        | 147 (14.8)                        | 172 (13.8)                                     | 28 (15.8)                       | 16 (9.9)                        | 119 (16.0)                       | 145 (13.4)                                     |
| Drug-related TEAEs associated with study drug interruption    | 75 (29.9)                       | 58 (23.6)                       | 330 (33.3)                        | 382 (30.7)                                     | 50 (28.2)                       | 40 (24.7)                       | 231 (31.1)                       | 304 (28.1)                                     |
| Drug-related TEAEs associated with dose reduction             | 54 (21.5)                       | 99 (40.2)                       | 188 (19.0)                        | 240 (19.3)                                     | 38 (21.5)                       | 54 (33.3)                       | 193 (26.0)                       | 247 (22.9)                                     |
| Drug-related TEAEs associatedwithanoutcome of death c         | 1 (0.4)                         | 0                               | 7 (0.7)                           | 10 (0.8)                                       | 4 (2.3)                         | 0                               | 13 (1.7)                         | 18 (1.7)                                       |

A patient was counted once at themaximum severity.

Duration of treatment (months) = (date of the last dose - date of the first dose + a cycle length (day)/30.44. 1 month = 365.25/12 = 30.44 days.

For specific TEAEs associated with outcome of death, refer to Table 15.

Percentages are calculated using the number of patients in the Safety Analysis Set as the denominator.

If relationship was missing, the TEAE was considered to be related to the drug.

<div style=\"page-break-after: always\"></div>

## Table 82 Overall Summary of Treatment-emergent Adverse Events by Renal Function (Safety Analysis Set)

| Parame ter                                          | Normal Renal Function            | Normal Renal Function            | Normal Renal Function               | Normal Renal Function                              | Mild Renal Impairment            | Mild Renal Impairment            | Mild Renal Impairment               | Moderate Renal Impairment                          | Moderate Renal Impairment        | Moderate Renal Impairment        | Moderate Renal Impairment           | Moderate Renal Impairment                          |
|-----------------------------------------------------|----------------------------------|----------------------------------|-------------------------------------|----------------------------------------------------|----------------------------------|----------------------------------|-------------------------------------|----------------------------------------------------|----------------------------------|----------------------------------|-------------------------------------|----------------------------------------------------|
| Parame ter                                          | Study DB-06                      | Study DB-06                      | Supportive Safety Pools             | Supportive Safety Pools                            | Study DB-06                      | Study DB-06                      | Supportive Safety Pools             | Supportive Safety Pools                            | Study DB-06                      | Study DB-06                      | Supportive Safety Pools             | Supportive Safety Pools                            |
| Parame ter                                          | T-DX d 5.4 mg/k g (N = 185)      | Che mo- ther apy (N = 187)       | T-DX d 5.4 mg/ kg BC Pool (N = 888) | T-DX d 5.4m g/kg All Tu mor Types Pool (N = 1106 ) | T-DX d 5.4 mg/ kg (N = 190)      | Che mo- ther apy (N = 175)       | T-DX d 5.4 mg/ kg BC Pool (N = 649) | T-DX d 5.4 mg/ kg All T umor Type s Pool (N = 902) | T-DX d 5.4 mg/ kg (N = 57)       | Che mo- ther apy (N = 5 5)       | T-DX d 5.4 mg/ kg BC Pool (N = 195) | T-DX d 5.4 mg/ kg All T umor Type s Pool (N = 317) |
| Duration of treatment (months) a                    | Duration of treatment (months) a | Duration of treatment (months) a | Duration of treatment (months) a    | Duration of treatment (months) a                   | Duration of treatment (months) a | Duration of treatment (months) a | Duration of treatment (months) a    | Duration of treatment (months) a                   | Duration of treatment (months) a | Duration of treatment (months) a | Duration of treatment (months) a    | Duration of treatment (months) a                   |
| Media n                                             | 11.76                            | 5.65                             | 11.22                               | 9.74                                               | 10.91                            | 5.59                             | 10.35                               | 8.76                                               | 8.28                             | 5.59                             | 8.71                                | 7.03                                               |
| Minim um, Maxim um                                  | 0.6, 32.1                        | 0.2, 32.0                        | 0.4, 44.0                           | 0.4, 44.0                                          | 1.3, 39.6                        | 0.1, 35.9                        | 0.2, 45.1                           | 0.2, 45.1                                          | 0.4, 37.1                        | 0.2, 18.8                        | 0.4, 38.6                           | 0.4, 38.6                                          |
| Patients with any TEAE                              | 184 (99.5 )                      | 178 (95.2 )                      | 883 (99.4 )                         | 1098 (99.3)                                        | 187 (98.4 )                      | 164 (93.7 )                      | 645 (99.4 )                         | 896 (99.3 )                                        | 56 (98.2 )                       | 55 (100 )                        | 193 (99.0 )                         | 313 (98.7 )                                        |
| TEAEs with worst CTCAE ≥Grad e 3 b                  | 105 (56.8 )                      | 67 (35.8 )                       | 482 (54.3 )                         | 598 (54.1)                                         | 87 (45.8 )                       | 79 (45.1 )                       | 334 (51.5 )                         | 476 (52.8 )                                        | 35 (61.4 )                       | 39 (70. 9)                       | 117 (60.0 )                         | 197 (62.1 )                                        |
| Treat ment- emerg ent SAEs                          | 37 (20.0 )                       | 29 (15.5 )                       | 221 (24.9 )                         | 290 (26.2)                                         | 32 (16.8 )                       | 22 (12.6 )                       | 142 (21.9 )                         | 243 (26.9 )                                        | 18 (31.6 )                       | 16 (29. 1)                       | 64 (32.8 )                          | 116 (36.6 )                                        |
| TEAEs associ ated with study drug discon tinuati on | 25 (13.5 )                       | 15 (8.0)                         | 140 (15.8 )                         | 159 (14.4)                                         | 24 (12.6 )                       | 16 (9.1)                         | 108 (16.6 )                         | 140 (15.5 )                                        | 12 (21.1 )                       | 8 (14. 5)                        | 55 (28.2 )                          | 73 (23.0 )                                         |
| TEAEs associ ated with study drug                   | 93 (50.3 )                       | 65 (34.8 )                       | 401 (45.2 )                         | 488 (44.1)                                         | 95 (50.0 )                       | 70 (40.0 )                       | 297 (45.8 )                         | 398 (44.1 )                                        | 21 (36.8 )                       | 25 (45. 5)                       | 91 (46.7 )                          | 148 (46.7 )                                        |

<div style=\"page-break-after: always\"></div>

| Parame ter                                       | Normal Renal Function       | Normal Renal Function      | Normal Renal Function               | Normal Renal Function                              | Mild Renal Impairment       | Mild Renal Impairment      | Mild Renal Impairment               | Mild Renal Impairment                              | Moderate Renal Impairment   | Moderate Renal Impairment   | Moderate Renal Impairment           | Moderate Renal Impairment                          |
|--------------------------------------------------|-----------------------------|----------------------------|-------------------------------------|----------------------------------------------------|-----------------------------|----------------------------|-------------------------------------|----------------------------------------------------|-----------------------------|-----------------------------|-------------------------------------|----------------------------------------------------|
| Parame ter                                       | Study DB-06                 | Study DB-06                | Supportive Safety Pools             | Supportive Safety Pools                            | Study DB-06                 | Study DB-06                | Supportive Safety Pools             | Supportive Safety Pools                            | Study DB-06                 | Study DB-06                 | Supportive Safety Pools             | Supportive Safety Pools                            |
| Parame ter                                       | T-DX d 5.4 mg/k g (N = 185) | Che mo- ther apy (N = 187) | T-DX d 5.4 mg/ kg BC Pool (N = 888) | T-DX d 5.4m g/kg All Tu mor Types Pool (N = 1106 ) | T-DX d 5.4 mg/ kg (N = 190) | Che mo- ther apy (N = 175) | T-DX d 5.4 mg/ kg BC Pool (N = 649) | T-DX d 5.4 mg/ kg All T umor Type s Pool (N = 902) | T-DX d 5.4 mg/ kg (N = 57)  | Che mo- ther apy (N = 5 5)  | T-DX d 5.4 mg/ kg BC Pool (N = 195) | T-DX d 5.4 mg/ kg All T umor Type s Pool (N = 317) |
| TEAEs associ ated with dose reducti on           | 44 (23.8 )                  | 65 (34.8 )                 | 218 (24.5 )                         | 256 (23.1)                                         | 47 (24.7 )                  | 66 (37.7 )                 | 142 (21.9 )                         | 192 (21.3 )                                        | 16 (28.1 )                  | 30 (54. 5)                  | 54 (27.7 )                          | 81 (25.6 )                                         |
| TEAEs associ ated with an outco me of            | 4 (2.2)                     | 1 (0.5)                    | 23 (2.6)                            | 31 (2.8)                                           | 5 (2.6)                     | 4 (2.3)                    | 23 (3.5)                            | 41 (4.5)                                           | 2 (3.5)                     | 1 (1.8)                     | 10 (5.1)                            | 23 (7.3)                                           |
| Patients with any drug- related TEAE d           | 179 (96.8 )                 | 166 (88.8 )                | 864 (97.3 )                         | 1053 (95.2)                                        | 181 (95.3 )                 | 155 (88.6 )                | 627 (96.6 )                         | 851 (94.3 )                                        | 55 (96.5 )                  | 52 (94. 5)                  | 189 (96.9 )                         | 294 (92.7 )                                        |
| Drug- related TEAEs with worst CTCAE Grade ≥ 3 b | 77 (41.6 )                  | 44 (23.5 )                 | 377 (42.5 )                         | 451 (40.8)                                         | 68 (35.8 )                  | 58 (33.1 )                 | 268 (41.3 )                         | 361 (40.0 )                                        | 30 (52.6 )                  | 29 (52. 7)                  | 99 (50.8 )                          | 152 (47.9 )                                        |
| Drug- related treatm ent- emerg ent SAEs         | 20 (10.8 )                  | 12 (6.4)                   | 114 (12.8 )                         | 131 (11.8)                                         | 14 (7.4)                    | 6 (3.4)                    | 59 (9.1)                            | 94 (10.4 )                                         | 12 (21.1 )                  | 6 (10. 9)                   | 35 (17.9 )                          | 56 (17.7 )                                         |
| Drug- related TEAEs associ ated with study drug  | 24 (13.0 )                  | 12 (6.4)                   | 119 (13.4 )                         | 132 (11.9)                                         | 20 (10.5 )                  | 14 (8.0)                   | 93 (14.3 )                          | 117 (13.0 )                                        | 12 (21.1 )                  | 7 (12. 7)                   | 51 (26.2 )                          | 65 (20.5 )                                         |

<div style=\"page-break-after: always\"></div>

| Parame ter                                                     | Normal Renal Function       | Normal Renal Function      | Normal Renal Function               | Normal Renal Function                              | Mild Renal Impairment       | Mild Renal Impairment      | Mild Renal Impairment               | Moderate Renal Impairment                          | Moderate Renal Impairment   | Moderate Renal Impairment   | Moderate Renal Impairment           | Moderate Renal Impairment                          |
|----------------------------------------------------------------|-----------------------------|----------------------------|-------------------------------------|----------------------------------------------------|-----------------------------|----------------------------|-------------------------------------|----------------------------------------------------|-----------------------------|-----------------------------|-------------------------------------|----------------------------------------------------|
| Parame ter                                                     | Study DB-06                 | Study DB-06                | Supportive Safety Pools             | Supportive Safety Pools                            | Study DB-06                 | Study DB-06                | Supportive Safety Pools             | Supportive Safety Pools                            | Study DB-06                 | Study DB-06                 | Supportive Safety Pools             | Supportive Safety Pools                            |
| Parame ter                                                     | T-DX d 5.4 mg/k g (N = 185) | Che mo- ther apy (N = 187) | T-DX d 5.4 mg/ kg BC Pool (N = 888) | T-DX d 5.4m g/kg All Tu mor Types Pool (N = 1106 ) | T-DX d 5.4 mg/ kg (N = 190) | Che mo- ther apy (N = 175) | T-DX d 5.4 mg/ kg BC Pool (N = 649) | T-DX d 5.4 mg/ kg All T umor Type s Pool (N = 902) | T-DX d 5.4 mg/ kg (N = 57)  | Che mo- ther apy (N = 5 5)  | T-DX d 5.4 mg/ kg BC Pool (N = 195) | T-DX d 5.4 mg/ kg All T umor Type s Pool (N = 317) |
| discon tinuati on                                              |                             |                            |                                     |                                                    |                             |                            |                                     |                                                    |                             |                             |                                     |                                                    |
| Drug- related TEAEs associ ated with                           | 61 (33.0 )                  | 40 (21.4 )                 | 288 (32.4 )                         | 331 (29.9)                                         | 52 (27.4 )                  | 48 (27.4 )                 | 205 (31.6 )                         | 259 (28.7 )                                        | 14 (24.6 )                  | 15 (27. 3)                  | 66 (33.8 )                          | 94 (29.7 )                                         |
| Drug- related TEAEs associ ated with dose reducti              | 39 (21.1 )                  | 61 (32.6 )                 | 201 (22.6 )                         | 236 (21.3)                                         | 41 (21.6 )                  | 64 (36.6 )                 | 130 (20.0 )                         | 175 (19.4 )                                        | 14 (24.6 )                  | 30 (54. 5)                  | 49 (25.1 )                          | 75 (23.7 )                                         |
| on Drug- related TEAEs associ ated with an outco me of death c | 2 (1.1)                     | 0                          | 7 (0.8)                             | 8 (0.7)                                            | 1 (0.5)                     | 0                          | 7 (1.1)                             | 10 (1.1)                                           | 2 (3.5)                     | 0                           | 6 (3.1)                             | 10 (3.2)                                           |

e Duration of treatment (months) = (date of the last dose - date of the first dose + a cycle length (day))/30.44. 1 month = 365.25/12 = 30.44 days.

A patient was counted once at the maximum severity.

For specific TEAEs associated with outcome of death, refer to.

If relationship was missing, the TEAE was considered to be related to the drug.

Percentages are calculated using the number of patients in the Safety Analysis Set as the denominator.

<div style=\"page-break-after: always\"></div>

Table 83 Overall Summary of Treatment-emergent Adverse Events by Hepatic Function (Safety Analysis Set)

| Parameter                                        | Normal Hepatic Functions         | Normal Hepatic Functions         | Normal Hepatic Functions          | Normal Hepatic Functions                        | Mild Hepatic impairment          | Mild Hepatic impairment          | Mild Hepatic impairment           | Mild Hepatic impairment                        |
|--------------------------------------------------|----------------------------------|----------------------------------|-----------------------------------|-------------------------------------------------|----------------------------------|----------------------------------|-----------------------------------|------------------------------------------------|
|                                                  | Study DB-06                      | Study DB-06                      | Supportive Safety Pools           | Supportive Safety Pools                         | Study DB-06                      | Study DB-06                      | Supportive Safety Pools           | Supportive Safety Pools                        |
|                                                  | T-DXd 5.4 mg/kg (N = 205)        | Chemo- therapy (N = 210)         | T-DXd 5.4 mg/kg BC Pool (N = 930) | T-DXd 5.4 mg/kg All Tumor Types Pool (N = 1370) | T-DXd 5.4 mg/kg (N = 225)        | Chemo- therapy (N = 205)         | T-DXd 5.4 mg/kg BC Pool (N = 792) | T-DXd 5.4 mg/kg All Tumor Types Pool (N = 937) |
| Duration of treatment (months) a                 | Duration of treatment (months) a | Duration of treatment (months) a | Duration of treatment (months) a  | Duration of treatment (months) a                | Duration of treatment (months) a | Duration of treatment (months) a | Duration of treatment (months) a  | Duration of treatment (months) a               |
| Median                                           | 13.27                            | 6.39                             | 12.40                             | 9.69                                            | 9.89                             | 5.52                             | 9.23                              | 8.34                                           |
| Minimum, maximum                                 | 0.7, 37.1                        | 0.1, 35.9                        | 0.4, 44.0                         | 0.4, 44.0                                       | 0.4, 39.6                        | 0.2, 26.9                        | 0.2, 45.1                         | 0.2, 45.1                                      |
| Patients with any TEAE                           | 204 (99.5)                       | 200 (95.2)                       | 923 (99.2)                        | 1358 (99.1)                                     | 222 (98.7)                       | 195 (95.1)                       | 789 (99.6)                        | 932 (99.5)                                     |
| TEAEs with worst CTCAE Grade ≥ 3 b               | 103 (50.2)                       | 81 (38.6)                        | 479 (51.5)                        | 720 (52.6)                                      | 123 (54.7)                       | 103 (50.2)                       | 446 (56.3)                        | 536 (57.2)                                     |
| Treatment- emergent SAEs                         | 40 (19.5)                        | 28 (13.3)                        | 219 (23.5)                        | 377 (27.5)                                      | 46 (20.4)                        | 38 (18.5)                        | 201 (25.4)                        | 260 (27.7)                                     |
| TEAEs associated with study drug discontinuation | 28 (13.7)                        | 16 (7.6)                         | 159 (17.1)                        | 208 (15.2)                                      | 33 (14.7)                        | 23 (11.2)                        | 144 (18.2)                        | 163 (17.4)                                     |
| TEAEs associated with study drug interruption    | 101 (49.3)                       | 76 (36.2)                        | 426 (45.8)                        | 611 (44.6)                                      | 109 (48.4)                       | 83 (40.5)                        | 358 (45.2)                        | 415 (44.3)                                     |
| TEAEs associated with dose reduction             | 52 (25.4)                        | 79 (37.6)                        | 222 (23.9)                        | 309 (22.6)                                      | 54 (24.0)                        | 80 (39.0)                        | 190 (24.0)                        | 214 (22.8)                                     |
| TEAEs associated with an outcome of death c      | 5 (2.4)                          | 3 (1.4)                          | 25 (2.7)                          | 55 (4.0)                                        | 6 (2.7)                          | 3 (1.5)                          | 29 (3.7)                          | 38 (4.1)                                       |
| Patients with any drug-related TEAE d            | 196 (95.6)                       | 188 (89.5)                       | 899 (96.7)                        | 1290 (94.2)                                     | 218 (96.9)                       | 183 (89.3)                       | 773 (97.6)                        | 896 (95.6)                                     |
| Drug-related TEAEs with worst CTCAE Grade ≥ 3 b  | 82 (40.0)                        | 58 (27.6)                        | 386 (41.5)                        | 538 (39.3)                                      | 92 (40.9)                        | 72 (35.1)                        | 352 (44.4)                        | 416 (44.4)                                     |
| Drug-related treatment- emergent SAEs            | 17 (8.3)                         | 7 (3.3)                          | 100 (10.8)                        | 148 (10.8)                                      | 27 (12.0)                        | 17 (8.3)                         | 105 (13.3)                        | 127 (13.6)                                     |
| Drug-related TEAEs associated with study drug    | 25 (12.2)                        | 14 (6.7)                         | 141 (15.2)                        | 176 (12.8)                                      | 30 (13.3)                        | 19 (9.3)                         | 122 (15.4)                        | 137 (14.6)                                     |
| Drug-related TEAEs associated with study         | 58 (28.3)                        | 50 (23.8)                        | 299 (32.2)                        | 392 (28.6)                                      | 69 (30.7)                        | 53 (25.9)                        | 257 (32.4)                        | 289 (30.8)                                     |

<div style=\"page-break-after: always\"></div>

| Parameter                                                | Normal Hepatic Functions   | Normal Hepatic Functions   | Normal Hepatic Functions          | Normal Hepatic Functions                        | Mild Hepatic impairment   | Mild Hepatic impairment   | Mild Hepatic impairment           | Mild Hepatic impairment                        |
|----------------------------------------------------------|----------------------------|----------------------------|-----------------------------------|-------------------------------------------------|---------------------------|---------------------------|-----------------------------------|------------------------------------------------|
|                                                          | Study DB-06                | Study DB-06                | Supportive Safety Pools           | Supportive Safety Pools                         | Study DB-06               | Study DB-06               | Supportive Safety Pools           | Supportive Safety Pools                        |
|                                                          | T-DXd 5.4 mg/kg (N = 205)  | Chemo- therapy (N = 210)   | T-DXd 5.4 mg/kg BC Pool (N = 930) | T-DXd 5.4 mg/kg All Tumor Types Pool (N = 1370) | T-DXd 5.4 mg/kg (N = 225) | Chemo- therapy (N = 205)  | T-DXd 5.4 mg/kg BC Pool (N = 792) | T-DXd 5.4 mg/kg All Tumor Types Pool (N = 937) |
| drug interruption                                        |                            |                            |                                   |                                                 |                           |                           |                                   |                                                |
| Drug-related TEAEs associated with dose reduction        | 45 (22.0)                  | 77 (36.7)                  | 204 (21.9)                        | 284 (20.7)                                      | 48 (21.3)                 | 76 (37.1)                 | 174 (22.0)                        | 196 (20.9)                                     |
| Drug-related TEAEs associated with an outcome of death c | 3 (1.5)                    | 0                          | 10 (1.1)                          | 17 (1.2)                                        | 2 (0.9)                   | 0                         | 9 (1.1)                           | 10 (1.1)                                       |

f

Duration of treatment (months) = (date of the last dose - date of the first dose + a cycle length (day))/30.44. 1 month = 365.25/12 = 30.44 days.

A patient was counted once at the maximum severity.

For specific TEAEs associated with outcome of death, refer to.

If relationship was missing, the TEAE was considered to be related to the drug.

Percentages are calculated using the number of patients in the Safety Analysis Set as the denominator.

## Extrinsic Factors

## Table 84 Overall Summary of Treatment-emergent Adverse Events by Geographic Region: Asia and North America (Safety Analysis Set)

| Parameter                                        | Asia                             | Asia                             | Asia                              | Asia                                           | North America                    | North America                    | North America                     | North America                                  |
|--------------------------------------------------|----------------------------------|----------------------------------|-----------------------------------|------------------------------------------------|----------------------------------|----------------------------------|-----------------------------------|------------------------------------------------|
|                                                  | Study DB-06                      | Study DB-06                      | Supportive Safety Pools           | Supportive Safety Pools                        | Study DB-06                      | Study DB-06                      | Supportive Safety Pools           | Supportive Safety Pools                        |
|                                                  | T-DXd 5.4 mg/kg (N = 148)        | Chemo- therapy (N = 144)         | T-DXd 5.4 mg/kg BC Pool (N = 645) | T-DXd 5.4 mg/kg All Tumor Types Pool (N = 877) | T-DXd 5.4 mg/kg (N = 47)         | Chemo- therapy (N = 46)          | T-DXd 5.4 mg/kg BC Pool (N = 269) | T-DXd 5.4 mg/kg All Tumor Types Pool (N = 368) |
| Duration of treatment (months) a                 | Duration of treatment (months) a | Duration of treatment (months) a | Duration of treatment (months) a  | Duration of treatment (months) a               | Duration of treatment (months) a | Duration of treatment (months) a | Duration of treatment (months) a  | Duration of treatment (months) a               |
| Median                                           | 11.52                            | 7.34                             | 11.17                             | 9.66                                           | 10.41                            | 6.88                             | 8.97                              | 8.15                                           |
| Minimum, maximum                                 | 0.7, 39.6                        | 0.1, 35.9                        | 0.7, 45.1                         | 0.7, 45.1                                      | 1.3, 30.6                        | 0.2, 25.1                        | 0.7, 32.4                         | 0.7, 32.4                                      |
| Patients with any TEAE                           | 148 (100)                        | 135 (93.8)                       | 643 (99.7)                        | 874 (99.7)                                     | 47 (100)                         | 46 (100)                         | 268 (99.6)                        | 366 (99.5)                                     |
| TEAEs with worst CTCAE Grade ≥ 3 b               | 92 (62.2)                        | 60 (41.7)                        | 381 (59.1)                        | 525 (59.9)                                     | 19 (40.4)                        | 25 (54.3)                        | 132 (49.1)                        | 189 (51.4)                                     |
| Treatment- emergent SAEs                         | 35 (23.6)                        | 18 (12.5)                        | 153 (23.7)                        | 241 (27.5)                                     | 8 (17.0)                         | 5 (10.9)                         | 70 (26.0)                         | 104 (28.3)                                     |
| TEAEs associated with study drug discontinuation | 25 (16.9)                        | 6 (4.2)                          | 130 (20.2)                        | 160 (18.2)                                     | 3 (6.4)                          | 7 (15.2)                         | 40 (14.9)                         | 46 (12.5)                                      |
| TEAEs associated with study                      | 79 (53.4)                        | 48 (33.3)                        | 328 (50.9)                        | 441 (50.3)                                     | 23 (48.9)                        | 22 (47.8)                        | 100 (37.2)                        | 131 (35.6)                                     |

<div style=\"page-break-after: always\"></div>

| Parameter                                                     | Asia                      | Asia                     | Asia                              | Asia                                           | North America            | North America           | North America                     | North America                                  |
|---------------------------------------------------------------|---------------------------|--------------------------|-----------------------------------|------------------------------------------------|--------------------------|-------------------------|-----------------------------------|------------------------------------------------|
| Parameter                                                     | Study DB-06               | Study DB-06              | Supportive Safety Pools           | Supportive Safety Pools                        | Study DB-06              | Study DB-06             | Supportive Safety Pools           | Supportive Safety Pools                        |
| Parameter                                                     | T-DXd 5.4 mg/kg (N = 148) | Chemo- therapy (N = 144) | T-DXd 5.4 mg/kg BC Pool (N = 645) | T-DXd 5.4 mg/kg All Tumor Types Pool (N = 877) | T-DXd 5.4 mg/kg (N = 47) | Chemo- therapy (N = 46) | T-DXd 5.4 mg/kg BC Pool (N = 269) | T-DXd 5.4 mg/kg All Tumor Types Pool (N = 368) |
| drug interruption                                             |                           |                          |                                   |                                                |                          |                         |                                   |                                                |
| TEAEs associated with dose reduction                          | 49 (33.1)                 | 49 (34.0)                | 182 (28.2)                        | 239 (27.3)                                     | 7 (14.9)                 | 24 (52.2)               | 49 (18.2)                         | 69 (18.8)                                      |
| TEAEs associated with an outcome of death c                   | 3 (2.0)                   | 2 (1.4)                  | 12 (1.9)                          | 28 (3.2)                                       | 1 (2.1)                  | 0                       | 11 (4.1)                          | 18 (4.9)                                       |
| Patients with any drug-related TEAE d                         | 146 (98.6)                | 128 (88.9)               | 633 (98.1)                        | 843 (96.1)                                     | 44 (93.6)                | 44 (95.7)               | 261 (97.0)                        | 346 (94.0)                                     |
| Drug-related TEAEs with worst CTCAE Grade ≥ 3 b               | 76 (51.4)                 | 50 (34.7)                | 330 (51.2)                        | 440 (50.2)                                     | 13 (27.7)                | 19 (41.3)               | 98 (36.4)                         | 129 (35.1)                                     |
| Drug-related treatment- emergent SAEs                         | 19 (12.8)                 | 8 (5.6)                  | 81 (12.6)                         | 113 (12.9)                                     | 4 (8.5)                  | 4 (8.7)                 | 31 (11.5)                         | 38 (10.3)                                      |
| Drug-related TEAEs associated with study drug discontinuation | 24 (16.2)                 | 5 (3.5)                  | 116 (18.0)                        | 138 (15.7)                                     | 3 (6.4)                  | 6 (13.0)                | 35 (13.0)                         | 40 (10.9)                                      |
| Drug-related TEAEs associated with study drug interruption    | 54 (36.5)                 | 33 (22.9)                | 264 (40.9)                        | 336 (38.3)                                     | 12 (25.5)                | 18 (39.1)               | 66 (24.5)                         | 79 (21.5)                                      |
| Drug-related TEAEs associated with dose reduction             | 41 (27.7)                 | 49 (34.0)                | 171 (26.5)                        | 224 (25.5)                                     | 7 (14.9)                 | 23 (50.0)               | 42 (15.6)                         | 59 (16.0)                                      |
| Drug-related TEAEs associated with an outcome of death c      | 2 (1.4)                   | 0                        | 4 (0.6)                           | 6 (0.7)                                        | 0                        | 0                       | 5 (1.9)                           | 7 (1.9)                                        |

g Duration of treatment (months) = (date of the last dose - date of the first dose + a cycle length (day))/30.44. 1 month = 365.25/12 = 30.44 days

A patient was counted once at the maximum severity.

For specific TEAEs associated with outcome of death, refer to.

If relationship was missing, the TEAE was considered to be related to the drug.

Percentages are calculated using the number of patients in the Safety Analysis Set as the denominator.

<div style=\"page-break-after: always\"></div>

Table 85 Overall Summary of Treatment-emergent Adverse Events by Geographic Region: Europe and Rest of the World (Safety Analysis Set)

| Parameter                                                     | Europe                          | Europe                          | Europe                          | Europe                                       | Rest of World                   | Rest of World                   | Rest of World                   | Rest of World                       |
|---------------------------------------------------------------|---------------------------------|---------------------------------|---------------------------------|----------------------------------------------|---------------------------------|---------------------------------|---------------------------------|-------------------------------------|
| Parameter                                                     | StudyDB-06                      | StudyDB-06                      | SupportiveSafetyPools           | SupportiveSafetyPools                        | StudyDB-06                      | StudyDB-06                      | SupportiveSafetyPools           | SupportiveSafetyPools               |
| Parameter                                                     | T-DXd 5.4 mg/kg (N = 227)       | Chemo- therapy (N =206)         | T-DXd 5.4 mg/kg BC Pool (N=687) | T-DXd 5.4 mg/kg All Tumor Types Pool (N=934) | T-DXd 5.4 mg/kg (N =12)         | Chemo- therapy (N =21)          | T-DXd 5.4 mg/kg BC Pool (N=140) | T-DXd 5.4 mg/kg Types Pool (N =156) |
| Duration of treatment (months)a                               | Duration of treatment (months)a | Duration of treatment (months)a | Duration of treatment (months)a | Duration of treatment (months)a              | Duration of treatment (months)a | Duration of treatment (months)a | Duration of treatment (months)a | Duration of treatment (months)a     |
| Median                                                        | 10.71                           | 5.19                            | 10.32                           | 8.64                                         | 11.50                           | 5.49                            | 14.00                           | 13.06                               |
| Minimum, maximum                                              | 0.4, 37.1                       | 0.1, 26.9                       | 0.2,39.0                        | 0.2, 39.0                                    | 0.6, 21.1                       | 0.2,23.3                        | 0.6, 39.1                       | 0.6, 39.1                           |
| Patients with any TEAE                                        | 223 (98.2)                      | 198 (96.1)                      | 680 (99.0)                      | 922 (98.7)                                   | 11 (91.7)                       | 18 (85.7)                       | 139 (99.3)                      | 155 (99.4)                          |
| TEAEs with worst CTCAE Grade ≥3 b                             | 112 (49.3)                      | 94 (45.6)                       | 347 (50.5)                      | 477 (51.1)                                   | 6 (50.0)                        | 6 (28.6)                        | 81 (57.9)                       | 89 (57.1)                           |
| Treatment-emergentSAEs                                        | 43 (18.9)                       | 40 (19.4)                       | 170 (24.7)                      | 264 (28.3)                                   | 2 (16.7)                        | 4 (19.0)                        | 36 (25.7)                       | 43 (27.6)                           |
| TEAEs associated with study drug discontinuation              | 32 (14.1)                       | 25 (12.1)                       | 120 (17.5)                      | 152 (16.3)                                   | 2 (16.7)                        | 1 (4.8)                         | 17 (12.1)                       | 18 (11.5)                           |
| TEAEs associated with study drug interruption                 | 103 (45.4)                      | 81 (39.3)                       | 302 (44.0)                      | 393 (42.1)                                   | 5 (41.7)                        | 9 (42.9)                        | 64 (45.7)                       | 74 (47.4)                           |
| TEAEs associated with dose reduction                          | 49 (21.6)                       | 85 (41.3)                       | 154 (22.4)                      | 189 (20.2)                                   | 2 (16.7)                        | 3 (14.3)                        | 32 (22.9)                       | 35 (22.4)                           |
| TEAEs associated with an outcome of death                     | 6 (2.6)                         | 3 (1.5)                         | 28 (4.1)                        | 44 (4.7)                                     | 1 (8.3)                         | 1 (4.8)                         | 5 (3.6)                         | 6 (3.8)                             |
| Patients with any drug-related TEAE d                         | 216 (95.2)                      | 185 (89.8)                      | 658 (95.8)                      | 868 (92.9)                                   | 11 (91.7)                       | 16 (76.2)                       | 137 (97.9)                      | 151 (96.8)                          |
| Drug-related TEAEs with worst CTCAE Grade ≥3 b                | 81 (35.7)                       | 59 (28.6)                       | 261 (38.0)                      | 335 (35.9)                                   | 6 (50.0)                        | 3 (14.3)                        | 61 (43.6)                       | 67 (42.9)                           |
| Drug-related treatment- emergent SAEs                         | 21 (9.3)                        | 11 (5.3)                        | 83 (12.1)                       | 114 (12.2)                                   | 2 (16.7)                        | 1 (4.8)                         | 36 (25.7)                       | 43 (27.6)                           |
| Drug-related TEAEs associated with study drug discontinuation | 27 (11.9)                       | 21 (10.2)                       | 101 (14.7)                      | 124 (13.3)                                   | 2 (16.7)                        | 1 (4.8)                         | 14 (10.0)                       | 15 (9.6)                            |
| Drug-relatedTEAEs associated with study drug interruption     | 57 (25.1)                       | 46 (22.3)                       | 192 (27.9)                      | 227 (24.3)                                   | 4 (33.3)                        | 6 (28.6)                        | 41 (29.3)                       | 46 (29.5)                           |
| Drug-relatedTEAEsassociated with dose reduction               | 44 (19.4)                       | 80 (38.8)                       | 142 (20.7)                      | 175 (18.7)                                   | 2 (16.7)                        | 3 (14.3)                        | 28 (20.0)                       | 31 (19.9)                           |
| Drug-related TEAEs associated with an outcome of death        | 2 (0.9)                         | 0                               | 10 (1.5)                        | 13 (1.4)                                     | 1 (8.3)                         | 0                               | 1 (0.7)                         | 2 (1.3)                             |

Percentages are calculated using the number of patients in theSafetyAnalysisSet asthe denominator.

If relationship was missing, the TEAE was considered to be related to the drug.

## Safety related to drug-drug interactions and other interactions

No interactions with strong cytochrome P450 3A and organic anion transporting polypeptide 1B inhibitors were observed in a dedicated drug-drug interaction study (DS8201-A-A104) with ritonavir and itraconazole in subjects with BC.

No new information on drug interactions is available since the time of study DS8201-A-A104 (submitted as part of EMEA/H/C/005124).

<div style=\"page-break-after: always\"></div>

## Discontinuation due to adverse events

## Interruption due to adverse events

## Table 86 Drug Related ILD/Pneumonitis Associated with Study Drug Interruption by Preferred Term (Safety Analysis Set)

<!-- image -->

|                               | Number （&)of Patients         | Number （&)of Patients                       | Number （&)of Patients                     | Number （&)of Patients                      |
|-------------------------------|-------------------------------|---------------------------------------------|-------------------------------------------|--------------------------------------------|
|                               | D9670C00001(DESTINY-BreaSt06) | D9670C00001(DESTINY-BreaSt06)               | Supportive Safety Pools                   | Supportive Safety Pools                    |
| MedDRA Preferred Term         | T-DXd5.4mg/kg (N=434)         | Investigator choice of chemotherapy (N=417) | T-DXd5.4mg/kg breast cancer pool (N=1741) | T-DXd5.4mg/kg tood seda xouma TTe (N=2335) |
| Patients with ILD/Pneumonitis | 10(2.3)                       |                                             | 50(2.9)                                   | 61 (2.6)                                   |
| Interstitial lung disease     | 9 (2.1)                       | D                                           | 26 (1.5)                                  | 33 (1.4)                                   |
| Pneumonitis                   | 1(0.2)                        |                                             | 24(1.4)                                   | 28(1.2)                                    |

Table 87 Adverse Events Associated with Study Drug Interruption in ≥ 2% of Patients in Either Treatment Arm of Study DB-06, by Preferred Term (Safety Analysis Set)

|                                                                | Number (%) of Patients    | Number (%) of Patients   | Number (%) of Patients             | Number (%) of Patients                          |
|----------------------------------------------------------------|---------------------------|--------------------------|------------------------------------|-------------------------------------------------|
|                                                                | Study DB-06               | Study DB-06              | Supportive Safety Pools            | Supportive Safety Pools                         |
|                                                                | T-DXd 5.4 mg/kg (N = 434) | Chemotherapy (N = 417)   | T-DXd 5.4 mg/kg BC Pool (N = 1741) | T-DXd 5.4 mg/kg All Tumor Types Pool (N = 2335) |
| Patients with any TEAE associated with study drug interruption | 210 (48.4)                | 160 (38.4)               | 794 (45.6)                         | 1039 (44.5)                                     |
| COVID-19                                                       | 63 (14.5)                 | 27 (6.5)                 | 121 (7.0)                          | 155 (6.6)                                       |
| Neutrophil count decreased                                     | 33 (7.6)                  | 17 (4.1)                 | 151 (8.7)                          | 182 (7.8)                                       |
| Neutropenia                                                    | 30 (6.9)                  | 20 (4.8)                 | 99 (5.7)                           | 114 (4.9)                                       |
| Anaemia                                                        | 15 (3.5)                  | 3 (0.7)                  | 77 (4.4)                           | 106 (4.5)                                       |
| Pyrexia                                                        | 12 (2.8)                  | 4 (1.0)                  | 32 (1.8)                           | 40 (1.7)                                        |
| Pneumonia                                                      | 10 (2.3)                  | 5 (1.2)                  | 35 (2.0)                           | 46 (2.0)                                        |
| White blood cell count decreased                               | 10 (2.3)                  | 6 (1.4)                  | 55 (3.2)                           | 59 (2.5)                                        |
| Interstitial lung disease                                      | 9 (2.1)                   | 0                        | 27 (1.6)                           | 35 (1.5)                                        |
| Diarrhoea                                                      | 4 (0.9)                   | 9 (2.2)                  | 15 (0.9)                           | 21 (0.9)                                        |
| Palmar-plantar erythrodysaesthesia syndrome                    | 1 (0.2)                   | 17 (4.1)                 | 2 (0.1)                            | 2 (0.1)                                         |

Percentages are calculated using the number of patients in the Safety Analysis Set as the denominator.

The pooled analysis group is based on first dose received for patients in each study.

PTs are sorted by descending frequency in the Study DB-06 T-DXd 5.4 mg/kg treatment arm.

If a patient had multiple occurrences of the same PT, the patient is counted once for the specific PT.

If a patient had multiple PTs, the patient is counted in each of the different PTs.

<div style=\"page-break-after: always\"></div>

Table 88 Treatment-Emergent Adverse Events PTs of ILD/Pneumonitis and COVID-19

|                                                                       | Study DB-06     | Study DB-06            | Supportive Safety Pools            | Supportive Safety Pools                         |
|-----------------------------------------------------------------------|-----------------|------------------------|------------------------------------|-------------------------------------------------|
|                                                                       | T-DXd (N = 434) | Chemotherapy (N = 417) | T-DXd 5.4 mg/kg BC Pool (N = 1741) | T-DXd 5.4 mg/kg All Tumor Types Pool (N = 2335) |
| Subjects with concurrent ILD/pneumonitis and COVID-                   | 4 (0.9)         | 0                      | 5 (0.3)                            | 7 (0.3)                                         |
| Subjects with concurrent ILD/pneumonitis and grouped term of COVID-19 | 4 (0.9)         | 0                      | 6 (0.3)                            | 8 (0.3)                                         |

Patients are counted only once per each category.

COVID-19 grouped term includes preferred terms Asymptomatic COVID-19, Congenital COVID-19, Coronavirus infection, Coronavirus test positive, COVID-19, COVID-19 pneumonia, COVID-19 treatment, Multisystem inflammatory syndrome in children, Post-acute COVID-19 syndrome, SARS-CoV-2 antibody test positive, SARS-CoV-2 carrier, SARS-CoV-2 RNA decreased, SARS-CoV-2 RNA fluctuation, SARS-CoV-2 RNA increased, SARS-CoV-2 sepsis, SARS-CoV-2 test false negative, SARS-CoV-2 test positive, SARSCoV-2 viraemia, Suspected COVID-19, Vaccine derived SARS-CoV-2 infection.

Table 89 Adverse Drug Reactions Associated with Dose Interruption in T-DXd 5.4 mg/kg breast cancer pool and T-DXd 5.4 mg/kg breast cancer pool and T-DXd 5.4 mg/kg all tumour types pool, by MedDRA System Organ Class, Preferred Term/Grouped Term and Frequency (Safety Analysis Set)

| MedDRASysteimOrganClass                                       | Nunber (%) of Subjects                  | Nunber (%) of Subjects                           |
|---------------------------------------------------------------|-----------------------------------------|--------------------------------------------------|
| Preferred Term/Grouped Term                                   | T-DXd5.4mg/kgbreastcancerpool (N =1741) | 1T-DXd 5.4 mg/kg all tumor types pool (N = 2335) |
| Subjects with any ADR associated with Study Drug Interruption | 602 (34.6)                              | 762 (32.6)                                       |
| Blood andlymphaticsystemdisorders                             |                                         |                                                  |
| Neutropenia a                                                 | 243 (14.0)                              | 289 (12.4)                                       |
| Anemia b                                                      | 78 (4.5)                                | 107 (4.6)                                        |
| Leukopenia c                                                  | 68 (3.9)                                | 74 (3.2)                                         |
| Thrombocytopenia d                                            | 49 (2.8)                                | 57 (2.4)                                         |
| Lymphopenia e                                                 | 7 (0.4)                                 | 8 (0.3)                                          |
| Febrile neutropenia                                           | 6 (0.3)                                 | 6 (0.3)                                          |
| Eye disorders                                                 |                                         |                                                  |
| Dry eye                                                       | 1 (0.1)                                 | 1 (0.0)                                          |
| Gastrointestinaldisorders                                     |                                         |                                                  |
| Nausea                                                        | 23 (1.3)                                | 33 (1.4)                                         |
| Diarrhoea                                                     | 15 (0.9)                                | 21 (0.9)                                         |
| Vomiting                                                      | 12 (0.7)                                | 16 (0.7)                                         |
| Stomatitis f                                                  | 8 (0.5)                                 | 10 (0.4)                                         |
| Abdominal pain                                                | 7 (0.4)                                 | 12 (0.5)                                         |
| Constipation                                                  | 3 (0.2)                                 | 3 (0.1)                                          |
| Gastritis                                                     | 3 (0.2)                                 | 4 (0.2)                                          |
| Generaldisorders and administrationsiteconditions             |                                         |                                                  |
| Fatigue h                                                     | 77 (4.4)                                | 110 (4.7)                                        |
| Pyrexia                                                       | 32 (1.8)                                | 40 (1.7)                                         |
| Oedema peripheral                                             | 2 (0.1)                                 | 4 (0.2)                                          |

<div style=\"page-break-after: always\"></div>

| MedDRASystemOrganClass                          | Number (%) of Subjects                                                      | Number (%) of Subjects   |
|-------------------------------------------------|-----------------------------------------------------------------------------|--------------------------|
| PreferredTerm/GroupedTerm                       | T-DXd 5.4 mg/kg breast cancer poolT-DXd 5.4 mg/kg all tumor types (N =1741) | pool (N = 2335)          |
| Hepatobiliary disorders                         |                                                                             |                          |
| Transaminases increased i                       | 37 (2.1)                                                                    | 41 (1.8)                 |
| Infectionsandinfestations                       |                                                                             |                          |
| Upper respiratory tract infection               | 55 (3.2)                                                                    | 70 (3.0)                 |
| Pneumonia                                       | 35 (2.0)                                                                    | 46 (2.0)                 |
| Injury,poisoning andprocedural complications    |                                                                             |                          |
| Infusion related reaction P                     | 4 (0.2)                                                                     | 5 (0.2)                  |
| Investigations                                  |                                                                             |                          |
| Blood bilirubin increased k                     | 30 (1.7)                                                                    | 34 (1.5)                 |
| Ejection fraction decreased 1                   | 22 (1.3)                                                                    | 27 (1.2)                 |
| Blood creatinine increased                      | 4 (0.2)                                                                     | 6 (0.3)                  |
| Blood alkaline phosphatase increased            | 1 (0.1)                                                                     | 3 (0.1)                  |
| Weight decreased                                | 1 (0.1)                                                                     | 1 (0.0)                  |
| Metabolismandnutritiondisorders                 |                                                                             |                          |
| Hypokalaemia 1                                  | 16 (0.9)                                                                    | 21 (0.9)                 |
| Decreased appetite                              | 7 (0.4)                                                                     | 8 (0.3)                  |
| Dehydration                                     | 3 (0.2)                                                                     | 3 (0.1)                  |
| Musculoskeletal and connective tissue disorders |                                                                             |                          |
| Musculoskeletal pain m                          | 4 (0.2)                                                                     | 4 (0.2)                  |
| Nervous system disorders                        |                                                                             |                          |
| Dizziness                                       | 4 (0.2)                                                                     | 5 (0.2)                  |
| Headache \"                                      | 2 (0.1)                                                                     | 3 (0.1)                  |
| Dysgeusia                                       | 0                                                                           | 1 (0.0)                  |
| Respiratory, thoracic and mediastinal disorders |                                                                             |                          |
| Interstitial lung disease q                     | 48 (2.8)                                                                    | 61 (2.6)                 |
| Dyspnoea                                        | 15 (0.9)                                                                    | 19 (0.8)                 |
| Cough                                           | 14 (0.8)                                                                    | 17 (0.7)                 |
| Epistaxis                                       | 1 (0.1)                                                                     | 2 (0.1)                  |
| Skin andsubcutaneoustissuedisorders             |                                                                             |                          |
| Pruritus                                        | 1 (0.1)                                                                     | 1 (0.0)                  |
| Rash°                                           | 1 (0.1)                                                                     | 3 (0.1)                  |

ADR = adverse drug reaction; MedDRA = Medical Dictionary for Regulatory Activities, version 26.1; N = total number of subjects treated; PT = preferred term; T-DXd=trastuzumab deruxtecan.

Percentages were calculated using the number of subjects in theSafetyAnalysisSet as the denominator.

Ifa subject had multiple occurrences of the sameADR,the subject wascounted onceforthat specificADR.

System Organ Class are presented by alphabetic order.PTs/grouped terms are presented by descending frequency in the T-DXd 5.4 mg/kg breast cancer pool.

Neutropenia (grouped term) includes PTs of Neutrophil count decreased, Neutropenia.

* Leukopenia (grouped term) includes PTs of White blood cell count decreased, Leukopenia.

b Anemia (grouped term) includes PTs of Haemoglobin decreased, Red blood cell count decreased, Anaemia, Haematocrit decreased.

- d Thrombocytopenia (grouped term) includes PTs of Platelet count decreased, Thrombocytopenia.

fStomatitis (grouped term)includes PTs of Stomatitis,Aphthous ulcer,Mouth ulceration, Oral mucosa erosion, Oral mucosal blistering, Oral mucosal eruption.

- Lymphopenia (grouped term) includes PTs of Lymphocyte count decreased, Lymphopenia.

Abdominal pain (grouped term) includes PTs of Abdominal discomfort, Abdominal pain,Abdominal pain lower, Abdominal pain upper, Gastrointestinal pain.

i Transaminases increased (grouped term) includes PTs of Transaminases increased, Aspartate aminotransferase increased,Alanine aminotransferase increased, h Fatigue (grouped term) includes PTs of Fatigue, Asthenia, Malaise, Lethargy.

Gamma-glutamyltransferase increased,Liverfunction test abnormal,Hepaticfunction abnormal,Liverfunction testincreased,Hypertransaminasaemia.

Sinusitis,Rhinitis,Laryngitis.

j Upper respiratory tract infection (grouped term) includes PTs of Influenza,Influenza like illness, Upper respiratory tract infection, Nasopharyngitis,Pharyngitis,

- k Blood bilirubin increased (grouped term) includes PTs of Blood bilirubin increased, Hyperbilirubinaemia, Bilirubin conjugated increased, Blood bilirubin unconjugated increased.
- m Musculoskeletal pain (grouped term) includes PTs of Back pain, Myalgia, Pain in extremity, Musculoskeletal pain, Muscle spasms, Bone pain, Neck pain,

IHypokalaemia (grouped term) includes PTs of Hypokalaemia, Blood potassium decreased.

Musculoskeletal chest pain, Limb discomfort.

°Rash (grouped term) includes PTs of Rash, Rash pustular, Rash maculo-papular, Rash papular, Rash macular, Rash pruritic.

- \" Headache (grouped term) includes PTs of Migraine, Headache, Sinus headache.

P Infusion related reaction (grouped term) includes PTs of Administration related reaction, Anaphylactic reaction, Hypersensitivity, Infusion related reaction and Infusion related hypersensitivity reaction.

Pulmonary toxicity, Radiation pneumonitis, Respiratory failure. These events were adjudicated as ILD and related to use of T-DXd.

4 Interstitial lung disease (grouped term) includes PTs of Bronchiectasis, Interstitial lung disease, Lung opacity, Pneumonia, Pneumonia bacterial, Pneumonitis,

<div style=\"page-break-after: always\"></div>

## Discontinuation due to adverse events

## Table 90 Summary of Patient Disposition (Safety Analysis Set)

|                                                          | Number (%) of Patients    | Number (%) of Patients   | Number (%) of Patients             | Number (%) of Patients                          |
|----------------------------------------------------------|---------------------------|--------------------------|------------------------------------|-------------------------------------------------|
|                                                          | Study DB-06               | Study DB-06              | Supportive Safety Pools            | Supportive Safety Pools                         |
|                                                          | T-DXd 5.4 mg/kg (N = 434) | Chemotherapy (N = 417)   | T-DXd 5.4 mg/kg BC Pool (N = 1741) | T-DXd 5.4 mg/kg All Tumor Types Pool (N = 2335) |
| Patients ongoing study drug at DCO                       | 89 (20.5)                 | 30 (7.2)                 | 356 (20.4)                         | 402 (17.2)                                      |
| Patients discontinued from study drug, by primary reason | 345 (79.5)                | 387 (92.8)               | 1385 (79.6)                        | 1933 (82.8)                                     |
| Progressive disease a                                    | 0                         | 0                        | 602 (34.6)                         | 735 (31.5)                                      |
| Clinical progression a                                   | 0                         | 0                        | 56 (3.2)                           | 75 (3.2)                                        |
| Objective disease progression a                          | 248 (57.1)                | 292 (70.0)               | 255 (14.6)                         | 456 (19.5)                                      |
| Subjective disease progression a                         | 0                         | 0                        | 1 (0.1)                            | 27 (1.2)                                        |
| Adverse event                                            | 61 (14.1)                 | 39 (9.4)                 | 300 (17.2)                         | 366 (15.7)                                      |
| Death                                                    | 5 (1.2)                   | 4 (1.0)                  | 26 (1.5)                           | 57 (2.4)                                        |
| Withdrawal by subject                                    | 0                         | 0                        | 75 (4.3)                           | 80 (3.4)                                        |
| Severe non-compliance to protocol                        | 0                         | 0                        | 0                                  | 0                                               |
| Physician decision                                       | 0                         | 0                        | 18 (1.0)                           | 27 (1.2)                                        |
| Subject decision                                         | 19 (4.4)                  | 34 (8.2)                 | 19 (1.1)                           | 34 (1.5)                                        |
| Lost to follow-up                                        | 0                         | 0                        | 1 (0.1)                            | 2 (0.1)                                         |
| Protocol deviation                                       | 0                         | 1 (0.2)                  | 1 (0.1)                            | 1 (0.0)                                         |
| Pregnancy                                                | 0                         | 0                        | 0                                  | 0                                               |
| Study terminated by Sponsor                              | 0                         | 0                        | 0                                  | 0                                               |
| Due to COVID-19 pandemic                                 | 0                         | 0                        | 0                                  | 0                                               |
| Other                                                    | 12 (2.8)                  | 17 (4.1)                 | 31 (1.8)                           | 73 (3.1)                                        |

a These 4 terms are considered synonymous, with differences due to differences in the terms used in the individual studies in the pools.

Percentages are calculated using the number of patients in the Safety Analysis Set as the denominator.

The pooled analysis group is based on first dose received for patients in each study.

<div style=\"page-break-after: always\"></div>

Table 91 Adverse Drug Reactions Associated with Study Drug Discontinuation in T-DXd 5.4 mg/kg breast cancer pool and T-DXd 5.4 mg/kg all tumour types pool, by MedDRA System Organ Class, Preferred Term/Groped Term and Frequency (Safety Analysis Set)

| MedDRASystem OrganClass                                  | Nunber (%) of Subjects                                        | Nunber (%) of Subjects                                        | Nunber (%) of Subjects                                        | Nunber (%) of Subjects                          | Nunber (%) of Subjects                          | Nunber (%) of Subjects                          |
|----------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|
| PreferredTerm/GroupedTerm                                | T-DXd 5.4 mg/kg breast cancer pool T-DXd 6.4 mg/kg (N = 1741) | T-DXd 5.4 mg/kg breast cancer pool T-DXd 6.4 mg/kg (N = 1741) | T-DXd 5.4 mg/kg breast cancer pool T-DXd 6.4 mg/kg (N = 1741) | T-DXd 5.4 mg/kg all tumor types pool (N = 2335) | T-DXd 5.4 mg/kg all tumor types pool (N = 2335) | T-DXd 5.4 mg/kg all tumor types pool (N = 2335) |
|                                                          | All Grades                                                    | Grade 3 or 4                                                  | Grade 5                                                       | All Grades                                      | Grade 3 or 4                                    | Grade 5                                         |
| SubjectswithanyADRassociatedwithStudyDrugDiscontinuation | 224 (12.9)                                                    | 55 (3.2)                                                      | 12 (0.7)                                                      | 274 (11.7)                                      | 63 (2.7)                                        | 17 (0.7)                                        |
| Blood and1ymphaticsystemdisorders                        |                                                               |                                                               |                                                               |                                                 |                                                 |                                                 |
| Thrombocytopenia a                                       | 10 (0.6)                                                      | 7 (0.4)                                                       | 0                                                             | 12 (0.5)                                        | 8 (0.3)                                         | 0                                               |
| Neutropenia b                                            | 5 (0.3)                                                       | 5 (0.3)                                                       | 0                                                             | 5 (0.2)                                         | 5 (0.2)                                         | 0                                               |
| Anemia c                                                 | 2 (0.1)                                                       | 2 (0.1)                                                       | 0                                                             | 4 (0.2)                                         | 4 (0.2)                                         | 0                                               |
| Febrile neutropenia                                      | 1 (0.1)                                                       | 0                                                             | 1 (0.1)                                                       | 1 (0.0)                                         | 0                                               | 1 (0.0)                                         |
| Leukopenia d                                             | 1 (0.1)                                                       | 1 (0.1)                                                       | 0                                                             | 1 (0.0)                                         | 1 (0.0)                                         | 0                                               |
| Lymphopenia e                                            | 1 (0.1)                                                       | 1 (0.1)                                                       | 0                                                             | 1 (0.0)                                         | 1 (0.0)                                         | 0                                               |
| Gastrointestinal disorders                               |                                                               |                                                               |                                                               |                                                 |                                                 |                                                 |
| Vomiting                                                 | 2 (0.1)                                                       | 0                                                             | 0                                                             | 2 (0.1)                                         | 0                                               | 0                                               |
| Diarrhoea                                                | 1 (0.1)                                                       | 1 (0.1)                                                       | 0                                                             | 1 (0.0)                                         | 1 (0.0)                                         | 0                                               |
| Nausea                                                   | 1 (0.1)                                                       | 0                                                             | 0                                                             | 1 (0.0)                                         | 0                                               | 0                                               |
| Generaldisordersandadministrationsiteconditions          |                                                               |                                                               |                                                               |                                                 |                                                 |                                                 |
| Fatigue f                                                | 8 (0.5)                                                       | 6 (0.3)                                                       | 0                                                             | 9 (0.4)                                         | 6 (0.3)                                         | 0                                               |
| Pyrexia                                                  | 1 (0.1)                                                       | 1 (0.1)                                                       | 0                                                             | 1 (0.0)                                         | 1 (0.0)                                         | 0                                               |
| Hepatobiliarydisorders                                   |                                                               |                                                               |                                                               |                                                 |                                                 |                                                 |
| Transaminases increased                                  | 4 (0.2)                                                       | 4 (0.2)                                                       | 0                                                             | 4 (0.2)                                         | 4 (0.2)                                         | 0                                               |
| Infectionsandinfestations                                |                                                               |                                                               |                                                               |                                                 |                                                 |                                                 |
| Pneumonia                                                | 13 (0.7)                                                      | 2 (0.1)                                                       | 3 (0.2)                                                       | 16 (0.7)                                        | 3 (0.1)                                         | 4 (0.2)                                         |
| Injury,poisoning and procedural complications            |                                                               |                                                               |                                                               |                                                 |                                                 |                                                 |
| Infusion related reaction k                              | 1 (0.1)                                                       | 1 (0.1)                                                       | 0                                                             | 1 (0.0)                                         | 1 (0.0)                                         | 0                                               |
| Investigations                                           |                                                               |                                                               |                                                               |                                                 |                                                 |                                                 |
| Ejection fraction decreased m                            | 8 (0.5)                                                       | 4 (0.2)                                                       | 0                                                             | 9 (0.4)                                         | 5 (0.2)                                         | 0                                               |
| Blood bilirubin increased h                              | 3 (0.2)                                                       | 2 (0.1)                                                       | 0                                                             | 5 (0.2)                                         | 2 (0.1)                                         | 0                                               |
| Weight decreased                                         | 1 (0.1)                                                       | 1 (0.1)                                                       | 0                                                             | 1 (0.0)                                         | 1 (0.0)                                         | 0                                               |
| Metabolismandnutritiondisorders                          |                                                               |                                                               |                                                               |                                                 |                                                 |                                                 |
| Hypokalaemia i                                           | 4 (0.2)                                                       | 4 (0.2)                                                       | 0                                                             | 5 (0.2)                                         | 5 (0.2)                                         | 0                                               |
| Decreased appetite                                       | 1 (0.1)                                                       | 1 (0.1)                                                       | 0                                                             | 1 (0.0)                                         | 1 (0.0)                                         | 0                                               |
| Nervous system disorders                                 |                                                               |                                                               |                                                               |                                                 |                                                 |                                                 |
| Dysgeusia                                                | 1 (0.1)                                                       | 1 (0.1)                                                       | 0                                                             | 1 (0.0)                                         | 1 (0.0)                                         | 0                                               |
| Respiratory,thoracicandmediastinaldisorders              |                                                               |                                                               |                                                               |                                                 |                                                 |                                                 |
| Interstitial lung disease 1                              | 157 (9.0)                                                     | 13 (0.7)                                                      | 9 (0.5)                                                       | 195 (8.4)                                       | 14 (0.6)                                        | 13 (0.6)                                        |
| Dyspnoea                                                 | 3 (0.2)                                                       | 0                                                             | 0                                                             | 4 (0.2)                                         | 1 (0.0)                                         | 0                                               |
| Cough                                                    | 1 (0.1)                                                       | 0                                                             | 0                                                             | 1 (0.0)                                         | 0                                               | 0                                               |
| Skinandsubcutaneoustissue disorders                      |                                                               |                                                               |                                                               |                                                 |                                                 |                                                 |
| Skin hyperpigmentation j                                 | 2 (0.1)                                                       | 0                                                             | 0                                                             | 2 (0.1)                                         | 0                                               | 0                                               |

ADR=adverse drug reaction;MedDRA=MedicalDictionary forRegulatoryActivities,version26.1;N=total number of subjects treated;PT=preferred term;T-DXd =trastuzumab deruxtecan.

Percentages were calculated using the number of subjects in the Safety AnalysisSet as the denominator.

System Organ Class are presented by alphabetic order. PTs/grouped terms are presented by descending frequency in the All Grades column of the T-DXd 5.4 mg/kg breast cancerpool.

IfasubjecthadmultipleoccurrencesofthesameADR,thesubjectwas countedoncefor thatspecificADR

- b Neutropenia (grouped term) includes PTs of Neutrophil count decreased, Neutropenia.

a Thrombocytopenia (grouped term) includes PTs of Platelet count decreased, Thrombocytopenia.

- Anemia (grouped term) includes PTs of Haemoglobin decreased, Red blood cell count decreased, Anaemia, Haematocrit decreased.
- Lymphopenia (grouped term) includes PTs of Lymphocyte count decreased, Lymphopenia.
- d Leukopenia (grouped term) includes PTs of White blood cell count decreased, Leukopenia.
- f Fatigue (grouped term) includes PTs of Fatigue, Asthenia, Malaise, Lethargy.

Transaminases increased (grouped term)includes PTs of Transaminases increased,Aspartate aminotransferase increased,Alanine aminotransferase increased,

Gamma-glutamyltransferaseincreased,Liverfunctiontestabnormal,Hepaticfunction abnormal,Liverfunctiontestincreased,Hypertransaminasaemia.

h Blood bilirubin increased (grouped term) includes PTs of Blood bilirubin increased, Hyperbilirubinaemia, Bilirubin conjugated increased, Blood bilirubin unconjugated increased.

i Hypokalaemia (grouped term) includes PTs of Hypokalaemia, Blood potassium decreased.

k Infusion related reaction (grouped term) includes PTs of Administration related reaction, Anaphylactic reaction, Hypersensitivity, Infusion related reaction and Infusion related hypersensitivity reaction.

- m Ejection fraction decreased (grouped term) includes PTs of Cardiac failure, Cardiac failure congestive,Ejection fraction decreased,Left ventricular dysfunction.

I Interstitial lung disease (grouped term) includes PTs of Alveolitis, Idiopathic interstitial pneumonia, Interstitial lung disease, Lung disorder, Organising pneumonia, Pneumonia,Pneumonitis,Pulmonary fibrosis,Pulmonary mass,Pulmonary toxicity.These events were adjudicated as ILD..

<div style=\"page-break-after: always\"></div>

Table 92 Adverse Events Associated with Study Drug Discontinuation in at Least 2 Patients in Either Treatment Arm of Study DB-06, by Preferred Term (Safety Analysis Set)

|                                                                   | Number (%) of Patients    | Number (%) of Patients   | Number (%) of Patients             | Number (%) of Patients                          |
|-------------------------------------------------------------------|---------------------------|--------------------------|------------------------------------|-------------------------------------------------|
|                                                                   | Study DB-06               | Study DB-06              | Supportive Safety Pools            | Supportive Safety Pools                         |
|                                                                   | T-DXd 5.4 mg/kg (N = 434) | Chemotherapy (N = 417)   | T-DXd 5.4 mg/kg BC Pool (N = 1741) | T-DXd 5.4 mg/kg All Tumor Types Pool (N = 2335) |
| Patients with any TEAE associated with study drug discontinuation | 62 (14.3)                 | 39 (9.4)                 | 307 (17.6)                         | 376 (16.1)                                      |
| Pneumonitis                                                       | 23 (5.3)                  | 0                        | 103 (5.9)                          | 131 (5.6)                                       |
| Interstitial lung disease                                         | 15 (3.5)                  | 0                        | 69 (4.0)                           | 81 (3.5)                                        |
| Platelet count decreased                                          | 3 (0.7)                   | 0                        | 8 (0.5)                            | 9 (0.4)                                         |
| General physical health deterioration                             | 2 (0.5)                   | 0                        | 2 (0.1)                            | 2 (0.1)                                         |
| Hypokalaemia                                                      | 2 (0.5)                   | 0                        | 4 (0.2)                            | 5 (0.2)                                         |
| Asthenia                                                          | 1 (0.2)                   | 3 (0.7)                  | 4 (0.2)                            | 4 (0.2)                                         |
| Angina pectoris                                                   | 0                         | 3 (0.7)                  | 0                                  | 0                                               |
| Colitis                                                           | 0                         | 3 (0.7)                  | 1 (0.1)                            | 1 (0.0)                                         |
| Fatigue                                                           | 0                         | 2 (0.5)                  | 4 (0.2)                            | 5 (0.2)                                         |
| Neuropathy peripheral                                             | 0                         | 2 (0.5)                  | 1 (0.1)                            | 1 (0.0)                                         |

<div style=\"page-break-after: always\"></div>

## Adverse Drug reactions leading to dose reduction

Table 93 Adverse Drug reactions Associated with Dose Reduction in T-DXd 5.4 mg/kg breast cancer pool and T-DXd 5.4 mg/kg all tumour types pool, by MedDRA System Organ Class, Preferred Term/Grouped Term and Frequency (Safety Analysis Set)

| MedDRASystemOrganClass                             | Number(%)ofSubjects   | Number(%)ofSubjects                                                              |
|----------------------------------------------------|-----------------------|----------------------------------------------------------------------------------|
| PreferredTerm/GroupedTerm                          | (N =1741)             | T-DXd 5.4 mg/kg breast cancer poolT-DXd 5.4 mg/kg all tumor types lood (N =2335) |
| Subjectswith anyADR associated with Dose Reduction | 366 (21.0)            | 474 (20.3)                                                                       |
| Bloodandlymphaticsystemdisorders                   |                       |                                                                                  |
| Neutropenia *                                      | 60 (3.4)              | 81 (3.5)                                                                         |
| Thrombocytopeniab                                  | 38 (2.2)              | 54 (2.3)                                                                         |
| Anemiac                                            | 22 (1.3)              | 27 (1.2)                                                                         |
| Leukopenia d                                       | 13 (0.7)              | 13 (0.6)                                                                         |
| Febrile neutropenia                                | 7 (0.4)               | 12 (0.5)                                                                         |
| Lymphopenia e                                      | 2 (0.1)               | 2 (0.1)                                                                          |
| Eye disorders                                      |                       |                                                                                  |
| Dry eye                                            | 1 (0.1)               | 1 (0.0)                                                                          |
| Visionblurredf                                     | 1 (0.1)               | 1 (0.0)                                                                          |
| Gastrointestinal disorders                         |                       |                                                                                  |
| Nausea                                             | 88 (5.1)              | 111 (4.8)                                                                        |
| Vomiting                                           | 28 (1.6)              | 33 (1.4)                                                                         |
| Diarrhoea                                          | 21 (1.2)              | 34 (1.5)                                                                         |
| Stomatitis                                         | 8 (0.5)               | 8 (0.3)                                                                          |
| Abdominal pain h                                   | 6 (0.3)               | 8 (0.3)                                                                          |
| Abdominal distension                               | 2 (0.1)               | 2 (0.1)                                                                          |
| Constipation                                       | 2 (0.1)               | 4 (0.2)                                                                          |
| Gastritis                                          | 2 (0.1)               | 2 (0.1)                                                                          |
| Dyspepsia                                          | 1 (0.1)               | 2 (0.1)                                                                          |
| General disorders and administrationsiteconditions |                       |                                                                                  |
| Fatigue '                                          | 91 (5.2)              | 118 (5.1)                                                                        |
| Oedema peripheral                                  | 2 (0.1)               | 2 (0.1)                                                                          |
| Pyrexia                                            | 1 (0.1)               | 3 (0.1)                                                                          |
| Hepatobiliary disorders                            |                       |                                                                                  |
| Transaminases increasedj                           | 17 (1.0)              | 19 (0.8)                                                                         |
| Infections andinfestations                         |                       |                                                                                  |
| Pneumonia                                          | 4 (0.2)               | 6 (0.3)                                                                          |
| Investigations                                     |                       |                                                                                  |
| Blood bilirubin increased k                        | 15 (0.9)              | 17 (0.7)                                                                         |
| Weight decreased                                   | 12 (0.7)              | 15 (0.6)                                                                         |
| Blood creatinine increased                         | 3 (0.2)               | 4 (0.2)                                                                          |
| Metabolismandnutritiondisorders                    |                       |                                                                                  |
| Decreased appetite                                 | 19 (1.1)              | 25 (1.1)                                                                         |
| Hypokalaemia'                                      | 5 (0.3)               | 6 (0.3)                                                                          |
| Dehydration                                        | 2 (0.1)               | 2 (0.1)                                                                          |
| Musculoskeletalandconnectivetissuedisorders        |                       |                                                                                  |
| Musculoskeletalpain m                              | 1 (0.1)               | 1 (0.0)                                                                          |
| Nervous systemdisorders                            |                       |                                                                                  |
| Headache\"                                          | 5 (0.3)               | 5 (0.2)                                                                          |
| Dizziness                                          | 4 (0.2)               | 5 (0.2)                                                                          |
| Dysgeusia                                          | 1 (0.1)               | 1 (0.0)                                                                          |
| Respiratory,thoracicandmediastinaldisorders        |                       |                                                                                  |
| Interstitial lung disease P                        | 20 (1.1)              | 24 (1.0)                                                                         |
| Dyspnoea                                           | 1 (0.1)               | 2 (0.1)                                                                          |
| Epistaxis                                          | 0                     | 1 (0.0)                                                                          |
| Skin and subcutaneous tissue disorders             |                       |                                                                                  |
| Alopecia                                           | 3 (0.2)               | 4 (0.2)                                                                          |
| Rasho                                              | 2 (0.1)               | 2 (0.1)                                                                          |

## Post marketing experience

Since the first approval of TDXd on 20 December 2019 through 19 December 2023 (the DCO of the latest PBRER), the estimated cumulative patient exposure was 42,929.2 patient-years. No new safety concerns have been identified based on post-marketing safety reports.

## 2.5.1. Discussion on clinical safety

The size of the safety pool and the length of exposure to T-DXd is adequate for safety assessment. The MAH presented a safety data set, based on the patients included in the pivotal DB-06 study and an All

<div style=\"page-break-after: always\"></div>

Tumours Pool (ATT Pool), including 2335 patients exposed to T-DXd 5.4 mg/kg IV Q3W. The median duration of T-DXd treatment in the DB-06 study was 11.02 months and 72.8% of patients in the BC Pool (which included the pivotal DB-06 study) were exposed to T-DXd for more than 6 months and 45% were exposed for more than 12 months.

Almost all patients in the pivotal DB-06 study experienced at least one adverse event (AE). The most common AEs during T-DXd treatment are in the broad categories of gastrointestinal and haematological toxicities, as well as alopecia and fatigue. The incidences of these toxicities are in line with those of the ATT Pool, in which the most common were nausea (71.1%), fatigue or asthenia (if grouped occurring in 52%), vomiting (37.3%), alopecia (36.1%), anaemia (35.3%) and neutropenia (35.1%).

The reported incidences of treatment-related adverse events with T-DXd in the pivotal DB-06 study were overall very similar to the incidences of the AEs reported in the DB-06 study. The most common ADRs were all notably more frequent in the T-DXd arm than in the chemotherapy arm. The gastrointestinal ADRs were, with regards to nausea (69.8%), vomiting (33.6%) and constipation (31.6%), more than twice as frequent in the T-DXd arm as in the chemotherapy arm. The haematological ADRs were all significantly more substantial than in the chemotherapy arm, as seen for the respective incidences of neutropenia (38.9% vs. 30.7%), anaemia (37.3% vs. 26.4%), thrombocytopenia (19.8% vs. 5.0%) and lymphopenia (10.8% vs. 3.8%). This pattern also applies to fatigue (52.8% vs. 39.8%) and alopecia (48.4% versus 20.9%).

Of note, COVID-19 was twice as frequent in the T-DXd arm as in the chemotherapy arm of the pivotal study DB-06. This is presumed to be due to more frequent testing for COVID-19 in the T-DXd arm, since testing was part of the ILD-workup, and thus indicating more frequent respiratory symptoms in this group. Another explanation for the higher frequency of COVID-19 cases may also be the median 5 months longer treatment time on T-DXd and the resulting longer time at risk of encountering COVID19. The exposure-adjusted incidence rate for the event was balanced between the two arms (0.24 in the T-DXd arm vs 0.20 in the chemotherapy arm). The explanations presented by the MAH are considered sufficient to justify the absence of an increased risk of COVID-19 infection during T-DXd treatment compared with chemotherapy.

Grade ≥ 3 AEs were seen in approximately half of the T-DXd treated population, both in the T-DXd arm of the pivotal study DB-06 and in the Safety Pools (54.8%). The chemotherapy arm had a 10% lower occurrence of grade ≥ 3 AEs. In both groups the grade ≥ 3 AEs were mainly haematological (neutropenia and anaemia). The incidence of grade ≥ 3 AEs in the other most common toxicities, such as nausea, other gastrointestinal AEs and fatigue, was low in the T-DXd arm.

AEs of special interest are ILD/pneumonitis and LVEF decrease.

ILD/pneumonitis occurred in more than 10% in the T-DXd arm, and thus classifies as a very common AE. Clinically, ILD and pneumonitis have similar presentations, implications and are managed according to the same treatment algorithm. For these reasons it is essential to present their occurrence as one category, i.e. ILD/pneumonitis The methodology used by the MAH for ascertaining the diagnosis of ILD/pneumonitis was the adoption of an adjudication committee (AC), blinded to treatment arm. All cases with suspected ILD/pneumonitis were reviewed by the AC. In the ATT Pool 16.2% of the ITT were referred for adjudication and 12.2% of the ITT were adjudicated by the AC as having ILD/pneumonitis. ILD/pneumonitis was the main reason for treatment-related fatal events (1.1%) as well as the main reason for drug-related discontinuation of treatment (8.4%). In 28.1% of the cases, the patients had not recovered from ILD/pneumonitis at a median follow up of ~9.4 months. Although the number of fatalities due to ILD/pneumonitis was reported as 2, it is noted that 8 patients had unresolved ILD/pneumonitis at the time of death. ILD/pneumonitis continues to be the greatest

<div style=\"page-break-after: always\"></div>

risk of T-DXd treatment. The management of ILD/pneumonitis is adequately described in sections 4.2, 4.4 and 4.8 of the SmPC and it is an important identified risk in the RMP.

Decrease in left ventricular ejection fraction to a grade 2 occurred in 14.6% of the T-DXd treated patients of the pivotal study, which is in line with the ATT Pool. There were few or no patients with LVEF decrease at a grade ≥ 3. The management of left ventricular dysfunction is adequately described in sections 4.2, 4.4 and 4.8 of the SmPC and left ventricular dysfunction is an important identified risk in the RMP.

Serious adverse events (SAEs) were seen in 20.3% in the T-DXd arm of study DB-06, which is lower than in the ATT Pool (27.9%). The most commonly observed SAE in the T-DXd arm was ILD/pneumonitis, which was classified as an SAE in 3.6% of patients. ILD grade 5 occurred in 3 patients and was the most frequent cause of treatment-related death in the T-DXd arm.

Discontinuation of treatment due to AEs was seen in 14.1% in the T-DXd arm and in 9.8% in the chemotherapy arm. The primary cause of discontinuation due to an AE was ILD/pneumonitis, accounting for 8.8%. Haematological toxicity led to drug discontinuation in very few cases in the pivotal study. There were 3 cases of discontinuation due to thrombocytopenia and 1 discontinuation due to anaemia in the T-DXd arm. In the chemotherapy arm, there was only one case of discontinuation in this category (neutropenia). This is in line with the Safety Pools. To conclude, the main cause of drug-related discontinuation of T-DXd was ILD/pneumonitis.

Overall, the toxicity profile of T-DXd is considerable. This is stressed by the high number of symptomatic AEs present in ≥ 10% of patients (17 categories for the T-DXd arm). Although the shorter duration of treatment in the chemotherapy arm may affect the generally lower incidence of AEs in this arm, toxicities such as nausea, vomiting, constipation, fatigue and alopecia were notably more frequent in the T-DXd arm. Particularly the observation that most AEs occur during the first 6 treatment cycles of T-DXd, indicates that the higher incidence of AEs in the T-DXd arm is not alone explained by the longer exposure time to T-DXd treatment, but underscores a worse safety profile with T-DXd treatment than with chemotherapy. Peripheral sensory neuropathy and Palmar-plantar erythrodysaesthesia (PPE) were characteristic of chemotherapy and rarely occur with T-DXd. The risk of any gastrointestinal toxicity related to T-DXd is high, with nausea taking the lead as the most common ADR in this category, and combined with the high risk of fatigue, has potential to significantly impact quality of life during treatment. Alopecia as well is considered an important ADR. On the positive side, there were only a few high grade gastrointestinal and hematological AEs and they seldomly led to dose interruption or discontinuation. Overall the toxicities were manageable. As stated above, the most serious risk of T-DXd treatment is still ILD/pneumonitis.

## 2.5.2. Conclusions on clinical safety

Based on safety data from 2335 patients with breast cancer and other tumours, who have had relevant exposure to the approved dose of trastuzumab deruxtecan (T-DXd 5.4 mg/kg iv Q3W), no clinically significant changes of the known safety profile nor any new safety findings were detected. In study DB06, the safety profile of T-DXd was compared to chemotherapy (investigators choice of capecitabine, paclitaxel  or  nab-paclitaxel)  after  prior  exposure  to  two  lines  of  endocrine  therapy.  The  toxicities observed with T-DXd are considered notably more frequent, numerous and for some also different in character,  than  those  observed  with  chemotherapy.  ILD/pneumonitis is  still  the  greatest  risk  in  the treatment  with  T-DXd  and  the  occurrence  of  drug-related  fatal  cases  stresses  the  importance  of continuous monitoring of this AESI, as reflected in the SmPC and the RMP. In the targeted setting of metastatic breast cancer, the observed toxicities of T-DXd are considered acceptable and manageable.

<div style=\"page-break-after: always\"></div>

## 2.5.3. PSUR cycle

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

## 2.6. Risk management plan

The MAH submitted an updated RMP version 9.0 with this application.

The CHMP received the following PRAC Advice on the submitted Risk Management Plan:

The PRAC considered that the risk management plan version 9.0 is acceptable.

The CHMP endorsed this advice without changes.

## Safety concerns

## Table 94 Summary of Safety Concerns

| Summary of safety concerns   | Summary of safety concerns                                             |
|------------------------------|------------------------------------------------------------------------|
| Important identified risks   | • Interstitial lung disease/Pneumonitis • Left ventricular dysfunction |
| Important potential risks    | • Embryo-foetal toxicity • Product confusion-related medication errors |
| Missing information          | • Use in patients with severe hepatic impairment • Long-term safety    |

## Pharmacovigilance plan

Table 95 Ongoing and Planned Additional Pharmacovigilance Activities

| Study: Status                                                                                                                                                                                                                    | Summary of objectives                                                                                                                                                                                                            | Safety concerns addressed                                                                                                                                                                                                        | Milestones                                                                                                                                                                                                                       | Due dates                                                                                                                                                                                                                        |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorisation: None                                                                                                 | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorisation: None                                                                                                 | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorisation: None                                                                                                 | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorisation: None                                                                                                 | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorisation: None                                                                                                 |
| Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorisation or a marketing authorisation under exceptional circumstances: None | Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorisation or a marketing authorisation under exceptional circumstances: None | Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorisation or a marketing authorisation under exceptional circumstances: None | Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorisation or a marketing authorisation under exceptional circumstances: None | Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorisation or a marketing authorisation under exceptional circumstances: None |
| Category 3 - Required additional pharmacovigilance activities : None                                                                                                                                                             | Category 3 - Required additional pharmacovigilance activities : None                                                                                                                                                             | Category 3 - Required additional pharmacovigilance activities : None                                                                                                                                                             | Category 3 - Required additional pharmacovigilance activities : None                                                                                                                                                             | Category 3 - Required additional pharmacovigilance activities : None                                                                                                                                                             |

<div style=\"page-break-after: always\"></div>

## Risk minimisation measures

Table 96 Summary Table of Pharmacovigilance Activities and Risk Minimisation Activities by Safety Concern

| Safety concern                        | Risk minimisation measures                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Pharmacovigilance activities                                                                                                                                       |
|---------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Important Identified Risks            | Important Identified Risks                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Important Identified Risks                                                                                                                                         |
| Interstitial Lung Disease/Pneumonitis | Routine risk minimisation measures: SmPC Section 4.2 SmPC Section 4.4 SmPC Section 4.8 Patient Information Leaflet Section 2 Patient Information Leaflet Section 4 Recommendations for ILD/pneumonitis monitoring and detecting early signs and symptoms of ILD/pneumonitis are included in SmPC Section 4.4. Dose modification guidance and recommendation for corticosteroid treatment for managing the risk of ILD/pneumonitis are included in SmPC Section 4.2. Recommendation for careful monitoring of patients with moderate or severe renal impairment is included in SmPC Section 4.2. Additional risk minimisation activities: HCP Guide and Patient Card | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: Targeted questionnaire Additional pharmacovigilance activities: None |
| Left ventricular dysfunction          | Routine risk minimisation measures: SmPC Section 4.2 SmPC Section 4.4 SmPC Section 4.8 Patient Information Leaflet Section 2 Recommendations for monitoring of left ventricular dysfunction are included in SmPC Section 4.4. Dose modification guidance for managing the risk of left ventricular dysfunction is included in SmPC Section 4.2. Additional risk minimisation activities: None                                                                                                                                                                                                                                                                       | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: Targeted questionnaire Additional pharmacovigilance activities: None |

| Safety concern                             | Risk minimisation measures                                                                                                                                                                                                                                                                          | Pharmacovigilance activities                                                                                                                     |
|--------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------|
| Important Potential Risks                  | Important Potential Risks                                                                                                                                                                                                                                                                           | Important Potential Risks                                                                                                                        |
| Embryo-foetal toxicity                     | Routine risk minimisation measures: SmPC Section 4.4 SmPC Section 4.6 Patient Information Leaflet Section 2 Recommendations for pregnancy monitoring and contraception usage are included in SmPC Section 4.4 and SmPC Section 4.6. Additional risk minimisation activities:                        | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None Additional pharmacovigilance activities: None |
| Product confusion-related medication error | Routine risk minimisation measures: SmPC Section 4.2 SmPC Section 4.4 SmPC Section 6.6 Pack and vials: specific livery for ENHERTU on the packaging and specific colours for vial cap and bottle to distinguish from other trastuzumab containing products Additional risk minimisation activities: | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None Additional pharmacovigilance activities: None |

<div style=\"page-break-after: always\"></div>

| Safety concern                                 | Risk minimisation measures                                                                                                           | Pharmacovigilance activities                                                                                                                     |
|------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------|
| Important Potential Risks                      | Important Potential Risks                                                                                                            | Important Potential Risks                                                                                                                        |
|                                                | HCP Guide                                                                                                                            |                                                                                                                                                  |
| Missing Information                            | Missing Information                                                                                                                  | Missing Information                                                                                                                              |
| Use in patients with severe hepatic impairment | Routine risk minimisation measures: SmPC Section 4.2 SmPC Section 4.4 SmPC Section 5.2 Additional risk minimisation activities: None | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None Additional pharmacovigilance activities: None |
| Long-term safety                               | Routine risk minimisation measures: None Additional risk minimisation activities: None                                               | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None Additional pharmacovigilance activities: None |

HCP = healthcare professional; ILD = interstitial lung disease; PK = pharmacokinetic; SmPC = Summary of Product Characteristics

## 2.7. Update of the Product information

As a consequence of this new indication, sections 4.1, 4.2, 4.4, 4.8 and 5.1 of the SmPC have been updated. The Package Leaflet has been updated accordingly.

Changes were also made to the PI to bring it in line with the current Agency/QRD template 10.4 and the Excipients guideline, which were reviewed and accepted by the CHMP.

## 2.7.1. User consultation

A justification for not performing a full user consultation with target patient groups on the package leaflet has been submitted by the MAH and has been found acceptable for the following reasons:

- In accordance with articles 59(3) and 61(1) of Directive 2001/83/EC, the MAH completed a full user test of the PIL during the review of the initial Marketing Authorisation Application (MAA) for Enhertu (EMEA/H/C/005124/0000).
- Enhertu is prescribed by a physician and administered intravenously under the supervision of a healthcare professional at a hospital/clinic setting. The posology, administration and method of reconstitution for the extension of indication is unchanged.
- The updates to the PIL, including the safety sections, are not significant and utilise well recognised lay terms. Furthermore, the PIL will be kept identical in format size, colours, layout/design as illustrated in the agreed mock-ups.

<div style=\"page-break-after: always\"></div>

## 3. Benefit-Risk Balance

## 3.1. Therapeutic Context

## 3.1.1. Disease or condition

The recommended indication reflecting the data evaluated is:

Enhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-low or HER2-ultralow breast cancer who have received at least one endocrine therapy in  the  metastatic  setting  and  who  are  not  considered  suitable  for  endocrine therapy as the next line of treatment (see sections 4.2 and 5.1).

## 3.1.2. Available therapies and unmet medical need

Metastatic HER2-low (tumour status defined as a score of IHC 1+ or IHC 2+/ISH-) and HER2-ultralow (tumour status described as IHC 0 with membrane staining (IHC &gt;0&lt;1+)) breast cancer remains an uncurable  disease.  Although  treatment  with  single-agent  chemotherapy  has  improved  the  disease outcomes  for  patients  with  unresectable  locally  advanced  or  metastatic  breast  cancer,  the  disease invariably progresses.

When the disease has progressed after multiple lines of endocrine therapy with or without targeted therapies or who have a short median PFS on first-line endocrine-based therapy, chemotherapy is considered the most appropriate option. Single-agent therapy is preferred over combination therapy (Cardoso et al. 2009, NCCN 2024, Cancer Facts and Figures 2024) and chemotherapy combinations are only used in patients with rapidly progressing disease and visceral crisis. Single-agent chemotherapy options include taxanes, anti-metabolites (e.g., capecitabine) and anthracyclines. In patients similar to the sought indication, who have HR+, although classified as HER2-negative breast cancer, and have received 0 to 1 prior line of chemotherapy for metastatic disease, single-agent chemotherapy led to a median PFS of approximately 6 to 7 months and a median OS of approximately 20 to 25 months (O'Shaughnessy et al. 2021a, O'Shaughnessy at al 2021b, Robert et al. 2011, Baselga et al. 2017). At this time, T-DXd is approved in HER2-low breast cancer following one line of chemotherapy and there are no approved HER2-targeting therapies for the HER2-ultralow population.

Overall, the modest benefits for patients with HER2-low or HER2-ultralow BC, who have received at least 1 line of endocrine therapy in the metastatic setting illustrate the high unmet medical need for new treatment options to delay progression and improve survival outcomes in the targeted earlier-line setting.

## 3.1.3. Main clinical studies

The current application is based on a single pivotal study DESTINY-Breast06 or DB-06: a phase III randomised open-label two-arm study comparing trastuzumab deruxtecan (T-DXd) head to head with the current SoC in the targeted setting of HER2-low and HER2-ultralow advanced breast cancer i.e. single-agent chemotherapy by Physician's choice (either capecitabine, nab-paclitaxel, paclitaxel). Eligible patients had disease progression on at least 2 lines of endocrine therapy in the metastatic setting or one line of endocrine therapy in the metastatic setting and demonstrated progression within 24 months of the start of adjuvant endocrine therapy, or within 6 months of starting first line endocrine therapy in combination with a CDK 4/6 inhibitor in the metastatic setting.

<div style=\"page-break-after: always\"></div>

866 patients were recruited from 273 study centres in 28 countries and the median duration of followup for OS in the HER2-low population was 19.0 months at the DCO of 18 March 2024, which is at the time of the final analysis of PFS and the first interim analysis (IA) of overall survival (OS). The pivotal study was fully recruited, and a relevant fraction of the patients is considered representative of the EU population (~62% from Europe or North America).

The study population (ITT) consisted of 713 patients (82.3%) whose tumours were HER2-low and 152 patients (17.6%) whose tumours were HER2-ultralow.

## 3.2. Favourable effect

The primary endpoint in study DB-06, PFS by BICR assessment in the HER2-low population, showed an improvement of 5.1 months from 8.1 months (95%CI: 7.0, 9.0) with chemotherapy to 13.2 months (95%CI: 11.4, 15.2) with T-DXd, HR 0.62 (95%CI: 0.52; 0.75) at the DCO of 18 March 2024. The data is considered mature with 62.7% events in the active T-DXd arm and 65.5% events in the control arm.

Below, the favourable effects are reflected for the entire study population (ITT), since this is the relevant population for the applied indication.

PFS by BICR assessment in the ITT population was a secondary endpoint and its results were in line with the primary endpoint showing an improvement of 5.1 months from 8.1 months with chemotherapy to 13.2 months with T-DXd, HR 0.64 (95%CI: 0.54, 0.76). The data is considered mature with 61.7% events in the active T-DXd arm and 63.0% events in the control arm.

Since the Interim Analysis (IA) of OS in the HER2-low population was not statistically significant, the confirmatory testing at the IA stopped, and OS was not formally tested in the ITT population. Therefore, all subsequent results are descriptive. At the IA, the HR for OS in the ITT population was 0.81 (95%CI: 0.66; 1.01) and 0.83 (95%CI: 0.66, 1.05) in the HER2-low population.

Confirmed ORR by BICR in the ITT population was improved from 31.2% in the control arm to 57.3% with T-DXd. CR was observed in 3.2% of the patients with T-DXd and 0 patients in the chemotherapy arm, while the rate of PR was 58.3% with T-DXd vs 36.7% in the chemotherapy arm.

The median duration of response (DoR) by BICR was longer for patients in the T-DXd arm i.e. 13.7 months (95%CI: 11.8; 15.4) vs 7.3 months with chemotherapy (95%CI: 6.0; 10.8).

The median PFS2 in the T-DXd arm was 20.3 months vs 14.7 months in the chemotherapy arm, HR 0.61 (95%CI: 0.51; 0.73). The KM curves for PFS2 separate early and remain separated.

The median treatment duration was 11.0 months in the T-DXd and 5.6 months in the chemotherapy arm.

## 3.3. Uncertainties and limitations about favourable effects

The limited sample size of the HER2-ultralow population of 152 patients represents an uncertainty on the treatment effect of T-DXd in the HR+ HER2-ultralow population due to the lower number of patients and events/unpowered analysis.

The comparator arm may be considered suboptimal for patients who did not receive prior anthracyclines (around ~55% of the included patients in study DB-06 (see section 5.1 of the SmPC)) especially since about 30% of patients presented with de-novo Stage IV disease. The beneficial effect

<div style=\"page-break-after: always\"></div>

of T-DXd in patients without prior use of anthracyclines is therefore uncertain. Nevertheless, a detrimental effect is considered unlikely.

## 3.4. Unfavourable effects

Almost all patients in both treatment arms in the pivotal study DB-06 experienced at least one adverse event (AE) and most of these were treatment-related. The majority of the AEs were at least twice as frequent in the T-DXd arm compared to the chemotherapy arm. All reported AE incidences for the T-DXd arm were within the same magnitude of the AE incidences reported in the All Tumour Pool (ATT Pool), with the exception of COVID-19 (24.4% in the T-DXd arm versus 12.5% in the chemotherapy arm of the DB-06 study) and no new categories of AEs were observed. In the ATT Pool, the most frequently observed events were nausea (71.1%), fatigue (52%), vomiting (37.3%), alopecia (36.1%), neutropenia (36.4%), anaemia (35.3%), constipation (31.7%) and diarrhoea (30.1%). Treatment-related AEs (ADRs) with T-DXd in the DB-06 study were also mainly gastrointestinal and haematological in nature, at nearly the same incidences as reported for the AEs. The incidences of ADRs in the T-DXd arm of the DB-06 study are in line with those of the ATT Pool.

In the DB-06 study 52.8% and 44.4% had a grade ≥ 3 AE in the T-DXd arm and chemotherapy arm respectively. The most common grade ≥ 3 AEs were neutropenia (22.3% versus 17%) and anaemia (8.8% versus 4.3%). The very common AEs, such as nausea, other gastrointestinal AEs and fatigue, seldomly were grade ≥ 3. This is in line with the data from the Safety Pools (BC and ATT).

Adverse events of special interest are ILD/pneumonitis and left ventricular ejection fraction decrease. ILD/pneumonitis continues to be the greatest risk for T-DXd treatment, with an incidence of 12.2%. Most events were Grade 1 or Grade 2, but there were three Grade 3 or 4 events (0.7%) and three Grade 5 events in the T-DXd arm. A decrease in left ventricular ejection fraction to a grade 2 occurred in 14.6% of the T-DXd treated patients of the pivotal study, which is in line with the ATT Pool.

In the T-DXd arm and the chemotherapy arm of the pivotal study, Serious AEs (SAEs) were observed in 20.3% in the T-DXd arm and 16.1% in the chemotherapy arm. In patients treated with T-DXd in 2.5% an AE was reported with the outcome of death, which was considered to be drug-related in 1.2% (ILD in 2 patients, sepsis in 2 patients and general physical health deterioration in 1 patient). In the chemotherapy arm, in 1.4% an AE was reported with an outcome of death and none of the cases were drug-related. The most commonly observed SAE in the DB-06 study was interstitial lung disease/pneumonitis (3.6%), which is in line with the most common SAE in the ATT Pool of 3.1% and was associated with death in 3 patients.

The main cause of discontinuation of treatment in the pivotal study, was objective disease progression in both treatment arms, which was 57.1% in the T-DXd arm and 70% in the chemotherapy arm. Discontinuation of treatment due to AEs was seen in 14.1% in the T-DXd arm and in 9.8% in the chemotherapy arm. The primary cause of discontinuation was ILD/pneumonitis (8.8%).

## 3.5. Uncertainties and limitations about unfavourable effects

None.

<div style=\"page-break-after: always\"></div>

## 3.6. Effects Table

Table 97 Effects Table for Enhertu (T-DXd) for advanced HR+, HER2-low and HER2-ultralow breast cancer (data cut-off: 18 March 2024)

| Effect                              | Short description                   | Unit                                | Treatment                           | Control                             | Uncertainties / Strength of evidence                                                                                                                                                     |
|-------------------------------------|-------------------------------------|-------------------------------------|-------------------------------------|-------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                     |                                     |                                     | T-DXd                               | Chemo- therapy                      |                                                                                                                                                                                          |
|                                     |                                     |                                     | N= 436                              |                                     |                                                                                                                                                                                          |
|                                     |                                     |                                     |                                     | N=430                               |                                                                                                                                                                                          |
| Favourable Effects (ITT population) | Favourable Effects (ITT population) | Favourable Effects (ITT population) | Favourable Effects (ITT population) | Favourable Effects (ITT population) | Favourable Effects (ITT population)                                                                                                                                                      |
| PFS by BICR                         | Progression- free survival          | Months (95%CI )                     | 13.2 12.0; 15.2                     | 8.1 7.0; 9.0                        | HR 0.64 (0.54; 0.76) 61.7% vs 63% events Strength: Independent of HER2 expression level Uncertainty: Effect size HER2- ultralow subgroup due to low number of events /unpowered analysis |
| OS                                  | Overall survival                    | Months                              | 28.9 26.4; 32.7                     | 27.4 23.9; 29.9                     | 36.9% vs 40.5% events, HR 0.81(NS) Uncertainty: Exploratory analysis due to immature data                                                                                                |
| ORR by BICR                         | Overall response rate               | %                                   | 57.3                                | 31.2                                | Confirmed ORR reported                                                                                                                                                                   |
| DOR by BICR                         | Duration of response                | Months                              | 13.7                                | 7.3                                 |                                                                                                                                                                                          |
| Unfavourable Effects-               | Unfavourable Effects-               | Unfavourable Effects-               | Unfavourable Effects-               | Unfavourable Effects-               | Unfavourable Effects-                                                                                                                                                                    |
| Grade ≥3 AEs                        | Grade ≥3 AEs                        | %                                   | 52.8                                | 44.4                                |                                                                                                                                                                                          |
| SAEs                                | SAEs                                | %                                   | 20.3                                | 16.1                                |                                                                                                                                                                                          |
| AEs leading to discontinuation      | AEs leading to discontinuation      | %                                   | 14.3                                | 9.4                                 |                                                                                                                                                                                          |
| AEs associated with                 | AEs associated with                 | %                                   | 2.5                                 | 1.4                                 |                                                                                                                                                                                          |
| death ILD/pneumonitis               | death ILD/pneumonitis               | %                                   | 12.2                                | (0.2 - 1.2)                         |                                                                                                                                                                                          |
| LVEF decrease ≥ grade 2             | LVEF decrease ≥ grade 2             | %                                   | 15.0                                | 8.4                                 |                                                                                                                                                                                          |

Abbreviations: BICR: Blinded independent review; NS: Not statistically significant; AE: Adverse Event; SAE: Serious Adverse Event.

## 3.7. Benefit-risk assessment and discussion

## 3.7.1. Importance of favourable and unfavourable effects

At the DCO of 18 March 2024, the primary endpoint of PFS by BICR in the HER2-low population was met and showed a statistically significant and clinically relevant improvement of 5.1 months from 8.1 months with chemotherapy to 13.2 months with T-DXd, HR 0.62 after a median follow up of almost 19 months and more than 60% of events in both arms. The secondary endpoint of OS in the HER2-low population show that with partly mature data at the time of the first IA (~40% events), the median OS was 28.9 months in the T-DXd arm vs 27.1 months in the control arm; HR of 0.83 (95%CI: 0.66; 1.05). The KM curves for OS do not clearly separate but there is no sign of a detriment.

The results of PFS by BICR assessment in the ITT population were in line with the primary analysis and also showed an improvement of 5.1 months from 8.1 months with chemotherapy to 13.2 months with T-DXd, HR 0.64 (95%CI: 0.54, 0.76).

<div style=\"page-break-after: always\"></div>

Of note, the subgroup analysis of the HER2-ultralow population showed a median PFS of 13.2 months in patients who had T-DXd (N=76) versus 8.3 months in the control arm, HR 0.78, and although this result is not statistically significant, the difference in PFS benefit observed is very similar to the primary analysis of the primary endpoint, and the numerical difference of 4.9 months is considered clinically relevant. The limited sample size of the HER2-ultralow population of 152 patients in total is considered the reason for the not statistically significant results. However, the efficacy results from the HER2-ultralow population is considered clinically relevant and the close similarity to the PFS, ORR and DoR and the PFS results from the HER2-low and the ITT populations are considered compelling, allowing to conclude that T-DXd has similar and clinically relevant efficacy in the HER2-ultralow population as well. Therefore, it is considered acceptable to grant an indication for T-DXd for both the HER2-low and the HER2-ultralow populations, meaning the ITT population in study DB-06.

In the absence of fully mature OS data, the provided PFS2 results from the ITT population are considered clinically important. The median PFS2 in the T-DXd arm was 20.3 months vs 14.7 months in the chemotherapy arm, HR 0.61, so the patients on T-DXd have a longer time to the second progression on next-line therapy. This is considered reassuring and indicates that any detriment on OS is unlikely. The MAH is recommended to submit the results of the next interim OS analysis data as well as the final OS analysis data from study DB-06 when available (Recommendation (REC)).

The safety profile of T-DXd was not changed with the added safety data from the pivotal study DB-06 and the main reported adverse events of trastuzumab deruxtecan are still haematological and gastrointestinal toxicities, which were rarely of high grade and seem to be manageable, while the major safety concern remains the risk of ILD/pneumonitis.

The clinically meaningful improvements in efficacy are shown in a direct head-to-head comparison with the current standard of care i.e. singe-agent chemotherapy, and although the toxicities of chemotherapy could be interpreted as less severe compared to T-DXd in the pivotal study DB-06, the safety profile of T-DXd is considered manageable. The risk of severe and potentially fatal toxicity is considered balanced against the markedly improved efficacy observed with T-DXd in study DB-06.

## 3.7.2. Balance of benefits and risks

When the advanced breast cancer has progressed in patients after multiple lines of endocrine therapy with or without targeted therapies or who have a short median PFS on first-line endocrine-based therapy, single-agent chemotherapy is considered the standard of care however with modest benefits for patients with HER2-low or HER2-ultralow BC, highlighting the high unmet medical need for new treatment options to delay progression and improve survival outcomes in this setting.

Based on the results from the DB-06 study, T-DXd as monotherapy for the treatment of adult patients with unresectable or metastatic HR+ HER2-low or HER2-ultralow breast cancer has demonstrated a statistically significant and clinically relevant benefit in PFS.

The safety profile of T-DXd is non-negligible and ILD/pneumonitis remains an important safety concern.

## 3.7.3. Additional considerations on the benefit-risk balance

N/A

<div style=\"page-break-after: always\"></div>

## 3.8. Conclusions

Overall, the B/R balance of Enhertu in the new claimed indication is considered positive.

## 4. Recommendations

## Outcome

Based on the review of the submitted data, the CHMP considers the following variation acceptable and therefore recommends the variation to the terms of the Marketing Authorisation, concerning the following change:

| Variation accepted   | Variation accepted                                                                                                             | Type    | Annexes affected     |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|----------------------|
| C.I.6.a              | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I, II, IIIA and IIIB |

Extension of indication to include treatment of adult patients with unresectable or metastatic HER2-low or HER2-ultralow breast cancer who have received at least one endocrine therapy in the metastatic setting and who are not considered suitable for endocrine therapy as the next line of treatment for ENHERTU, based on results from study D9670C00001 (DESTINY-Breast06); this is a phase 3, randomized, multicentre, open-label study of trastuzumab deruxtecan (DS-8201a) compared with investigator's choice chemotherapy in, hormone receptor-positive, HER2-low and HER2-ultralow BC patients whose disease has progressed on endocrine therapy in the metastatic setting. As a consequence, sections 4.1, 4.2, 4.4, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 9.0 of the RMP has also been submitted. In addition, the MAH took the opportunity to introduce editorial changes to the PI, and to update the PI according to the Excipients Guideline. Furthermore, the PI is brought in line with the latest QRD template version 10.4.

The variation leads to amendments to the Summary of Product Characteristics, Annex II, Labelling and Package Leaflet and to the Risk Management Plan (RMP).

## Amendments to the marketing authorisation

In view of the data submitted with the variation, amendments to Annexes I, II, IIIA and IIIB and to the Risk Management Plan are recommended.

This recommendation is subject to the following amended conditions:

## Conditions or restrictions with regard to the safe and effective use of the medicinal product

## Additional risk minimisation measures

Prior to the launch of trastuzumab deruxtecan in each member state, the Marketing Authorisation Holder (MAH) must agree on the content and format of the educational programme (Healthcare Professional [HCP] Guide, Patient Card for ILD/pneumonitis and HCP Guide for product confusion-

<div style=\"page-break-after: always\"></div>

related medication errors), including communication media, distribution modalities, and other aspects of the programme, with the National Competent Authority.

The educational programme is aimed at:

- I) ensuring early recognition of interstitial lung disease (ILD)/pneumonitis, to allow prompt appropriate treatment and to mitigate worsening of the condition.
2. II) improving HCP awareness of the potential risk for product confusion-related medication errors due to the availability of multiple trastuzumab-containing products and trastuzumab emtansine

The MAH shall ensure that in each member state where trastuzumab deruxtecan is marketed, all HCPs and patients who are expected to administer/be administered trastuzumab deruxtecan are provided with the following educational materials:

## I) Healthcare Professional (HCP) Guide for ILD/pneumonitis

The HCP Guide contains the following key elements:

- Summary of important findings of trastuzumab deruxtecan-induced ILD/pneumonitis (eg, frequency, grade, time to onset) observed in the clinical trial setting
- Description of the appropriate monitoring and evaluation of ILD/pneumonitis in patients receiving trastuzumab deruxtecan
- Detailed description of management of ILD/pneumonitis in patients treated with trastuzumab deruxtecan including guidance on drug interruption, reduction and treatment discontinuation for ILD/pneumonitis
- Reminder to HCP that they should repeat the information about signs and symptoms of ILD/pneumonitis at each patient visit, including when the patient should seek attention from an HCP (eg, the symptoms to watch for; the importance to adhere to scheduled appointments)
- Reminder to HCP to provide the patient with the Patient Card (PC), including advice that the PC should be kept with the patient at all times

## II) Healthcare Professional Guide for prevention of medication errors

The HCP Guide contains the following key elements:

- Alert to HCPs about a potential risk of confusion between Enhertu (trastuzumab deruxtecan) and other trastuzumab-containing products and the HER2-targeted antibody-drug conjugate Kadcyla (trastuzumab emtansine)
- Mitigation measures for prescribing errors due to similarities in active ingredient names and measures to avoid errors during prescription phase by physicians
- Comparison of commercial appearance between Enhertu (trastuzumab deruxtecan) and other trastuzumab-containing products and the HER2-targeted antibody-drug conjugate Kadcyla (trastuzumab emtansine)
- Potential mitigation strategies to avoid errors during preparation phase by pharmacists
- Detailed Information about the dosage, method of administration and preparation as well as instructions to avoid medication errors during administration phase by nurses

## III) Patient Card

The Patient Card contains the following key elements:

<div style=\"page-break-after: always\"></div>

- Description of the important risks of ILD/pneumonitis associated with the use of trastuzumab deruxtecan
- Description of key signs and symptoms of ILD/pneumonitis and guidance on when to seek attention from an HCP
- Contact details of the trastuzumab deruxtecan prescriber
- Cross-reference to Patient Information Leaflet